,id,pert_iname,smiles,pubchem_cid,clinical_phase,moa,target,disease_area,indication,target_entrez
0,BRD-K76022557,(R)-(-)-apomorphine,CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31,6005.0,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A,neurology/psychiatry,Parkinson's Disease,3352|3361|50632|1815|1816|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358
1,BRD-K75516118,(R)-(-)-rolipram,COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1,448055.0,Phase 1,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,,,8654|5141|5142|5143|5144
2,BRD-K62353271,(R)-baclofen,NC[C@H](CC(O)=O)c1ccc(Cl)cc1,6918881.0,Phase 3,benzodiazepine receptor agonist,GABBR1|GABBR2,,,9568|10537
3,BRD-K65856711,(S)-(+)-rolipram,COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1,158758.0,Phase 1,phosphodiesterase inhibitor,PDE4B|PDE4D,,,5144|5142
4,BRD-K89787693,"[sar9,met(o2)11]-substance-p",CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O,163829.0,Preclinical,tachykinin antagonist,TACR1,,,6869
9,BRD-K03273112,1-azakenpaullone,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,6538897.0,Preclinical,glycogen synthase kinase inhibitor,CCNB1|CDK1|CDK5|GSK3B,,,2932|891|1020|983
10,BRD-K89665618,1-deoxymannojirimycin,OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O,72258.0,Preclinical,alpha mannosidase inhibitor,MAN2A1,,,4124
11,BRD-K70586315,1-EBIO,CCn1c2ccccc2[nH]c1=O,82320.0,Preclinical,potassium channel activator,KCNN1|KCNN2|KCNN3|KCNN4,,,3780|3781|3782|3783
13,BRD-K35114608,1-hexadecanal,CCCCCCCCCCCCCCCC=O,984.0,Preclinical,sphingosine 1-phosphate receptor substrate,DBI|RHO,,,706|6010
15,BRD-K29542628,1-naphthyl-PP1,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12,4877.0,Preclinical,SRC inhibitor,SRC,,,6714
17,BRD-K09338665,1-octanol,CCCCCCCCO,957.0,Phase 2,,GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1,,,81025|2697|2700|2701|2702|2703|2705|2706|2707|2709|57369|127534|10804|125111|57165|84694|349149|375519|219770
18,BRD-K31491153,1-phenylbiguanide,NC(N)=NC(=N)Nc1ccccc1,4780.0,Preclinical,serotonin receptor agonist,HTR3A|HTR3B,,,9177|3359
20,BRD-K06817181,"1,2,3,4,5,6-hexabromocyclohexane",BrC1C(Br)C(Br)C(Br)C(Br)C1Br,74603.0,Preclinical,JAK inhibitor,JAK2,,,3717
22,BRD-K22346679,"1,4-butanediol",OCCCCO,8064.0,Phase 1,benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,MAN1B1|PLA2G2A|PLA2G2E,,,5320|11253|30814
25,BRD-K70792160,10-DEBC,CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12,10521421.0,Preclinical,AKT inhibitor,PIM1,,,9361
26,BRD-K63784565,10-hydroxycamptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O,97226.0,Preclinical,topoisomerase inhibitor,TOP1,,,7150
28,BRD-K68552125,12-O-tetradecanoylphorbol-13-acetate,"CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|",27924.0,Phase 2,PKC activator,KCNT2|TRPV4,,,343450|59341
29,BRD-K30237152,1400W,CC(=N)NCc1cccc(CN)c1,1433.0,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,,339345|342977|340719
30,BRD-K92301463,"16,16-dimethylprostaglandin-e2",CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,5283066.0,Phase 2,prostanoid receptor agonist,HPGD,,,3248
31,BRD-K70264088,17-hydroxyprogesterone-caproate,CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|,169870.0,Launched,progesterone receptor agonist,AR|ESR1|ESR2|NR1H4|NR1I2|NR3C1|PGR,obstetrics/gynecology,spontaneous preterm birth,367|2099|2100|9971|8856|5241|2908
36,BRD-A66788520,2-(3-mercaptopropyl)pentanedioic-acid,"OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|",11735892.0,Phase 1,glutamate carboxypeptidase inhibitor,FOLH1,,,2346
38,BRD-K91868854,2-[1-(4-piperonyl)piperazinyl]benzothiazole,C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1,127902.0,Preclinical,serotonin receptor agonist,HTR4,,,3360
39,BRD-K32681104,2-aminobenzenesulfonamide,Nc1ccccc1S(N)(=O)=O,72894.0,Preclinical,carbonic anhydrase inhibitor,CA12|CA14|CA2|CA6|CA9,,,768|771|23632|760|765
40,BRD-K13346085,2-APB,NCCOB(c1ccccc1)c1ccccc1,1598.0,Preclinical,"1,4,5-trisphosphate inhibitor",TRPC1|TRPC3|TRPC4|TRPC5|TRPC6|TRPC7|TRPM2|TRPM3|TRPM6|TRPV1|TRPV6,,,140803|80036|1191|55503|7442|7220|7222|7223|7224|7225|7226
41,BRD-K22745370,2-BFI,C1CN=C(N1)c1cc2ccccc2o1 |c:2|,3080926.0,Preclinical,imidazoline receptor ligand,ADRA2A|ADRA2B|ADRA2C|MAOA|MAOB,,,4128|4129|150|151|152
42,BRD-K70088346,2-chloro-N6-cyclopentyladenosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12,123807.0,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
43,BRD-K79511609,2-chloroadenosine,Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,8974.0,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B,,,136|134|135
45,BRD-K92588747,2-CMDO,CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|,32224.0,Preclinical,dopamine receptor antagonist,DRD2|DRD4,,,1813|1815
47,BRD-K97808269,2-deoxyglucose,OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O,9062.0,Phase 2,glycolysis inhibitor,SLC2A1|SLC2A2|SLC2A3|SLC2A4,,,6513|6514|6515|6517
50,BRD-A53037300,2-fluoro-2-deoxy-D-galactose,"OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|",445913.0,Phase 1,,LCT,,,3938
54,BRD-K82027074,2-hydroxyflutamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,91649.0,Phase 2,androgen receptor antagonist,AR,,,367
55,BRD-A27924917,2-hydroxysaclofen,"NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|",7005135.0,Preclinical,GABA receptor antagonist,GABBR1|GABBR2,,,9568|10537
56,BRD-K07954936,2-iminobiotin,NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|,135678104.0,Phase 2,nitric oxide synthase inhibitor,NOS1|NOS2,,,339345|340719
58,BRD-K25649279,2-iodomelatonin,COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1,115348.0,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B|NQO2,,,4544|4835|4543
59,BRD-K44408410,2-methoxyestradiol,COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O,66414.0,Phase 2,hypoxia inducible factor inhibitor,COMT|CYP19A1|CYP1A1|CYP1B1|HIF1A|TUBB,,,1312|1543|1545|7280|3091|1588
60,BRD-K64137799,2-methyl-5-hydroxytryptamine,Cc1[nH]c2ccc(O)cc2c1CCN,1574.0,Preclinical,serotonin receptor agonist,HTR1B|HTR1D|HTR1E|HTR1F|HTR3A|HTR3B|HTR6,,,3362|3351|3352|9177|3354|3355|3359
64,BRD-K77087341,2-oleoylglycerol,CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO,5319879.0,Phase 1,glucose dependent insulinotropic receptor ligand,GPR119,,,139760
65,BRD-K89712525,2-oxoglutaric-acid,OC(=O)CCC(=O)C(O)=O,51.0,Preclinical,,OXGR1,,,27199
66,BRD-K86587225,2-oxopropanoate,OC(=C)C(O)=O,37873.0,Preclinical,pyruvate dehydrogenase kinase inhibitor,ABAT,,,18
67,BRD-K41869275,2-phenylmelatonin,COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1,4018512.0,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,,4544|4543
68,BRD-A04661934,2-PMDQ,"O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|",,Preclinical,adrenergic receptor antagonist,ADRA1A,,,146
69,BRD-K17874705,2-pyridylethylamine,NCCc1ccccn1,75919.0,Preclinical,histamine receptor agonist,HRH1,,,3269
70,BRD-K89072800,2-TEDC,Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O,6069552.0,Preclinical,lipoxygenase inhibitor,ALOX12,,,239
74,BRD-K61734568,"2,3-DCPE",OCCNCCCOc1cccc(Cl)c1Cl,2250975.0,Preclinical,BCL-XL downregulator,BCL2L1,,,598
75,BRD-K97833335,"2,4-dinitrochlorobenzene",[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O,6.0,Phase 2,thioredoxin inhibitor,TXN,,,25828
76,BRD-K21910317,"2,4-dinitrophenol",Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O,1493.0,Preclinical,ATP synthase inhibitor,APP,,,351
77,BRD-K29791386,"2,5-furandimethanol",OCc1ccc(CO)o1,74663.0,Phase 2,hemoglobin modulator,HBB,,,85344
80,BRD-K63932022,2'-MeCCPA,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12,10475082.0,Preclinical,adenosine receptor agonist,ADORA1,,,134
84,BRD-K00004218,3-alpha-bis-(4-fluorophenyl)-methoxytropane,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|",,Preclinical,dopamine uptake inhibitor,CHRM1|SLC6A2|SLC6A3|SLC6A4,,,1128|6530|6531|6532
85,BRD-A43598550,3-alpha-hydroxy-5-beta-androstan-17-one,"C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1,5,8,10,14,16,&1:4|",5880.0,Preclinical,,HSD17B11|IGHG2|SULT2A1,,,51170|3501|6822
86,BRD-K08703257,3-amino-benzamide,NC(=O)c1cccc(N)c1,1645.0,Phase 2,PARP inhibitor,PARP1,,,142
88,BRD-K38370968,3-AQC,C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N,3073499.0,Preclinical,serotonin receptor agonist,HTR3A,,,3359
89,BRD-K24689407,3-bromo-7-nitroindazole,[O-][N+](=O)c1cccc2c(Br)[nH]nc12,1649.0,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,,339345|342977|340719
91,BRD-K92980438,3-bromopyruvate,OC(=O)C(O)=CBr,129924149.0,Preclinical,hexokinase inhibitor,HK2,,,3099
92,BRD-K76592088,3-carboxy-4-hydroxyphenylglycine-(R),N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,6604713.0,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C,,,2904|2905|114787|2903
93,BRD-K61585876,3-carboxy-4-hydroxyphenylglycine-(S),N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,5311460.0,Preclinical,glutamate receptor antagonist,GRM1|GRM5,,,2915|2911
95,BRD-A79431551,3-deazaadenosine,"Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|",12769724.0,Phase 2,adenosylhomocysteinase inhibitor,AHCY,,,191
96,BRD-K77791657,3-deazaneplanocin-A,Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|,73087.0,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,,2146
99,BRD-K43187796,3-indolebutyric-acid,OC(=O)CCCc1c[nH]c2ccccc12,8617.0,Preclinical,,B2M|HLA-A|TRAC|TRBC1,,,3105|28639|28755|567
100,BRD-A87125127,3-MATIDA,"Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|",92327883.0,Preclinical,glutamate receptor antagonist,GRM1,,,2911
101,BRD-K01825682,3-methyl-GABA,C[C@@H](CN)CC(O)=O |&1:1|,6604938.0,Preclinical,GABA aminotransferase activator,ABAT,,,18
102,BRD-K81647657,3-methyladenine,Cn1cnc(=N)c2[nH]cnc12,135398661.0,Preclinical,PI3K inhibitor,PI3,,,5266
103,BRD-K62581435,3-MPPI,COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1,4013695.0,Preclinical,adrenergic receptor ligand,ADRA1A,,,146
104,BRD-K82903013,"3,3'-dichlorobenzaldazine",Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1,6861557.0,Preclinical,glutamate receptor modulator,GRM5,,,2915
105,BRD-K37846922,"3,3'-diindolylmethane",C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12,3071.0,Phase 3,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",AR|HIF1A|IFNG|PI3,,,5266|3458|3091|367
106,BRD-A49947412,"3,4-DCPG-(+/-)","N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|",6604849.0,Preclinical,glutamate receptor agonist,GRM8,,,2918
108,BRD-K86305586,"3,4-DCPG-(S)",N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O,16062593.0,Preclinical,glutamate receptor agonist,GRM8,,,2918
109,BRD-K42205652,"3,4-methylenedioxy-beta-nitrostyrene",[O-][N+](=O)\C=C\c1ccc2OCOc2c1,672296.0,Preclinical,SRC inhibitor|SYK inhibitor,SRC|SYK,,,6850|6714
110,BRD-K57796080,"3,5-DHPG-(S)",N[C@H](C(O)=O)c1cc(O)cc(O)c1,71668376.0,Preclinical,glutamate receptor agonist,GRM1,,,2911
111,BRD-K45662124,3'-fluorobenzylspiperone,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1,3248000.0,Preclinical,dopamine receptor ligand,DRD2,,,1813
112,BRD-K58413118,3PO,O=C(\C=C\c1cccnc1)c1ccncc1,5720233.0,Preclinical,phosphofructokinase inhibitor,PFKFB3,,,5209
113,BRD-K47337578,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1,5234410.0,Preclinical,serotonin receptor antagonist,HTR2A,,,3356
116,BRD-K65544384,4-aminohippuric-acid,Nc1ccc(cc1)C(=O)NCC(O)=O,2148.0,Launched,,SLC22A6,nephrology,renal diagnostic agent,9356
117,BRD-A80383043,4-carboxy-3-hydroxyphenylglycine-(RS),"N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|",6604709.0,Preclinical,glutamate receptor agonist|glutamate receptor antagonist,GRM1,,,2911
118,BRD-K74133873,4-carboxy-3-hydroxyphenylglycine-(S),N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1,5311455.0,Preclinical,glutamate receptor agonist|glutamate receptor antagonist,GRM1|GRM2,,,2912|2911
119,BRD-K39160765,4-chlorophenylguanidine,NC(=N)Nc1ccc(Cl)cc1,2757788.0,Preclinical,urokinase inhibitor,PLAUR,,,5329
120,BRD-A54139254,4-CMTB,"CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|",854190.0,Preclinical,free fatty acid receptor agonist,FFAR2,,,2867
121,BRD-K29313239,4-DAMP,C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1,1734.0,Preclinical,cholinergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,,1128|1129|1131|1132|1133
123,BRD-K91758890,4-HQN,O=c1nc[nH]c2ccccc12,135408753.0,Preclinical,PARP inhibitor,PARP1,,,142
125,BRD-K62537556,4-IBP,Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1,132995.0,Preclinical,sigma receptor agonist,SIGMAR1,,,10280
126,BRD-K25690923,4-iodo-6-phenylpyrimidine,Ic1cc(ncn1)-c1ccccc1,817368.0,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,,4282
127,BRD-K66664625,4-iodo-L-phenylalanine,N[C@H](Cc1ccc(I)cc1)C(O)=O,7047041.0,Preclinical,,DPP4,,,1803
128,BRD-K73303757,4-methylgenistein,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,5280373.0,Preclinical,protein tyrosine kinase inhibitor,CYP19A1|ESRRA|ESRRB|ESRRG|FASN,,,2194|1588|2101|2103|2104
129,BRD-K70821460,4-methylhistamine,Cc1nc[nH]c1CCN,37463.0,Preclinical,histamine receptor agonist,HRH4,,,59340
130,BRD-K81316007,4-mu-8C,Cc1cc(=O)oc2c(C=O)c(O)ccc12,12934390.0,Preclinical,IRE1 inhibitor,ERN1,,,2081
131,BRD-K00004224,4-P-PDOT,"CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|",24750357.0,Preclinical,melatonin receptor antagonist,MTNR1A|MTNR1B,,,4544|4543
134,BRD-K78061844,4-PPBP,C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1,3035672.0,Preclinical,sigma receptor ligand,SIGMAR1,,,10280
140,BRD-K97118047,"4,5,6,7-tetrabromobenzotriazole",Brc1c(Br)c(Br)c2n[nH]nc2c1Br,1694.0,Preclinical,casein kinase inhibitor,AKT1|CHEK1|CSNK2A1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1,,,5600|5604|5578|6093|6446|207|6300|1459|2932|6198|1111|1432|5594|3932|5599
141,BRD-A18598741,4BP-TQS,"NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|",6979017.0,Preclinical,nicotinic receptor agonist,CHRNA7,,,89832
142,BRD-K67173685,4E1RCat,OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|,16195554.0,Preclinical,protein synthesis inhibitor,EIF4E|EIF4G1,,,1977|1981
143,BRD-K00004308,4EGI-1,OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1,2831024.0,Preclinical,protein synthesis inhibitor,EIF4E,,,1977
144,BRD-K11773281,4SC-202,Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1,15985904.0,Phase 1,HDAC inhibitor,HDAC1,,,3065
146,BRD-K87535339,"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,135409474.0,Preclinical,,TLR7,,,51284
147,BRD-K57631554,5-aminolevulinic-acid,NCC(=O)CCC(O)=O,7048523.0,Launched,oxidizing agent,ALAD,oncology|dermatology,glioma|actinic keratosis (AK),210
148,BRD-K33690734,5-BDBD,Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|,9841560.0,Preclinical,purinergic receptor antagonist,P2RX4,,,5025
149,BRD-K92382976,5-carboxamidotryptamine,NCCc1c[nH]c2ccc(cc12)C(N)=O,1809.0,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,,3361|3362|3363|106480180|3350|3351|3352|3354|3355|3356|3358
152,BRD-K24844714,5-fluorouracil,Fc1c[nH]c(=O)[nH]c1=O,3385.0,Launched,thymidylate synthase inhibitor,DPYD|TYMS,oncology,colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma,7298|1806
153,BRD-K34437622,5-FP,Fc1cnc(=O)[nH]c1,101498.0,Phase 1,thymidylate synthase inhibitor,TYMS,,,7298
157,BRD-K24603946,5-hydroxymethyl-tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C,9819382.0,Phase 1,acetylcholine receptor antagonist,CHRM3,,,1131
158,BRD-A73930134,5-hydroxytryptophan,"N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|",6971044.0,Launched,neurotransmitter,SLC36A1|SLC36A2,neurology/psychiatry,insomnia,153201|206358
160,BRD-K45437867,5-methylfurmethiodide,Cc1ccc(C[N+](C)(C)C)o1,4141.0,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,,1128|1129|1131|1132
164,BRD-K60287130,"5,7-dichlorokynurenic-acid",OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1,1779.0,Preclinical,glutamate receptor antagonist,GLRA2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,114787|2742|2903|2904|2905|2906
165,BRD-K00004289,5'-chloro-5'-deoxy-ENBA-(+/-),"O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|",,Preclinical,adenosine receptor agonist,ADORA1,,,134
169,BRD-K34663752,6-chloromelatonin,COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl,1858.0,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,,4544|4543
171,BRD-K49236613,6-iodo-nordihydrocapsaicin,CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I,5149140.0,Preclinical,TRPV antagonist,TRPV1,,,7442
174,BRD-K84214706,7-chlorokynurenic-acid,OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1,1884.0,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C,,,2904|2905|114787|2903
175,BRD-K01826780,7-hydroxy-DPAT,CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|,23928184.0,Preclinical,dopamine receptor agonist,DRD2|DRD3,,,1813|1814
176,BRD-K01825667,7-hydroxy-PIPAT,CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|,10317104.0,Preclinical,dopamine receptor ligand,DRD3,,,1814
177,BRD-K45293975,7-hydroxystaurosporine,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,3078519.0,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,,,11200|5578|4139|4140|5579|5580|5581|5582|983|5170|2932|1111|1432|3932
179,BRD-K53156626,7-methoxytacrine,COc1ccc2nc3CCCCc3c(N)c2c1,119053.0,Phase 2,acetylcholinesterase inhibitor,ACHE,,,43
181,BRD-K04430056,7-nitroindazole,[O-][N+](=O)c1cccc2c[nH]nc12,1893.0,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,,339345|342977|340719
184,BRD-A00077618,8-bromo-cGMP,"Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|",135419186.0,Preclinical,PKA activator,PRKG1,,,5592
185,BRD-K01826732,8-hydroxy-DPAT,CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|,10125797.0,Preclinical,serotonin receptor agonist,HTR5A|HTR7,,,3361|3363
186,BRD-A60594020,8-hydroxy-PIPAT,CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|,15288637.0,Preclinical,dopamine receptor ligand,DRD2|DRD3,,,1813|1814
187,BRD-A07232941,8-M-PDOT,"CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|",92211535.0,Preclinical,melatonin receptor agonist,MTNR1A|MTNR1B,,,4544|4543
190,BRD-K09291936,9-aminocamptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O,72402.0,Phase 2,topoisomerase inhibitor,TOP1,,,7150
191,BRD-K62607075,9-anthracenecarboxylic-acid,OC(=O)c1c2ccccc2cc2ccccc12,2201.0,Preclinical,,ANO1|CLCN1,,,55107|1180
192,BRD-K70329400,A-1070722,COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1,49830684.0,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,,2931|2932
193,BRD-K59060513,A-1120,OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F,25138295.0,Preclinical,retinoid receptor ligand,RBP4,,,5433
194,BRD-K38019854,A-317491,OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12,9829395.0,Preclinical,purinergic receptor antagonist,P2RX3,,,5024
196,BRD-K06182768,A-366,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|,76285486.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,,79813|10919
198,BRD-K62066682,A-412997,Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1,10425450.0,Preclinical,dopamine receptor agonist,DRD4,,,1815
199,BRD-K13223831,A-438079,Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl,11673921.0,Preclinical,purinergic receptor antagonist,P2RX7,,,5027
201,BRD-K79743788,A-582941,CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1,44190553.0,Preclinical,nicotinic receptor agonist,CHRNA7,,,89832
202,BRD-K00004225,A-61603,"CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|",10804826.0,Preclinical,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,,,146|147
203,BRD-K78177893,A-674563,Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,11314340.0,Preclinical,AKT inhibitor,AKT1|PKIA|PRKACA,,,5569|5578|207
206,BRD-K87665527,A-784168,FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|,11420211.0,Preclinical,transient receptor potential channel antagonist,TRPV1,,,7442
207,BRD-K28570407,A-803467,COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1,16038374.0,Preclinical,sodium channel blocker,SCN10A,,,6336
208,BRD-K94313941,A-804598,C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1,53325874.0,Preclinical,purinergic receptor antagonist,P2RX7,,,5027
209,BRD-K76894955,A-804598,C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1,53325874.0,Preclinical,purinergic receptor antagonist,P2RX7,,,5027
210,BRD-K60427831,A-839977,Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1,53325875.0,Preclinical,purinergic receptor antagonist,P2RX7,,,5027
211,BRD-K33059059,A-867744,CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O,23642319.0,Preclinical,acetylcholine receptor allosteric modulator,CHRNA3|CHRNA4|CHRNA7,,,1136|1137|89832
212,BRD-K20239555,A-887826,CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1,46919335.0,Preclinical,sodium channel blocker,SCN10A,,,6336
213,BRD-K81614372,A-922500,OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1,24768261.0,Preclinical,diacylglycerol O acyltransferase inhibitor,DGAT1,,,8694
214,BRD-K99308908,A-939572,CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1,24905400.0,Preclinical,stearoyl-CoA desaturase inhibitor,SCD,,,6319
215,BRD-K70744942,A-967079,CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1,42641861.0,Preclinical,transient receptor potential channel antagonist,TRPA1,,,8989
216,BRD-K68982262,A-987306,Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|,25109291.0,Preclinical,histamine receptor antagonist,ADORA1|AVPR1A|CCR1|CHRM1|CHRM2|CHRM3|CHRM4|DRD3|HTR1A|HTR1B|HTR2A|HTR2B|HTR3A|TACR2,,,134|552|1129|1128|1131|1132|1230|6865|106480180|3356|1814|3350|3351|3359
218,BRD-A30000356,A12B4C3,"CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|",,Preclinical,polynucleotide kinase/phosphatase inhibitor,PNKP,,,11284
219,BRD-K77627880,A205804,Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1,9839311.0,Preclinical,ICAM1 expression inhibitor,ICAM1|SELE,,,6401|3383
220,BRD-A83650191,A61603,"CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|",6604803.0,Preclinical,adrenergic receptor agonist,ADRA1A,,,146
221,BRD-K49055432,A66,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C,42636535.0,Preclinical,PI3K inhibitor,PIK3CA,,,5290
222,BRD-A78952587,A740003,"COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|",98050091.0,Preclinical,purinergic receptor antagonist,P2RX7,,,5027
223,BRD-K72226571,A77636,NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2,,Preclinical,dopamine receptor agonist,CALY,,,50632
224,BRD-K28861668,A922500,OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1,24768273.0,Preclinical,diacylglycerol O acyltransferase inhibitor,DGAT1,,,8694
225,BRD-K13944729,AA-29504,CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N,23188887.0,Preclinical,GABA receptor positive allosteric modulator,GABRA1|GABRA4|GABRB3,,,2554|2562|2557
230,BRD-K00004970,abamectin,"[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,54,t:6,37,64|",6858005.0,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2,infectious disease,gastrointestinal parasites,9568|10537
231,BRD-K65498798,abametapir,Cc1ccc(nc1)-c1ccc(C)cn1,15664.0,Phase 3,metalloproteinase inhibitor,MMP9,,,4318
232,BRD-K00003158,abarelix,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,16131215.0,Phase 3,gonadotropin releasing factor hormone receptor antagonist,GNRHR,,,2798
234,BRD-K01825984,ABC-294640,"Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|",,Phase 2,sphingosine kinase inhibitor,SPHK2,,,56848
235,BRD-K33622447,abemaciclib,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,46220502.0,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer,1019|1021
236,BRD-K50071428,abiraterone,"C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|",132971.0,Launched,androgen biosynthesis inhibitor,CYP11B1|CYP17A1,oncology,prostate cancer,1584|1586
237,BRD-K24048528,abiraterone-acetate,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|",9821849.0,Launched,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,1586
240,BRD-K22749967,ABT-239,C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N,9818903.0,Phase 1,histamine receptor antagonist,HRH1|HRH2|HRH3,,,1665|3269|11255
241,BRD-K97233161,ABT-491,CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C,154087.0,Phase 1,platelet activating factor receptor antagonist,PTAFR,,,5724
242,BRD-K11792081,ABT-639,Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F,46851313.0,Phase 2,calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,,,8912|8913|150350
243,BRD-K36021395,ABT-702,Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1,1973.0,Preclinical,adenosine kinase inhibitor,ADK,,,132
244,BRD-K37714784,ABT-724,C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1,5025739.0,Phase 2,dopamine receptor agonist,DRD4,,,1815
245,BRD-K56301217,ABT-737,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1,11228183.0,Phase 1/Phase 2,BCL inhibitor,BCL2|BCL2L1|BCL2L2,,,596|598|599
246,BRD-K91623615,ABT-751,COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1,3035714.0,Phase 2,tubulin polymerization inhibitor,TUBB,,,7280
249,BRD-K53788420,AC-186,Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F,71245042.0,Preclinical,estrogen receptor agonist,ESR2,,,2100
250,BRD-K31144453,AC-261066,CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1,11530459.0,Preclinical,retinoid receptor agonist,RARB,,,5915
251,BRD-K81548480,AC-264613,C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1,25108278.0,Preclinical,PAR agonist,F2RL1,,,2150
252,BRD-A27911617,AC-55541,"C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|",129362181.0,Preclinical,PARP inhibitor,PARP2,,,10038
253,BRD-K93176058,AC-55649,CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O,1714884.0,Preclinical,retinoid receptor agonist,RARA|RARB,,,5914|5915
254,BRD-K15819326,AC-710,CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1,54760053.0,Preclinical,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB,,,5156|5159|3815|2322|1436
255,BRD-A49544621,AC-7954-(+/-),CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|,10937426.0,Preclinical,urotensin receptor agonist,UTS2R,,,2837
259,BRD-K64034691,acalabrutinib,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12,71226662.0,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BTK,hematologic malignancy,mantle cell lymphoma (MCL),695
260,BRD-K92517771,acalisib,C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,11618268.0,Phase 1,PI3K inhibitor,PIK3CB|PIK3CD,,,5291|22883
261,BRD-K26262077,acamprosate,CC(=O)NCCCS(O)(=O)=O,71158.0,Launched,glutamate receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM5,neurology/psychiatry,abstinence from alcohol,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|2903|2904|2905|2906|116443|116444|114787|2915|2554|2555|2556|2557|2558|2559
262,BRD-K44276885,acarbose,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|,444254.0,Launched,glucosidase inhibitor,AMY2A|MGAM,endocrinology,diabetes mellitus,8972|279
263,BRD-K68633617,ACDPP,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,16759169.0,Preclinical,glutamate receptor antagonist,GRM5,,,2915
265,BRD-A29260609,acebutolol,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O,657184.0,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension|ventricular arrhythmias,153
266,BRD-K07753030,acecainide,CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1,4342.0,Phase 3,polarization inhibitor,SCN5A,,,6331
267,BRD-K01825000,aceclidine,"CC(=O)O[C@H]1CN2CCC1CC2 |&1:4,r|",1273944.0,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,ophthalmology,glaucoma,1128|1129|1131|1132|1133
268,BRD-K68538666,aceclofenac,OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,71771.0,Launched,prostanoid receptor antagonist,PTGS2,rheumatology,rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|periarthritis|lumbago|ischiadynia,5743
271,BRD-K44004064,acefylline,Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O,69550.0,Launched,adenosine receptor agonist,ADORA1,pulmonary,asthma,134
274,BRD-K67563174,acemetacin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1,1981.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis,5742|5743
275,BRD-K36262466,aceneuramic-acid,CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O,445063.0,Phase 3,,CES1|SELE|SELP,,,6401|1066|6414
276,BRD-A65051990,acenocoumarol,"CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|",54683745.0,Launched,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),79001
277,BRD-K37814297,acepromazine,CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O,6077.0,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,sedative,146|147|1812|1813|3350|3356
281,BRD-K43457670,acetazolamide,CC(=O)Nc1nnc(s1)S(N)(=O)=O,1986.0,Launched,carbonic anhydrase inhibitor,AQP1|CA1|CA12|CA14|CA2|CA3|CA4|CA7,ophthalmology,glaucoma,771|23632|84182|759|760|761|762|766
282,BRD-K52960356,acetohexamide,CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,1989.0,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ10|KCNJ11,endocrinology,diabetes mellitus,6833|3766|3758|3767
283,BRD-K21615095,acetohydroxamic-acid,CC(=O)NO,1990.0,Launched,urease inhibitor,MMP12,infectious disease,urinary tract infections,4321
284,BRD-K42938903,acetophenazine,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,17676.0,Launched,dopamine receptor antagonist,DRD1|DRD2,neurology/psychiatry,psychosis,1812|1813
286,BRD-A44696962,acetyl-11-keto-beta-boswellic-acid,"C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|",,Phase 2,lipoxygenase inhibitor,HSD11B1|HSD11B2,,,3290|3291
287,BRD-K79437791,acetyl-farnesyl-cysteine,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O,6438381.0,Launched,methyltransferase inhibitor,PPARG,dermatology,acne vulgaris (AV),5468
289,BRD-K82381502,acetylcholine,CC(=O)OCC[N+](C)(C)C,187.0,Launched,acetylcholine receptor agonist,ACHE|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2,neurology/psychiatry|gastroenterology|pulmonary,drowsiness|fatigue|headache|indigestion|chest congestion,1128|1129|43|1132|1131|1133|1135
290,BRD-K59058747,acetylcysteine,CC(=O)N[C@@H](CS)C(O)=O,12035.0,Launched,mucolytic agent,ACY1|CHUK|GRIN1|GRIN2A|GRIN2B|GRIN2D|GRIN3A|GSS|IKBKB|RELA|SLC7A11,gastroenterology,acetaminophen overdose|hepatic injury,114787|3551|682|5970|5621|2903|2904|2906|1147|116443|95
293,BRD-K72215350,acexamic-acid,CC(=O)NCCCCCC(O)=O,2005.0,Launched,5 alpha reductase inhibitor,GAST,dermatology,wound healing,2520
294,BRD-A29520968,acifran,"C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|",76969700.0,Phase 3,cholesterol inhibitor,HCAR2|HCAR3,,,338442|8843
295,BRD-K63736853,acipimox,Cc1cnc(c[n+]1[O-])C(O)=O,5310993.0,Launched,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,338442
297,BRD-K62012036,acitretin,COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C,5284513.0,Launched,retinoid receptor agonist,RARA|RARB|RARG|RBP1|RXRA|RXRB|RXRG|STAT3,dermatology,psoriasis,5926|6256|6257|6258|6774|5914|5915|5916
298,BRD-K13050541,acivicin,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|,16758175.0,Phase 2,gamma glutamyltransferase inhibitor,CTPS1,,,1503
299,BRD-K31965398,aclarubicin,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC,86289437.0,Launched,topoisomerase inhibitor,TOP1|TOP2A,hematologic malignancy,acute myeloid leukemia (AML),7153|7150
300,BRD-K74363950,aclidinium,OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1,11434515.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,pulmonary,bronchitis|emphysema|chronic obstructive pulmonary disease (COPD),1128|1129|1131|1132|1133
304,BRD-M87138257,acriflavine,Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12,452192.0,Launched,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection,3091
305,BRD-K97874492,acriflavinium,C[n+]1c2cc(N)ccc2cc2ccc(N)cc12,2016.0,Launched,hypoxia inducible factor inhibitor,HIF1A,infectious disease,fungal infection,3091
307,BRD-K50163129,acrivastine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1,5284514.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269
309,BRD-K34843150,ACT-132577,NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,25099191.0,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH),1909|1910
310,BRD-K19781342,ACT-462206,COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1,40924317.0,Phase 1,orexin receptor antagonist,HCRTR1|HCRTR2,,,131450|3061
312,BRD-K35936936,ACTB-1003,COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1,23653175.0,Phase 1,FGFR inhibitor|VEGFR inhibitor,KDR|TEK,,,7010|3791
316,BRD-K82928847,ACY-1215,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,53340666.0,Phase 1/Phase 2,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC6|HDAC8,,,55869|8841|3065|3066|10013
317,BRD-K32318651,acyclovir,Nc1nc(=O)c2ncn(COCCO)c2[nH]1,135398513.0,Launched,DNA polymerase inhibitor,PNP,infectious disease,genitial herpes|shingles|chicken pox,5539
318,BRD-A80280426,AD-5467,"CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|",6933882.0,Phase 2,aldose reductase inhibitor,AKR1B1,,,231
319,BRD-K33127281,adapalene,COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O,60164.0,Launched,retinoid receptor agonist,RARA|RARB|RARG|RXRA|RXRB|RXRG,dermatology,acne vulgaris (AV),6256|6257|6258|5914|5915|5916
320,BRD-A73427433,adaprev,"O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|",439284.0,Phase 3,TGF beta receptor inhibitor,AKR1B1|GPI|HK1|M6PR|PYGM,,,231|4074|5837|10007|3098
321,BRD-K37151368,adaptavir,C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O,184644.0,Phase 2,CC chemokine receptor antagonist,CCR5,,,1234
322,BRD-K00152668,adarotene,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,9864378.0,Phase 1,retinoid receptor agonist,RARB|RARG,,,5915|5916
323,BRD-K67789209,adatanserin,O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2,130918.0,Phase 2,serotonin receptor agonist|serotonin receptor antagonist,HTR1A|HTR2A,,,3356|3350
330,BRD-K26060080,adenine,Nc1ncnc2nc[nH]c12,190.0,Preclinical,protein synthesis stimulant,ACACB|ACP1|APRT|MTAP|PECR|SRPK2,,,32|353|4706|6733|55825|4507
331,BRD-K01577834,adenosine,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,60961.0,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3|PI4K2A|PI4K2B|TRPM4,cardiology,Wolff-Parkinson-White Syndrome (WPW),55361|55300|134|135|136|54795|140
332,BRD-K85767870,adenosine-phosphate,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,6083.0,Launched,adenosine receptor agonist,ACSL1|ACSS1|ACSS2|ADCY1|ADK|CREB1|FBP1|HINT1|PDE4B|PDE4D|PIM1|PRKAA1|PRKAB1|PRKAB2|PYGL|TRPM4,,,2180|132|1385|107|5836|54795|9361|84532|3094|5142|5144|5562|2203|5564|5565|55902
333,BRD-K00003709,adenosine-triphosphate,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,5957.0,Phase 2,adenosine receptor agonist,ABCA1|ABCB1|ABCB11|ABCC2|ABCC8|ABCC9|ABCG1|ABL1|ABL2|ACSL1|ACSS1|ACSS2|ACVR1|ACVR1B|ACVRL1|ADCY1|ADRBK1|ADRBK2|AFG3L2|AKT1|ALK|AMHR2|APAF1|ARAF|ASNA1|ASNS|ASS1|CDK15|GPR17|ITPR1|NAE1|NT5C2|P2RY1|P2RY11|P2RY13|P2RY2|P2RY4|PRKAA1|RYR1|RYR2|RYR3|SLC25A4|TNK2|TRPM4|TRPM7,,,2180|54795|269|19|9619|2840|25|27|156|157|291|5028|65061|5029|5030|54822|6833|8883|84532|439|440|5562|10939|317|445|22978|53829|8647|10060|10188|207|692312|90|91|1244|94|55902|107|238|369|6261|6262|6263|5243|3708
334,BRD-K60907894,adiphenine,CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1,2031.0,Launched,acetylcholine receptor antagonist,CHRNA1,neurology/psychiatry,spasms,1134
335,BRD-K10656395,adipic-acid,OC(=O)CCCCC(O)=O,22494954.0,Preclinical,solute carrier family member inhibitor,SLC22A6,,,9356
336,BRD-K68810443,adiporon,O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1,16307093.0,Preclinical,adiponectin receptor agonist,ADIPOR1|ADIPOR2,,,79602|51094
337,BRD-K39624409,ADL5859,CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|,11417954.0,Phase 2,opioid receptor agonist,OPRD1,,,4985
339,BRD-K34870043,adoprazine,Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1,9887537.0,Phase 2,dopamine receptor antagonist|serotonin receptor agonist,DRD2|HTR1A,,,1813|3350
341,BRD-K82343404,adrenalone,CNCC(=O)c1ccc(O)c(O)c1,7436.0,Launched,adrenergic receptor agonist,ADRA1A,hematology,hemorrhage,146
342,BRD-K17368287,adrenosterone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|,223997.0,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1|HSD11B2,,,3290|3291
343,BRD-K77911775,ADX-10059,Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1,10331863.0,Phase 2,glutamate receptor negative allosteric modulator,GRM5,,,2915
344,BRD-K56543881,ADX-47273,Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1,11383075.0,Preclinical,glutamate receptor modulator,GRM5,,,2915
345,BRD-K40718343,AEE788,CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1,10297043.0,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR,,,1956|3791|2064|2066|2261|2263
347,BRD-K47816470,AF38469,Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1,72706115.0,Preclinical,sortilin inhibitor,SORT1,,,6272
348,BRD-K53205568,afalanine,CC(=O)N[C@@H](Cc1ccccc1)C(O)=O,74839.0,Phase 3,dopamine receptor agonist,DRD2,,,1813
350,BRD-K66175015,afatinib,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,10184653.0,Launched,EGFR inhibitor,EGFR|ERBB2|ERBB4,oncology,non-small cell lung cancer (NSCLC),2064|2066|1956
351,BRD-K04210847,afimoxifene,CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,449459.0,Phase 2,estrogen receptor antagonist,ESR1|ESR2|ESRRG|PLD1|PRKCD|PRKCE|PRKCQ|PRKCZ,,,5580|5581|2099|2100|5589|5588|5590|2104
355,BRD-K08310154,AG-1024,CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O,2044.0,Preclinical,insulin growth factor receptor inhibitor,IGF1R,,,3480
356,BRD-K00615600,AG-14361,CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23,9840076.0,Preclinical,PARP inhibitor,PARP1,,,142
357,BRD-K47105409,AG-490,Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O,5328779.0,Preclinical,EGFR inhibitor|JAK inhibitor,EGFR|JAK2|JAK3,,,1956|3717|3718
358,BRD-K34428485,AG-555,Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O,5328770.0,Preclinical,tyrosine kinase inhibitor,CDK2,,,1017
360,BRD-A56371469,AGI-5198,"Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|",97161269.0,Preclinical,isocitrate dehydrogenase inhibitor,IDH1,,,3417
361,BRD-K04691817,AGI-6780,FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1,71299339.0,Preclinical,isocitrate dehydrogenase inhibitor,IDH2,,,3418
362,BRD-A78111609,AGM-1470,"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|",14942882.0,Phase 2,cell cycle inhibitor,METAP2,,,10988
363,BRD-K49738308,agmatine,NCCCCNC(N)=N,199.0,Phase 3,nitric oxide synthase inhibitor,ADRA2C|ASIC3|CACNA1B|CHRNA1|GRIN1|KCNJ1|NISCH,,,114787|774|1134|3758|11188|152|9311
364,BRD-A18074780,AGN-192403,"CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|",124581813.0,Preclinical,imidazoline receptor ligand,NISCH,,,11188
365,BRD-K70262971,AGN-194310,CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|,9867046.0,Phase 3,retinoid receptor antagonist,RXRA|RXRB|RXRG,,,6256|6257|6258
366,BRD-K32533226,AGN-195183,CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1,9867758.0,Phase 1/Phase 2,retinoid receptor agonist,RARA,,,5914
367,BRD-K84698278,agomelatine,COc1ccc2cccc(CCNC(C)=O)c2c1,82148.0,Launched,melatonin receptor agonist|serotonin receptor antagonist,HTR2A|HTR2B|HTR2C|MTNR1A|MTNR1B,neurology/psychiatry,depression,4544|106480180|3356|3358|4543
369,BRD-K10852420,AH-7614,Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12,233085.0,Preclinical,free fatty acid receptor antagonist,FFAR4,,,338557
370,BRD-A64808605,AH11110,O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|,6604792.0,Preclinical,adrenergic receptor ligand,ADRA1B,,,147
371,BRD-K59339270,AH6809,CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O,119461.0,Preclinical,prostanoid receptor antagonist,PTGDR|PTGER1|PTGER2|PTGER3,,,5729|5731|5732|5733
372,BRD-K89899948,AI-10-49,FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1,49806644.0,Preclinical,core binding factor inhibitor,CBFB,,,865
373,BRD-K85139301,AIM-100,C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1,11501591.0,Preclinical,tyrosine kinase inhibitor,TNK2,,,10188
374,BRD-K76677554,AJ76-(+),CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C,122334.0,Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4,,,1813|1814|1815
376,BRD-K09143580,AK-7,Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1,1328033.0,Preclinical,SIRT inhibitor,SIRT2,,,22933
377,BRD-K54907283,AKBA,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|,11168203.0,Phase 3,lipoxygenase inhibitor,ALOX5,,,240
379,BRD-K44731351,AL-8697,Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1,25060093.0,Preclinical,p38 MAPK inhibitor,MAPK14,,,1432
380,BRD-K51784806,alacepril,C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O,71992.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636
385,BRD-K53731810,alantolactone,C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|,72724.0,Preclinical,apoptosis stimulant|STAT inhibitor,STAT3,,,6774
386,BRD-K01826783,alaproclate,C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|,23622192.0,Phase 2,serotonin receptor antagonist,SLC6A4,,,6532
387,BRD-K42140276,alarelin,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,9855027.0,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRH1,,,2796
388,BRD-K79131256,albendazole,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,2082.0,Launched,tubulin polymerization inhibitor,TUBA1A|TUBB|TUBB4B,infectious disease,cystic hydatid disease|parenchymal neurocysticercosis,7280|7846|10383
390,BRD-K01825118,albuterol,CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|,182176.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154
391,BRD-K55991142,alcaftadine,CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12,19371515.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic conjunctivitis,3269
392,BRD-K47492008,alclofenac,OC(=O)Cc1ccc(OCC=C)c(Cl)c1,30951.0,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis,5742
393,BRD-A17407635,alclometasone-dipropionate,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|",,Launched,glucocorticoid receptor agonist,CYP3A4|NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses,1576|866|2908
394,BRD-A84907376,alcuronium,"OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5,11,12,14,29,31,32,35,&1:18,&2:22,c:21,t:17,TLB:2:3:13:11.15.22,20:19:30:35.39.40,10:11:3.4.5:13,41:40:30:18.19.32,28:11:3.4.5:13,THB:34:35:30:18.19.32,16:15:3.4.5:13,33:32:30:35.39.40,36:35:30:18.19.32,6:5:13:11.15.22,9:5:13:11.15.22,44:32:30:35.39.40|",,Launched,muscle relaxant,CHRM1|CHRM2|CHRM3|CHRM4|CHRNA7,neurology/psychiatry,muscle relaxant,1128|1129|89832|1131|1132
395,BRD-K06890060,alda-1,Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1,831629.0,Preclinical,aldehyde dehydrogenase activator,ALDH2,,,217
396,BRD-K68928792,aldoxorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|,9810709.0,Phase 3,topoisomerase inhibitor,TOP2A,,,7153
397,BRD-K11267252,alectinib,CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1,49806720.0,Launched,ALK tyrosine kinase receptor inhibitor,ALK|MET,oncology,non-small cell lung cancer (NSCLC),8731|238
398,BRD-K75527158,alendronate,NCCCC(O)(P(O)(O)=O)P(O)(O)=O,44400013.0,Launched,bone resorption inhibitor,ATP6V1A|FDPS|PTPN4|PTPRE|PTPRS,orthopedics,osteoporosis,5802|523|5775|2224|5791
399,BRD-A42335949,alexidine,"CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|",40488318.0,Preclinical,phosphatidylglycerophosphatase inhibitor,PTPMT1,,,114971
400,BRD-K49522529,alfacalcidol,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5282181.0,Launched,vitamin D receptor agonist,CYP27B1|VDR,endocrinology,vitamin D deficiency,1594
402,BRD-K01826519,alfuzosin,COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|,37888195.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,urology,benign prostatic hyperplasia (BPH),6336|11280|146|147|6323|6326|6328|6329|6331|6332|6334|6335
405,BRD-K01827280,alimemazine,C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|,6604496.0,Launched,histamine receptor agonist|histamine receptor antagonist,HRH1,neurology/psychiatry|allergy|pulmonary,sedative|urticaria|itching|cough suppressant,3269
407,BRD-K75295174,alisertib,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|,24771867.0,Phase 3,Aurora kinase inhibitor,AURKA,,,6790
408,BRD-K30020243,aliskiren-hemifumarate,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC,5493444.0,Launched,renin inhibitor,REN,cardiology,hypertension,147040
413,BRD-A60402836,allicin,"C=CCS[S@@](=O)CC=C |&1:4,r|",51399529.0,Phase 2,cytokine production inhibitor,TRPA1|TRPV1,,,7442|8989
414,BRD-K86307448,allopurinol,O=c1nc[nH]c2n[nH]cc12,135401907.0,Launched,xanthine oxidase inhibitor,XDH,rheumatology|urology,gout|kidney stones,6652
417,BRD-K12872829,allylestrenol,C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|,235905.0,Launched,steroidal progestin,ESR1|PGR|SLC6A9,obstetrics/gynecology,premature labor,6536|5241|2099
418,BRD-K33219225,allylisothiocyanate,C=CCN=C=S,5971.0,Preclinical,TRPV agonist,TRPA1,,,8989
420,BRD-K82677201,almitrine,Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1,33887.0,Launched,neurotransmitter agonist,ATP1A1,pulmonary,chronic obstructive pulmonary disease (COPD),476
421,BRD-K84810405,almorexant,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,23727689.0,Phase 3,orexin receptor antagonist,HCRTR1|HCRTR2,,,131450|3061
422,BRD-K67601717,almotriptan,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,123606.0,Launched,serotonin receptor agonist,HTR1B|HTR1D,neurology/psychiatry,migraine headache,3352|3351
423,BRD-K04851519,aloe-emodin,OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,10207.0,Preclinical,anticancer agent,CASP8,,,841
424,BRD-K83003151,alogliptin,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,11450633.0,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
427,BRD-K46742498,alosetron,Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C,2099.0,Withdrawn,serotonin receptor antagonist,HTR3A,,,3359
429,BRD-K91188791,aloxistatin,CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C,65663.0,Phase 3,protease inhibitor,CTSG,,,1511
430,BRD-K54997624,alpelisib,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,56649450.0,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,oncology,breast cancer,5290|5291|5294|22883
431,BRD-K72536715,alpha-asarone,COc1cc(OC)c(\C=C\C)cc1OC,636822.0,Preclinical,cytochrome P450 inhibitor|HMGCR inhibitor,HMGCR,,,3156
434,BRD-K33396764,alpha-linolenic-acid,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O,5280934.0,Phase 3,omega 3 fatty acid stimulant,ELOVL4|FADS1|FADS2|FFAR1|FFAR4|PTGS2|SLC8A1|TRPV1,,,6785|5743|2864|4593|6546|7442|5913|338557
435,BRD-K80028314,alpha-methylhistamine-dihydrobromide-(R)-(-),C[C@@H](N)Cc1cnc[nH]1,156615.0,Preclinical,histamine receptor agonist,HRH3,,,11255
436,BRD-K28308851,alpha-methylhistamine-dihydrobromide-(S)-(+),C[C@H](N)Cc1cnc[nH]1,6603865.0,Preclinical,histamine receptor agonist,HRH3,,,11255
437,BRD-K01826806,alpha-methylserotonin,C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|,14083218.0,Preclinical,serotonin receptor agonist,HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR4,,,3360|106480180|3352|3354|3355|3356|3358
440,BRD-K66896751,alpidem,CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1,54897.0,Withdrawn,benzodiazepine receptor agonist,GABRA1,,,2554
441,BRD-K01825817,alprenolol,"CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|",203685.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology,angina pectoris,153|154
442,BRD-K52459643,alprostadil,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,5280723.0,Launched,prostanoid receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGER1|PTGER2|PTGER4|PTGIR,cardiology,congenital heart defects,5729|117155|5731|5732|5734|5739|347732|378807|117144
443,BRD-K35498378,alrestatin,OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23,2120.0,Preclinical,aldose reductase inhibitor,AKR1B1,,,231
446,BRD-K00610438,altanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,3033677.0,Phase 2,serotonin receptor antagonist,HTR2A,,,3356
448,BRD-K52681925,altinicline,CN1CCC[C@H]1c1cncc(c1)C#C,3036156.0,Phase 2,nicotinic receptor agonist,CHRNA4|CHRNB2,,,1137|1141
449,BRD-K78627070,altiratinib,Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1,54576299.0,Phase 1,MET inhibitor|VEGFR inhibitor,KDR|MET|TEK,,,7010|8731|3791
450,BRD-K50276048,altrenogest,"C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|",10041070.0,Launched,progestogen hormone,PGR,endocrinology,estrus,5241
452,BRD-K89055274,alverine,CCN(CCCc1ccccc1)CCCc1ccccc1,3678.0,Launched,muscle relaxant,HTR1A,gastroenterology,irritable bowel syndrome|diverticular disease,3350
453,BRD-K83988098,alvespimycin,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|",59996481.0,Phase 2,HSP inhibitor,HSP90AA1,,,3320
454,BRD-K07857022,alvimopan,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1,5488548.0,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,postoperative ileus,4985|4986|4988
455,BRD-K87909389,alvocidib,CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,5287969.0,Phase 2,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK6|CDK7|CDK8|CDK9|EGFR|PYGM,,,1024|1025|1956|5837|983|1017|1019|1020|1021|1022
457,BRD-K53979406,ALX-5407,CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O,86306255.0,Phase 1,glycine transporter inhibitor,SLC6A9,,,6536
458,BRD-A66116161,AM-1241,"CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|",23583507.0,Preclinical,cannabinoid receptor agonist,CNR1|CNR2,,,1268|56142
459,BRD-K59013864,AM-24,Oc1c(I)cc(I)cc1I,11862.0,Phase 2,lipoxygenase inhibitor,ALOX5,,,240
460,BRD-K92000912,AM-251,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,2125.0,Preclinical,cannabinoid receptor antagonist,CNR1|GPR18|GPR55,,,2841|9290|1268
461,BRD-K59419204,AM-281,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1,4302962.0,Preclinical,cannabinoid receptor antagonist,CNR1|CNR2|GPR55,,,9290|1268|56142
462,BRD-K55462201,AM-404,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,6604822.0,Preclinical,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,CNR1|CNR2|FAAH|TRPV1,,,79152|7442|1268|56142
463,BRD-K06854232,AM-580,CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O,2126.0,Preclinical,retinoid receptor agonist,RARA,,,5914
464,BRD-K63533170,AM-630,COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12,4302963.0,Preclinical,cannabinoid receptor antagonist,CNR1|CNR2,,,1268|56142
465,BRD-K01826811,AM-92016,CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|,6604771.0,Preclinical,potassium channel blocker,GRIN1,,,114787
468,BRD-K88443722,AM679,COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1,44627267.0,Preclinical,cannabinoid receptor agonist|lipoxygenase inhibitor,ALOX5AP|CNR1|CNR2,,,241|1268|56142
469,BRD-K70330367,amantadine,NC12CC3CC(CC(C3)C1)C2,2130.0,Launched,glutamate receptor antagonist,DRD2|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A,infectious disease|neurology/psychiatry,influenza A virus infection|Parkinson's Disease,1813|2903|2904|2905|2906|116443
471,BRD-K11292736,ambenonium,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl,2131.0,Launched,cholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,43
472,BRD-K41185545,ambrisentan,COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1,6918493.0,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH),1909|1910
473,BRD-K56558538,ambroxol,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|,,Launched,sodium channel blocker,CYP3A4,pulmonary,bronchitis,1576
475,BRD-A36010170,amcinonide,"CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|",40469418.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
476,BRD-K03019184,AMD-3465,C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1,483559.0,Preclinical,CC chemokine receptor antagonist,CXCR4,,,7852
477,BRD-K42948882,AMD11070,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12,11256587.0,Phase 3,CC chemokine receptor antagonist,CCR5|CXCR4,,,1234|7852
482,BRD-K51387999,amezinium,COc1cc(N)cn[n+]1-c1ccccc1,71927.0,Launched,adrenergic receptor agonist,ADRB2,cardiology,hypotension,154
483,BRD-K82122102,amfenac,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,2136.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
484,BRD-K50813454,amflutizole,Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O,54833.0,Phase 2,xanthine oxidase inhibitor,XDH,,,6652
486,BRD-K32285926,AMG-208,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,24864821.0,Phase 1,tyrosine kinase inhibitor,MET,,,8731
487,BRD-K64925568,AMG-232,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,58573469.0,Phase 2,MDM inhibitor,MDM2,,,4193
488,BRD-K21077415,AMG-319,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1,68947304.0,Phase 2,PI3K inhibitor,PIK3CD,,,22883
489,BRD-K27061362,AMG-337,COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1,44181686.0,Phase 2,MET inhibitor,MET,,,8731
491,BRD-A01307728,AMG-487-(+/-),"CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|",24957182.0,Phase 2,CC chemokine receptor antagonist,CXCR3,,,2833
493,BRD-K34185671,AMG-517,CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1,16007367.0,Phase 1,TRPV antagonist,TRPV1,,,7442
494,BRD-K86673452,AMG-548,Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,11167112.0,Phase 1,MAP kinase inhibitor,MAPK11|MAPK12|MAPK13|MAPK14,,,5600|5603|6300|1432
495,BRD-K43802723,AMG-837,CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1,46854655.0,Phase 1,free fatty acid receptor agonist,FFAR1,,,2864
496,BRD-K97452254,AMG-925,C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|,,Phase 1,CDK inhibitor|FLT3 inhibitor,CDK4|CDK6|FLT3,,,2322|1019|1021
497,BRD-K01995783,AMG-9810,CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1,680502.0,Preclinical,TRPV antagonist,TRPV1,,,7442
498,BRD-K04374714,AMG-PERK-44,Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N,86583045.0,Preclinical,PERK inhibitor,EIF2AK4,,,440275
499,BRD-A58947127,AMG319,"C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|",133547162.0,Phase 2,PI3K inhibitor,PIK3CD,,,22883
500,BRD-K21782625,AMG458,COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1,24764449.0,Preclinical,MET inhibitor,MET,,,8731
501,BRD-K21728777,AMG900,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,24856041.0,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,,6795|9212|6790
502,BRD-K75114721,AMI-1,Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O,67254.0,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT1,,,3276
503,BRD-K24610819,amibegron,CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1,3035442.0,Phase 3,adrenergic receptor agonist,ADRB3,,,155
506,BRD-A19401019,amiflamine,"C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|",6336525.0,Phase 1,monoamine oxidase inhibitor,MAOA|SLC6A2,,,4128|6530
507,BRD-K73947551,amifostine,NCCCNCCSP(O)(O)=O,29927142.0,Launched,reducing agent,ALPPL2|ENPP1,nephrology,renal toxicity,251|5167
509,BRD-K97181089,amiloride,NC(=N)NC(=O)c1nc(Cl)c(N)nc1N,16231.0,Launched,sodium channel blocker,AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2,cardiology,hypertension|congestive heart failure,6337|6338|6339|6340|7226|51393|40|41|25865|9033|5328|6548|26|9311
510,BRD-K24219278,amineptine,OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12,38988248.0,Withdrawn,dopamine receptor agonist,SLC6A2|SLC6A4,,,6530|6532
511,BRD-K64931368,aminocaproic-acid,NCCCCCC(O)=O,564.0,Launched,plasminogen activator inhibitor,LPA|PLAT|PLG,hematology,fibrinolytic bleeding,4018|5340|5327
512,BRD-A25234499,aminoglutethimide,"CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|",1548995.0,Launched,glucocorticoid receptor antagonist,CYP11A1|CYP19A1,endocrinology|oncology,Cushing's syndrome|breast cancer,1588|1583
513,BRD-K25114078,aminoguanidine,NN=C(N)N,2146.0,Phase 3,nitric oxide synthase inhibitor,AKR1B1|NOS2|TIMP3,,,339345|7078|231
516,BRD-A28318179,aminomethyltransferase,"C[C@H]1CCN=C(N)S1 |&1:1,t:4|",7059445.0,Preclinical,nitric oxide synthase inhibitor,NOS2,,,339345
517,BRD-A69917777,aminopentamide,CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C,176163.0,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,acute abdominal visceral spasm|hypertrophic gastritis (GHG)|nausea,1128
518,BRD-K97799481,aminophylline,Cn1c2nc[nH]c2c(=O)n(C)c1=O,2153.0,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary,asthma|bronchitis|emphysema,134|135|136|140|8654|5139|5140|5141|5142|5143|5144|3066
519,BRD-K87544030,aminopterin,Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,169371.0,Phase 3,dihydrofolate reductase inhibitor,DHFR|SLC46A1,,,113235|1719
520,BRD-K07762753,aminopurvalanol-a,CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1,6604931.0,Preclinical,CDK inhibitor|tyrosine kinase inhibitor,CDK1|CDK2|CDK5,,,1017|1020|983
521,BRD-K80267133,aminosalicylate,Nc1ccc(C(O)=O)c(O)c1,4649.0,Launched,cyclooxygenase inhibitor,ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2,gastroenterology,inflammatory bowel disease|ulcerative colitis,5742|5743|240|1147|30814
522,BRD-K94837153,aminothiadiazole,Nc1nncs1,19909.0,Phase 2,inosine monophosphate dehydrogenase inhibitor,ADORA3|IMPDH1,,,727833|140
523,BRD-K13421763,aminothiazole,Nc1nccs1,2155.0,Preclinical,cyclin D inhibitor,NOS2,,,339345
524,BRD-K17561142,amiodarone,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,2157.0,Launched,potassium channel blocker,ADRB1|CACNA1H|CACNA2D2|KCNA7|KCNH2,cardiology,ventricular arrhythmias,9254|3757|8912|153|3743
527,BRD-A60197193,amisulpride,"CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|",5746246.0,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,psychosis|bipolar disorder|schizophrenia,1813
528,BRD-A68942014,amitifadine,"Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|",11658655.0,Phase 3,serotonin transporter (SERT) inhibitor,SLC6A2|SLC6A3|SLC6A4,,,6530|6531|6532
529,BRD-K33335792,amitraz,CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C,,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A,infectious disease,generalized demodicosis,146|150
530,BRD-K53737926,amitriptyline,CN(C)CCC=C1c2ccccc2CCc2ccccc12,2160.0,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninânorepinephrine reuptake inhibitor (SNRI),ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression,1665|6530|6532|146|147|150|3350|3352|153|154|155|3356|3351|3358|3736|3362|3363|3751|3752|10280|4914|4915|3269|3785|3786|59340|1128|1129|1131|1132|1133|4985|4986|4988
531,BRD-K29530284,amlexanox,CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O,2161.0,Launched,histamine receptor modulator,FGF1|IL3|PDE4A|PDE4B|PDE4C|PDE4D|S100A12|S100A13,dental|pulmonary|ophthalmology|allergy,aphthous ulcers|asthma|conjunctivitis|allergic rhinitis,2246|3562|6283|6284|5141|5142|5143|5144
532,BRD-K01825117,amlodipine,"CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|",9801597.0,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNA2D1,cardiology,hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD),775|776|778|779|781
533,BRD-K83486494,ammonium-glycyrrhizinate,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|,14982.0,Launched,thrombin inhibitor,HSD11B1|HSD11B2|SLCO1B1|SLCO1B3,dermatology,cosmetic,3290|3291|28234|10599
534,BRD-M29182745,ammonium-lactate,"N.C[C@@H](O)C(O)=O |&1:2,r|",10313098.0,Launched,,HCAR1,dermatology,xerosis cutis|ichthyosis vulgaris,27198
535,BRD-K32531356,ammonium-perfluorocaprylate,OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,9554.0,Phase 1,Pim kinase inhibitor,PIM1,,,9361
536,BRD-K23335153,AMN-082,C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1,1894361.0,Preclinical,glutamate receptor modulator,GRM7,,,2917
537,BRD-K91290917,amodiaquine,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,3647519.0,Launched,histamine receptor agonist,HNMT,infectious disease,malaria,3176
538,BRD-K56334280,amonafide,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,50515.0,Phase 3,topoisomerase inhibitor,TOP2A|TOP2B,,,7153|7155
540,BRD-K02265150,amoxapine,Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|,2170.0,Launched,norepinephrine reputake inhibitor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH4|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,2560|2561|2562|2563|2564|2565|2566|2567|2568|6530|6531|6532|146|147|1812|1813|150|1815|1816|151|152|1814|3350|3351|3356|3358|3359|3362|3363|106480180|3269|55879|59340|1128|1129|1131|1132|1133|2554|2555|2556|2557|2558|2559
541,BRD-K55044200,amoxicillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O,40467057.0,Launched,penicillin binding protein inhibitor,CYP2C19|SLC15A1|SLC15A2|SLC22A6,infectious disease|gastroenterology,skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections,9356|6564|1557|6565
542,BRD-K01826817,AMPA-(RS),Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|,7059442.0,Preclinical,glutamate receptor agonist,GRIN1,,,114787
543,BRD-K92493880,AMPA-(S),Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O,7000183.0,Preclinical,glutamate receptor agonist,GRIA2|GRIN1,,,114787|2891
544,BRD-K24771047,ampalex,O=C(N1CCCCC1)c1ccc2nccnc2c1,148184.0,Phase 2,glutamate receptor agonist,GRIA1|GRIA2|GRIA3|GRIA4,,,2890|2891|2892|2893
545,BRD-K52397688,amperozide,CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,73333.0,Launched,dopamine receptor antagonist,FAAH|HTR2A,neurology/psychiatry,psychosis,79152|3356
548,BRD-A39172021,ampiroxicam,"CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|",25273583.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
552,BRD-K45924332,amrinone,Nc1cc(c[nH]c1=O)-c1ccncc1,3698.0,Launched,phosphodiesterase inhibitor,PDE3A|PDE3B|PDE4B|TNF,cardiology,congestive heart failure,5139|5140|5142|7124
553,BRD-K13843533,amrubicin,CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1,3035016.0,Launched,topoisomerase inhibitor,TOP2A|TOP2B,oncology,small cell lung cancer,7153|7155
554,BRD-K68346641,amsacrine,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,2179.0,Launched,topoisomerase inhibitor,KCNH2|TOP2A,hematologic malignancy,acute lymphoblastic leukemia (ALL),7153|3757
555,BRD-K39670393,amthamine,Cc1nc(N)sc1CCN,126688.0,Preclinical,histamine receptor agonist,HRH2,,,1665
556,BRD-K70924353,amtolmetin-guacil,COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C,65655.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743
557,BRD-K66538826,amuvatinib,S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12,11282283.0,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,KIT|MET,,,8731|3815
558,BRD-K03504028,amygdalin,OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,656516.0,Phase 2,caspase activator,CASP3,,,836
564,BRD-A19609491,ANA-12,"O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|",6977265.0,Preclinical,tropomyosin receptor kinase inhibitor,NTRK2,,,4915
566,BRD-K77118600,anacetrapib,COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C,11556427.0,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,,1071
567,BRD-K05355328,anagliptin,Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N,44513473.0,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
568,BRD-K62200014,anagrelide,Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|,135409400.0,Launched,phosphodiesterase inhibitor,PDE3A,hematology|hematologic malignancy,thrombocythemia|myeloproliferative neoplasms,5139
569,BRD-K01174345,anamorelin,CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N,9828911.0,Phase 3,growth hormone secretagogue receptor agonist,GHSR,,,2693
570,BRD-K42352790,anandamide,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO,5281969.0,Phase 2,cannabinoid receptor agonist,CACNA1G|CACNA1H|CACNA1I|CNR1|CNR2|GLRA1|GPR18|GPR55|KCNA2|KCNK3|KCNK9|TRPM8|TRPV1,,,3777|51305|9290|150350|56142|8912|8913|3737|79054|1268|2741|7442|2841
571,BRD-K52172416,anastrozole,CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N,2187.0,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer,1588
572,BRD-K82164249,andarine,CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1,9824562.0,Phase 1,androgen receptor modulator,AR,,,367
573,BRD-K89282837,andrographolide,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12,5318517.0,Phase 2,tumor necrosis factor production inhibitor,IL1B|IL6|NFKB1|NFKB2|TNF,,,3553|3569|7124|4790|4791
579,BRD-K45724504,anguidine,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|,91518.0,Phase 2,protein synthesis inhibitor,SLC5A1,,,6523
581,BRD-K88611939,aniracetam,COc1ccc(cc1)C(=O)N1CCCC1=O,2196.0,Launched,glutamate receptor agonist,DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A,,,2890|2891|2892|2893|1813|3356
582,BRD-K47458712,anisindione,COc1ccc(cc1)C1C(=O)c2ccccc2C1=O,2197.0,Launched,vitamin K antagonist,GGCX,hematology,deep vein thrombosis (DVT),2677
583,BRD-A29623586,anisodamine,"CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|",,Phase 3,lipid peroxidase inhibitor,ADRA1A,,,146
584,BRD-K91370081,anisomycin,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,253602.0,Preclinical,DNA synthesis inhibitor,NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1,,,23521|140801|6147|9349|4809|6122|51121|51187|6167|6132|6135|6138|6143
586,BRD-K36949735,anlotinib,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,25017411.0,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR|PDGFRB,,,5159|3791
587,BRD-K55424922,anpirtoline,Clc1cccc(SC2CCNCC2)n1,65854.0,Phase 1,serotonin receptor agonist,HTR1B,,,3351
588,BRD-K31170746,ANR-94,CCOc1nc2c(N)ncnc2n1CC,11805896.0,Preclinical,adenosine receptor antagonist,ADORA2A,,,135
590,BRD-K25863791,antagonist-g,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O,163960.0,Phase 1,neuropeptide receptor antagonist,MAPK8,,,5599
591,BRD-K01363385,antalarmin,CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C,177990.0,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,,1394
592,BRD-K99300445,antazoline,C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|,2200.0,Launched,antihistamine,HRH1,ophthalmology|otolaryngology,conjunctivitis|nasal congestion,3269
594,BRD-K15957397,anthraquinone,O=C1c2ccccc2C(=O)c2ccccc12,6780.0,Preclinical,CDC inhibitor,CDC25B,,,994
597,BRD-K90152265,antimycin-A,CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O,14957.0,Preclinical,ATP synthase inhibitor,CYCS,,,54205
599,BRD-K32143970,AP-18,C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O,9584673.0,Preclinical,transient receptor potential channel antagonist,TRPA1,,,8989
600,BRD-K28383148,AP1903,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,16135625.0,Phase 1/Phase 2,,MTOR,,,2475
601,BRD-K56032964,AP26113,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,57390074.0,Phase 2,ALK tyrosine kinase receptor inhibitor,ALK|EGFR,,,1956|238
602,BRD-K20001883,apabetalone,COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1,135564749.0,Phase 3,apolipoprotein expression enhancer,BRD3,,,8019
603,BRD-K28115081,apafant,Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|,65889.0,Phase 3,platelet activating factor receptor antagonist,PTAFR,,,5724
606,BRD-K25244359,apatinib,O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1,11315474.0,Phase 3,RET tyrosine kinase inhibitor,CSK|KDR|KIT|RET,,,5979|3815|1445|3791
607,BRD-K07449869,APC-100,Cc1c(C)c2OC(C)(C)CCc2c(C)c1O,99479.0,Phase 1/Phase 2,androgen receptor antagonist|anti-inflammatory agent,AR,,,367
608,BRD-K72748448,APcK-110,COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1,24786010.0,Preclinical,KIT inhibitor,KIT|STAT3,,,6774|3815
609,BRD-K86226872,APD597,COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C,11691484.0,Phase 1,glucose dependent insulinotropic receptor agonist,GPR119,,,139760
610,BRD-K10859802,APD668,CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O,11705608.0,Phase 1,glucose dependent insulinotropic receptor agonist,GPR119,,,139760
612,BRD-K26325692,API-001,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,44247568.0,Phase 2,sigma receptor antagonist,SIGMAR1,,,10280
613,BRD-K97840621,API-1,NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O,24773090.0,Preclinical,AKT inhibitor,AKT1|AKT2|AKT3,,,208|10000|207
614,BRD-K01493881,apigenin,Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1,5280443.0,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,AKR1B1|AR|CDK6|CFTR|CYP19A1|CYP1B1|HSD17B1,,,231|1545|367|1588|1080|3292|1021
615,BRD-K67121414,apixaban,COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O,10182969.0,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT),2159
616,BRD-K64990520,apocynin,COc1cc(ccc1O)C(C)=O,2214.0,Phase 1,NADPH oxidase inhibitor,NOX4,,,50507
617,BRD-K15164005,apoptosis-activator-II,Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl,1901244.0,Preclinical,carboxylesterase inhibitor,BCHE|CES1,,,1066|590
618,BRD-A09004963,APR-246,"COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|",76965201.0,Phase 3,p53 activator,TP53,,,7157
619,BRD-K38911213,apraclonidine,Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|,2216.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C,ophthalmology,glaucoma|intraocular pressure,152|146|150|151
621,BRD-K06883221,apratastat,CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1,11452716.0,Phase 2,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,ADAM17|MMP1|MMP13|MMP9,,,4312|4322|6868|4318
622,BRD-K93208532,apremilast,CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O,11561674.0,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,dermatology|rheumatology,psoriasis|psoriatic arthritis,5144|5141|5142|5143
623,BRD-K52827117,aprepitant,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,135413536.0,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting,6869
625,BRD-K53236343,aprindine,CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1,2218.0,Launched,voltage-gated sodium channel blocker,CALM1|SCN5A,cardiology,cardiac arrythmia,801|6331
627,BRD-K63919159,aptiganel,CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12,60840.0,Phase 3,glutamate receptor antagonist,GRIN1,,,114787
628,BRD-K68003372,APTO-253,Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21,11960271.0,Phase 1,krÃ¼ppel-like factor expression enhancer,KLF4,,,9314
629,BRD-K17511755,APY-29,C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1,42627755.0,Preclinical,serine/threonine kinase inhibitor,ERN1,,,2081
630,BRD-K38627885,APY0201,Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1,56927660.0,Preclinical,phosphoinositide dependent kinase inhibitor,IL12A|IL12B|PIKFYVE,,,3592|3593|200576
633,BRD-K81729199,AQ-RA741,CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,129989.0,Preclinical,acetylcholine receptor antagonist,CHRM2,,,1129
635,BRD-K90497590,AR-12,NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F,10027278.0,Phase 1,phosphoinositide dependent kinase inhibitor,PDPK1,,,5170
636,BRD-K13167095,AR-42,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,6918848.0,Phase 1,HDAC inhibitor,HDAC1,,,3065
637,BRD-K67860401,AR-A014418,COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1,448014.0,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,,2932
638,BRD-K42325600,AR-C155858,CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O,10226546.0,Preclinical,monocarboxylate transporter inhibitor,SLC16A1|SLC16A7,,,9194|6566
639,BRD-K03070961,arachidonic-acid,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,444899.0,Phase 1,cytochrome P450 inhibitor,CLCN2|KCNJ4|KCNK10|KCNK18|KCNK2|PRKCZ|PTGS1|TRPC6|TRPM2,,,3776|338567|1191|5742|3761|5590|7225|1181|54207
641,BRD-K73881242,arbidol,CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12,28446253.0,Launched,cytochrome P450 inhibitor,CYP3A4,infectious disease,influenza A virus infection,1576
642,BRD-K08037784,arbutin,OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,440936.0,Phase 2/Phase 3,melanin inhibitor,TYR,,,7299
643,BRD-K93188295,ARC-239,COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,609483.0,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C,,,152|150|151
644,BRD-K53523901,arctigenin,COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC,64981.0,Preclinical,MEK inhibitor,CHUK|MAP2K1,,,1147|5604
645,BRD-K72726508,arcyriaflavin-a,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,5327723.0,Preclinical,CDK inhibitor,CCND1|CDK4,,,595|1019
646,BRD-K00003590,ardeparin,CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O,100942142.0,Withdrawn,thrombin inhibitor,SERPIND1,,,3053
647,BRD-K63792901,arecaidine-but-2-ynyl-ester,CC#CCOC(=O)C1=CCCN(C)C1 |t:7|,4214594.0,Preclinical,acetylcholine receptor agonist,CHRM2,,,1129
648,BRD-K23922020,arecaidine-propargyl-ester,CN1CCC=C(C1)C(=O)OCC#C |c:4|,2229.0,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,,1128|1129|1131|1132
649,BRD-K88646909,arecoline,COC(=O)C1=CCCN(C)C1 |t:4|,2230.0,Phase 1,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,,1128|1129|1131|1132
650,BRD-A48261811,argatroban,"C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|",152951.0,Launched,thrombin inhibitor,F2,hematology,heparin-induced thrombocytopenia (HIT),2147
652,BRD-K62734952,arglabin,CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|,5574924.0,Launched,farnesyltransferase inhibitor,FNTA|NFKB1,,,2339|4790
653,BRD-K70358946,aripiprazole,Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl,60795.0,Launched,serotonin receptor agonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7,neurology/psychiatry,depression|schizophrenia|bipolar disorder,146|147|1812|1813|150|1815|3352|1816|151|152|1814|3350|3351|3354|3356|3358|3359|3362|3363|3269|1128|1129|1131|1132|1133
655,BRD-K33852358,arofylline,CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O,166553.0,Phase 3,phosphodiesterase inhibitor,PDE4A,,,5141
656,BRD-A28044053,arotinolol,"CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|",12797283.0,Launched,adrenergic receptor antagonist,ADRB3,cardiology|neurology/psychiatry,hypertension|tremors,155
657,BRD-K60171656,ARQ-092,Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1,53262401.0,Phase 1,AKT inhibitor,AKT2,,,208
658,BRD-K43436647,ARQ-621,NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F,25110841.0,Phase 1,kinesin-like spindle protein inhibitor,KIF11,,,3832
659,BRD-K46386702,ARRY-334543,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|,42642648.0,Phase 2/Phase 3,EGFR inhibitor,ERBB2,,,2064
660,BRD-K24179883,arsanilic-acid,Nc1ccc(cc1)[As](O)(O)=O,7389.0,Phase 1,,LYZ,,,4069
661,BRD-K32786395,arsenic-trioxide,O=[As]O[As]=O,261004.0,Launched,apoptosis stimulant,AKT1|CCND1|IKBKB|JUN|MAPK1|MAPK3|TXNRD1,gastroenterology,diarrhea,7296|3725|207|595|5594|5595|3551
662,BRD-K39621635,artemether,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,68911.0,Launched,antimalarial agent,ATP1A1,infectious disease,malaria,476
663,BRD-K13112821,artemisinin,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,68827.0,Launched,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,1555
667,BRD-K49223707,arundic-acid,CCCCCC[C@@H](CCC)C(O)=O,208925.0,Phase 2/Phase 3,astrocyte modulating agent,PTGS2|S100B,,,6285|5743
668,BRD-A00047421,ARV-825,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|",124870683.0,Preclinical,bromodomain inhibitor,BRD4,,,23476
669,BRD-K07656463,AS-1269574,Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1,5332859.0,Preclinical,glucose dependent insulinotropic receptor agonist,GPR119,,,139760
670,BRD-K27051047,AS-1892802,OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1,46911016.0,Preclinical,rho associated kinase inhibitor,ROCK1,,,6093
671,BRD-K61936403,AS-1949490,C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1,44473434.0,Preclinical,SHIP2 phosphatase inhibitor,INPP5D,,,3635
672,BRD-K75254015,AS-2034178,OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F,24808572.0,Preclinical,free fatty acid receptor agonist,FFAR1,,,2864
673,BRD-K73565918,AS-2444697,Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1,52913874.0,Preclinical,interleukin inhibitor,IRAK4,,,51135
674,BRD-K14988953,AS-252424,Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1,11630874.0,Preclinical,PI3K inhibitor,PIK3CG,,,5294
675,BRD-K63915849,AS-604850,FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1,5287855.0,Preclinical,PI3K inhibitor,PIK3CA|PIK3CG,,,5290|5294
676,BRD-K89014967,AS-703026,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,44187362.0,Phase 2,MEK inhibitor,MAP2K1|MAP2K2,,,5604|5605
677,BRD-K62427771,AS-77,O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1,11302540.0,Phase 1,potassium channel blocker,KCNA3|KCNA5|KCNN4,,,3738|3741|3783
680,BRD-K88219015,asaraldehyde,COc1cc(OC)c(C=O)cc1OC,20525.0,Preclinical,cyclooxygenase inhibitor,PTGS2,,,5743
681,BRD-K30331124,ASC-J9,COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC,74891315.0,Phase 2,androgen receptor enhancer,AR,,,367
683,BRD-K88882192,ascomycin,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|,134129697.0,Preclinical,calcineurin inhibitor,FKBP1A,,,2280
684,BRD-A85242401,ascorbic-acid,"OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|",,Launched,antioxidant,SLC23A1|SLC23A2,endocrinology,scurvy,9962|9963
685,BRD-K00003551,asenapine,"[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|",163091.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder,3269|1813|3350|3351|3352|3354|3356
686,BRD-K35079116,asiatic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|,119034.0,Preclinical,apoptosis stimulant,PYGM,,,5837
687,BRD-K00003477,asimadoline,CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1,179340.0,Phase 3,opioid receptor agonist,OPRK1,,,4986
689,BRD-K07150325,ASP-2535,CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12,9800113.0,Phase 1,glycine transporter inhibitor,SLC6A9,,,6536
692,BRD-K06542892,ASP3026,COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,25134326.0,Phase 1,ALK tyrosine kinase receptor inhibitor,ALK,,,238
693,BRD-K78841970,aspartame,COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O,6992066.0,Launched,,TAS1R2|TRPV1,,,80834|7442
694,BRD-K11433652,aspirin,CC(=O)Oc1ccccc1C(O)=O,2244.0,Launched,cyclooxygenase inhibitor,AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53,neurology/psychiatry|endocrinology|dental,headache|fever|toothache|muscle pain,53632|6197|4790|4791|4792|5562|5563|5564|5565|5571|51422|9311|3551|3309|1645|5742|5743|7157|1909
695,BRD-K26838195,AST-1306,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,24739943.0,Phase 1,EGFR inhibitor,EGFR|ERBB2,,,2064|1956
697,BRD-K37249724,astemizole,COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1,2247.0,Withdrawn,histamine receptor antagonist,HRH1|KCNH1|KCNH2,,,3756|3269|3757
702,BRD-K36269323,asymmetrical-dimethylarginine,CN(C)C(=N)NCCC[C@H](N)C(O)=O,123831.0,Phase 1,nitric oxide synthase inhibitor,NOS2|NOS3,,,339345|342977
703,BRD-K06496777,AT-1015,O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|,9805664.0,Preclinical,serotonin receptor antagonist,HTR2A,,,3356
705,BRD-K13390322,AT-7519,Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1,11338033.0,Phase 2,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK6|CDK9,,,1025|983|1017|1019|1020|1021
706,BRD-K24576554,AT-9283,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1,135398495.0,Phase 2,Aurora kinase inhibitor|JAK inhibitor,AURKA|AURKB|JAK2|JAK3|RPS6KA6|STK17A,,,27330|3717|3718|6790|9263|9212
707,BRD-K32127727,AT13148,NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1,24905401.0,Phase 1,protein kinase inhibitor,AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3,,,9475|6093|207|208|10000|23678
708,BRD-K58435339,AT13387,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,11955716.0,Phase 2,HSP inhibitor,HSP90AA1,,,3320
709,BRD-K12040459,AT7867,Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1,11175137.0,Preclinical,AKT inhibitor,AKT2|GSK3B|PKIA|PRKACA,,,208|5569|5578|2932
710,BRD-K94830329,ataluren,OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F,11219835.0,Launched,CFTR channel agonist|dystrophin stimulant,DMD,genetics|pulmonary,duchenne muscular dystrophy (DMD)|cystic fibrosis,1756
712,BRD-A52551912,ATB-346,"COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|",76963724.0,Phase 2,cyclooxygenase inhibitor,PTGER2,,,5732
715,BRD-A20239487,atenolol-(+/-),"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|",180559.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|LTF|PLA2G2E,cardiology,hypertension|angina pectoris,153|154|4057|30814
719,BRD-K38527262,atiprimod,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,129869.0,Phase 2,JAK inhibitor|STAT inhibitor,JAK2|STAT3,,,3717|6774
720,BRD-K76614248,atizoram,COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1,9861730.0,Phase 2,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,,,5144|5141|5142|5143
721,BRD-K00521308,ATN-161,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O,9960285.0,Phase 2,integrin antagonist,ITGA5|ITGAV|ITGB1|ITGB3,,,3688|3690|3685|3678
722,BRD-K20141153,atomoxetine,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,54841.0,Launched,norepinephrine transporter inhibitor,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,attention-deficit/hyperactivity disorder (ADHD),6530|114787|6531|6532|2903|2904|2905|2906|116443|116444
723,BRD-K69726342,atorvastatin,CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1,60823.0,Launched,HMGCR inhibitor,AHR|DPP4|HMGCR,neurology/psychiatry|cardiology,stroke|heart attack,1803|196|3156
724,BRD-A85261566,atosiban,"CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|",,Launched,oxytocin receptor antagonist,AVPR1A|AVPR1B|AVPR2|OXTR,neurology/psychiatry|cardiology|endocrinology,stroke|angina pectoris|myocardial infarction|hyperlipidemia,552|553|554|5021
726,BRD-A65145453,ATPA,"CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|",11345201.0,Preclinical,glutamate receptor agonist,GRIK1,,,2897
729,BRD-K16295392,atrasentan,CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1,159594.0,Phase 3,endothelin receptor antagonist,EDNRA,,,1909
730,BRD-K01825666,atropine,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|",,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,ophthalmology,cycloplegia|mydriasis|amblyopia,1128|1129|1131
731,BRD-K00004526,atropine-oxide,"C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|",,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,,1128|1129|1131|1132|1133
733,BRD-K45995181,auranofin,CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,6918453.0,Launched,NFkB pathway inhibitor,IKBKB|PRDX5|TRPA1,rheumatology,rheumatoid arthritis,25824|8989|3551
734,BRD-K53561341,aurora-a-inhibitor-i,CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1,44139710.0,Preclinical,Aurora kinase inhibitor,AURKA,,,6790
735,BRD-K00003601,aurothioglucose,OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,6916934.0,Launched,PKC inhibitor,PRKCI,rheumatology,rheumatoid arthritis,5584
737,BRD-A94640958,autotaxin-modulator-1,"C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|",,Preclinical,autotaxin inhibitor,ENPP2,,,5168
738,BRD-K23190681,AV-412,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,9806229.0,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2,,,2064|1956
739,BRD-K96615647,AV-608,FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12,9917079.0,Phase 2,tachykinin antagonist,TACR1,,,6869
742,BRD-K83720053,avagacestat,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1,46883536.0,Phase 2,gamma secretase inhibitor,PSEN1,,,5663
743,BRD-K65781196,avanafil,COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl,9869929.0,Launched,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,8654
745,BRD-K67901620,avasimibe,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C,166558.0,Phase 3,ACAT inhibitor,CES1,,,1066
746,BRD-K68544925,avatrombopag,OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1,9852519.0,Launched,thrombopoietin receptor agonist,MPL,hematology,thrombocytopenia,4352
747,BRD-K36154108,AVE-0991,CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1,9851724.0,Preclinical,angiotensin receptor agonist,MRGPRX1,,,259249
752,BRD-K87782578,AVL-292,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,59174488.0,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,BTK|YES1,,,7525|695
754,BRD-K62196610,AVN-944,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,9918559.0,Phase 2,inosine monophosphate dehydrogenase inhibitor,IMPDH1|IMPDH2,,,727833|3615
759,BRD-K29905972,axitinib,CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1,6450551.0,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1|FLT1|FLT4|KDR|PLK4,oncology,renal cell carcinoma (RCC),10733|3791|2321|2324|1435
761,BRD-K36258877,AZ-10417808,[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1,135665263.0,Preclinical,caspase inhibitor,CASP3,,,836
762,BRD-K09907507,AZ-10606120,OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1,10310632.0,Preclinical,purinergic receptor antagonist,P2RX7,,,5027
763,BRD-K05973499,AZ-12080282,Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1,25253556.0,Preclinical,hedgehog pathway inhibitor,DHH,,,50846
764,BRD-K05804044,AZ-628,Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1,11676786.0,Preclinical,RAF inhibitor,BRAF|RAF1,,,673|6037
766,BRD-K80935598,AZ191,COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1,72716071.0,Preclinical,DYRK inhibitor,DYRK1B,,,9149
767,BRD-K42436189,AZ20,C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O,46244454.0,Preclinical,ATR kinase inhibitor,ATR|MTOR,,,545|2475
769,BRD-K76244476,AZ505,Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12,24961094.0,Preclinical,histone lysine methyltransferase inhibitor,SMYD2,,,56950
770,BRD-K81958169,AZ5104,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12,71496460.0,Preclinical,EGFR inhibitor,EGFR,,,1956
772,BRD-K64888243,AZ960,C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1,25099184.0,Preclinical,JAK inhibitor,JAK2,,,3717
773,BRD-K03406345,azacitidine,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,9444.0,Launched,DNA methyltransferase inhibitor,DNMT1|DNMT3A,hematologic malignancy|hematology,myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL),1786|1788
774,BRD-K97061094,azacyclonol,OC(C1CCNCC1)(c1ccccc1)c1ccccc1,15723.0,Preclinical,histamine receptor antagonist,HRH1,,,3269
775,BRD-K53114651,azaguanine-8,Nc1nc2nn[nH]c2c(=O)[nH]1,135403646.0,Preclinical,purine antagonist,PNP,,,5539
777,BRD-K45861246,azaperone,Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1,15443.0,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,sedative,1813|1814
778,BRD-A70182876,azapropazone,"CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|",6604340.0,Withdrawn,cyclooxygenase inhibitor,PTGS2,,,5743
780,BRD-K01826751,azasetron,CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|,25271863.0,Launched,serotonin receptor antagonist,HTR3A|HTR3B,infectious disease,genitial herpes,9177|3359
781,BRD-K77821588,azatadine,CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12,19861.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269
782,BRD-K32821942,azathioprine,Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O,2265.0,Launched,dehydrogenase inhibitor,HPRT1|IMPDH1|PPAT,transplant|rheumatology,renal homotransplantation|rheumatoid arthritis,727833|3251|80347
784,BRD-K61041538,AZD1080,O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N,10065474.0,Phase 1,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,,2931|2932
785,BRD-K21908111,AZD1208,N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1,58423153.0,Phase 1,Pim kinase inhibitor,PIM1|PIM2|PIM3,,,11040|9361|415116
786,BRD-K77060810,AZD1283,CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1,23649325.0,Preclinical,purinergic receptor antagonist,P2RY12,,,64805
788,BRD-A44188509,AZD1446,"Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|",96568205.0,Phase 2,acetylcholine receptor agonist,CHRNA4|CHRNB2,,,1137|1141
789,BRD-K65928735,AZD1480,C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1,16659841.0,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,,3716|3717|3718
790,BRD-K83186168,AZD1981,CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12,11292191.0,Phase 2,CRTH receptor antagonist,PTGDR2,,,11251
791,BRD-K99113996,AZD2014,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,25262792.0,Phase 2,mTOR inhibitor,MTOR,,,2475
793,BRD-K85849709,AZD2858,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,10138980.0,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,,2932
794,BRD-K14287049,AZD3264,Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1,91666658.0,Preclinical,IKK inhibitor,IKBKB,,,3551
795,BRD-K24593301,AZD3463,COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1,56599293.0,Preclinical,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,ALK|IGF1R,,,3480|238
796,BRD-K84996356,AZD3514,CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|,46893585.0,Phase 1,androgen receptor modulator,AR,,,367
797,BRD-K41626799,AZD3759,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,78209992.0,Phase 2/Phase 3,EGFR inhibitor,EGFR,,,1956
798,BRD-K00004606,AZD3839,NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|,46202416.0,Phase 1,beta-secretase inhibitor,BACE1,,,23621
799,BRD-K25210703,AZD3965,CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O,10369242.0,Phase 1,monocarboxylate transporter inhibitor,SLC16A1,,,6566
800,BRD-K73984371,AZD3988,OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|,,Preclinical,diacylglycerol kinase inhibitor,DGAT1,,,8694
801,BRD-K72369578,AZD4282,NCC(O)=O,750.0,Phase 1,glutamate receptor antagonist,AGXT|AGXT2|ALAS1|ALAS2|BAAT|GARS|GATM|GCAT|GCSH|GLDC|GLRA1|GLRA2|GLRA3|GLRB|GLYAT|GLYATL1|GLYATL2|GNMT|GPR18|GPRC6A|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3B|GSS|PIPOX|SHMT1|SHMT2|SLC32A1|SLC36A1|SLC6A5|SLC6A9,,,6530|92292|64902|140679|6536|10249|206358|2841|23464|2731|2741|2742|2743|570|189|8001|219970|2628|51268|6470|6472|222545|211|212|2903|2904|2905|2906|116444|2653|27232|114787|5621
802,BRD-K28392481,AZD4547,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1,51039095.0,Phase 2/Phase 3,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|IGF1R|KDR,,,3480|3791|2260|2261|2263|2264
805,BRD-K00003297,AZD5069,C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO,56645576.0,Phase 2,CC chemokine receptor antagonist,CXCR2,,,3579
807,BRD-K99023089,AZD5363,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,25227436.0,Phase 3,AKT inhibitor,AKT1|AKT2|AKT3,,,208|10000|207
808,BRD-K72414522,AZD5438,CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1,16747683.0,Phase 1,CDK inhibitor,KCNH2,,,3757
809,BRD-K88767641,AZD5582,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1,49847690.0,Preclinical,XIAP inhibitor,BIRC2|BIRC3|XIAP,,,329|330|331
811,BRD-K58772419,AZD6482,C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1,44137675.0,Phase 1,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,5290|5291|5294|22883
812,BRD-A36013532,AZD6738,"C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|",54761305.0,Phase 2,ATR kinase inhibitor,ATR,,,545
813,BRD-A94033181,AZD6765,"N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|",9794203.0,Phase 2,glutamate receptor antagonist,GRIN1,,,114787
814,BRD-K52836380,AZD7545,CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1,16741245.0,Phase 1,pyruvate dehydrogenase kinase inhibitor,PDK1,,,5170
816,BRD-K31495718,AZD7687,Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|,,Phase 1,diacylglycerol O acyltransferase inhibitor,DGAT1,,,8694
817,BRD-K86525559,AZD7762,NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1,11152667.0,Phase 1,CHK inhibitor,CHEK1|CHEK2,,,11200|1111
819,BRD-K69932463,AZD8055,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,25262965.0,Phase 1,mTOR inhibitor,MTOR,,,2475
820,BRD-K47289408,AZD8186,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C,52913813.0,Phase 1,PI3K inhibitor,PIK3CB|PIK3CD,,,5291|22883
821,BRD-K37687095,AZD8330,Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,16666708.0,Phase 1,MEK inhibitor,MAP3K1,,,4214
823,BRD-K82894950,AZD8835,CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO,76685059.0,Phase 1,PI3K inhibitor,PIK3CA|PIK3CD,,,5290|22883
824,BRD-K98572433,AZD8931,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,11488320.0,Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB3,,,2064|2065|1956
826,BRD-K61043483,AZD9272,Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N,9838729.0,Preclinical,glutamate receptor antagonist,GRM5,,,2915
827,BRD-K73235735,AZD9496,C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F,86287635.0,Phase 1,estrogen receptor agonist,ESR1,,,2099
828,BRD-K31476763,AZD9668,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,46861623.0,Phase 2,elastase inhibitor,ELANE,,,1991
829,BRD-K08976401,azelaic-acid,OC(=O)CCCCCCCC(O)=O,2266.0,Launched,tyrosinase inhibitor,AKR1D1|SRD5A2|TYR,dermatology,rosacea,7299|6716|6718
830,BRD-A68888262,azelastine,CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|,12831281.0,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269
831,BRD-K51899933,azeliragon,CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1,11180124.0,Phase 3,RAGE receptor antagonist,AGER,,,177
832,BRD-A01098288,azelnidipine,"CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|",9873077.0,Launched,calcium channel blocker,CACNA1C,cardiology,hypertension,775
833,BRD-K81074237,azilsartan,CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1,135415867.0,Launched,angiotensin receptor antagonist,AGTR1|AGTR2,cardiology,hypertension,185|186
834,BRD-K25723200,azilsartan-medoxomil,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1,135409642.0,Launched,angiotensin receptor antagonist,AGTR1|AGTR2,cardiology,hypertension,185|186
835,BRD-K38913877,azimilide,CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1,9571004.0,Phase 3,potassium channel blocker,KCNA5,,,3741
836,BRD-K74501079,azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,71206984.0,Launched,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,pelvic inflammatory disease|pneumonia,2862
838,BRD-K51329597,AZM-475271,COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1,5330175.0,Preclinical,SRC inhibitor,SRC,,,6714
841,BRD-K68770713,azosemide,NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl,2273.0,Launched,electrolyte reabsorption inhibitor,SLC12A1|SLC12A2,cardiology,edema,6557|6558
844,BRD-K14079729,bacitracin,CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|,,Launched,bacterial cell wall synthesis inhibitor,IDE,infectious disease,first-aid antibiotic,3416
846,BRD-K01826724,baclofen,NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|,6923772.0,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,neurology/psychiatry,multiple sclerosis|spasms,9568|115207|10537|57528|386617
847,BRD-A16694057,BADGE,"CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|",6994088.0,Preclinical,PPAR receptor antagonist,PPARG,,,5468
848,BRD-K82196541,bafetinib,CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1,11387605.0,Phase 2,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,ABL1|BCR|LYN,,,25|4067|106480993
850,BRD-K00652956,BAG-956,Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1,24882589.0,Preclinical,phosphoinositide dependent kinase inhibitor,PIK3CG,,,5294
851,BRD-K72327355,baicalein,Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1,,Preclinical,lipoxygenase inhibitor,ALOX5|GLO1|PREP|SELL|SELP|TNF|XDH,,,6402|5550|6414|240|2739|7124|6652
852,BRD-K49962337,baicalin,O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O,,Launched,beta glucuronidase inhibitor,PREP,neurology/psychiatry,anxiety,5550
853,BRD-K09785578,bakuchiol,CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1,5468522.0,Phase 2,DNA polymerase inhibitor,HIF1A,,,3091
854,BRD-A00147595,balaglitazone,Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|,76968728.0,Phase 3,insulin sensitizer|PPAR receptor partial agonist,PPARG,,,5468
856,BRD-K27204852,balicatib,CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N,10201696.0,Phase 2,cathepsin inhibitor,CTSK,,,1513
860,BRD-K00003656,balsalazide,OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O,,Launched,cyclooxygenase inhibitor,ALOX5|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis,240|5468|5742|5743
861,BRD-K07442505,BAM7,CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|,,Preclinical,BAX activator,BAX,,,581
863,BRD-A17462676,bambuterol,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C,57515921.0,Launched,adrenergic receptor agonist,ADRB2|BCHE,pulmonary,asthma,154|590
864,BRD-K47049295,BAN-ORL-24,O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1,10296561.0,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,,,4987
865,BRD-K00003159,banoxantrone,C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12,9955116.0,Phase 1/Phase 2,topoisomerase inhibitor,TOP2A,,,7153
866,BRD-K31928526,barasertib,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O,11497983.0,Phase 2/Phase 3,Aurora kinase inhibitor,AURKA|AURKB,,,9212|6790
867,BRD-K63923597,barasertib-HQPA,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1,16007391.0,Phase 2/Phase 3,Aurora kinase inhibitor,AURKB,,,9212
868,BRD-K20545304,bardoxolone,"CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|",400010.0,Phase 1,nuclear factor erythroid derived|like (NRF2) activator,NOS2|PPARG,,,339345|5468
869,BRD-K69694239,bardoxolone-methyl,"COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|",400769.0,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,PPARG|STAT3,,,5468|6774
870,BRD-K53581288,baricitinib,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,44205240.0,Launched,JAK inhibitor,JAK1|JAK2,rheumatology,rheumatoid arthritis,3716|3717
874,BRD-K62387885,basimglurant,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,11438771.0,Phase 2,glutamate receptor antagonist,GRM5,,,2915
877,BRD-K82818427,batimastat,CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO,5362422.0,Phase 3,matrix metalloprotease inhibitor,ADAM28|ADAMTS5|MMP12|MMP16|MMP2|MMP8,,,4321|4325|10863|11096|4313|4317
878,BRD-K79595931,bavisant,O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1,16061509.0,Phase 2,histamine receptor antagonist,HRH3,,,11255
879,BRD-K01826533,BAX-channel-blocker,O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|,981054.0,Preclinical,cytochrome C release inhibitor,BAX,,,581
880,BRD-K15025317,BAY-11-7082,Cc1ccc(cc1)S(=O)(=O)\C=C\C#N,5353431.0,Preclinical,NFkB pathway inhibitor,RELA,,,5970
881,BRD-K48684885,BAY-11-7085,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,5353432.0,Preclinical,NFkB pathway inhibitor,NFKBIA,,,4792
886,BRD-K32033120,BAY-41-2272,Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12,9798973.0,Preclinical,guanylyl cyclase activator,GUCY1A3|GUCY1B3,,,2982|2983
887,BRD-K32952627,BAY-60-6583,NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N,11717831.0,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
888,BRD-K86932920,BAY-60-7550,COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC,135564787.0,Preclinical,phosphodiesterase inhibitor,PDE2A,,,5138
889,BRD-K53281329,BAY-61-3606,COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1,10200390.0,Preclinical,SYK inhibitor,SYK,,,6850
892,BRD-K70463136,BAY-87-2243,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,67377767.0,Phase 1,hypoxia inducible factor inhibitor,HIF1A,,,3091
894,BRD-K14329163,BAY-K-8644-(s)-(-),"COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|",6603728.0,Preclinical,L-type calcium channel activator,CACNA1C,,,775
898,BRD-K66830666,BAZ2-ICR,Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1,91654625.0,Preclinical,bromodomain inhibitor,ZNF215,,,7762
899,BRD-K90195324,bazedoxifene,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,154257.0,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|endocrinology,osteoporosis|menopause,2099|2100
900,BRD-K14646328,BC-11,NC(=N)SCc1ccc(cc1)B(O)O,60126757.0,Preclinical,urokinase inhibitor,PLAU,,,5328
902,BRD-K66541497,BCTC,CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1,9929425.0,Preclinical,TRPV antagonist,TRPV1,,,7442
903,BRD-K90472149,BCX-1470,NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1,9822205.0,Phase 1,complement inhibitor|serine protease inhibitor,CFD,,,200576
905,BRD-K36864847,BD-1047,CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1,188914.0,Preclinical,adrenergic receptor antagonist,SIGMAR1,,,10280
906,BRD-K29668683,BD-1063,CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1,574780.0,Preclinical,sigma receptor antagonist,SIGMAR1,,,10280
907,BRD-A24429032,BE-2254,Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|,86308637.0,Phase 2,adrenergic receptor antagonist,ADRA1A,,,146
911,BRD-A73385064,beclomethasone,"C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|",,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis,866|2908
912,BRD-K97810537,beclomethasone-dipropionate,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|",21700.0,Launched,glucocorticoid receptor agonist,GPR97|NR3C1,allergy,allergic rhinitis,2908|222487
915,BRD-K58319700,begacestat,OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F,11269353.0,Phase 1,gamma secretase inhibitor,PSEN1,,,5663
917,BRD-K17743125,belinostat,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,6918638.0,Launched,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,peripheral T-cell lymphoma (PTCL),55869|9734|8841|10013|79885|3065|3066|83933|10014|9759
920,BRD-K14993104,bemegride,CCC1(C)CC(=O)NC(=O)C1,2310.0,Launched,chemoreceptor agonist,GABRA1,critical care,poison antidote,2554
921,BRD-K00004211,bemesetron,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r,THB:0:1:3.4:6.7.8|",,Phase 3,serotonin receptor antagonist,HTR3A|HTR3B,,,9177|3359
923,BRD-K63177377,bempedoic-acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,10472693.0,Launched,AMPK inhibitor,ACLY,,,47
926,BRD-K49807096,benazepril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O,5362124.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636
928,BRD-K19515365,bendazac,OC(=O)COc1nn(Cc2ccccc2)c2ccccc12,2313.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain,5742|5743
930,BRD-A80017228,bendroflumethiazide,"NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|",9845085.0,Launched,sodium/potassium/chloride transporter inhibitor,SLC12A1|SLC12A3,cardiology,hypertension,6557|6559
932,BRD-K00003672,benfluorex,C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|,6604374.0,Withdrawn,gluconeogenesis inhibitor,HMGCR,,,3156
933,BRD-K33903083,benfluralin,CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O,2319.0,Phase 3,,CYP1A1|CYP1A2|CYP2B6|CYP3A4|ESR1|MMP1|SULT2A1|UGT1A1,,,54658|6822|1543|1544|1576|2099|1555|4312
934,BRD-K05319475,benfotiamine,C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1,3032771.0,Launched,antioxidant,AGER,rheumatology,lumbago,177
935,BRD-K97181463,benidipine,COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1,656667.0,Launched,calcium channel blocker,CACNA1C|CACNA1G,cardiology,hypertension,8913|775
936,BRD-K79425933,benperidol,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O,16363.0,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,1813
937,BRD-K01826024,benproperine,"C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|",14456347.0,Launched,antitussive,SCN5A,pulmonary,cough suppressant,6331
938,BRD-A61194565,benserazide,NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,657280.0,Launched,DOPA decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease,1644
939,BRD-K58794715,bentiromide,OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1,6957673.0,Launched,,HPN,gastroenterology,pancreas diagnostic agent,3249
942,BRD-K87158025,benzamil,NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N,108107.0,Phase 2,sodium channel blocker,ASIC1|PKD2L1|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC8A1,,,6337|6338|6339|6340|9033|41|6546
943,BRD-K11717138,benzbromarone,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,2333.0,Launched,chloride channel blocker,ABCC1,rheumatology,gout,4363
945,BRD-K72723676,benzethonium,CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,2335.0,Launched,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,6336
948,BRD-K75466013,benzocaine,CCOC(=O)c1ccc(N)cc1,2337.0,Launched,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,6336
951,BRD-K53397409,benzoic-acid,OC(=O)c1ccccc1,243.0,Launched,food preservative,DAO|HRSP12|PRDX5|RAB9A,infectious disease,tinea pedis,25824|26|9367|10247
952,BRD-A55748233,benzoin,"O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|",640038.0,Preclinical,,CES1,,,1066
953,BRD-K91699951,benzonatate,CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,7699.0,Launched,local anesthetic,SCN5A,pulmonary,cough suppressant,6331
954,BRD-K18772613,benzoquinonium-dibromide,"CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|",9394.0,Preclinical,cholinergic receptor antagonist,CHRNA1,,,1134
955,BRD-K33219230,benzotript,OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1,2060890.0,Phase 1,CCK receptor antagonist,CCKAR|CCKBR,,,886|887
959,BRD-K21450440,benzthiazide,NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl,132458842.0,Launched,carbonic anhydrase inhibitor,CA2,cardiology,hypertension|edema,760
960,BRD-K68804560,benztropine-mesylate,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1,,Launched,acetylcholine receptor antagonist,CHRM1|HRH1|SLC6A3,neurology/psychiatry,extrapyramidal symptoms (EPS)|Parkinson's Disease,1128|6531|3269
963,BRD-K52072429,benzyl-benzoate,O=C(OCc1ccccc1)c1ccccc1,2345.0,Launched,lipase inhibitor,LIPE,allergy,sweet itch,3991
969,BRD-K98624455,bepotastine,OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1,25273609.0,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269
970,BRD-A91008255,bepridil,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,50088.0,Launched,calcium channel blocker,KCNQ4,cardiology,angina pectoris,9132
971,BRD-K14796088,berberine,COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC,2353.0,Launched,LDL receptor activator,LDLR,,,3949
973,BRD-K04176066,bergenin,COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O,66065.0,Preclinical,interleukin inhibitor,IL1B|TNF,,,3553|7124
976,BRD-K38687824,beta-amyloid-synthesis-inhibitor,Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1,9882580.0,Preclinical,beta amyloid synthesis inhibitor,APP,,,351
978,BRD-K87349602,beta-CCB,CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21,128618.0,Launched,benzodiazepine receptor ligand,GABRA1|GABRG2,,,2554|2566
979,BRD-K21045639,beta-elemene,CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C,6918391.0,Launched,apoptosis stimulant,MMP2|MMP9,,,4313|4318
980,BRD-K95110148,beta-funaltrexamine,COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45,5311018.0,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,,4985|4986|4988
982,BRD-M02899238,beta-hydroxy-beta-methylbutyrate,CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O,129010087.0,Launched,protein synthesis stimulant,MTOR,,,2475
983,BRD-A41387824,beta-hydroxybutyrate,CC(O)CC(O)=O,441.0,Phase 1,,HCAR2,,,338442
984,BRD-K28061410,beta-lapachone,CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|,3885.0,Phase 2,topoisomerase inhibitor,TOP1,,,7150
986,BRD-K91315211,betahistine,CNCCc1ccccn1,2366.0,Launched,histamine receptor agonist|histamine receptor antagonist,HRH1|HRH3,neurology/psychiatry,Meniere's disease,3269|11255
988,BRD-K39188321,betamethasone,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|",9782.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
989,BRD-K00025439,betamethasone-acetate,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|",443967.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
991,BRD-K58148589,betamethasone-dipropionate,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|",21800.0,Launched,anti-inflammatory agent,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
993,BRD-K34032314,betamethasone-valerate,"CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|",16533.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
995,BRD-K01825592,betaxolol,"CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|",6093355.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,153|154
996,BRD-K20075662,betazole,NCCc1ccn[nH]1,7741.0,Launched,histamine receptor agonist,HRH2,gastroenterology,gastric hypersecretion diagnostic,1665
997,BRD-K00003637,bethanechol,C[C@@H](C[N+](C)(C)C)OC(N)=O |r|,6603779.0,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,urology,urinary retention,1128|1129|1131|1132
998,BRD-K00004305,BETP,"CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|",97182196.0,Preclinical,GLP receptor positive allosteric modulator,GLP1R,,,2740
999,BRD-K45275534,betrixaban,COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1,10275777.0,Launched,coagulation factor inhibitor,KCNH2,hematology,deep vein thrombosis (DVT),3757
1000,BRD-K45401373,betulinic-acid,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O,64971.0,Phase 1/Phase 2,apoptosis stimulant|NFkB pathway inhibitor,GPBAR1,,,151306
1005,BRD-K92441787,bexarotene,Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,82146.0,Launched,retinoid receptor agonist,RXRA|RXRB|RXRG,hematologic malignancy,cutaneous T-cell lymphoma (CTCL),6256|6257|6258
1006,BRD-K46018455,bezafibrate,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O,39042.0,Launched,PPAR receptor agonist,PPARA|PPARD|PPARG,cardiology,cholesterol,5465|5467|5468
1009,BRD-K29415052,BGT226,COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1,11978790.0,Phase 1/Phase 2,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CG,,,5290|2475|5291|5294
1010,BRD-K95603879,BHQ,CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C,2374.0,Preclinical,ATPase inhibitor,ATP2A1,,,487
1012,BRD-K64890080,BI-2536,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,11364421.0,Phase 2,PLK inhibitor,BRD4|PLK1|PLK2|PLK3,,,10769|5347|23476|1263
1014,BRD-K73982490,BI-78D3,[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1,2747117.0,Preclinical,JNK inhibitor,MAPK8,,,5599
1015,BRD-K37492701,BI-847325,CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1,,Phase 1,Aurora kinase inhibitor|MEK inhibitor,AURKA|AURKB|AURKC|MAP2K1|MAP2K2,,,5604|5605|6790|6795|9212
1016,BRD-A81370665,BI-D1870,"CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|",44141268.0,Preclinical,ribosomal protein inhibitor,RPS6KA1|RPS6KA2|RPS6KA3|RPS6KA6,,,27330|6195|6196|6197
1019,BRD-K43927145,BIBN4096,NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1,6918509.0,Phase 2,calcitonin antagonist,CALCA|CALCRL|RAMP1,,,10267|10203|796
1020,BRD-K04623885,BIBR-1532,C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1,9927531.0,Preclinical,telomerase inhibitor,TERT,,,7015
1021,BRD-K49294207,BIBU-1361,CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,17756796.0,Preclinical,EGFR inhibitor,EGFR,,,1956
1022,BRD-K70914287,BIBX-1382,CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,6918508.0,Phase 1,EGFR inhibitor,EGFR|ERBB2,,,2064|1956
1023,BRD-A29485665,bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|,2375.0,Launched,androgen receptor antagonist,AR,oncology,prostate cancer,367
1026,BRD-K84363966,bicuculline-(+),CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21,10237.0,Preclinical,GABA receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|KCNN1,,,3780|2554|2555|2556|2557|2558|2559
1028,BRD-K16546375,bicyclol,COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO,9821754.0,Launched,NFkB pathway inhibitor,HSPA1A|HSPB1,infectious disease,hepatitis B|hepatitis C,3315|3303
1029,BRD-K18779551,bifemelane,CNCCCCOc1ccccc1Cc1ccccc1,2377.0,Launched,acetylcholine release enhancer,MAOA|MAOB,ophthalmology|neurology/psychiatry,glaucoma|senile dementia,4128|4129
1032,BRD-K51967704,BIIB021,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C,16736529.0,Phase 2,HSP inhibitor,HSP90AA1,,,3320
1033,BRD-K51937257,bilastine,CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1,40467029.0,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269
1034,BRD-K32039267,bilobalide,CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123,73581.0,Preclinical,GABA receptor modulator,GLRA1|GLRA2|GLRB|HTR3A|HTR3B,,,2741|2742|2743|9177|3359
1035,BRD-K00003616,bimatoprost,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1,5311027.0,Launched,prostanoid receptor agonist,AKR1C3|PTGER1|PTGER3|PTGFR,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,5737|5731|8644|5733
1036,BRD-K00004300,BIMU-8,"CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|",,Preclinical,serotonin receptor agonist,HTR4,,,3360
1037,BRD-K00004296,BINA,"Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|",86311024.0,Preclinical,glutamate receptor positive allosteric modulator,GRM2,,,2912
1038,BRD-K36467523,bindarit,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,71354.0,Phase 2,NFkB pathway inhibitor,CCL2|CCL7|CCL8,,,6354|6347|6355
1039,BRD-K82244583,binimetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,10288191.0,Launched,MEK inhibitor,MAP2K1|MAP2K2,oncology,melanoma,5604|5605
1040,BRD-K03399463,BIO-1211,CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O,9961766.0,Phase 2,integrin antagonist,ITGA4|ITGB1,,,3688|3676
1041,BRD-K21318844,BIO-5192,CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O,10350459.0,Preclinical,integrin inhibitor,ITGA4|ITGB1,,,3688|3676
1042,BRD-K89210380,biotin,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,171548.0,Launched,vitamin B,ACACA|ACACB|HLCS|MCCC1|MCCC2|PC|PCCA|PCCB|SLC5A6,,,32|5091|3141|5095|5096|8884|64087|56922|31
1043,BRD-K47690382,bipenamol,NCc1ccccc1Sc1ccccc1CO,43961.0,Phase 2,dipeptidyl peptidase inhibitor,CTSC,,,1075
1044,BRD-K01824983,biperiden,"O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|",12147323.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,neurology/psychiatry,Parkinson's Disease,1128|1129|1131|1132|1133
1045,BRD-K71221037,birinapant,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC,49836020.0,Phase 2,XIAP inhibitor,BIRC2|XIAP,,,329|331
1046,BRD-K64880136,BIRT-377,CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1,9803375.0,Preclinical,lymphocyte function-associated antigen negative modulator,ICAM1,,,3383
1047,BRD-K16180792,bis(maltolato)oxovanadium(IV),Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,3035454.0,Phase 2,tyrosine phosphatase inhibitor,PTPN1,,,5770
1050,BRD-K06543683,bisindolylmaleimide-IX,Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|,5083.0,Preclinical,PKC inhibitor,AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1,,,5600|5578|6093|207|6300|23411|2932|6198|1432|5594|3932|5599
1053,BRD-K65978409,bismuth-subgallate,O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O,73415769.0,Launched,nitric oxide synthase inhibitor,NOS1,gastroenterology,internal deoderant,340719
1057,BRD-A89175223,bisoprolol,CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|,6604464.0,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,153
1058,BRD-K41494493,bisphenol-A,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,6623.0,Phase 1,synthetic estrogen,AR|ESR1|ESR2|ESRRG|PPARG,,,367|2099|2100|2104|5468
1059,BRD-K39120595,bithionol,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O,2406.0,Withdrawn,autotaxin inhibitor,ESR1|ESR2|MCL1,,,4170|2099|2100
1060,BRD-K13756951,bitopertin,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,24946690.0,Phase 3,glycine transporter inhibitor,SLC6A5|SLC6A9,,,6536|6530
1062,BRD-K73504359,bivalirudin,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O,73952246.0,Launched,thrombin inhibitor,F2,cardiology,angina pectoris,2147
1063,BRD-K26818574,BIX-01294,COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1,25150857.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,,79813|10919
1064,BRD-K20290250,BIX-02188,CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1,,Preclinical,MEK inhibitor,MAP2K5,,,5607
1065,BRD-K73368362,BIX-02189,CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1,,Preclinical,MEK inhibitor,MAP2K5|MAPK7,,,5598|5607
1068,BRD-A75817871,blebbistatin-(+/-),"Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|",5287792.0,Preclinical,ATPase inhibitor,MYH14|MYH2,,,57644|4620
1071,BRD-K25943794,blonanserin,CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1,125564.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia,3356|1813
1072,BRD-K72898849,BLU9931,COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1,72710839.0,Preclinical,FGFR inhibitor,FGFR4,,,2264
1074,BRD-K94379058,BML-190,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1,2415.0,Preclinical,cannabinoid receptor inverse agonist,CNR2,,,56142
1076,BRD-K56509348,BMS-182874,CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C,122272.0,Phase 2,endothelin receptor antagonist,EDNRA,,,1909
1077,BRD-K95609758,BMS-191011,Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F,10474339.0,Preclinical,potassium channel activator,KCNMA1,,,3778
1081,BRD-K62814476,BMS-265246,CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F,5329775.0,Preclinical,CDK inhibitor,CDK1|CDK2,,,1017|983
1083,BRD-K87956243,BMS-309403,CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1,16122583.0,Preclinical,fatty acid binding protein inhibitor,FABP4,,,2167
1084,BRD-K13566078,BMS-345541,Cc1cnc2c(NCCN)nc3ccc(C)cc3n12,9813758.0,Preclinical,IKK inhibitor,CHUK|IKBKB,,,1147|3551
1085,BRD-K43389698,BMS-387032,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,3025986.0,Phase 1,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,CDK2|CDK7|CDK9,,,1025|1017|1022
1086,BRD-K22000702,BMS-470539,CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1,9915813.0,Preclinical,melanocortin receptor agonist,MC1R,,,4157
1087,BRD-K34581968,BMS-536924,Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1,135440466.0,Preclinical,IGF-1 inhibitor,AKT1|CCNE1|CDK2|CYP3A4|ERBB2|IGF1R|KDR|LCK|MAPK1|MET|PDGFRA|PDGFRB,,,898|5156|5159|1576|207|2064|3791|3480|1017|5594|8731|3932
1088,BRD-K56932272,BMS-566419,CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F,9913339.0,Preclinical,inosine monophosphate dehydrogenase inhibitor,IMPDH1|IMPDH2,,,727833|3615
1090,BRD-K20093108,BMS-587101,CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1,11635371.0,Phase 2,integrin antagonist,ITGAL|ITGB2,,,3689|3683
1091,BRD-K07106112,BMS-599626,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12,10437018.0,Phase 1,EGFR inhibitor|protein tyrosine kinase inhibitor,EGFR|ERBB2|ERBB4,,,2064|2066|1956
1094,BRD-K25991633,BMS-649,CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O,127019.0,Preclinical,retinoid receptor agonist,RXRA,,,6256
1095,BRD-K85649978,BMS-688521,CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1,11699447.0,Preclinical,ICAM1 antagonist|leukocyte function-associated antigen receptor antagonist,ICAM1,,,3383
1096,BRD-K76239644,BMS-690514,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,11349170.0,Phase 2,EGFR inhibitor|VEGFR inhibitor,EGFR|ERBB2|FLT3|KDR,,,2064|2322|1956|3791
1098,BRD-K13049116,BMS-754807,C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1,24785538.0,Phase 2,IGF-1 inhibitor,AKT1|IGF1R,,,3480|207
1100,BRD-K40738845,BMS-777607,CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,24794418.0,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,AXL|MERTK|MET|MST1R|TYRO3,,,7301|4486|558|8731|10461
1104,BRD-K81026553,BMS-817378,Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,44137813.0,Phase 1,c-Met inhibitor|VEGFR inhibitor,KDR|MET,,,8731|3791
1105,BRD-K33245965,BMS-833923,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1,57662985.0,Phase 2,smoothened receptor antagonist,SMO,,,54498
1106,BRD-K12511835,BMS-863233,Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1,135564632.0,Phase 1/Phase 2,CDC inhibitor,CDC7|PIM1,,,9361|8317
1111,BRD-K00004586,BMS-986020,C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1,49792850.0,Phase 2,lysophosphatidic acid receptor antagonist,LPAR1,,,1902
1116,BRD-K15119094,BMS-CCR2-22,CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F,24801690.0,Preclinical,CC chemokine receptor antagonist,CCR2,,,729230
1117,BRD-A15435692,BMY-14802,O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|,10020651.0,Phase 2,sigma receptor antagonist,HTR1A,,,3350
1118,BRD-K84895041,BMY-45778,OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1,127861.0,Preclinical,IP1 prostacyclin receptor agonist,PTGIR,,,5739
1119,BRD-K31054881,BMY-7378,COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,2419.0,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A,,,146|147|3350
1121,BRD-K18722736,BNTX,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1,5310988.0,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,,4985|4986|4988
1122,BRD-A09735281,boceprevir,"CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|",10324368.0,Launched,HCV inhibitor,CMA1|CTSA|CTSF|CTSK|CTSL|CTSS,infectious disease,hepatitis C,5476|1513|1514|1520|8722|1215
1127,BRD-K88510285,bortezomib,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,387447.0,Launched,NFkB pathway inhibitor|proteasome inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL),106480180|5682|5683|5684|5685|5686|5687|5688|5689|5690|5691|5692|5693|5694|5695|5696|5698|5699|5708|122706|5970|143471
1129,BRD-K74763371,bosentan,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,104865.0,Launched,endothelin receptor antagonist,EDNRA|EDNRB,pulmonary,pulmonary arterial hypertension (PAH),1909|1910
1130,BRD-K99964838,bosutinib,COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl,5328940.0,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK,hematologic malignancy,chronic myeloid leukemia (CML),6789|6793|2444|25|57118|11183|818|6714|10188|106480993|4067|5604|5605|2534|8428|3055|1017|10746|7294
1131,BRD-K45479396,BP-554,C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1,134117.0,Preclinical,serotonin receptor agonist,HTR1A,,,3350
1132,BRD-K17378184,BP-897,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1,3038495.0,Phase 2,dopamine receptor agonist,ADRA1A|ADRA1D|ADRA2A|DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2B,,,1815|146|1812|1813|150|1814|3350|106480180
1133,BRD-K00003554,BQ-123,[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C,443289.0,Phase 2,endothelin receptor antagonist,EDNRA,,,1909
1134,BRD-K02490038,BQ-788,CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O,5311032.0,Phase 1,endothelin receptor antagonist,EDNRB,,,1910
1135,BRD-A40257118,BQU57,"Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|",,Preclinical,Ras GTPase inhibitor,RALA|RALB,,,5898|5899
1136,BRD-K72264770,BRD4770,COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1,72193870.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,,10919
1137,BRD-K15107389,BRD7389,O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23,1080352.0,Preclinical,ribosomal protein inhibitor,RPS6KA1|RPS6KA2|RPS6KA3,,,6195|6196|6197
1138,BRD-K89329876,BRD9876,CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N,613000.0,Preclinical,kinesin inhibitor,KIF11,,,3832
1139,BRD-K77841042,brefeldin-A,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|",5287620.0,Preclinical,protein synthesis inhibitor,ARF1|CYTH2,,,9266|442334
1140,BRD-K06328344,bremelanotide,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O,,Launched,melanocortin receptor agonist,MC1R|MC2R|MC3R|MC4R|MC5R,neurology/psychiatry,hypoactive sexual desire disorder,4160|4161|4157|4158|4159
1141,BRD-K96123349,brequinar,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,57030.0,Phase 2,dihydroorotate dehydrogenase inhibitor,DHODH,,,1723
1142,BRD-K96936751,bretazenil,CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21,107926.0,Phase 2,GABA benzodiazepine site receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,,2554|2555|2556|2557|2558|2559
1143,BRD-K49669424,bretylium,CC[N+](C)(C)Cc1ccccc1Br,2431.0,Launched,norepinephrine inhibitor,ATP1A1,cardiology,ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT),476
1144,BRD-K00911143,brexpiprazole,O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1,11978813.0,Launched,dopamine receptor partial agonist,DRD2,neurology/psychiatry,depression|schizophrenia,1813
1145,BRD-K05531427,briciclib,COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1,11248490.0,Phase 1,cyclin D inhibitor,CCND1,,,595
1146,BRD-K56981171,brigatinib,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1,68165256.0,Launched,ALK tyrosine kinase receptor inhibitor|EGFR inhibitor,ALK|EGFR,oncology,non-small cell lung cancer (NSCLC),1956|238
1148,BRD-K68264559,brimonidine,Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|,2435.0,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,152|150|151
1150,BRD-K74913225,brinzolamide,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,68844.0,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA5A|CA7,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,771|23632|759|760|762|763|766
1151,BRD-K28428262,brivanib,C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,11234052.0,Phase 3,FGFR inhibitor|VEGFR inhibitor,CYP3A4|FGFR1|FLT1|KCNH2|KDR,,,1576|3757|3791|2321|2260
1152,BRD-K57187269,brivanib-alaninate,C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N,11154925.0,Phase 3,FGFR inhibitor|VEGFR inhibitor,FGFR3,,,2261
1154,BRD-K01826777,BRL-15572,O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|,92844253.0,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6,,,3362|106480180|3350|3351|3352|3354|3355|3356|3358
1155,BRD-A57806482,BRL-26314,"OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|",14259155.0,Phase 1,cholesterol inhibitor,LPL,,,3936
1156,BRD-K07507905,BRL-37344,C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,9841972.0,Phase 2,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,,153|154|155
1157,BRD-K01825677,BRL-44408,"C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|",6604824.0,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C,,,152|150|151
1158,BRD-K84266862,BRL-50481,CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,2921148.0,Preclinical,phosphodiesterase inhibitor,PDE7A|PDE7B,,,27115|5150
1159,BRD-A37347161,BRL-52537,Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|,14810948.0,Preclinical,opioid receptor agonist,OPRK1,,,4986
1160,BRD-K17868609,BRL-54443,CN1CCC(CC1)c1c[nH]c2ccc(O)cc12,2438.0,Preclinical,serotonin receptor agonist,HTR1E|HTR1F,,,3354|3355
1161,BRD-K76021681,brolitene,OCCNC(=O)\C=C\c1ccccc1,1550874.0,Launched,muscle relaxant,RYR1,rheumatology,lumbago,6261
1164,BRD-K47679368,bromfenac,Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1,60726.0,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,,,5742|5743
1168,BRD-K14496212,bromocriptine,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|,31101.0,Launched,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7,endocrinology|neurology/psychiatry,hyperprolactinemia|Parkinson's Disease|acromegaly,3352|3362|3363|1815|1816|146|147|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358
1169,BRD-K73642618,bromopride,CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,2446.0,Launched,dopamine receptor antagonist,DRD2,gastroenterology,nausea|vomiting|gastroesophageal reflux disease (GERD),1813
1171,BRD-K78643075,bromperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1,2448.0,Launched,dopamine receptor antagonist,DRD2,neurology/psychiatry,schizophrenia,1813
1172,BRD-K01825159,brompheniramine,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|,16960.0,Launched,histamine receptor antagonist,HRH1,allergy|otolaryngology,allergic rhinitis|common cold,3269
1176,BRD-A08316590,broxaterol,"CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|",13626987.0,Phase 3,adrenergic receptor agonist,ADRB2,,,154
1180,BRD-K68077509,brucine,COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|,442021.0,Preclinical,glycine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,,1128|1129|1131|1132|1133
1181,BRD-K31313613,BS-181,CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12,49867929.0,Preclinical,CDK inhibitor,CDK7,,,1022
1183,BRD-K37933329,BTB06584,[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1,2799764.0,Preclinical,ATPase inhibitor,ATP5F1,,,515
1184,BRD-K89000287,BTB1,[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1,291461.0,Preclinical,mitotic kinesin inhibitor,KIF18A,,,81930
1187,BRD-A68304895,BTS-54505,CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|,9900576.0,Withdrawn,dopamine reuptake inhibitor,SLC6A2|SLC6A3|SLC6A4,,,6530|6531|6532
1189,BRD-A65793993,BTS-72664,"C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|",1480409.0,Phase 1,GABA receptor antagonist,GABBR1,,,10537
1190,BRD-K01492390,BTT-3033,CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1,49841251.0,Preclinical,integrin inhibitor,ITGA2|ITGB1,,,3688|3673
1192,BRD-K55344148,BU-224,C1CN=C(N1)c1ccc2ccccc2n1 |c:2|,2457.0,Preclinical,imidazoline receptor ligand,MAOA|MAOB,,,4128|4129
1197,BRD-A94624445,bucladesine,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|",9687.0,Launched,adenosine receptor agonist|cAMP stimulant,PRKACA,dermatology,skin ulcer,5578
1198,BRD-K01825692,bucladesine,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|",9687.0,Launched,adenosine receptor agonist|cAMP stimulant,PRKACA,dermatology,skin ulcer,5578
1199,BRD-A91444184,buclizine,CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|,3246096.0,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,migraine headache,3269
1200,BRD-A34299591,budesonide,"CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|",63006.0,Launched,glucocorticoid receptor agonist,NR3C1,gastroenterology,Crohn's disease,2908
1201,BRD-K18324993,budipine,CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1,68778.0,Launched,glutamate receptor antagonist,GRIN1,neurology/psychiatry,Parkinson's Disease,114787
1202,BRD-K36660044,bufexamac,CCCCOc1ccc(CC(=O)NO)cc1,2466.0,Withdrawn,cyclooxygenase inhibitor,HDAC10|HDAC6,,,10013|83933
1203,BRD-K19462402,buflomedil,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,2467.0,Launched,adrenergic receptor antagonist|calcium channel blocker,ADRA1A,cardiology,peripheral artery disease (PAD),146
1204,BRD-K38197229,bumetanide,CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O,2471.0,Launched,solute carrier family member inhibitor,CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5,cardiology,edema|congestive heart failure,6560|2859|1080|57468|6557|6558
1205,BRD-K35034482,bunazosin,CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1,2472.0,Launched,adrenergic receptor antagonist,ADRA1A,ophthalmology,glaucoma|intraocular pressure,146
1206,BRD-K42191735,buparlisib,Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,16654980.0,Phase 3,PI3K inhibitor,PIK3CA|PIK3CG,,,5290|5294
1208,BRD-A36267905,buphenine,CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1,657392.0,Launched,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,154
1209,BRD-K51700582,bupicomide,CCCCc1ccc(nc1)C(N)=O,31447.0,Phase 1,adrenergic receptor antagonist,ADRB1,,,153
1210,BRD-K00003636,bupivacaine,"CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9,r|",92253.0,Launched,sodium channel blocker,KCNA5|SCN10A,neurology/psychiatry,peripheral nerve block|caudal epidural block|lumbar epidural block,6336|3741
1211,BRD-A48420483,bupranolol,"Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|",66601885.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology|ophthalmology,hypertension|glaucoma,153|154|155
1212,BRD-K01826729,bupropion,"C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1,r|",688387.0,Launched,dopamine reuptake inhibitor,SLC6A2|SLC6A3,neurology/psychiatry,depression,6530|6531
1215,BRD-K93461745,buspirone,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,2477.0,Launched,serotonin receptor agonist,DRD2|HTR1A,neurology/psychiatry,generalized anxiety disorder (GAD),1813|3350
1217,BRD-K40581315,butabindide,CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC,9817923.0,Preclinical,tripeptidyl peptidase inhibitor,TPP2,,,7174
1219,BRD-K20620780,butaclamol,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34,37459.0,Phase 2,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A,,,1812|1813|1814|1815|1816|3350|3356
1220,BRD-K71350836,butalbital,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,2481.0,Launched,GABA receptor antagonist,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2,neurology/psychiatry,headache|muscle relaxant,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|2891|2901|89832|1137|2554|2555|2556|2557|2558|2559
1223,BRD-K17497770,butein,Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1,5281222.0,Preclinical,EGFR inhibitor|SRC inhibitor,ACE,,,1636
1224,BRD-K90630139,butenafine,CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12,2484.0,Launched,fungal squalene epoxidase inhibitor,SQLE,infectious disease,tinea pedis|tinea cruris|tinea corporis,6713
1225,BRD-A47706533,buthionine-sulfoximine,"CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|",1548918.0,Phase 1,glutathione transferase inhibitor,GCLM,,,2730
1231,BRD-K53153417,butylated-hydroxytoluene,Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,31404.0,Phase 1,carbonic anhydrase inhibitor,CA2,,,760
1233,BRD-A59378440,butylphthalide,"CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|",9990075.0,Launched,potassium channel antagonist,KCNK2,neurology/psychiatry,stroke,3776
1236,BRD-K01742705,BVT-2733,CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1,6918651.0,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,HSD17B1,,,3292
1237,BRD-K68567222,BVT-948,CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|,6604934.0,Preclinical,tyrosine phosphatase inhibitor,PTPN1|PTPN11|PTPN2,,,5770|5771|5781
1238,BRD-K00003548,BW-180C,CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,6917707.0,Phase 2,opioid receptor agonist,OPRD1|OPRM1,,,4985|4988
1240,BRD-K74990253,BW-373U86,CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1,119029.0,Preclinical,opioid receptor agonist,OPRD1,,,4985
1241,BRD-K07061232,BW-616U,CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1,11722381.0,Preclinical,monoamine oxidase inhibitor,MAOA,,,4128
1242,BRD-K01826747,BW-723C86,C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|,40418385.0,Preclinical,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
1243,BRD-K80194255,BW-A4C,CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1,6438354.0,Phase 1,lipoxygenase inhibitor,ALOX5,,,240
1244,BRD-A55946879,BW-B70C,"C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|",88473969.0,Preclinical,lipoxygenase inhibitor,ALOX5,,,240
1245,BRD-K47983010,BX-795,Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1,10077147.0,Preclinical,IKK inhibitor,CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1,,,3791|5170|2932|1111|1017
1246,BRD-K49669041,BX-912,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1,11754511.0,Preclinical,pyruvate dehydrogenase kinase inhibitor,CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1,,,3791|5170|2932|1111|1017
1247,BRD-K61665160,BYK-204165,Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12,25113764.0,Preclinical,PARP inhibitor,PARP1,,,142
1248,BRD-K98179423,C-021,COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1,25141190.0,Preclinical,CC chemokine receptor antagonist,CCR4,,,57472
1249,BRD-K72462751,C-1,O=S(=O)(N1CCNCC1)c1cccc2cnccc12,3545.0,Preclinical,protein kinase inhibitor,PRKCA,,,5578
1252,BRD-K83914624,C11-Acetate,[Y+3],168049.0,Phase 3,,ABAT|ACE|AKR1C3|CA2|CELA1|ESR2|FFAR2|FFAR3|HPRT1|LTA4H|MMP12|NOS1|NOS3|PLA2G1B|PTPN1|SOD1|TXN,,,4321|342977|8644|1636|1990|5319|25828|5770|340719|4048|2865|18|2867|2100|3251|6647|760
1254,BRD-K43167535,C34,CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O,91691128.0,Preclinical,toll-like receptor inhibitor,TLR4,,,7099
1255,BRD-K73383190,C646,CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|,2871948.0,Preclinical,histone acetyltransferase inhibitor,EP300,,,2033
1259,BRD-K10384176,cabazitaxel,CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|,9854073.0,Launched,microtubule inhibitor,TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,prostate cancer,7846|10376|84617|112714|347688|7277|7278|10381|7280|113457|10382|10383|347733|84790|203068
1260,BRD-K86882815,cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1,54746.0,Launched,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR7,endocrinology,hyperprolactinemia,146|147|1812|1813|150|1815|3352|3351|1816|151|152|153|154|1814|3356|3358|3363|106480180|3350
1262,BRD-K51544265,cabozantinib,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC,25102847.0,Launched,RET tyrosine kinase inhibitor|VEGFR inhibitor,KDR|MET|RET,oncology,medullary thyroid cancer (MTC),5979|8731|3791
1263,BRD-A90751343,CaCCinh-A01,"CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|",747218.0,Preclinical,calcium-activated chloride channel inhibitor,CLCA1,,,1179
1267,BRD-K09900591,caffeic-acid,OC(=O)\C=C\c1ccc(O)c(O)c1,689043.0,Preclinical,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,ALOX5|MIF,,,240|4282
1268,BRD-K96188950,caffeic-acid-phenethyl-ester,Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O,5281787.0,Preclinical,HIV integrase inhibitor,RELA,,,5970
1269,BRD-K02404261,caffeine,Cn1cnc2n(C)c(=O)n(C)c(=O)c12,2519.0,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADORA3|ATM|ITPR1|ITPR2|ITPR3|PDE10A|PDE11A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|PIK3CA|PIK3CB|PIK3CD|PRKDC|RYR1|RYR2|RYR3,neurology/psychiatry,fatigue|drowsiness,134|135|136|140|5136|5137|5138|5139|5140|5141|5142|5143|5144|5145|5146|5150|5151|5152|5153|5158|5290|5291|8622|8654|5591|472|10846|3708|22883|27115|6261|6262|6263|50940|3709|3710
1270,BRD-K77175907,calcifediol,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,5283731.0,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,1594
1271,BRD-K56429665,calcipotriol,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5288783.0,Launched,vitamin D receptor agonist,VDR,dermatology,psoriasis,1594
1273,BRD-K27316855,calcitriol,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5280453.0,Launched,vitamin D receptor agonist,VDR,endocrinology|orthopedics,hypocalcemia|hypoparathyroidism|osteoporosis,1594
1276,BRD-K19811997,Calhex-231,C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12,11849514.0,Preclinical,calcium sensing receptor negative allosteric modulator,CASR,,,846
1278,BRD-K23248433,camicinal,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1,15984937.0,Phase 2,motilin receptor agonist,MLNR,,,2862
1279,BRD-K35772771,CaMKII-IN-1,Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12,50898538.0,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,AKT1|CAMK2A|CAMK4|MYLK,,,4638|815|814|207
1281,BRD-K43806473,camostat-mesilate,CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1,2536.0,Launched,protease inhibitor,PRSS1,gastroenterology,pancreatitis,136541
1283,BRD-K15714472,camphor-(1R),CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2,5284500.0,Phase 1,TRPV activator,TRPV1,,,7442
1284,BRD-K37890730,camptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O,24360.0,Phase 3,topoisomerase inhibitor,TOP1,,,7150
1286,BRD-K90868879,canagliflozin,Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,24812758.0,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus,6523|6524
1287,BRD-K84091759,candesartan,CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,2541.0,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure,185
1290,BRD-K50168500,canertinib,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,156414.0,Phase 3,EGFR inhibitor,AKT1|EGFR|ERBB2|ERBB4,,,2064|2066|1956|207
1292,BRD-K81644801,canrenone,"C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|",13789.0,Withdrawn,mineralocorticoid receptor antagonist,NR3C2,,,4306
1294,BRD-K97025174,capadenoson,Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N,9936489.0,Phase 2,adenosine receptor agonist,ADORA1,,,134
1295,BRD-K61192372,capecitabine,CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,60953.0,Launched,DNA synthesis inhibitor|thymidylate synthase inhibitor,TYMS,oncology,breast cancer|colorectal cancer,7298
1300,BRD-K50590187,capsaicin,COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O,1548943.0,Launched,TRPV agonist,CFTR|TRPV1,neurology/psychiatry|rheumatology,muscle pain|rheumatoid arthritis,1080|7442
1301,BRD-K44849676,capsazepine,Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1,2733484.0,Preclinical,TRPV agonist,TRPV1|TRPV4,,,7442|59341
1304,BRD-K54529596,captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,44093.0,Launched,angiotensin converting enzyme inhibitor,ACE|LTA4H|MMP2|MMP9,cardiology|endocrinology|nephrology,hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy,4048|4313|1636|4318
1305,BRD-K62790656,caracemide,CNC(=O)ON(C(C)=O)C(=O)NC,54747.0,Phase 2,ribonucleotide reductase inhibitor,RRM1,,,6240
1306,BRD-K59895502,caramiphen,CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1,6472.0,Launched,cholinergic receptor antagonist,CHRM1|CHRM2,neurology/psychiatry,Parkinson's Disease,1128|1129
1307,BRD-A50675490,carazolol,"CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|",13023331.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,angina pectoris|cardiac arrythmia|hypertension|myocardial infarction,153|154|155
1308,BRD-K75037734,carbachol,C[N+](C)(C)CCOC(N)=O,2551.0,Launched,cholinergic receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2,ophthalmology,intraocular pressure,1128|1129|1131|1132|1133|1135
1310,BRD-K71799949,carbamazepine,NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|,2554.0,Launched,carboxamide antiepileptic,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335
1314,BRD-K12906202,carbendazim,COC(=O)Nc1nc2ccccc2[nH]1,25429.0,Launched,microtubule inhibitor|tubulin polymerization inhibitor,TP53|TUBB,infectious disease,fungicide,7280|7157
1316,BRD-K12765235,carbenoxolone,CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|,636403.0,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|HSD11B1|PANX1|PANX2|PANX3,gastroenterology|dental,peptic ulcer disease (PUD)|mouth inflammation,81025|2697|2700|2701|2702|2703|2705|2706|2707|2709|57369|127534|10804|125111|57165|24145|84694|3290|56666|349149|375519|116337|219770
1317,BRD-K06181161,carbetapentane,CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1,2562.0,Launched,acetylcholine receptor antagonist,CHRM2,otolaryngology|pulmonary,common cold|nasal congestion|bronchitis,1129
1318,BRD-K56107812,carbetocin,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,,Launched,oxytocin receptor agonist,OXTR,hematology,hemorrhage,5021
1319,BRD-K78712176,carbidopa,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O,34359.0,Launched,aromatic L-amino acid decarboxylase inhibitor,DDC,neurology/psychiatry,Parkinson's Disease,1644
1320,BRD-K87156652,carbimazole,CCOC(=O)n1ccn(C)c1=S,31072.0,Launched,antithyroid agent,TPO,endocrinology,hyperthyroidism,7066
1321,BRD-K01826745,carbinoxamine,CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|,170336.0,Launched,histamine receptor antagonist,HRH1,allergy|ophthalmology|otolaryngology|dermatology,allergic rhinitis|conjunctivitis|vasomotor rhinitis|dermatographism,3269
1323,BRD-K68408772,carboxyamidotriazole,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,108144.0,Phase 3,calcium channel blocker,CXCL8,,,3576
1324,BRD-K23533833,carboxylosartan,CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,108185.0,Phase 1,angiotensin antagonist,AGTR1,,,185
1327,BRD-K50905564,cardionogen-1,C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1,663145.0,Preclinical,WNT signaling inhibitor,CTNNB1,,,1499
1328,BRD-K49554218,carebastine,CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,65820.0,Phase 1,histamine receptor antagonist,HRH1,,,3269
1329,BRD-K15179879,carfilzomib,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,11556711.0,Launched,proteasome inhibitor,PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9,hematologic malignancy,multiple myeloma,5682|5683|5684|5685|5686|5687|5688|5689|5690|5691|5692|5693|5694|5695|5696|5698|5699|122706|143471
1330,BRD-K60240222,carglumic-acid,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,121396.0,Launched,carbamoyl phosphate synthase activator,CPS1,metabolism,hyperammonemia,1589
1331,BRD-K90215590,caricotamide,"NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|",403128.0,Phase 2,NADPH quinone oxidoreductase inhibitor,NQO2,,,4835
1332,BRD-K21670884,cariporide,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,151172.0,Phase 3,sodium/hydrogen exchanger inhibitor,SLC9A1,,,6548
1333,BRD-K57764956,cariprazine,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|,,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,schizophrenia,1813|1814
1334,BRD-K11630072,carmofur,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,2577.0,Launched,thymidylate synthase inhibitor,TYMS,oncology,breast cancer|colorectal cancer,7298
1335,BRD-K25095405,carmoterol,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,86306667.0,Phase 2,adrenergic receptor agonist,ADRB2,,,154
1336,BRD-K82484965,carmoxirole,OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|,86308157.0,Phase 2,dopamine receptor agonist,DRD2,,,1813
1337,BRD-K36234266,carmustine,[O-][NH2+]N(CCCl)C(=O)NCCCl,59087767.0,Launched,DNA alkylating agent|DNA inhibitor,GSR,hematologic malignancy|oncology,non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|multiple myeloma|glioblastoma|brainstem glioma|medulloblastoma|astrocytoma|ependymoma,2936
1341,BRD-K92129045,caroxazone,NC(=O)CN1Cc2ccccc2OC1=O,29083.0,Withdrawn,monoamine oxidase inhibitor,MAOA|MAOB,,,4128|4129
1342,BRD-A17411484,carprofen,"C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|",6997572.0,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,5743
1344,BRD-A42167015,carteolol,CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12,49852288.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,ophthalmology,intraocular pressure|glaucoma|ocular hypertension,153|154|155
1346,BRD-K01826535,carvedilol,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|,185394.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,myocardial infarction|hypertension,153|154|155
1347,BRD-K09295674,carzenide,NS(=O)(=O)c1ccc(cc1)C(O)=O,8739.0,Preclinical,,CA1|CA12|CA14|CA2|CA6|CA9,,,768|771|23632|759|760|765
1349,BRD-A25043798,casin,"OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|",1600664.0,Preclinical,GTPase inhibitor,CDC42,,,998
1351,BRD-K20897876,castanospermine,O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12,54445.0,Phase 2,glucosidase inhibitor,GAA|GBA,,,2548|2630
1353,BRD-K40269473,cathepsin-inhibitor-1,Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C,44224135.0,Preclinical,cathepsin inhibitor,CTSB|CTSL|CTSV,,,1514|1515|1508
1354,BRD-K40366680,CAY10505,Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1,1204893.0,Preclinical,PI3K inhibitor,PIK3CG,,,5294
1355,BRD-K41779183,CB-03-01,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|,11750009.0,Phase 3,androgen receptor antagonist,AR,,,367
1357,BRD-K49048664,CB-5083,Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O,73051434.0,Phase 1,valosin-containing protein inhibitor,VCP,,,7415
1358,BRD-K58070273,CB-839,FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1,71577426.0,Phase 2,glutaminase inhibitor,GLS,,,27165
1359,BRD-K34675210,CBiPES,CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N,9864510.0,Preclinical,glutamate receptor positive allosteric modulator,GRM2,,,2912
1361,BRD-K91874254,CBS-1114,NC(=NNc1ccccc1)c1ccccc1,6338223.0,Phase 1,lipoxygenase inhibitor,ALOX5,,,240
1362,BRD-K16755045,CC-115,"CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|",58298318.0,Phase 2,DNA protein kinase inhibitor|mTOR inhibitor,MTOR,,,2475
1363,BRD-K88737571,CC-223,CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|,,Phase 2,mTOR inhibitor,MTOR,,,2475
1364,BRD-K00004320,CC-401,C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1,10430360.0,Phase 1,JNK inhibitor,MAPK8,,,5599
1367,BRD-K17751100,CC4,O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12,91654624.0,Preclinical,nicotinic receptor agonist,CHRNB2,,,1141
1368,BRD-A79726147,CCG-1423,"C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|",40782280.0,Preclinical,apoptosis stimulant,RHOC|SRF,,,6722|389
1369,BRD-K08893438,CCG-50014,Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O,2733079.0,Preclinical,G protein signaling inhibitor,RGS4|RGS8,,,85397|5999
1370,BRD-K26970495,CCG-63802,Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1,6057678.0,Preclinical,G protein signaling inhibitor,RGS4,,,5999
1371,BRD-K68474505,CCG-63808,Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O,5948316.0,Preclinical,G protein signaling inhibitor,RGS4,,,5999
1372,BRD-K16338837,CCMI,Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1,67042344.0,Preclinical,acetylcholine receptor allosteric modulator,CHRNA7,,,89832
1374,BRD-K90999434,CCT-031374,O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|,2853753.0,Preclinical,WNT signaling inhibitor,CTNNB1,,,1499
1375,BRD-K65503129,CCT018159,CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O,984170.0,Preclinical,HSP inhibitor,HSP90AA1|HSP90AB1,,,3320|3326
1377,BRD-K57136142,CCT129202,CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1,16202152.0,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,,6795|9212|6790
1378,BRD-K03289018,CCT137690,CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1,25154041.0,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,,6795|9212|6790
1381,BRD-K09619322,CD-1530,OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2,9952709.0,Preclinical,retinoid receptor agonist,RARG,,,5916
1382,BRD-K28907958,CD-437,OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,135411.0,Preclinical,retinoid receptor agonist,RARG,,,5916
1384,BRD-K87932577,CDK1-5-inhibitor,Nc1[nH]nc2nc3ccccc3nc12,438981.0,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK5|GSK3B,,,2932|1020|983
1385,BRD-K43914553,CDK9-IN-6,COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1,,Preclinical,CDK inhibitor,CDK9,,,1025
1386,BRD-K02213468,CDPPB,O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N,11245456.0,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,,2915
1387,BRD-A47940219,CE3F4,"C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|",73669656.0,Preclinical,rap guanine nucleotide exchange factor inhibitor,RAPGEF3,,,10411
1388,BRD-K48141473,cebranopadol,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|,,Phase 3,opioid receptor agonist,OPRL1|OPRM1,,,4987|4988
1389,BRD-K86930074,cediranib,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,9933475.0,Phase 3,KIT inhibitor|VEGFR inhibitor,CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB,,,5156|3815|5159|3791|2321|2322|2324|1436
1393,BRD-K63242551,cefadroxil,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|,6560167.0,Launched,bacterial cell wall synthesis inhibitor,SLC15A1|SLC15A2|SLC22A6|SLC22A8,infectious disease|otolaryngology,urinary tract infections|skin infections|tonsillitis|pharyngitis,9376|9356|6564|6565
1398,BRD-K99750640,cefazolin,Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|,33255.0,Launched,bacterial cell wall synthesis inhibitor,PON1,infectious disease,urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections,5444
1400,BRD-K15766189,cefdinir,Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|,6915944.0,Launched,bacterial cell wall synthesis inhibitor,MPO,infectious disease|otolaryngology|pulmonary,pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis,4353
1425,BRD-K13797099,cefradine,"CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|",40467109.0,Launched,bacterial cell wall synthesis inhibitor,CYP3A4,infectious disease|otolaryngology,respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia,1576
1436,BRD-K02637541,celecoxib,Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,2662.0,Launched,cyclooxygenase inhibitor,CA12|PDPK1|PTGS2,rheumatology|endocrinology,osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD),5170|771|5743
1438,BRD-A95602221,celiprolol,CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|,11406333.0,Launched,adrenergic receptor antagonist,ADRA2A|ADRB1|ADRB2,genetics,Ehlers-Danlos syndrome (EDS),153|154|150
1446,BRD-K20722021,CEP-32496,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,56846693.0,Phase 1/Phase 2,RAF inhibitor,BRAF|RAF1,,,673|6037
1447,BRD-K37237504,CEP-33779,CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1,57336812.0,Preclinical,JAK inhibitor,JAK2,,,3717
1448,BRD-K72827473,CEP-37440,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,71721648.0,Phase 1,ALK tyrosine kinase receptor inhibitor,ALK,,,238
1458,BRD-K22149900,ceritinib,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,57379345.0,Launched,ALK tyrosine kinase receptor inhibitor,ALK|FLT3|IGF1R|INSR|TSSK1B,oncology,non-small cell lung cancer (NSCLC),83942|238|2322|3480|3643
1459,BRD-K52075040,cerulenin,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O,5282054.0,Launched,fatty acid synthase inhibitor,FASN,infectious disease,fungal infection,2194
1460,BRD-K00003320,ceruletide,[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,16129675.0,Preclinical,CCK receptor agonist,CCKAR,,,886
1461,BRD-K86954340,cetaben,CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O,47263.0,Phase 2,ACAT inhibitor|cholesterol inhibitor,PPARA,,,5465
1462,BRD-K94863486,cetilistat,CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1,9952916.0,Phase 3,triacylglycerol lipase inhibitor,PNLIP,,,5406
1463,BRD-K01826520,cetirizine,OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|,28145930.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269
1465,BRD-K76315403,cetrorelix,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,25074887.0,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR|LHCGR,endocrinology,premature luteinizing hormone surges,3973|2798
1467,BRD-K00004291,cevimeline,"C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1,3|",18642481.0,Launched,acetylcholine receptor agonist,CHRM3,rheumatology,sjogren's syndrome,1131
1468,BRD-K00003570,cevipabulin,[H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F,11488110.0,Phase 1,microtubule stimulant|tubulin polymerization inhibitor,TUBB,,,7280
1469,BRD-K52396582,CF102,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12,3035850.0,Phase 2,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
1474,BRD-K72004355,CFTRinh-172,OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1,1554210.0,Preclinical,chloride channel blocker,CFTR,,,1080
1476,BRD-K82028950,CGH2466,Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1,5282339.0,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2B|ADORA3,,,136|140|134
1477,BRD-A50737080,CGK-733,"[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|",92509770.0,Preclinical,ATM kinase inhibitor|ATR kinase inhibitor,ATM|ATR,,,472|545
1478,BRD-K79584249,CGM097,COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1,,Phase 1,MDM inhibitor,MDM2,,,4193
1479,BRD-A40084411,CGP-12177,CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|,76962943.0,Phase 1,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,,153|154|155
1480,BRD-K95851186,CGP-13501,CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C,3519541.0,Preclinical,GABA receptor modulator,GABBR1,,,10537
1481,BRD-K01827291,CGP-20712A,"CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|",91667713.0,Preclinical,adrenergic receptor antagonist,ADRB1|ADRB3,,,153|155
1483,BRD-A35623999,CGP-37157,"Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|",6604821.0,Preclinical,mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor,SLC8A1,,,6546
1484,BRD-A90272038,CGP-37849,"C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|",6604869.0,Phase 1,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,2904|2905|2906|2903
1486,BRD-K13087974,CGP-52411,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12,1697.0,Preclinical,EGFR inhibitor,EGFR,,,1956
1487,BRD-K32292990,CGP-53353,Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1,6711154.0,Preclinical,EGFR inhibitor|PKC inhibitor,EGFR|PRKCB,,,5579|1956
1488,BRD-A74208568,CGP-54626,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|",197584.0,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,,9568|115207|10537|57528|386617
1489,BRD-K00004232,CGP-55845,C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1,5311042.0,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,,9568|115207|10537|57528|386617
1490,BRD-K42500029,CGP-57380,Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12,11644425.0,Preclinical,MAP kinase inhibitor,AURKB|LCK|MKNK1|MKNK2|SGK1,,,3932|6446|2872|8569|9212
1491,BRD-K79090631,CGP-60474,OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1,644215.0,Preclinical,CDK inhibitor,CDK1|CDK2,,,1017|983
1492,BRD-K34321528,CGP-71683,Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|,,Preclinical,neuropeptide receptor antagonist,NPY5R,,,4889
1493,BRD-K56239177,CGP-74514,CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12,2794188.0,Preclinical,CDK inhibitor,CDK1,,,983
1495,BRD-K65786282,CGP-7930,CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,5024764.0,Preclinical,GABA receptor modulator,GABBR1,,,10537
1496,BRD-K49049886,CGS-15943,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,2690.0,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
1497,BRD-K68103045,CGS-20625,COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O,163844.0,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,,2554|2555|2556|2557|2558|2559
1498,BRD-K27176996,CGS-21680,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12,3086599.0,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
1499,BRD-K54093161,CGS-9896,Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O,108030.0,Preclinical,GABA receptor antagonist,GABRA1|GABRB2|GABRG2,,,2561|2554|2566
1501,BRD-K11683436,CH-5183284,Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N,66555680.0,Phase 2,fibroblast growth factor inhibitor,FGFR1|FGFR2|FGFR3,,,2260|2261|2263
1502,BRD-K22314899,CH223191,Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1,,Preclinical,aryl hydrocarbon receptor antagonist,AHR,,,196
1503,BRD-K28352084,CH5132799,CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1,49784945.0,Phase 1,PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,22883|5290|2475|5291|5294
1504,BRD-K71487808,CH55,CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O,6184667.0,Preclinical,retinoid receptor binder,RARA|RARB,,,5914|5915
1505,BRD-K60302405,CHC,OC(=O)C(=C\c1ccc(O)cc1)\C#N,5328791.0,Preclinical,monocarboxylate transporter inhibitor,SLC16A1,,,6566
1506,BRD-K18135438,chenodeoxycholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,10133.0,Launched,11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist,HSD11B1|NR1H4,cardiology|gastroenterology,cerebral cholesterosis|gallstones,3290|9971
1507,BRD-K34508702,CHF5074,OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1,9996409.0,Phase 2,gamma secretase modulator,PSEN1,,,5663
1508,BRD-K56483981,chicago-sky-blue-6b,"COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|",6817703.0,Preclinical,glutamate inhibitor|macrophage migration inhibiting factor inhibitor,MIF,,,4282
1509,BRD-K28537285,chidamide,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,9800555.0,Launched,HDAC inhibitor,HDAC10|HDAC3,hematologic malignancy,peripheral T-cell lymphoma (PTCL),8841|83933
1511,BRD-K02241333,CHIR-124,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,135399748.0,Preclinical,CHK inhibitor,CHEK1,,,1111
1512,BRD-K42973005,CHIR-98014,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,53396311.0,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B,,,2931|2932
1513,BRD-K16189898,CHIR-99021,Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl,9956119.0,Preclinical,glycogen synthase kinase inhibitor,CDK1|GSK3A|GSK3B|MAPK1,,,5594|2931|2932|983
1517,BRD-K08111712,chloramphenicol,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,5959.0,Launched,bacterial 50S ribosomal subunit inhibitor,CD55,infectious disease|endocrinology,meningitis|fever|cholera,1604
1526,BRD-K18030938,chlorisondamine-diiodide,C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl,6244.0,Preclinical,acetylcholine receptor antagonist,CHRNA1,,,1134
1527,BRD-K38704569,chlormadinone-acetate,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",9324.0,Launched,5 alpha reductase inhibitor,PGR,endocrinology,hypermenorrhea|amenorrhea|oligomenorrhea|polymenorrhea,5241
1528,BRD-A20348246,chlormezanone,"CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|",6604211.0,Withdrawn,GABA receptor modulator,GABRA1,,,2554
1532,BRD-K47114202,chlorogenic-acid,O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O,1794427.0,Launched,antioxidant,SLC37A4,neurology/psychiatry|pulmonary|allergy,headache|chest congestion|allergic rhinitis,2542
1535,BRD-K86864073,chloroprocaine,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,8612.0,Launched,sodium channel blocker,ATP1A1|CHRNA10|GRIN3A|HTR3A|SCN10A|SLC6A3,neurology/psychiatry,local anesthetic,6336|6531|116443|476|57053|3359
1536,BRD-K83257731,chloropyramine,CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,25295.0,Launched,histamine receptor antagonist,HRH1,cardiology|ophthalmology|allergy|pulmonary,edema|conjunctivitis|allergic rhinitis|asthma,3269
1537,BRD-A91699651,chloroquine,CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|,444810.0,Launched,antimalarial agent,MRGPRX1,infectious disease,malaria|amebiasis,259249
1538,BRD-K88682005,chlorothiazide,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|,2720.0,Launched,diuretic,CA1|CA2|CA4|SLC12A3,cardiology,hypertension,760|762|6559|759
1540,BRD-K27062708,chlorotrianisene,COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1,11289.0,Launched,estrogenic hormone,ESR1|ESR2,endocrinology|oncology,menopause|prostate cancer,2099|2100
1541,BRD-K17075857,chloroxine,Oc1c(Cl)cc(Cl)c2cccnc12,2722.0,Launched,opioid receptor antagonist,OPRK1,gastroenterology|infectious disease|dermatology,diarrhea|inflammatory bowel disease|giardiasis|dandruff,4986
1548,BRD-K25494650,chlorproguanil,CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1,9571037.0,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,1719
1549,BRD-K89997465,chlorpromazine,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12,2726.0,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALM1|CHRM1|CHRM3|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR2A|HTR2B|HTR2C|HTR6|HTR7|KCNH2|ORM1|ORM2|SMPD1|TRPC5,neurology/psychiatry|gastroenterology|hematology|infectious disease,schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus,5004|5005|146|147|1812|1813|150|1815|1816|151|152|1814|3350|3356|3358|801|3362|3363|3757|106480180|7224|3269|59340|6609|1128|1131
1550,BRD-K97746869,chlorpropamide,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,2727.0,Launched,ATP channel blocker,ABCC8|KCNJ10,endocrinology,diabetes mellitus,6833|3766
1552,BRD-K36207157,chlorprothixene,CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12,667467.0,Launched,dopamine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C,neurology/psychiatry,schizophrenia|bipolar disorder,3269|1128|1129|1131|1132|1133|1812|1813|1814|106480180|3356|3358
1553,BRD-K08303368,chlorpyrifos,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,2730.0,Launched,acetylcholinesterase inhibitor,ACHE,,,43
1556,BRD-A26384407,chlorthalidone,"NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|",688424.0,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7|SLC12A1,cardiology|gastroenterology|rheumatology|nephrology,hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure,771|23632|759|760|762|6557|766
1557,BRD-K98174813,chlorzoxazone,Clc1ccc2oc(=O)[nH]c2c1,2733.0,Launched,bacterial 30S ribosomal subunit inhibitor,KCNMA1|KCNN4,neurology/psychiatry,muscle relaxant,3778|3783
1558,BRD-K62779383,cholecalciferol,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,5280795.0,Launched,,VDR,endocrinology,vitamin D deficiency,1594
1559,BRD-K19338361,cholesterol,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|,5997.0,Preclinical,,RORA,,,6095
1560,BRD-K43164539,cholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,221493.0,Launched,bile acid,ADH1C|CES1|COX4I1|COX5A|COX5B|COX6A2|COX6B1|COX6C|COX7A1|COX7B|COX7C|COX8A|ESRRG|FABP6|FECH|GPBAR1|MT-CO1|MT-CO2|MT-CO3|PLA2G1B,gastroenterology|neurology/psychiatry|genetics,bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome,9377|1345|1346|1349|1350|1351|5319|1066|151306|2235|107075310|1327|2172|1329|2104|1339|1340|126
1561,BRD-K77300776,choline,C[N+](C)(C)CCO,305.0,Phase 3,acetylcholine precursor,ACHE|BCHE|CHRNA2|PCYT1A|PCYT1B|PHOSPHO1|PLD1|PLD2,,,162466|5130|43|590|1135|5589|5338|9468
1563,BRD-A19381518,CHPG,"N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|",6604802.0,Preclinical,glutamate receptor agonist,GRM5,,,2915
1564,BRD-K76259716,CHR-6494,CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1,70679308.0,Preclinical,serine/threonine kinase inhibitor,GSG2,,,83903
1569,BRD-K22861715,chrysin,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1,5281607.0,Phase 1,breast cancer resistance protein inhibitor,AKR1B1|CDK6|CYP19A1|CYP1B1,,,1545|1588|1021|231
1570,BRD-K59284035,chrysophanic-acid,Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,10208.0,Preclinical,EGFR inhibitor,EGFR|MTOR,,,2475|1956
1575,BRD-K67680372,CI-966,OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|,198693.0,Phase 1,GAT inhibitor,SLC6A1,,,6529
1576,BRD-K88544581,CI-976,CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC,122327.0,Phase 1,ACAT inhibitor,ACAT1|CES1,,,1066|6646
1578,BRD-K58736316,cianidanol,O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1,9064.0,Withdrawn,fatty acid synthase inhibitor,PTGS1,,,5742
1580,BRD-K35245662,ciclesonide,"CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|",6918155.0,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis,866|2908
1581,BRD-K13044802,ciclopirox,Cc1cc(C2CCCCC2)n(O)c(=O)c1,2749.0,Launched,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,476
1582,BRD-A94965935,cicloprofen,"C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|",14694110.0,Preclinical,cyclooxygenase inhibitor,PTGS1|PTGS2,,,5742|5743
1583,BRD-K00004311,CID-16020046,"Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|",51436118.0,Preclinical,G protein-coupled receptor antagonist,GPR55,,,9290
1584,BRD-K92781136,CID-2011756,Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1,2011756.0,Preclinical,protein kinase inhibitor,PKD1,,,5310
1585,BRD-K06405316,CID-2745687,COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F,9581011.0,Preclinical,G protein-coupled receptor antagonist,GPR35,,,2859
1586,BRD-A08840375,CID-5458317,"OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|",,Preclinical,MAP kinase phosphatase inhibitor,MAPK3,,,5595
1588,BRD-A93000692,ciglitazone,CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|,6604850.0,Phase 2,PPAR receptor agonist,PPARG,,,5468
1589,BRD-K85518562,cilastatin,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O,6435415.0,Launched,dehydropeptidase inhibitor,DPEP1,,,1800
1590,BRD-K96177243,cilazapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O,56330.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure,1636
1591,BRD-K57252450,cilengitide,CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,176873.0,Phase 3,integrin antagonist,ITGAV|ITGB3,,,3690|3685
1592,BRD-K00004281,cilnidipine,"COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|",28248392.0,Launched,calcium channel blocker,CACNA1B,cardiology,hypertension,774
1594,BRD-K00003550,cilomilast,COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|,,Phase 3,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4D,,,5144|5141|5142
1595,BRD-K28578425,cilostamide,CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1,2753.0,Preclinical,phosphodiesterase inhibitor,PDE3A|PDE3B,,,5139|5140
1596,BRD-K67017579,cilostazol,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,2754.0,Launched,phosphodiesterase inhibitor,PDE3A|PDE3B,cardiology,claudication,5139|5140
1598,BRD-A75514485,CIM-0216,"Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|",25331887.0,Preclinical,transient receptor potential channel agonist,TRPM3,,,80036
1599,BRD-A65440446,cimaterol,"CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|",10911051.0,Preclinical,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,,153|154|155
1600,BRD-K34157611,cimetidine,CN\C(NCCSCc1[nH]cnc1C)=N/C#N,2756.0,Launched,histamine receptor antagonist,HRH2|SLC29A4|SLC47A1|SLC47A2,gastroenterology|hematologic malignancy|endocrinology,duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma,1665|222962|55244|146802
1601,BRD-A99899486,cimetropium,"C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|",,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,1128
1602,BRD-K73838513,cinacalcet,C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,156419.0,Launched,calcium channel activator,CASR,endocrinology|nephrology|oncology,hyperparathyroidism|chronic kidney disease (CKD)|parathyroid carcinoma|hypercalcemia,846
1603,BRD-K73440166,cinaciguat,OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O,9808022.0,Phase 2,guanylate cyclase activator,GUCY1A3|GUCY1B3,,,2982|2983
1604,BRD-K53720352,cinalukast,CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O,6436135.0,Phase 2,leukotriene receptor antagonist,CYSLTR1,,,10800
1605,BRD-K40901640,cinanserin,CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1,5475158.0,Preclinical,serotonin receptor antagonist,HTR2A,,,3356
1606,BRD-K99121711,cinchocaine,CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1,3025.0,Launched,sodium channel blocker,CALM1|SCN10A|SCN5A,neurology/psychiatry,local anesthetic,6336|801|6331
1608,BRD-K36551084,cinchonine,O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12,90454.0,Preclinical,P glycoprotein inhibitor,CYP2D6,,,1565
1613,BRD-K26875402,cinnamaldehyde,O=C\C=C\c1ccccc1,637511.0,Preclinical,aldose reductase inhibitor|TRPV agonist,TRPA1,,,8989
1619,BRD-K24570280,CINPA-1,CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1,969470.0,Preclinical,CAR antagonist,NR1H4|NR1I3|PPARG,,,9970|9971|5468
1625,BRD-K95362002,cipemastat,CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C,9824350.0,Phase 3,metalloproteinase inhibitor,ADAM17|MMP1|MMP13|MMP2|MMP3|MMP8|MMP9,,,4322|6868|4312|4313|4314|4317|4318
1626,BRD-A49358627,ciprofibrate,"CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|",9882424.0,Launched,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,5465
1627,BRD-K04804440,ciprofloxacin,OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,4011971.0,Launched,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology,otitis,7153
1628,BRD-K01767299,ciproxifan,O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1,6422124.0,Preclinical,histamine receptor antagonist,ADRA2A|ADRA2C|HRH3|HRH4|HTR3A,,,59340|150|11255|152|3359
1629,BRD-A35425966,CIQ,"COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|",40450008.0,Preclinical,glutamate receptor potentiator,GRIN2C|GRIN2D,,,2905|2906
1630,BRD-K54142781,cirazoline,C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|,2765.0,Preclinical,adrenergic receptor agonist,ADRA1A,,,146
1632,BRD-K71756122,cis-aconitic-acid,OC(=O)C\C(=C\C(O)=O)C(O)=O,643757.0,Preclinical,,ACO2,,,50
1633,BRD-K00004205,cis-ACPD,"[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|",231345.0,Preclinical,glutamate receptor agonist,GRM2|GRM3|GRM6|GRM7|GRM8,,,2912|2913|2916|2917|2918
1634,BRD-K41962502,"cis-exo-camphanediol-2,3",CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O,21626088.0,Phase 1,nitric oxide stimulant,NOS3,,,342977
1635,BRD-K52670952,cis-urocanic-acid,OC(=O)\C=C\c1cnc[nH]1,736715.0,Phase 2,serotonin receptor agonist,HTR2A,,,3356
1636,BRD-K25146005,cis-urocanic-acid,OC(=O)\C=C/c1cnc[nH]1,1549103.0,Phase 2,serotonin receptor agonist,HTR2A,,,3356
1637,BRD-K06895174,cisapride,CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC,6917698.0,Withdrawn,serotonin receptor agonist,HTR2A|HTR3A|HTR4|KCNH2,,,3360|3356|3757|3359
1638,BRD-K17498618,cisatracurium,COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC,62887.0,Launched,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry|critical care,muscle relaxant|endotracheal intubation,1135
1639,BRD-K69172251,cisplatin,N[Pt](N)(Cl)Cl,86820626.0,Launched,DNA alkylating agent|DNA synthesis inhibitor,XIAP,oncology,testicular carcinoma|ovarian cancer|bladder cancer,331
1640,BRD-A47598013,citalopram,CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|,146570.0,Launched,selective serotonin reuptake inhibitor (SSRI),ADRA1A|CHRM1|HRH1|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,6530|6531|6532|3269|1128|146
1642,BRD-K53263234,CITCO,Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1,9600409.0,Preclinical,constitutive androstane receptor (CAR) agonist,NR1I3,,,9970
1643,BRD-K01827268,citicoline,"C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|",13805.0,Launched,glutathione transferase stimulant|membrane permeability enhancer,ACHE|SLC1A2,neurology/psychiatry|ophthalmology,stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma,6506|43
1645,BRD-K76792669,citric-acid,OC(=O)CC(O)(CC(O)=O)C(O)=O,88113319.0,Preclinical,coagulation factor inhibitor,AKR1B1|ANG|APRT|BHMT|C8G|CA4|CPB1|CS|CTDSP1|GNMT|HGS|HS3ST3A1|IL4I1|ITPA|LSM6|MDH2|MIF|PDE5A|PKD2L1|PLEKHA1|RNASE1|RNASE3|SRC|TNFSF13B|UCK2,,,6035|11157|6037|1431|283|10673|9146|4282|6714|9033|59338|7371|58190|8654|1360|733|4191|27232|353|9955|231|259307|3704|762|635
1646,BRD-K21306330,CJ-033466,CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1,10429706.0,Preclinical,serotonin receptor agonist,HTR4,,,3360
1649,BRD-K81572616,CK-636,Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1,588963.0,Preclinical,actin related protein inhibitor,ACTR2|ACTR3|ARPC1B|ARPC2|ARPC3|ARPC4|ARPC5,,,100526693|10092|10094|10095|10096|10097|10109
1650,BRD-A26458246,CKD-712,Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|,9861304.0,Phase 1,NFkB pathway inhibitor,JAK2|STAT1,,,6772|3717
1651,BRD-K34303607,CKI-7,NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12,129236.0,Preclinical,casein kinase inhibitor,CSNK1G2,,,1455
1652,BRD-K00662280,CL-218872,Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F,107950.0,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2,,,2561|2566|2554|2555|2556|2558
1654,BRD-K06467130,CL316243,C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1,5486546.0,Phase 2,adrenergic receptor agonist,ADRB3|UCP1|UCP2|UCP3,,,7352|155|7350|7351
1655,BRD-K93034159,cladribine,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,20279.0,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,ADA|PNP|POLA1|POLE|POLE2|POLE3|POLE4|RRM1|RRM2|RRM2B,hematologic malignancy,hairy cell leukemia,6240|6241|5539|100|5422|56655|5426|5427|50484|54107
1658,BRD-K49668410,clarithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,,Launched,bacterial 50S ribosomal subunit inhibitor,CYP3A4,otolaryngology|pulmonary|infectious disease,pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis,1576
1660,BRD-K17294426,clebopride,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,2780.0,Launched,dopamine receptor antagonist,ACHE|DRD2,gastroenterology,nausea,43|1813
1661,BRD-K30240666,clemastine,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,26987.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269
1663,BRD-K00003701,clenbuterol,CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|,688428.0,Launched,adrenergic receptor agonist,ABCC8|ADRB2|KCNJ11,pulmonary,chronic obstructive pulmonary disease (COPD)|asthma,6833|154|3767
1664,BRD-A01563671,cleviprex,"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|",22884799.0,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S,cardiology,hypertension,776|778|779|775
1666,BRD-K01827265,clidinium,"C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|",24867263.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM3,gastroenterology,peptic ulcer disease (PUD)|irritable bowel syndrome|enterocolitis,1128|1131
1672,BRD-A90625545,clinofibrate,"CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|",,Launched,lipase clearing factor inhibitor,LPL,endocrinology,hypertriglyceridemia,3936
1673,BRD-K09255212,clioquinol,Oc1c(I)cc(Cl)c2cccnc12,2788.0,Withdrawn,chelating agent,OPRK1,,,4986
1674,BRD-K71430621,clobenpropit,Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1,2790.0,Preclinical,histamine receptor antagonist,HRH1|HRH2|HRH3|HRH4,,,1665|59340|3269|11255
1675,BRD-K10799896,clobetasol-propionate,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|",32798.0,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses,2908|5319
1676,BRD-K58810291,clobetasone-butyrate,"CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|",71386.0,Launched,corticosteroid agonist,NR3C1,dermatology,eczema|psoriasis|dermatitis,2908
1678,BRD-K38003476,clocortolone-pivalate,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|",5282493.0,Launched,steroid,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses,2908|5319
1679,BRD-K72542090,clodronic-acid,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,25419.0,Launched,bone resorption inhibitor,SLC25A4|SLC25A5|SLC25A6,orthopedics|endocrinology|hematologic malignancy,osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma,291|292|293
1680,BRD-K34022604,clofarabine,Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,119182.0,Launched,ribonucleotide reductase inhibitor,POLA1|POLD1|POLE|RRM1|RRM2|RRM2B,hematologic malignancy,acute lymphoblastic leukemia (ALL),6240|6241|5422|5424|5426|50484
1682,BRD-A15687940,clofedanol,"CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5,r|",688422.0,Launched,histamine receptor antagonist,HRH1,pulmonary,cough suppressant,3269
1683,BRD-K45252063,clofibrate,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,2796.0,Launched,PPAR receptor agonist,LPL|PPARA,endocrinology|cardiology,hyperlipidemia|cholesterol,3936|5465
1684,BRD-K19111024,clofibric-acid,CC(C)(Oc1ccc(Cl)cc1)C(O)=O,2797.0,Launched,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,5465
1685,BRD-K02680176,clofilium,CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1,2798.0,Phase 2,potassium channel blocker,KCNA5|KCNH1,,,3756|3741
1688,BRD-K50422030,clomethiazole,Cc1ncsc1CCCl,10783.0,Launched,GABA receptor antagonist|GABA receptor modulator,GABRA1,neurology/psychiatry,Parkinson's Disease|sedative|muscle relaxant,2554
1689,BRD-K29950728,clomifene,CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1,1548955.0,Launched,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,2099
1690,BRD-K52989797,clomipramine,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12,2801.0,Launched,serotonin transporter (SERT) inhibitor,GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD),6530|6531|6532|2950|106480180|3356|3358
1691,BRD-K98530306,clonidine,Clc1cccc(Cl)c1NC1=NCCN1 |t:10|,2803.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,cardiology|neurology/psychiatry,hypertension|attention-deficit/hyperactivity disorder (ADHD),146|147|150|151|152
1692,BRD-K18399440,clonixin,Cc1c(Cl)cccc1Nc1ncccc1C(O)=O,28718.0,Preclinical,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|infectious disease,rheumatoid arthritis|soft tissue infection,5742|5743
1697,BRD-K27721098,clopidogrel,COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl,60606.0,Launched,purinergic receptor antagonist,P2RY12,cardiology|neurology/psychiatry,myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS),64805
1699,BRD-K17850764,cloprostenol-(+/-),O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,5311053.0,Launched,prostaglandin receptor agonist,PTGDR|PTGER1|PTGER3|PTGFR|TBXA2R,obstetrics/gynecology,endometriosis,5729|5731|6915|5733|5737
1700,BRD-A04971881,cloranolol,CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|,76964677.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,hypertension,153|154|155
1701,BRD-K73251053,clorgiline,CN(CCCOc1ccc(Cl)cc1Cl)CC#C,4380.0,Phase 2,monoamine oxidase inhibitor,MAOA,,,4128
1702,BRD-A19053834,clorotepine,CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|,12765746.0,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|HRH1|HTR2C|HTR6,neurology/psychiatry,psychosis,3362|3269|146|147|1813|3358
1703,BRD-K01825579,clorprenaline,CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|,12463921.0,Launched,adrenergic receptor agonist,ADRB1|ADRB2,pulmonary,asthma,153|154
1707,BRD-K15916496,clotrimazole,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,2812.0,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8,infectious disease,vulvovaginal candidiasis|oropharyngeal candidiasis,1191|1576|3783|54795|79054|9970|8856
1709,BRD-K46982791,cloxyquin,Oc1ccc(Cl)c2cccnc12,2817.0,Preclinical,potassium channel activator,KCNK18,,,338567
1710,BRD-K37289225,clozapine,CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|,135398737.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia,146|147|1812|1813|150|1815|1816|151|152|1814|3350|3351|3352|3354|3355|3356|3358|3359|3361|3362|3363|106480180|3269|50632|59340|1128|1129|1131|1132|1133
1712,BRD-K54095730,CMPD-1,Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1,11382492.0,Preclinical,p38 MAPK inhibitor,GNRHR|MAPK14,,,1432|2798
1713,BRD-K19438463,CNQX,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N,3721046.0,Phase 1,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,,2890|2891|2892|2893
1714,BRD-K24869513,CNX-2006,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,56968072.0,Preclinical,EGFR inhibitor,EGFR,,,1956
1715,BRD-K48443249,CNX-774,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,59174579.0,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,695
1716,BRD-K55677650,CO-101244,Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1,6918409.0,Preclinical,glutamate receptor antagonist,GRIN2B,,,2904
1717,BRD-K70912147,CO-102862,NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1,9816959.0,Phase 1,sodium channel blocker,SCN4A|SCN9A,,,6329|6335
1718,BRD-K51040301,cobicistat,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,25151504.0,Launched,cytochrome P450 inhibitor,CYP3A4|CYP3A43|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1),1576|1577|64816|100861540
1719,BRD-K03390685,cobimetinib,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,16222096.0,Launched,MEK inhibitor,MAP2K1,oncology,melanoma,5604
1720,BRD-A67956599,coenzyme-A,"CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14,16,17,19,35,&1:5,&2:9|",87642.0,Launched,,ACAT2|CRAT|CS|DBI|HMGCR|KAT2A|KAT2B|KAT5,,,706|1384|8850|8435|3156|1431|2648|10524
1721,BRD-K01825730,coenzyme-I,"NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|",439153.0,Phase 2,,AASS|ACADS|ADH1A|ADH1B|ADH1C|ADH4|ADH5|ADH7|AKR1B1|AKR1C1|AKR1C2|AKR1C3|AKR1C4|ALDH1A1|ALDH1A2|ALDH1A3|ALDH1B1|ALDH2|ALDH3A1|ALDH3A2|ALDH3B1|ALDH3B2|ALDH4A1|ALDH5A1|ALDH6A1|ALDH7A1|ALDH9A1|AMT|BDH1|BLVRA|BLVRB|CDO1|CYB5R3|CYP17A1|CYP4A11|DHCR7|DHFR|DLAT|DLD|EHHADH|GAPDH|GAPDHS|GLUD1|GLUD2|GPD1|GSR|H6PD|HADH|HADHA|HIBADH|HMGCR|HMOX1|HMOX2|HPGD|HSD11B1|HSD11B2|HSD17B1|HSD17B10|HSD17B2|HSD17B3|HSD17B4|HSD17B7|HSD17B8|HSD3B1|HSD3B2|IDH3A|IDH3B|IDH3G|IMPDH1|IMPDH2|LDHA|LDHAL6A|LDHAL6B|LDHB|LDHC|MDH1|MDH2|ME1|ME2|ME3|MSMO1|MT-ND1|MT-ND2|MT-ND3|MT-ND4|MT-ND4L|MT-ND5|MT-ND6|MTHFD1|MTHFD2|NDUFA1|NDUFA10|NDUFA11|NDUFA12|NDUFA13|NDUFA2|NDUFA3|NDUFA4|NDUFA4L2|NDUFA5|NDUFA6|NDUFA7|NDUFA8|NDUFA9|NDUFAB1|NDUFB1|NDUFB10|NDUFB2|NDUFB3|NDUFB4|NDUFB5|NDUFB6|NDUFB7|NDUFB8|NDUFB9|NDUFC1|NDUFC2|NDUFS1|NDUFS2|NDUFS3|NDUFS4|NDUFS5|NDUFS6|NDUFS7|NDUFS8|NDUFV1|NDUFV2|NDUFV3|NNT|NQO2|NSDHL|OGDH|PDHA1|PDHA2|PDHB|PHGDH|PYCR1|PYCR2|QDPR|RDH5|SORD|TSTA3|TYR|UGDH,,,29920|1036|374291|3615|160287|35|5160|5161|5162|1579|10797|1586|56901|3156|1109|4694|4695|4696|3162|3163|4698|4700|4190|4191|4701|4705|4702|4704|4706|4707|4708|4709|4200|4710|4711|4712|4716|1645|1646|622|4713|4714|4715|4717|4718|4719|4720|4722|4724|4725|4726|4728|124|125|126|4729|128|4731|50814|131|644|645|7299|8854|55967|6307|3248|1717|1719|2746|2747|7358|1727|7264|5831|1737|1738|3283|3284|4723|216|217|3290|3291|218|3293|219|3295|220|221|222|223|224|3292|3294|231|360165|4329|4835|7915|5860|7923|2819|275|727833|56110|92483|100240709|5959|3419|3420|3421|9563|3939|4967|11112|3945|3948|26227|57717|2936|26330|126328|51079|1962|4522|10157|8644|158160|8659|3028|3030|23530|501|6652
1724,BRD-K00259736,colchicine,COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC,6167.0,Launched,microtubule inhibitor,GLRA1|GLRA2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,rheumatology|endocrinology,gout|fever,7846|10376|84617|112714|347688|7277|7278|10381|7280|113457|10382|10383|2741|84790|2742|347733|203068
1725,BRD-A55416093,colforsin,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|",47936.0,Phase 2,adenylyl cyclase activator,ADCY2|ADCY5,,,108|111
1731,BRD-K19655798,compound-401,O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1,10039361.0,Preclinical,DNA dependent protein kinase inhibitor,MTOR|PRKDC,,,2475|5591
1733,BRD-K98143539,compound-w,OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1,16760376.0,Preclinical,beta-secretase inhibitor,BACE1,,,23621
1734,BRD-K37385792,conivaptan,Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1,151171.0,Launched,vasopressin receptor antagonist,AVPR1A|AVPR2,endocrinology,hyponatremia,552|554
1736,BRD-K24666289,copanlisib,"COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|",,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,hematologic malignancy,follicular lymphoma,5290|5291|5294|22883
1737,BRD-K36449075,copper-histidine,N[C@H](Cc1cnc[nH]1)C(O)=O,71083.0,Phase 3,,SLC15A3|SLC15A4|SLC38A5,,,51296|92745|121260
1738,BRD-K74965187,COR-170,CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1,25033736.0,Preclinical,cannabinoid receptor inverse agonist,CNR2,,,56142
1740,BRD-K27885593,corosolic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|,6918774.0,Phase 2,PKC inhibitor|protein tyrosine kinase inhibitor,HSD11B1|PTPN1,,,3290|5770
1742,BRD-K73589401,corticosterone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|,5753.0,Preclinical,mineralocorticoid receptor agonist,HSD11B1|NCOA1|NR3C2,,,8648|4306|3290
1743,BRD-K00025572,cortisone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|,222786.0,Launched,glucocorticoid receptor agonist,NR3C1,gastroenterology|rheumatology|dermatology,ulcerative colitis|rheumatoid arthritis|psoriasis|joint inflammation|eczema,2908
1744,BRD-K86161929,cortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|,5745.0,Launched,glucocorticoid receptor agonist,NR3C1,pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease,asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis,2908
1745,BRD-K32891457,cortodoxone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|,440707.0,Phase 3,androgen receptor antagonist,AR,,,367
1747,BRD-K98710228,cot-inhibitor-1,Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl,11584834.0,Preclinical,MAPK-interacting kinase inhibitor,MAP3K8,,,1326
1748,BRD-K49468759,cot-inhibitor-2,CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1,44143370.0,Preclinical,MAPK-interacting kinase inhibitor,MAP3K8,,,1326
1751,BRD-K23913458,coumarin,O=c1ccc2ccccc2o1,323.0,Launched,vitamin K antagonist,CA1|CA12|CA14|CA2|CA4|CA6|CA9|CYP2A6,gastroenterology|pulmonary,ulcerative colitis|asthma|celiac disease,768|771|1548|23632|759|760|762|765
1754,BRD-K53913008,CP-316819,CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,10273347.0,Preclinical,glycogen phosphorylase inhibitor,PYGL,,,5836
1755,BRD-K00004233,CP-339818,CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12,,Preclinical,potassium channel blocker,KCNA3,,,3738
1756,BRD-K31394475,CP-376395,CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C,9862166.0,Phase 1,corticotropin releasing factor receptor antagonist,CRHR1,,,1394
1757,BRD-K33234937,CP-471474,CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO,9907286.0,Preclinical,matrix metalloprotease inhibitor,MMP1|MMP13|MMP2|MMP3|MMP9,,,4322|4312|4313|4314|4318
1758,BRD-K36611520,CP-532623,CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F,10145345.0,Phase 1,cholesteryl ester transfer protein inhibitor,CETP,,,1071
1760,BRD-K26921335,CP-640186,O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1,449097.0,Preclinical,acetyl-CoA carboxylase inhibitor,ACACA|ACACB,,,32|31
1761,BRD-K43621685,CP-673451,COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1,10158940.0,Preclinical,PDGFR tyrosine kinase receptor inhibitor,KIT|PDGFRA|PDGFRB,,,5156|5159|3815
1762,BRD-K76908866,CP-724714,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,9874913.0,Phase 2,EGFR inhibitor|protein tyrosine kinase inhibitor,ERBB2,,,2064
1763,BRD-K96843359,CP-775146,CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1,10410059.0,Preclinical,PPAR receptor agonist,PPARA,,,5465
1764,BRD-K19171642,CP-91149,CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1,9843900.0,Preclinical,glycogen phosphorylase inhibitor,PYGL,,,5836
1765,BRD-K81876028,CP-93129,O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|,124007.0,Preclinical,serotonin receptor agonist,HTR1A,,,3350
1766,BRD-K33860217,CP-94253,CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|,4029677.0,Preclinical,serotonin receptor agonist,HTR1B,,,3351
1767,BRD-K09090949,"CP-945,598",CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,10052040.0,Phase 3,cannabinoid receptor antagonist,CNR1,,,1268
1768,BRD-K09946180,CP-99994,COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1,5311057.0,Phase 2,tachykinin antagonist,TACR1,,,6869
1769,BRD-A69126730,CPA-inhibitor,"ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|",124386386.0,Preclinical,carboxypeptidase inhibitor,CPA1|CPA2,,,1357|1358
1770,BRD-K00004223,CPCCOEt,"CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|",10106002.0,Preclinical,glutamate receptor antagonist,GRM1,,,2911
1771,BRD-K19871656,CPI-0610,Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|,57389999.0,Phase 2,bromodomain inhibitor,BRD4,,,23476
1772,BRD-K11073688,CPI-1189,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,151118.0,Phase 2,tumor necrosis factor release inhibitor,TNF,,,7124
1774,BRD-K97181972,CPI-169,CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12,71712226.0,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,,2146
1775,BRD-K15811707,CPI-203,Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|,71291068.0,Preclinical,bromodomain inhibitor,BRD4,,,23476
1776,BRD-K18319422,CPI-360,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12,73442743.0,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,,2146
1778,BRD-A06916187,CPI-613,"OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|",70881528.0,Phase 3,pyruvate dehydrogenase inhibitor,PDHA1,,,5160
1779,BRD-K66094457,CPP,OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1,6603754.0,Phase 2,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,114787|2903|2904|2905|2906
1780,BRD-A81603255,CPSI-1306-(+/-),"Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|",52936269.0,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,,4282
1782,BRD-K40331046,CR8-(R),CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1,10224714.0,Preclinical,CDK inhibitor,CCNA2,,,890
1783,BRD-K19615002,creatine,CN(CC(O)=O)C(N)=N,586.0,Launched,,CKB|CKM|CKMT1A|CKMT2|GAMT|SLC6A8,,,1120|2593|1158|6535|1160|548596
1787,BRD-K22127577,crenolanib,CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,10366136.0,Phase 3,PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB,,,5156|5159|3815|2322|1436
1790,BRD-K97939847,cridanimod,OC(=O)Cn1c2ccccc2c(=O)c2ccccc12,38072.0,Launched,progesterone receptor agonist,PGR,infectious disease,influenza A virus infection,5241
1791,BRD-K43230258,crisaborole,OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12,44591583.0,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,dermatology,dermatitis,5144|5141|5142|5143
1793,BRD-K78431006,crizotinib,C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,11626560.0,Launched,ALK tyrosine kinase receptor inhibitor,ALK|MET,oncology,non-small cell lung cancer (NSCLC),8731|238
1794,BRD-K40308497,crizotinib-(S),C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,56671814.0,Preclinical,MTH1 inhibitor,NUDT1,,,4521
1797,BRD-M89827113,cromakalim,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,76968376.0,Phase 2,,KCNJ8,,,3764
1798,BRD-K20920669,cromoglicic-acid,OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O,2882.0,Launched,immunosuppressant,KCNMA1|S100P,pulmonary|ophthalmology|allergy|gastroenterology,asthma|conjunctivitis|urticaria|ulcerative colitis,3778|6286
1801,BRD-K33336844,cryptotanshinone,C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|,160254.0,Preclinical,acetylcholinesterase inhibitor|STAT inhibitor,STAT3,,,6774
1803,BRD-K15519488,CS-110266,C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1,123692.0,Preclinical,dopamine receptor agonist,SLC6A3,,,6531
1804,BRD-K35601925,CS-917,CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O,11289630.0,Phase 2,fructose biphosphate inhibitor,FBP1,,,2203
1805,BRD-K40870905,CT-7758,OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|,10186367.0,Phase 2,integrin antagonist,ITGA4,,,3676
1807,BRD-K30572193,CTEP,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1,11646823.0,Preclinical,glutamate receptor antagonist,GRM5,,,2915
1808,BRD-K53508936,CTS-1027,ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1,3342298.0,Phase 2,metalloproteinase inhibitor,MMP1|MMP13|MMP2|MMP3|MMP9,,,4322|4312|4313|4314|4318
1809,BRD-K89071957,CTS21166,CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O,445649.0,Phase 1,beta-secretase inhibitor,BACE1,,,23621
1810,BRD-K58234744,CU-CPT-4a,OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl,53242268.0,Preclinical,toll-like receptor inhibitor,TLR3,,,7098
1811,BRD-K89462779,CU-T12-9,CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O,91826088.0,Preclinical,toll-like receptor agonist,TLR1|TLR2,,,7096|7097
1812,BRD-K41278234,CUDC-101,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,24756910.0,Phase 1,EGFR inhibitor,EGFR|ERBB2,,,2064|1956
1813,BRD-K69351586,CUDC-427,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1,71600094.0,Phase 1,apoptosis inhibitor,XIAP,,,331
1814,BRD-K77638923,CUDC-907,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,54575456.0,Phase 2,PI3K inhibitor,HDAC2|PIK3R1,,,3066|5295
1815,BRD-K69624312,CUR-61414,COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1,10392802.0,Phase 1,smoothened receptor antagonist,DHH|IHH|SMO,,,54498|3549|50846
1816,BRD-K07572174,curcumin,COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O,6971205.0,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH,,,768|4322|771|1576|1789|1131|5742|5743|23632|2033|339345|759|760|762|6652|765|4318|351
1817,BRD-K41933240,curcumol,CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C,14240392.0,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,,3716|3717|3718
1818,BRD-K90777969,cutamesine,COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC,9907323.0,Phase 2,sigma receptor agonist,SIGMAR1,,,10280
1819,BRD-K49197823,CV-1808,Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,6917803.0,Preclinical,adenosine receptor agonist,ADORA2A,,,135
1820,BRD-K60659193,CVT-10216,CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O,23661666.0,Phase 1,aldehyde dehydrogenase inhibitor,ALDH2,,,217
1821,BRD-K84068331,CW-008,COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1,59528098.0,Preclinical,PKA activator,PRKACA,,,5578
1822,BRD-K81458380,CX-4945,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,24748573.0,Phase 1/Phase 2,casein kinase inhibitor,CSNK2A1|CSNK2A2|DAPK3|HIPK3,,,10114|1459|1613
1826,BRD-K79353516,CY208-243,CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13,58144.0,Phase 2,dopamine receptor agonist,CALY,,,50632
1828,BRD-A42881122,cyamemazine,"C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|",14050069.0,Launched,serotonin receptor antagonist,HTR1A|HTR2A|HTR2C|HTR7,neurology/psychiatry,schizophrenia|anxiety,3363|3356|3350|3358
1829,BRD-A18627414,cyanocobalamin,"C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|",,Launched,methylmalonyl CoA mutase stimulant|vitamin B,MUT,hematology|infectious disease|gastroenterology,anemia|fish tapeworm infestation|celiac disease,4594
1830,BRD-K01825675,cyanopindolol,CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|,6604791.0,Phase 2,adrenergic receptor antagonist,ADRB1|HTR1A|HTR1D,,,3352|153|3350
1832,BRD-K64866502,CYC116,Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1,6420138.0,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|KDR,,,9212|6790|3791
1835,BRD-A41840684,cyclic-AMP,"Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|",40467852.0,Preclinical,,CNGA3|TRPM7,,,1261|54822
1836,BRD-K79501723,cyclizine,CN1CCN(CC1)C(c1ccccc1)c1ccccc1,6726.0,Launched,histamine receptor modulator,HRH1|SULT1E1,gastroenterology|neurology/psychiatry,nausea|vomiting|vertigo|motion sickness,3269|6783
1837,BRD-K42348709,cyclobenzaprine,CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|,2895.0,Launched,adrenergic receptor agonist|serotonin receptor agonist,HTR2A,neurology/psychiatry,spasms,3356
1840,BRD-K36055864,cycloheximide,C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1,6197.0,Preclinical,protein synthesis inhibitor,RPL3,,,6122
1844,BRD-A09722536,cyclophosphamide,ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|,9554282.0,Launched,DNA alkylating agent,CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP3A4|CYP3A5|CYP3A7,hematologic malignancy|oncology,Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer,100861540|1576|1577|1548|1555|1557|1558|1559|1562|1565
1845,BRD-A10420615,cyclopiazonic-acid,"CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|",54682463.0,Preclinical,ATPase inhibitor,ATP2A1,,,487
1846,BRD-K87226815,cycloserine-(D),N[C@@H]1CONC1=O,6234.0,Launched,bacterial cell wall synthesis inhibitor,GRIN1,infectious disease,tuberculosis|tuberculosis,114787
1847,BRD-K13533483,cyclosporin-A,"CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|",,Launched,calcineurin inhibitor,ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3,rheumatology|dermatology,rheumatoid arthritis|psoriasis,5478|8647|10599|28234|6554|819|2357|10105|5530|5535
1848,BRD-K13533483,cyclosporin-A,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,5284373.0,Launched,calcineurin inhibitor,ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3,rheumatology|dermatology,rheumatoid arthritis|psoriasis,5478|8647|10599|28234|6554|819|2357|10105|5530|5535
1849,BRD-A38675539,cyclothiazide,"NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|",101691640.0,Launched,glutamate receptor modulator,CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3,cardiology,hypertension,2890|2891|2892|2893|760|6559
1850,BRD-K59866480,cyclovalone,COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O,1550234.0,Launched,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,9429
1853,BRD-K69877120,CYM-50260,FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1,44620894.0,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR4,,,8698
1854,BRD-K80666802,CYM-50358,Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl,53358422.0,Preclinical,sphingosine 1-phosphate receptor antagonist,S1PR4,,,8698
1855,BRD-K27732927,CYM-50769,COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1,50904505.0,Preclinical,neuropeptide receptor antagonist,NPBWR1,,,2831
1856,BRD-A43005764,CYM-5442,CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|,93977386.0,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,,1901
1857,BRD-K29151923,CYM-5520,Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1,25110470.0,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR2,,,9294
1858,BRD-K75940276,CYM-5541,O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1,17253208.0,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR3,,,1903
1860,BRD-K28143534,cyproheptadine,CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|,2913.0,Launched,histamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7,allergy|otolaryngology|ophthalmology|dermatology,allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism,3362|3363|3269|1128|1129|1131|146|147|3356|3358
1861,BRD-K41141507,cyproterone-acetate,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",9880.0,Launched,androgen receptor antagonist,ADORA1|AR,oncology,prostate cancer,134|367
1863,BRD-K92611362,cysteamine,NCCS,6058.0,Launched,tissue transglutaminase inhibitor,NPY2R|SST,metabolism,cystinosis,6750|4887
1864,BRD-K23363278,CYT-997,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,11351021.0,Phase 2,tubulin polymerization inhibitor,TUBB,,,7280
1865,BRD-K87737963,cyt387,O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1,25062766.0,Phase 3,JAK inhibitor,JAK1|JAK2|JAK3,,,3716|3717|3718
1866,BRD-K33106058,cytarabine,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,6253.0,Launched,ribonucleotide reductase inhibitor,POLA1|POLB|POLD1|POLE,hematologic malignancy,acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL),11232|5424|5426|5422
1868,BRD-K74186897,cytisine,O=c1cccc2[C@H]3CNC[C@H](C3)Cn12,10235.0,Launched,acetylcholine receptor agonist,CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4,neurology/psychiatry,nicotinism,89832|8973|1135|1136|1137|1141|1143
1869,BRD-K26664453,cytochalasin-B,"C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|",5311281.0,Phase 2,microtubule inhibitor,ACTB,,,728378
1871,BRD-K87021635,CZC-54252,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1,44252734.0,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,,120892
1872,BRD-K01377300,CZC24832,CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1,42623951.0,Preclinical,PI3K inhibitor,PIK3CG,,,5294
1873,BRD-K74377520,D-(+)-maltose,OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O,6255.0,Preclinical,,MGAM,,,8972
1876,BRD-K09132007,D-4476,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1,6419753.0,Preclinical,TGF beta receptor inhibitor,CSNK1A1|CSNK1D|TGFB1,,,7040|1452|1453
1877,BRD-K26997899,D-64131,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,3921152.0,Preclinical,microtubule inhibitor,TUBB,,,7280
1882,BRD-K00911807,D-phenylalanine,N[C@H](Cc1ccccc1)C(O)=O,71567.0,Preclinical,enkephalinase inhibitor,CCBL1|CRH|HCAR3,,,1392|883|8843
1883,BRD-K71822263,D-serine,N[C@H](CO)C(O)=O,71077.0,Launched,glutamate receptor agonist,GLRA1|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|SERPINB3,,,114787|6317|2741|2903|2904|2905|2906
1886,BRD-K01080633,DAA-1106,COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1,10430788.0,Preclinical,benzodiazepine receptor agonist,TSPO,,,706
1887,BRD-K38168441,dabigatran,Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1,216210.0,Launched,thrombin inhibitor,F2,neurology/psychiatry|hematology,stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT),2147
1888,BRD-K57041787,dabigatran-etexilate,CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1,9578572.0,Launched,thrombin inhibitor,F2,neurology/psychiatry|hematology,stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT),2147
1889,BRD-K09951645,dabrafenib,CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F,44462760.0,Launched,RAF inhibitor,BRAF|LIMK1|NEK11|RAF1|SIK1,oncology,melanoma,673|102724428|3984|79858|6037
1890,BRD-K35520305,dacarbazine,CN(C)\N=N\c1nc[nH]c1C(N)=O,135398738.0,Launched,DNA alkylating agent,PGD|POLA2,oncology|hematologic malignancy,melanoma|Hodgkin's lymphoma,23649|26227
1891,BRD-K56957086,dacinostat,OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1,6445533.0,Phase 1,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,,55869|9734|8841|3065|3066|10013|10014|9759
1893,BRD-K57169635,dacomitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,11511120.0,Launched,EGFR inhibitor,EGFR|ERBB2|ERBB4,,,2064|2066|1956
1894,BRD-K70578146,dactinomycin,CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O,457193.0,Launched,RNA polymerase inhibitor,POLR2A,oncology,testicular carcinoma|Wilm's tumor|rhabdomyosarcoma|Ewing's sarcoma|gestational trophoblastic disease (GTD),5430
1895,BRD-K42095107,daidzein,Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,5281708.0,Phase 2,estrogen receptor agonist,ESRRA|ESRRB|ESRRG|TRPC5,,,2104|7224|2101|2103
1896,BRD-K12979078,daidzin,OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O,107971.0,Phase 1,antioxidant,ALDH2,,,217
1897,BRD-A89196962,dalargin,"CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|",,Phase 2,opioid receptor agonist,OPRM1,,,4988
1898,BRD-K30177383,dalbavancin,CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2,16134627.0,Launched,bacterial cell wall synthesis inhibitor,PNLIP,infectious disease,skin infections,5406
1899,BRD-K18849474,dalcetrapib,CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C,6918540.0,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,,1071
1900,BRD-K22482860,dalfampridine,Nc1ccncc1,1727.0,Launched,potassium channel blocker,KCNA1|KCNA10|KCNA2|KCNA3|KCNA4|KCNA5|KCNA6|KCNA7|KCNB1|KCNB2|KCNC1|KCNC2|KCNC3|KCNC4|KCND1|KCND2|KCND3|KCNF1|KCNG1|KCNG2|KCNG3|KCNG4|KCNH1|KCNH2|KCNH3|KCNH4|KCNH5|KCNH6|KCNH7|KCNH8|KCNJ13|KCNJ5|KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5|KCNS1|KCNS2|KCNS3|KCNV1|KCNV2,neurology/psychiatry,multiple sclerosis,56479|27012|81033|26251|90134|3736|3737|3738|3739|131096|3741|3742|3743|3744|3745|3746|3747|3748|3749|3750|3751|3752|3754|3755|3756|3757|9132|3762|93107|169522|3769|3784|3785|3786|3787|3788|3790|9312|170850|23415|23416|27133
1902,BRD-K26813177,daltroban,OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1,54343.0,Phase 3,thromboxane receptor antagonist,TBXA2R,,,6915
1903,BRD-K83452553,daminozide,CN(C)NC(=O)CCC(O)=O,72200802.0,Preclinical,KDM2A inhibitor,KDM2A|KDM7A|PHF8,,,22992|23133|80853
1904,BRD-K48970916,danazol,C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|,28417.0,Launched,estrogen receptor antagonist|progesterone receptor agonist,AR|CCL2|ESR1|GNRHR|GNRHR2|PGR,obstetrics/gynecology|cardiology,endometriosis|angioedema,6347|2798|367|2099|5241|114814
1906,BRD-K13769342,danirixin,Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1,24780598.0,Phase 2,CC chemokine receptor antagonist,CXCR2,,,3579
1909,BRD-K81272440,dantrolene,[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1,6914273.0,Launched,calcium channel blocker,RYR1|RYR3,neurology/psychiatry|endocrinology,spasms|malignant hyperthermia (MH),6261|6263
1911,BRD-K07881437,danusertib,CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1,11442891.0,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,AURKA|AURKB|AURKC|FGFR1|NTRK1|RET|SLK,,,6790|2534|6795|4914|2260|5979|9212
1912,BRD-K58160573,dapagliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,9887712.0,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus,6523|6524
1915,BRD-K33133047,dapiprazole,Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1,3033538.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,ophthalmology,mydriasis,146|147
1916,BRD-K12885236,dapivirine,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,214347.0,Phase 3,non-nucleoside reverse transcriptase inhibitor,CYP3A4|CYP3A5,,,1576|1577
1917,BRD-K51579475,dapoxetine,CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,71353.0,Launched,selective serotonin reuptake inhibitor (SSRI),HTR1A|HTR1B|HTR2C|SLC6A4,urology,premature ejaculation (PE),6532|3358|3350|3351
1918,BRD-K06455935,daprodustat,OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O,24831508.0,Phase 3,hypoxia inducible factor inhibitor,EGLN1,,,54583
1919,BRD-K62363391,dapsone,Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1,2955.0,Launched,bacterial antifolate,DHFR,dermatology|infectious disease,dermatitis herpetiformis (DH)|leprosy,1719
1922,BRD-K19085898,darapladib,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,9939609.0,Phase 3,phospholipase inhibitor,PLA2G7,,,7941
1923,BRD-K82908348,darglitazone,Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1,60870.0,Phase 2,PPAR receptor antagonist,PPARG,,,5468
1924,BRD-K95773607,darifenacin,NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1,444031.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence,1128|1129|1131|1132|1133
1925,BRD-A44971162,darolutamide,"C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|",121489720.0,Launched,androgen receptor antagonist,AR,oncology,prostate cancer,367
1926,BRD-K84986517,darunavir,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,213039.0,Launched,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1576
1927,BRD-K54863166,darusentan,COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1,177236.0,Phase 3,endothelin receptor antagonist,EDNRA,,,1909
1929,BRD-K49328571,dasatinib,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1,3062316.0,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL),640|4067|6725|2534|3815|3932|5159|7525|2444|3055|1969|6777|25|6714|27|2268
1931,BRD-K31633810,DAU-5884,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O,,Preclinical,acetylcholine receptor antagonist,CHRM3,,,1131
1933,BRD-K43389675,daunorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O,30323.0,Launched,RNA synthesis inhibitor|topoisomerase inhibitor,TOP2A|TOP2B,hematologic malignancy,acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL),7153|7155
1934,BRD-K20738689,dazmegrel,Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O,53555.0,Phase 2,thromboxane synthase inhibitor,TBXAS1,,,6916
1935,BRD-K82767007,dazoxiben,OC(=O)c1ccc(OCCn2ccnc2)cc1,53001.0,Phase 2,thromboxane synthase inhibitor,TBXAS1,,,6916
1936,BRD-K59204667,DBeQ,C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1,676352.0,Preclinical,ATPase inhibitor,CASP3,,,836
1938,BRD-K83020231,DBPR108,CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N,44201003.0,Phase 1,dipeptidyl peptidase inhibitor,DPP4,,,1803
1939,BRD-K10596918,DC-260126,CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1,2843133.0,Preclinical,free fatty acid receptor antagonist,FFAR1,,,2864
1940,BRD-K49246350,DCC-2618,Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1,46208890.0,Phase 1,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,KIT|PDGFRA,,,5156|3815
1941,BRD-K89299012,DCEBIO,CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O,656765.0,Preclinical,potassium channel activator,KCNN2|KCNN3|KCNN4,,,3781|3782|3783
1943,BRD-A39255369,DCPIB,"CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|",12761153.0,Preclinical,chloride channel blocker|gap junction modulator|glutamate inhibitor,SLC1A2,,,6506
1944,BRD-K61845293,DDR1-IN-1,CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1,72836888.0,Preclinical,discoidin domain receptor inhibitor,DDR1|DDR2,,,4921|780
1947,BRD-K80419150,debrisoquin,NC(=N)N1CCc2ccccc2C1,2966.0,Launched,adrenergic neuron blocker,SLC6A2,cardiology,hypertension,6530
1948,BRD-K49783248,decamethonium,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,2968.0,Launched,acetylcholine receptor agonist,ACHE|CHRNA2,neurology/psychiatry,muscle relaxant,43|1135
1950,BRD-A95300432,decernotinib,"CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|",59422203.0,Phase 2/Phase 3,JAK inhibitor,JAK3,,,3718
1951,BRD-K79254416,decitabine,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,451668.0,Launched,DNA methyltransferase inhibitor,DNMT1|DNMT3A,hematologic malignancy|hematology,myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML),1786|1788
1955,BRD-K43578482,defactinib,CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1,25117126.0,Phase 2,focal adhesion kinase inhibitor,PTK2,,,5747
1956,BRD-K97010173,deferasirox,OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,214348.0,Launched,chelating agent,CYP3A4,hematology,transfusional hemosiderosis|thalassemia|iron overload,1576
1958,BRD-K06878038,deferiprone,Cc1c(O)c(=O)ccn1C,2972.0,Launched,chelating agent,UGT1A6,hematology,transfusional hemosiderosis|thalassemia|iron overload,54578
1960,BRD-K30468934,deflazacort,"CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23,t:8,19|",189821.0,Launched,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,2908
1961,BRD-K62304154,deforolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|",,Phase 3,mTOR inhibitor,MTOR,,,2475
1962,BRD-K00003578,degarelix,CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,16136245.0,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR,oncology,prostate cancer,2798
1966,BRD-K67186445,dehydrocorydaline,COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC,34781.0,Phase 3,acetylcholinesterase inhibitor,ACHE,,,43
1967,BRD-K41256143,dehydroepiandrosterone,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|,5881.0,Launched,protein synthesis stimulant,ESR1|ESR2|G6PD|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|HSD17B1|NR1I2|NR1I3|PPARA|SIGMAR1|SULT2A1|SULT2B1,endocrinology,menopause,2560|2561|2562|2563|2564|2565|2566|2567|2568|8856|6820|6822|10280|2099|2100|55879|8266|2903|2904|2905|2906|116443|116444|3292|5465|114787|9970|2554|2555|2556|2557|2558|2559
1968,BRD-K15360631,dehydroepiandrosterone-sulfate,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|,12594.0,Launched,androgen receptor agonist|estrogen receptor agonist,AR|ESR1|ESR2,endocrinology,menopause,2099|2100|367
1971,BRD-K59325863,delanzomib,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O,24800541.0,Phase 1/Phase 2,proteasome inhibitor,CMA1|CTSG|CYP3A4|ELANE,,,1576|1991|1511|1215
1972,BRD-K00573984,delapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1,5362116.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636
1973,BRD-K34068325,delavirdine,CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1,5625.0,Launched,non-nucleoside reverse transcriptase inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1576
1976,BRD-K45503887,delivert,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O,78357780.0,Launched,angiotensin receptor agonist,AGTR1|AGTR2,critical care,sepsis,185|186
1978,BRD-K79107392,delphinidin,Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1,128853.0,Phase 2,membrane permeability inhibitor,GLO1,,,2739
1979,BRD-K85776940,delta-tocotrienol,CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1,5282350.0,Phase 1,HMGCR inhibitor,HMGCR,,,3156
1980,BRD-K90830492,deltarasin,C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1,73292904.0,Preclinical,phosphodiesterase inhibitor,KRAS,,,3265
1981,BRD-K51471001,demecarium,CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,5966.0,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,ophthalmology,intraocular pressure|glaucoma,43|590
1987,BRD-K41170226,deoxycholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,222528.0,Launched,biliverdin reductase A activator|G protein-coupled receptor agonist,FPR1|GPBAR1,endocrinology,submental fat,151306|2357
1988,BRD-K24556098,deoxycorticosterone-acetate,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|,5952.0,Preclinical,progestogen hormone,NR3C2,,,4306
1989,BRD-K33151569,deoxyepinephrine,CNCCc1ccc(O)c(O)c1,4382.0,Preclinical,adrenergic receptor agonist|dopamine receptor agonist,ADRA1A|DRD1|DRD2,,,146|1812|1813
1990,BRD-K00005351,deptropine,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r,THB:0:1:3.4:6.7.8|",,Preclinical,histamine receptor antagonist,HRH1,,,3269
1991,BRD-K77685957,dequalinium,Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12,2993.0,Launched,PKC inhibitor,KCNN1|KCNN3,infectious disease,first-aid antiseptic,3780|3782
1992,BRD-K68558722,deracoxib,COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F,3058754.0,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,5743
1994,BRD-K29462201,deserpidine,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1,8550.0,Launched,angiotensin converting enzyme inhibitor,ACE|SLC18A2,cardiology,hypertension,6571|1636
1996,BRD-K60762818,desipramine,CNCCCN1c2ccccc2CCc2ccccc12,2995.0,Launched,tricyclic antidepressant,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A4|SMPD1,neurology/psychiatry,depression,6530|6532|146|147|1813|150|151|152|153|154|3350|3356|3358|3269|6609|1128|1129|1131|1132|1133
1998,BRD-K99919177,deslanoside,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|,28620.0,Launched,Na/K-ATPase inhibitor,ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2,cardiology,congestive heart failure|cardiac arrythmia,480|481|482|483|486|476|477|478
1999,BRD-K82357231,desloratadine,Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1,124087.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269
2001,BRD-K10042277,desmethylclozapine,Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|,135409468.0,Phase 2,acetylcholine receptor agonist,HTR2C,,,3358
2002,BRD-K00003582,desmopressin-acetate,NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|,,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,endocrinology|urology,central diabetes insipidus|nocturnal enuresis,552|553|554|5021
2003,BRD-K46061689,desogestrel,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|,40973.0,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive,5241|2099
2004,BRD-K21528677,desonide,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|",5311066.0,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,gastroenterology,Crohn's disease,2908|5319
2005,BRD-K30697463,desoximetasone,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11,t:7|",5311067.0,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses,2908|5319
2006,BRD-K26024145,desoxycorticosterone-pivalate,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|,11876263.0,Launched,corticosteroid agonist,NR3C2,endocrinology,Addison's disease,4306
2007,BRD-K98521173,desoxycortone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|,6166.0,Preclinical,mineralocorticoid receptor agonist,NR3C1|NR3C2,,,4306|2908
2008,BRD-K13819402,desoxypeganine,C1CN2Cc3ccccc3N=C2C1 |c:11|,442894.0,Phase 1,acetylcholinesterase inhibitor|monoamine oxidase inhibitor,ACHE,,,43
2009,BRD-K01825598,desvenlafaxine,CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|,12018336.0,Launched,serotoninânorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,6530|6531|6532
2010,BRD-K77597856,detomidine,Cc1cccc(Cc2cnc[nH]2)c1C,56032.0,Launched,adrenergic receptor agonist,ADRA2A,neurology/psychiatry,sedative,150
2012,BRD-K38775274,dexamethasone,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|",5743.0,Launched,glucocorticoid receptor agonist,ANXA1|NOS2|NR0B1|NR3C1|NR3C2,endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology,hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis,301|339345|4306|2908|190
2015,BRD-K30019776,dexfosfoserine,N[C@@H](COP(O)(O)=O)C(O)=O,68841.0,Preclinical,membrane integrity inhibitor,CFTR|GRM4|GRM6|GRM7|GRM8|KCNC4|PDPK1|PIM1|PRKACA|PRKCQ|PYGL|PYGM|REG1A|RHO|SERPINB3|SMAD2|TAOK2,,,9344|2914|2916|2917|2918|3749|5578|5836|5837|6317|5967|9361|5170|5588|4087|1080|6010
2016,BRD-K05900209,dexlansoprazole,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,9578005.0,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|erosive esophagitis (EE),495
2017,BRD-K07609981,dexloxiglumide,CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1,65937.0,Phase 3,CCK receptor antagonist,CCKAR,,,886
2018,BRD-K18423410,dexmedetomidine,C[C@H](c1cnc[nH]1)c1cccc(C)c1C,5311068.0,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,sedative,152|150|151
2019,BRD-K44309363,dexniguldipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|",6918097.0,Phase 2,calmodulin antagonist,ADORA3,,,140
2021,BRD-K07265709,dexrazoxane,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,71384.0,Launched,chelating agent|topoisomerase inhibitor,TOP2A|TOP2B,cardiology,cardiomyopathy,7153|7155
2023,BRD-K33211335,dextromethorphan,COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1,5360696.0,Launched,glutamate receptor antagonist|sigma receptor agonist,CHRNA2|CHRNA3|CHRNA4|CHRNA7|CHRNB2|CHRNB4|CYBA|CYBB|GRIN3A|NCF1|NCF2|NCF4|OPRD1|OPRK1|OPRM1|PGRMC1|RAC1|RAC2|SIGMAR1|SLC6A2|SLC6A4,pulmonary,cough suppressant,1536|6530|6532|6035|10280|653361|4688|4689|116443|89832|10857|1135|1136|1137|1141|1143|5880|4985|4986|4988|1535
2026,BRD-K82002057,DFB,Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1,6604893.0,Preclinical,glutamate receptor agonist,GRM5,,,2915
2027,BRD-K75748943,DG-172,CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1,57342889.0,Preclinical,PPAR receptor inverse agonist,PPARD,,,5467
2029,BRD-K06014311,DH-97,CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,3467177.0,Preclinical,melatonin receptor antagonist,MTNR1B,,,4544
2031,BRD-K69122748,diacerein,CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O,26248.0,Launched,interleukin inhibitor,IL1B,rheumatology,osteoarthritis,3553
2033,BRD-A52394261,diadenosine-tetraphosphate,"Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|",21706.0,Phase 1,adenosine kinase inhibitor,P2RY13|P2RY2,,,53829|5029
2035,BRD-A27143604,diarylpropionitrile,"Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|",6604873.0,Preclinical,estrogen receptor agonist,ESR2,,,2100
2038,BRD-K73109821,diazoxide,CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|,3019.0,Launched,potassium channel activator,ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3,endocrinology,hypoglycemia,3778|759|3764|3767|760|476|6559
2042,BRD-K73477617,dibutyl-phthalate,CCCCOC(=O)c1ccccc1C(=O)OCCCC,3026.0,Preclinical,,TRPA1,,,8989
2048,BRD-K08252256,diclofenac,OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,3033.0,Launched,cyclooxygenase inhibitor,AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A,rheumatology|neurology/psychiatry,rheumatoid arthritis|osteoarthritis|migraine headache,8644|5320|41|3785|3786|5742|5743|240|6329|5468|9311
2049,BRD-K71499074,diclofenamide,NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O,3038.0,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA4|CA7,ophthalmology|neurology/psychiatry,glaucoma|epilepsy,771|759|760|762|766
2050,BRD-A51078674,diclofensine,COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|,23872188.0,Phase 3,dopamine reuptake inhibitor,DRD1|MAOA|MAOB,,,4128|4129|1812
2053,BRD-K82236179,dicoumarol,Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12,54676038.0,Launched,NADPH inhibitor,CRYZ|NQO1|VKORC1,hematology,deep vein thrombosis (DVT),1728|79001|1429
2055,BRD-K68507560,dicycloverine,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,3042.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,gastroenterology,irritable bowel syndrome,1128|1129|1131
2056,BRD-K99063460,didanosine,OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O,135398739.0,Launched,nucleoside reverse transcriptase inhibitor,PNP,infectious disease,human immunodeficiency virus (HIV-1),5539
2058,BRD-K94146583,didox,ONC(=O)c1ccc(O)c(O)c1,3045.0,Launched,ribonucleotide reductase inhibitor,RRM1,oncology,breast cancer,6240
2059,BRD-K95309561,dienestrol,C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1,667476.0,Launched,estrogen receptor agonist,ESR1,endocrinology,menopause,2099
2060,BRD-K50853363,dienogest,"C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|",68861.0,Launched,progesterone receptor agonist,PGR,endocrinology|obstetrics/gynecology,contraceptive|endometriosis,5241
2061,BRD-K45542189,diethylcarbamazine,CCN(CC)C(=O)N1CCN(C)CC1,3052.0,Launched,lipoxygenase inhibitor,ALOX5|PTGS1,infectious disease,filariasis,240|5742
2062,BRD-K45330754,diethylstilbestrol,CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1,448537.0,Withdrawn,estrogen receptor agonist,ESR1|ESR2|ESRRB|ESRRG,,,2104|2099|2100|2103
2065,BRD-A66869276,diflorasone-diacetate,"C[C@H]1C[C@H]2[C@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O |a:1,6,14,16,18,21,23,&1:3,&2:4,c:12,t:8|",51895260.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
2067,BRD-K22031190,diflunisal,OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F,3059.0,Launched,prostanoid receptor antagonist,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743
2068,BRD-K72992801,difluprednate,"CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18,t:14|",443936.0,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,2908
2070,BRD-K18518344,digitoxigenin,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|,4369270.0,Preclinical,ATPase inhibitor,ATP1A1,,,476
2071,BRD-K63668566,digitoxin,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|,441207.0,Launched,ATPase inhibitor,ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2,cardiology,congestive heart failure|cardiac arrythmia,480|481|482|483|486|476|477|478
2073,BRD-K00004302,digoxin,[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|,12940973.0,Launched,ATPase inhibitor,ATP1A1,cardiology,congestive heart failure|atrial fibrillation (AF),476
2074,BRD-K20152659,dihomo-gamma-linolenic-acid,CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O,5280581.0,Phase 2,prostanoid receptor agonist,PTGS1|PTGS2,,,5742|5743
2075,BRD-K31471398,dihydrexidine,Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O,6603820.0,Phase 2,dopamine receptor agonist,DRD1|DRD2|DRD3|DRD4|DRD5,,,1812|1813|1814|1815|1816
2077,BRD-K97440753,dihydroergocristine,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,107715.0,Launched,adrenergic receptor antagonist|prolactin inhibitor,ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7,neurology/psychiatry,senile dementia|cerebrovascular insufficiency,3360|3361|3362|3363|146|1812|1813|1814|1815|1816|153|3350|3356|3359
2078,BRD-K72166146,dihydroergotamine,CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,10531.0,Launched,serotonin receptor agonist,ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7,neurology/psychiatry,migraine headache,3363|106480180|1813|150|3351|3352|3354|3355
2081,BRD-A34455052,dihydrotachysterol,"CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3,&2:7,&3:9,&4:12,&5:17,&6:23,&7:27,r|",,Launched,vitamin analog,VDR,orthopedics|endocrinology,rickets|hypocalcemia|osteomalacia,1594
2083,BRD-A20589515,dihydroxyphenylglycine,"N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|",10197959.0,Preclinical,glutamate receptor agonist,GRM1|GRM5,,,2915|2911
2085,BRD-K48722258,dilazep,COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1,3074.0,Launched,adenosine reuptake inhibitor,SLC29A1,cardiology,coronary heart disease,2030
2088,BRD-K24023109,diltiazem,COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,39186.0,Launched,calcium channel blocker,CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5,cardiology,hypertension|angina pectoris,775|779|781|786|3741|3359
2090,BRD-K23541596,dimaprit,CN(C)CCCSC(N)=N,3077.0,Preclinical,histamine receptor agonist,HRH2|HRH3|HRH4,,,1665|59340|11255
2091,BRD-K29812331,dimemorfan,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31,3037918.0,Launched,sigma receptor agonist,SIGMAR1,pulmonary,cough suppressant,10280
2092,BRD-M98649031,dimenhydrinate,Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1,10660.0,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|gastroenterology,motion sickness|nausea|vomiting,3269
2094,BRD-K88701661,dimercaptosuccinic-acid,OC(=O)[C@@H](S)[C@@H](S)C(O)=O,2724354.0,Launched,chelating agent,DNMT1,neurology/psychiatry,metal toxicity,1786
2098,BRD-K83192048,dimethindene-(S)-(+),C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|,6604866.0,Preclinical,acetylcholine receptor antagonist,HRH1,,,3269
2100,BRD-K31111078,dimethyl-fumarate,COC(=O)\C=C\C(=O)OC,637568.0,Launched,nuclear factor erythroid derived|like (NRF2) activator,KEAP1,neurology/psychiatry,multiple sclerosis,9817
2102,BRD-K01826026,dimetindene,"C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1,r,c:2|",6604866.0,Launched,cholinergic receptor antagonist|histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269
2104,BRD-K92848252,diminazene-aceturate,NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1,2354.0,Phase 3,angiotensin converting enzyme activator,AOC1|PRDX5|PRSS1,,,25824|26|136541
2105,BRD-K60567437,dimpylate,CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C,3017.0,Launched,acetylcholinesterase inhibitor,ACHE,infectious disease,flea control,43
2106,BRD-K13662825,dinaciclib,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,46926350.0,Phase 3,CDK inhibitor,CDK1|CDK2|CDK5|CDK9,,,1017|1020|1025|983
2108,BRD-K81672972,dinoprost,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,5280363.0,Launched,prostacyclin analog,PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R,obstetrics/gynecology,labor induction,5729|5731|5732|5733|5734|6915|5737|11251
2109,BRD-K26521938,dinoprostone,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,5280360.0,Withdrawn,prostanoid receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R,,,5729|117155|5731|5732|5733|5734|6915|5737|11251|347732|378807|117144
2110,BRD-K67340225,dioscin,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|,119245.0,Preclinical,apoptosis stimulant,CXCR3,,,2833
2112,BRD-K26862302,diosmetin,COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1,5281612.0,Launched,aryl hydrocarbon receptor agonist,CYP1B1,dermatology,cosmetic,1545
2113,BRD-K94436377,diosmin,COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1,5281613.0,Launched,aryl hydrocarbon receptor agonist|capillary stabilizing agent,AHR,cardiology|hematology|dermatology,chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome,196
2117,BRD-K93441486,diphemanil,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,6127.0,Launched,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,1131
2119,BRD-K47278471,diphenhydramine,CN(C)CCOC(c1ccccc1)c1ccccc1,3100.0,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,headache,3269
2120,BRD-K01663662,diphenidol,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,3055.0,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,neurology/psychiatry,vertigo,1128|1129|1131|1132
2121,BRD-K65814004,diphenyleneiodonium,[I]1c2ccccc2-c2ccccc12 |^1:0|,,Preclinical,nitric oxide synthase inhibitor,NOS2|NOS3,,,339345|342977
2123,BRD-K22936972,diphenylpyraline,CN1CCC(CC1)OC(c1ccccc1)c1ccccc1,3103.0,Launched,dopamine reuptake inhibitor,HRH1|SLC6A3,allergy,allergic rhinitis,6531|3269
2125,BRD-K64838454,dipraglurant,Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1,44557636.0,Phase 2,glutamate receptor negative allosteric modulator,GRM5,,,2915
2126,BRD-K75385383,DIPT,CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,26903.0,Launched,dopamine reuptake inhibitor|serotonin reuptake inhibitor,HTR1A|HTR2A|HTR2C,,,3356|3350|3358
2127,BRD-K86301799,dipyridamole,OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO,3108.0,Launched,phosphodiesterase inhibitor,ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1,cardiology,coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension,5136|5137|5138|5139|5140|5141|5142|5143|5144|5145|5146|5147|5148|5149|5150|5151|5152|5153|5158|8622|8654|10846|100|27115|2030
2132,BRD-K66672047,disodium-sebacate,OC(=O)CCCCCCCCC(O)=O,5192.0,Phase 1,,HBB,,,85344
2133,BRD-A29734509,disopyramide,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|,3114.0,Launched,sodium channel blocker,CHRM1|CHRM2|CHRM3|KCND2|KCND3|KCNH2|SCN5A,cardiology,ventricular tachycardia (VT)|ventricular arrhythmias,3751|1128|1129|3752|1131|3757|6331
2134,BRD-K32744045,disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,3117.0,Launched,aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist,ALDH2|DBH,neurology/psychiatry,abstinence from alcohol,217|1621
2136,BRD-K40654626,ditiocarb-sodium-trihydrate,CCN(CC)C(S)=S,8987.0,Phase 3,immunostimulant,CA1|CA2|CA4,,,760|762|759
2137,BRD-K33459542,ditolylguanidine,Cc1ccccc1NC(=N)Nc1ccccc1C,7333.0,Preclinical,sigma receptor agonist,GRIN1|GRIN2A|GRIN2B|SIGMAR1,,,2904|10280|114787|2903
2141,BRD-K58930050,dizocilpine-(+),C[C@]12N[C@H](Cc3ccccc13)c1ccccc21,180081.0,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,114787|2903|2904|2905|2906
2142,BRD-K26573499,DMAB-anabaseine,CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|,9926048.0,Preclinical,adrenergic receptor agonist,CHRNA7,,,89832
2143,BRD-K36775483,DMeOB,COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1,6891506.0,Preclinical,glutamate receptor modulator,GRM5,,,2915
2144,BRD-K39381259,DMH1,CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12,50997747.0,Preclinical,ALK tyrosine kinase receptor inhibitor,ACVR1,,,90
2145,BRD-K40575944,DMH4,C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1,5329447.0,Preclinical,VEGFR inhibitor,KDR,,,3791
2148,BRD-K54936858,DMP-777,CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1,177992.0,Phase 2,elastase inhibitor,MPO,,,4353
2151,BRD-K64400208,DNQX,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O,3899541.0,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B,,,114787|2890|2891|2897|2903|2904
2152,BRD-A78322124,dobutamine,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,65324.0,Launched,adrenergic receptor agonist,ADRB1|ADRB2,cardiology,congestive heart failure,153|154
2153,BRD-K08290224,docebenone,"CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|",1967.0,Phase 2,lipoxygenase inhibitor,ALOX5,,,240
2154,BRD-K30577245,docetaxel,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|,148124.0,Launched,tubulin polymerization inhibitor,BCL2|MAP2|MAP4|MAPT|NR1I2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC),10376|84617|10381|10382|10383|8856|4134|7846|347688|4137|113457|84790|203068|112714|596|347733|10988|7277|7278|7280
2155,BRD-K39965020,doconexent,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O,445580.0,Launched,PPAR receptor agonist,FFAR1|PTGS1|PTGS2,,,2864|5742|5743
2157,BRD-K50050533,docosanol,CCCCCCCCCCCCCCCCCCCCCCO,12620.0,Launched,lipase clearing factor inhibitor,TLR7,dental,cold sore,51284
2159,BRD-K05680146,dodecyl-sulfate,CCCCCCCCCCCCOS(O)(=O)=O,8778.0,Preclinical,,LYZ,,,4069
2160,BRD-A14941520,dofequidar,OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1,9960287.0,Phase 3,MRP inhibitor|P glycoprotein inhibitor,ABCB1,,,5243
2161,BRD-K86887724,dofetilide,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,71329.0,Withdrawn,potassium channel blocker,KCNH1|KCNH2|KCNJ12|KCNK2,,,3768|3756|3757|3776
2162,BRD-K28029915,dolasetron,O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12,,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting,3359
2163,BRD-K78567475,dolastatin-10,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,9810929.0,Phase 2,tubulin polymerization inhibitor,TUBB,,,7280
2164,BRD-K67463151,dolutegravir,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,54726191.0,Launched,HIV integrase inhibitor,CYP3A4|CYP3A5|CYP3A7|POU2F2|UGT1A1,infectious disease,human immunodeficiency virus (HIV-1),54658|100861540|1576|1577|5452
2166,BRD-K38305202,domperidone,Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1,3151.0,Launched,dopamine receptor antagonist,DRD2|DRD3,infectious disease,fescue toxicosis,1813|1814
2167,BRD-A49160188,donepezil,COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|,1150567.0,Launched,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,Alzheimer's disease,43
2168,BRD-K31092604,donitriptan,NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12,197706.0,Phase 2,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR5A|HTR6,,,3361|3362|3350|3351|3352|3354|3355|3356
2169,BRD-K43887077,dopamine,NCCc1ccc(O)c(O)c1,681.0,Launched,dopamine receptor agonist,DBH|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR7|SLC6A2|SLC6A3|SLC6A4,cardiology|neurology/psychiatry,ventricular arrhythmias|depression|headache|tremors,6530|3363|6531|6532|1815|1812|1813|1621|1814|1816|3350
2170,BRD-K74065929,doramapimod,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C,156422.0,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK12|MAPK13|MAPK14,,,5600|5603|6300|1432
2173,BRD-K45319714,doripenem,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|,73303.0,Launched,bacterial cell wall synthesis inhibitor,DPEP1,infectious disease,intra-abdominal infections|urinary tract infections|pyelonephritis,1800
2174,BRD-K54233340,dorsomorphin,C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1,11524144.0,Preclinical,AMPK inhibitor,ACVR1|BMPR1A|BMPR1B|EPHA2|FKBP1A|FLT1|FLT3|KDR|LCK|MKNK1|PRKAA1|RPS6KA1|SRC,,,2280|3791|5562|657|1969|658|2321|2322|6195|6714|8569|90|3932
2175,BRD-K48617017,dorzolamide,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,5284549.0,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7,ophthalmology,intraocular pressure|glaucoma,771|23632|759|760|762|766
2176,BRD-K54759182,dosulepin,CN(C)CC\C=C1/c2ccccc2CSc2ccccc12,5284550.0,Launched,norepinephrine reuptake inhibitor|serotoninânorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression,6530|6532|3269|1128|1129|1131|1132|1133
2178,BRD-K85402309,dovitinib,CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O,135398510.0,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB,,,1956|5156|3815|5159|3791|2321|2322|2260|2261|2324|2263|3643|1436
2180,BRD-K01825125,doxazosin,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|",6604102.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension,146|147
2181,BRD-K37694030,doxepin,CN(C)CC\C=C1\c2ccccc2COc2ccccc12,667468.0,Launched,histamine receptor antagonist,HRH1|SLC6A2|SLC6A4,neurology/psychiatry,depression|anxiety,6530|6532|3269
2182,BRD-K82928892,doxercalciferol,CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C,46931009.0,Launched,vitamin D receptor agonist,VDR,nephrology|endocrinology,chronic kidney disease (CKD)|hyperparathyroidism,1594
2183,BRD-K58262659,doxifluridine,C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O,18343.0,Launched,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,7298
2184,BRD-K70507123,doxofylline,Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O,50942.0,Launched,adenosine receptor antagonist,ADORA1|PDE4A|PDE4B|PDE4C|PDE4D,pulmonary,asthma,134|5141|5142|5143|5144
2185,BRD-K92093830,doxorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,31703.0,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy|oncology,acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma,7153
2186,BRD-K01825679,doxycycline,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|",,Launched,bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor,MMP8,dental,periodontitis,4317
2187,BRD-A44008656,doxylamine,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,43833352.0,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry,sedative,3269
2190,BRD-K01824921,DPCPX,CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1,1329.0,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
2191,BRD-A64553394,DPI-201106,"O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|",10389826.0,Phase 2,sodium channel activator,ADRB2,,,154
2192,BRD-K99922388,DPO-1,CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1,21678144.0,Preclinical,potassium channel blocker,KCNA5,,,3741
2193,BRD-K80315159,DPPE,CCN(CC)CCOc1ccc(Cc2ccccc2)cc1,108092.0,Phase 3,histamine receptor antagonist,ABCB1|HRH1,,,5243|3269
2194,BRD-A67976398,DQP-1105,"Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|",136902743.0,Preclinical,glutamate receptor antagonist,GRIN2C|GRIN2D,,,2905|2906
2195,BRD-K94920105,DR-2313,Cc1nc(=O)c2CSCCc2[nH]1,135522417.0,Preclinical,PARP inhibitor,PARP1|PARP3,,,142|10039
2196,BRD-A39794701,DR-4485,"Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|",92211523.0,Preclinical,serotonin receptor antagonist,HTR7,,,3363
2197,BRD-K25486274,DRF053-(R),CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1,25168304.0,Preclinical,CDK inhibitor,CSNK1A1,,,1452
2199,BRD-K38477637,droloxifene,CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,3033767.0,Phase 3,selective estrogen receptor modulator (SERM),ESR1,,,2099
2200,BRD-A38706605,dromostanolone-propionate,"CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|",,Launched,androgen receptor modulator,AR,oncology,breast cancer,367
2201,BRD-K05524748,dronedarone,CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,208898.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|KCNA5|KCNH2|KCNK2|SCN1A,cardiology,atrial fibrillation (AF),3776|775|776|778|779|3757|782|783|784|785|146|147|6323|150|151|152|153|3741
2202,BRD-K97158071,droperidol,Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|,3168.0,Launched,dopamine receptor antagonist,ADRA1A|DRD2|DRD3|DRD4|HTR2A,gastroenterology,nausea|vomiting,146|1813|1814|1815|3356
2204,BRD-K04394237,drospirenone,C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|,68873.0,Launched,mineralocorticoid receptor antagonist,AR|NR3C2|PGR,endocrinology,contraceptive,5241|4306|367
2206,BRD-K17219082,droxicam,CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O,65679.0,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology,rheumatoid arthritis|osteoarthritis,5742
2207,BRD-K20372197,droxidopa,N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O,92974.0,Launched,norepinephrine precursor,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH,cardiology|neurology/psychiatry,hypertension|Parkinson's Disease,146|147|150|151|152|153|154|155|5053
2208,BRD-K11558771,droxinostat,Cc1cc(Cl)ccc1OCCCC(=O)NO,568416.0,Preclinical,HDAC inhibitor,HDAC6|HDAC8,,,55869|10013
2212,BRD-K46384285,DSR-6434,CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1,25071151.0,Preclinical,toll-like receptor agonist,TLR7,,,51284
2213,BRD-K08859203,DU-728,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,107775.0,Phase 1,structural glycoprotein antagonist,ITGA2B|ITGB3,,,3674|3690
2214,BRD-K71103788,duloxetine,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,60835.0,Launched,norepinephrine reuptake inhibitor|serotoninânorepinephrine reuptake inhibitor (SNRI),HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy,3362|6531|6530|6532|3356|3358
2215,BRD-K06221026,DUP-697,CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1,3177.0,Phase 1,cyclooxygenase inhibitor,PTGS2,,,5743
2216,BRD-K30373883,dutasteride,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|,6918296.0,Launched,5 alpha reductase inhibitor,SRD5A1|SRD5A2|SRD5A3,urology,benign prostatic hyperplasia (BPH),6715|6716|79644
2217,BRD-K93468883,duvelisib,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,50905713.0,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,5290|5291|5294|22883
2220,BRD-K58343622,DY131,CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1,5497124.0,Preclinical,estrogen-related receptor agonist,ESRRB|ESRRG,,,2104|2103
2221,BRD-K72259270,dyclonine,CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1,3180.0,Launched,sodium channel blocker,SCN10A|SCN5A,neurology/psychiatry,local anesthetic,6336|6331
2222,BRD-K68620903,dydrogesterone,"CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|",9051.0,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,infertility,5241
2223,BRD-K87718015,dynasore,Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O,135533054.0,Preclinical,dynamin inhibitor,DNM1|DNM1L|DNM2,,,1785|10059|1759
2224,BRD-K23479488,dynole-34-2,CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N,44157463.0,Preclinical,dynamin inhibitor,DNM1,,,1759
2225,BRD-A00827783,dyphylline,"Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|",688353.0,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,PDE4A,pulmonary,asthma|bronchitis|emphysema,5141
2227,BRD-K50564936,E-2012,COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1,11560787.0,Phase 1,gamma secretase modulator,APH1A|APH1B|PSENEN,,,83464|55851|51107
2228,BRD-K41713976,E-4031,Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1,3185.0,Phase 1,potassium channel blocker,KCNH1|KCNH2,,,3756|3757
2229,BRD-K00004314,E-64,CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N,123985.0,Preclinical,calpain inhibitor|cysteine protease inhibitor,CTSS,,,1520
2232,BRD-K05444225,E7449,O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23,135565981.0,Phase 2,PARP inhibitor,PARP1|PARP2|TNKS|TNKS2,,,10038|8658|142|80351
2234,BRD-K53030960,eact,COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1,3173542.0,Preclinical,calcium-activated chloride channel inhibitor,ANO1,,,55107
2235,BRD-K66998413,EB-47,Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1,53229989.0,Preclinical,PARP inhibitor,PARP1,,,142
2236,BRD-K13314656,ebastine,CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,3191.0,Launched,histamine receptor antagonist,CYP3A4|HRH1,allergy,allergic rhinitis|urticaria,1576|3269
2237,BRD-K00004209,EBPC,"CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|",6919079.0,Preclinical,aldose reductase inhibitor,AKR1B1,,,231
2238,BRD-K22421059,ebrotidine,NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1,65869.0,Withdrawn,histamine receptor antagonist,HRH2,,,1665
2239,BRD-K29359156,ebselen,O=c1n([se]c2ccccc12)-c1ccccc1,3194.0,Phase 2/Phase 3,cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor,ALB,,,213
2240,BRD-K41705163,EC-144,COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C,11517212.0,Preclinical,HSP inhibitor,HSP90AA1|HSP90AB1,,,3320|3326
2241,BRD-K81004638,EC-23,CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O,10314719.0,Preclinical,retinoid receptor agonist,RARA|RARB|RARG,,,5914|5915|5916
2243,BRD-K03353589,ecabet,CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O,65781.0,Launched,gastrin inhibitor|urease inhibitor,NOXO1,ophthalmology,dry eye syndrome,124056
2246,BRD-A51820102,econazole,Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|,6604378.0,Launched,lanosterol demethylase inhibitor|sterol demethylase inhibitor,NPY1R|NPY2R|TRPM2|TRPV5,infectious disease,tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis,1191|56302|4886|4887
2248,BRD-K00004306,edaglitazone,"Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|",76961439.0,Phase 2,PPAR receptor agonist,PPARG,,,5468
2249,BRD-K35458079,edaravone,Cc1cc(=O)n([nH]1)-c1ccccc1,70335.0,Launched,nootropic agent,BCL2,neurology/psychiatry,stroke,596
2255,BRD-K97058489,edoxaban,CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1,10280735.0,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|pulmonary embolism (PE)|systemic embolism|deep vein thrombosis (DVT)|atrial fibrillation (AF),2159
2257,BRD-K81128206,edrophonium,CC[N+](C)(C)c1cccc(O)c1,3202.0,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,myasthenia gravis,43|590
2259,BRD-K19002914,EED226,CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12,123132228.0,Preclinical,polycomb protein inhibitor,EED,,,8726
2261,BRD-K37355418,efaproxiral,Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1,122335.0,Phase 3,hemoglobin oxygen release stimulant,HBA1|HBB,,,85344|3039
2262,BRD-A10739734,efaroxan,CCC1(Cc2ccccc2O1)C1=NCCN1,11957548.0,Phase 2,adrenergic receptor antagonist,ADORA2A,,,135
2263,BRD-A24560335,efatutazone,Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|,76962475.0,Phase 2,PPAR receptor agonist,PPARG,,,5468
2264,BRD-K40758068,efavirenz,FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1,64139.0,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1544|1576|1555|1557|1559|1565
2265,BRD-A30774155,efinaconazole,"C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1,&1:9|",9819704.0,Launched,lanosterol demethylase inhibitor,CYP51A1,infectious disease,onychomycosis,1595
2267,BRD-A96292436,eflornithine,NCCCC(N)(C(F)F)C(O)=O |&1:4|,3009.0,Launched,ornithine decarboxylase inhibitor,ARG2|ODC1,dermatology,facial hair reduction,384|89874
2270,BRD-K50653584,EG00229,NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O,44631827.0,Preclinical,neuropilin receptor antagonist,NRP1,,,4745
2271,BRD-K22514639,EGF816,CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12,72703790.0,Phase 2,EGFR inhibitor,EGFR,,,1956
2272,BRD-K65359424,eglumetad,N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,213056.0,Phase 2,glutamate receptor agonist,GRM2|GRM3|GRM6|GRM8,,,2912|2913|2916|2918
2273,BRD-K32289541,EHop-016,CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12,51031035.0,Preclinical,Ras GTPase inhibitor,RAC1|RAC3,,,8202|6035
2274,BRD-K91535048,EI1,CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O,72199293.0,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,,2146
2275,BRD-K88120876,EIPA,CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N,1795.0,Preclinical,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,ADRA2A|ASIC1|PKD2L1,,,9033|41|150
2276,BRD-K81623406,EIT-hydrobromide,CCSC(N)=N,5139.0,Preclinical,nitric oxide synthase inhibitor,NOS2|NOS3,,,339345|342977
2278,BRD-K88807631,elacridar,COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC,119373.0,Phase 1,P glycoprotein inhibitor,ABCB1,,,5243
2279,BRD-K63876426,elactocin,CC\C(\C=C\[C@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(\C)=C\[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C\C(C)=C\C(O)=O |c:9|,16760536.0,Phase 1,exportin antagonist,XPO1,,,7514
2280,BRD-K00004609,elacytarabine,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O,6438895.0,Phase 3,antineoplastic agent,DCK,,,1633
2281,BRD-K03165895,elafibranor,CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1,9864881.0,Phase 3,PPAR receptor agonist,PPARA|PPARD|PPARG,,,5465|5467|5468
2282,BRD-K55808645,elagolix,COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O,11250647.0,Launched,gonadotropin releasing factor hormone receptor antagonist,GNRHR,,,2798
2284,BRD-K00003316,eldecalcitol,[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C,6918141.0,Phase 3,bone formation stimulant,VDR,,,1594
2287,BRD-K82135108,elesclomol,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,300471.0,Phase 3,oxidative stress inducer,HSPA1A,,,3303
2288,BRD-K30652337,eletriptan,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,77993.0,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7,neurology/psychiatry,migraine headache,3363|106480180|3350|3351|3352|3354|3355
2289,BRD-K86410485,eliglustat,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1,23652731.0,Launched,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease,7357
2290,BRD-K59271229,elinogrel,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,16066663.0,Phase 2,purinergic receptor antagonist,P2RY12,,,64805
2291,BRD-A61392169,eliprodil,"O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|",9798372.0,Phase 3,glutamate receptor antagonist,GRIN1|GRIN2B,,,2904|114787
2292,BRD-K30466858,ellagic-acid,Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O,5281855.0,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK,,,768|6850|771|11238|5578|5579|6713|23632|1459|2932|759|760|761|762|763|765|766
2293,BRD-K50699835,ELN-441958,Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1,11848206.0,Preclinical,bradykinin receptor antagonist,BDKRB1,,,623
2295,BRD-K30827431,eltanolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,31402.0,Phase 3,GABA receptor positive allosteric modulator,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2,,,2561|2566|2554|2555|2556|2557|2558|2559
2296,BRD-K86171477,eltoprazine,C1CN(CCN1)c1cccc2OCCOc12,65853.0,Phase 2,serotonin receptor agonist,HTR1A|HTR1B,,,3350|3351
2297,BRD-K00003572,eltrombopag,CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|,,Launched,thrombopoietin receptor agonist,MPL,hematology|infectious disease,anemia|hepatitis C|thrombocytopenia,4352
2298,BRD-K39560679,eluxadoline,COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O,130406582.0,Launched,opioid receptor agonist|opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome,4985|4986|4988
2301,BRD-K86727142,embelin,CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|,,Preclinical,HCV inhibitor|XIAP inhibitor,XIAP,,,331
2302,BRD-K97963946,EMD-1214063,CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1,25171648.0,Phase 2,hepatocyte growth factor receptor inhibitor,MET,,,8731
2303,BRD-K47659338,EMD-386088,Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|,10131112.0,Preclinical,serotonin receptor agonist,HTR6,,,3362
2304,BRD-A65248799,EMD-53998,"COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|",446286.0,Phase 1,phosphodiesterase inhibitor,TNNC1,,,7137
2305,BRD-K88759641,EMD-66684,CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,9892554.0,Preclinical,angiotensin receptor antagonist,AGTR1,,,185
2307,BRD-K15010214,emedastine,CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1,3219.0,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269
2309,BRD-K03067624,emetine,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12,10219.0,Phase 2,protein synthesis inhibitor,RPS2,,,6187
2313,BRD-K58685305,emodin,Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1,3220.0,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,CSNK2A1,,,1459
2316,BRD-K53765467,empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1,11949646.0,Launched,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,endocrinology,diabetes mellitus,6523|6524
2317,BRD-K00023644,emricasan,C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F,12000240.0,Phase 2,caspase inhibitor,CASP1|CASP3|CASP7,,,840|834|836
2319,BRD-K86063171,EN460,OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|,1016023.0,Preclinical,endoplasmic reticulum oxidation inhibitor,ERO1A,,,30001
2320,BRD-K57545991,enalapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,5388962.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD),1636
2321,BRD-K99447003,enalaprilat,C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,5462501.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636
2322,BRD-K70601687,enasidenib,CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F,89683805.0,Launched,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML),3417
2324,BRD-A62197763,enciprazine,"COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|",29919953.0,Phase 3,GABA receptor modulator,GABRA1,,,2554
2325,BRD-K00003576,encorafenib,COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,50922675.0,Launched,RAF inhibitor,BRAF,oncology,melanoma,673
2326,BRD-K61314889,endo-IWR-1,O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|,44483163.0,Preclinical,PARP inhibitor,TNKS|TNKS2,,,8658|80351
2327,BRD-K62752296,endoxifen,CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1,10090750.0,Phase 2,estrogen receptor antagonist,ESR1,,,2099
2328,BRD-A51831848,enflurane,"FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|",7059516.0,Launched,membrane permeability inhibitor,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,anesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|338567|2741|2743|54207|3776|3777|55879|51305|2554|2555|2556|2557|2558|2559
2329,BRD-K01825690,enilconazole,Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|,6992070.0,Launched,sterol demethylase inhibitor,CYP19A1|CYP1A2|CYP2B6|CYP2C9|CYP2J2|CYP3A4|CYP3A5|NR1I2|PPARA|PTGER2,infectious disease,skin infections,5732|1573|1544|1576|1577|1555|1588|1559|8856|5465
2330,BRD-K26425819,eniluracil,O=c1[nH]cc(C#C)c(=O)[nH]1,43157.0,Phase 3,dihydropyrimidine dehydrogenase inhibitor,AOX1|DPYD|XDH,,,6652|316|1806
2333,BRD-K68488863,ENMD-2076,CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1,16041424.0,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,AURKA|FLT3|KDR|PDGFRA|PTK2|SRC,,,5156|6790|3791|2322|5747|6714
2334,BRD-K32007074,enocitabine,CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,71734.0,Launched,DNA synthesis inhibitor,CMPK1|RRM1|TYMS,hematologic malignancy,acute myeloid leukemia (AML),6240|7298|51727
2335,BRD-K78113049,enoxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1,3229.0,Launched,topoisomerase inhibitor,TOP2A,infectious disease,urinary tract infections|gonorrhea,7153
2336,BRD-K21152241,enoximone,CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C,53708.0,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,5139
2337,BRD-K96137854,enoxolone,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|,10114.0,Launched,gap junction modulator,HSD11B1,gastroenterology|otolaryngology,peptic ulcer disease (PUD)|common cold,3290
2338,BRD-K35007173,enprofylline,CCCn1c2nc[nH]c2c(=O)[nH]c1=O,1676.0,Phase 3,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADORA3|PDE4A|PDE4B,,,134|135|136|140|5141|5142
2340,BRD-K83636919,entacapone,CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N,5281081.0,Launched,catechol O methyltransferase inhibitor,COMT,neurology/psychiatry,Parkinson's Disease,1312
2343,BRD-K77908580,entinostat,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,4261.0,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC9,,,3065|3066|8841|9734
2344,BRD-K39009484,entrectinib,CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1,25141092.0,Launched,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,ALK|NTRK1|NTRK2|NTRK3|ROS1,oncology,non-small cell lung cancer (NSCLC),238|6098|4914|4915|4916
2345,BRD-K56851771,enzalutamide,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,15951529.0,Launched,androgen receptor antagonist,AR,oncology,prostate cancer,367
2346,BRD-K79404599,enzastaurin,Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|,176167.0,Phase 3,PKC inhibitor,AKT1|GSK3B|PRKCA|PRKCB|PRKCD|PRKCG,,,5578|5579|5580|5582|207|2932
2347,BRD-K42452249,EO-1428,Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl,9801969.0,Preclinical,p38 MAPK inhibitor,MAPK11|MAPK14,,,5600|1432
2348,BRD-K79450420,epacadostat,NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1,135564890.0,Phase 3,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,3620
2349,BRD-K98054437,epalrestat,C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1,1549120.0,Launched,aldose reductase inhibitor,AKR1B1,nephrology,diabetic nephropathy,231
2351,BRD-K01825729,eperisone,CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|,37888265.0,Launched,acetylcholine receptor antagonist,CYP2J2,neurology/psychiatry,amyotrophic lateral sclerosis (ALS)|spasms|head injury|spinal injury,1573
2353,BRD-K45014108,ephedrine,CN[C@@H](C)[C@H](O)c1ccccc1,9294.0,Launched,adrenergic receptor agonist,ACHE|ADRA1A|ADRB2|SLC18A2|SLC6A2,cardiology|pulmonary|neurology/psychiatry|endocrinology,hypotension|asthma|narcolepsy|obesity,6530|43|6571|146|154
2354,BRD-A54236247,ephedrine-(racemic),"CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|",7028.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A|ADRB1|ADRB2|ATF1|ATF2|ATF3|ATF4|ATF5|ATF6|ATF7|FOS|IL2|JDP2|JUN|NFATC1|SLC6A2|SLC6A3|SLC6A4|TNF,cardiology|pulmonary|neurology/psychiatry|endocrinology,hypotension|asthma|narcolepsy|obesity,6530|6531|6532|11016|3725|22926|146|150|22809|153|154|4772|2353|122953|467|468|7124|3558|2668
2355,BRD-K03972660,epiandrosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,441302.0,Preclinical,steroid,G6PD,,,8266
2356,BRD-K50660797,epicatechin-gallate-(-),Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1,107905.0,Phase 2,bacterial DNA gyrase inhibitor,BACE1|FASN,,,2194|23621
2359,BRD-K55591206,epigallocatechin-gallate-(-),Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1,65064.0,Phase 2/Phase 3,bacterial DNA gyrase inhibitor,ELANE|EP300|FASN|KAT2B|MMP14|MMP2,,,4323|1991|2033|2194|8850|4313
2360,BRD-A98990573,epinastine,"NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|",15629776.0,Launched,histamine receptor antagonist,HRH1,ophthalmology,conjunctivitis,3269
2361,BRD-K63126190,epinephrine,CNC[C@H](O)c1ccc(O)c(O)c1,5816.0,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF,cardiology|allergy|pulmonary,cardiac arrest|anaphylactic shock|asthma,146|147|7124|150|151|152|153|154|155|5053
2362,BRD-K39339537,epirizole,COc1cc(C)nn1-c1nc(C)cc(OC)n1,3242.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
2363,BRD-K04548931,epirubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,41867.0,Launched,topoisomerase inhibitor,CHD1|TOP2A,oncology,breast cancer,1105|7153
2364,BRD-K02314383,epitiostanol,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O,443935.0,Launched,androgen receptor agonist,AR,oncology,breast cancer,367
2365,BRD-K19761926,eplerenone,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|,443872.0,Launched,cytochrome P450 inhibitor,NR3C2,cardiology,congestive heart failure|hypertension,4306
2366,BRD-A59329714,epomediol,"CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11,&2:9,&3:6,r,THB:12:11:1.3:8.6,7:6:1.3:11.10|",,Launched,cholesterol inhibitor,CYP7A1,neurology/psychiatry,itching,1581
2367,BRD-K64054020,epoprostenol,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O,5282411.0,Launched,prostacyclin analog,P2RY12|PTGER1|PTGER4|PTGIR|PTGIS,cardiology,hypertension,5731|64805|5734|5739|5740
2369,BRD-K48935217,epothilone-B,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,118184795.0,Phase 3,microtubule stabilizing agent|tubulin polymerization inhibitor,TUBB,,,7280
2370,BRD-K52762805,epothilone-D,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|,,Phase 2,microtubule stabilizing agent|tubulin polymerization inhibitor,TUBB,,,7280
2371,BRD-K42536037,EPPTB,CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1,25175634.0,Preclinical,trace amine associated receptor antagonist,TAAR1,,,134864
2375,BRD-K17979676,eprobemide,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,65659.0,Launched,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,4128
2376,BRD-K11463116,eprodisate,OS(=O)(=O)CCCS(O)(=O)=O,428573.0,Phase 3,amyloid protein inhibitor|antiamyloidogenic agent,SAA1,,,6289
2377,BRD-K67977190,eprosartan,CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O,5281037.0,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,185
2378,BRD-K68830460,eptifibatide,NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O,134812820.0,Launched,platelet aggregation inhibitor,ITGA2B|ITGB3,cardiology,acute coronary syndrome (ACS)|percutaneous coronary intervention (PCI),3674|3690
2379,BRD-K26531771,EPZ-5676,CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1,,Phase 1,histone lysine methyltransferase inhibitor,DOT1L,,,84444
2380,BRD-K69070623,EPZ004777,CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12,56962336.0,Preclinical,histone lysine methyltransferase inhibitor,DOT1L,,,84444
2381,BRD-K57754230,EPZ005687,Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1,60160561.0,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,,2146
2382,BRD-K87468701,EPZ011989,CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|,,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,,2146
2383,BRD-K70446295,EPZ015666,O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1,90241673.0,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT5,,,10419
2384,BRD-K33586289,EPZ020411,CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|,,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT6,,,55170
2385,BRD-A88080608,equilin,"C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|",41097932.0,Preclinical,estrogen receptor agonist,HSD17B1,,,3292
2386,BRD-K54847683,equol,Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1,91469.0,Launched,estrogen receptor agonist,ESR1|ESR2,,,2099|2100
2387,BRD-K11927976,ER-27319,Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O,9799509.0,Preclinical,mediator release inhibitor|SYK inhibitor,SYK,,,6850
2388,BRD-K18347943,ER-50891,CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1,10094345.0,Preclinical,retinoid receptor antagonist,RARA,,,5914
2389,BRD-A25004090,erastin,"CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|",91669533.0,Preclinical,ion channel antagonist,VDAC2,,,7417
2391,BRD-K35573744,erbstatin-analog,COC(=O)\C=C\c1cc(O)ccc1O,5353609.0,Preclinical,EGFR inhibitor|tyrosine kinase inhibitor,EGFR,,,1956
2392,BRD-K84163249,ercalcitriol,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,9547243.0,Phase 1,vitamin D receptor agonist,VDR,,,1594
2393,BRD-K84868168,erdafitinib,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,67462786.0,Launched,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4,,,2264|2260|2261|2263
2395,BRD-K56155962,ergocalciferol,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,5280793.0,Launched,vitamin analog,VDR,endocrinology|orthopedics,hypoparathyroidism|rickets|hypophosphatemia,1594
2396,BRD-K17311468,ergonovine,C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|,443884.0,Launched,adrenergic receptor agonist|serotonin receptor agonist,ADRA1A|HTR1E,hematology,postpartum hemorrhage (PPH),146|3354
2398,BRD-K15380626,ergotamine,CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|,8223.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|DRD1|DRD2|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|SLC6A2,neurology/psychiatry,migraine headache,3352|3361|3362|6530|146|147|1812|1813|150|151|1816|3350|3354|3355|3351|3356|106480180|3358
2400,BRD-K64857848,ERK5-IN-1,COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1,46844147.0,Preclinical,MAP kinase inhibitor,MAPK7,,,5598
2401,BRD-K70401845,erlotinib,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,176870.0,Launched,EGFR inhibitor,EGFR|NR1I2,oncology,non-small cell lung cancer (NSCLC)|pancreatic cancer,8856|1956
2403,BRD-K80608265,erteberel,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,10286159.0,Phase 2,estrogen receptor agonist,ESR1|ESR2,,,2099|2100
2404,BRD-K00003574,ertugliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1,44814423.0,Launched,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,6524
2406,BRD-K63550407,erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,Launched,NFkB pathway inhibitor,MLNR,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma,2862
2407,BRD-K39746403,erythromycin-estolate,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,Launched,bacterial 50S ribosomal subunit inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma,1576|5243|55244|3757|2862|213|1595
2408,BRD-K51677086,erythromycin-ethylsuccinate,CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,132274075.0,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1,infectious disease,listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma,1576|5243|55244|3757|2862|213|1595
2413,BRD-K70301876,escitalopram,CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1,146570.0,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD),6532
2414,BRD-K01825597,escitalopram,"OC(=O)C(O)=O.CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:12,r|",146571.0,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD),6532
2416,BRD-K13629382,eseroline-(-),CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21,119198.0,Preclinical,acetylcholinesterase inhibitor,OPRD1|OPRM1,,,4985|4988
2417,BRD-K77139516,ESI-09,CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N,6077765.0,Preclinical,EPAC inhibitor,RAPGEF3|RAPGEF4,,,10411|11069
2418,BRD-K61237927,eslicarbazepine-acetate,CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12,179344.0,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335
2419,BRD-K01825842,esmolol,"COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|",28125476.0,Launched,adrenergic receptor antagonist,ADRB1,cardiology,ventricular tachycardia (VT)|hypertension,153
2420,BRD-K61443506,esomeprazole,COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C,9568614.0,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD),495
2422,BRD-K75445017,estetrol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,27125.0,Phase 3,selective estrogen receptor modulator (SERM),ESR1,,,2099
2423,BRD-K18910433,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,5757.0,Launched,estrogen receptor agonist,ESR1|ESR2|GPER1|KCNMA1|NR1I2,endocrinology,contraceptive,3778|2852|2099|2100|8856
2425,BRD-K53319039,estradiol-acetate,CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1,9818306.0,Launched,estrogen receptor agonist,ESR1,endocrinology|obstetrics/gynecology,menopause|vaginal atrophy,2099
2426,BRD-K44412991,estradiol-benzoate,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O,222757.0,Preclinical,contraceptive agent,ESR1,,,2099
2427,BRD-K64984393,estradiol-cypionate,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,9403.0,Launched,estrogen receptor agonist,ESR1,endocrinology,hypoestrogenism|menopause,2099
2428,BRD-K66766661,estradiol-valerate,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,13791.0,Launched,estrogen receptor agonist,ESR1,oncology|endocrinology|obstetrics/gynecology,prostate cancer|hypoestrogenism|menopause|vaginal atrophy,2099
2429,BRD-A70858459,estramustine,"C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2O |a:1,27,&1:4,&2:5,&3:24|",259331.0,Launched,DNA alkylating agent,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer,2099|2100|23173|10988
2430,BRD-K00077635,estramustine-phosphate,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,259329.0,Launched,DNA synthesis inhibitor|microtubule inhibitor,ESR1|ESR2|MAP1A|MAP2,oncology,prostate cancer,2099|2100|23173|10988
2431,BRD-K17016787,estriol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O,5756.0,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology|obstetrics/gynecology|infectious disease,menopause|vaginal atrophy|urinary tract infections,2099|2100
2432,BRD-K81839095,estrone,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O,5870.0,Launched,estrogen receptor agonist|estrogenic hormone,ESR1|ESR2,endocrinology,menopause,2099|2100
2433,BRD-K51095933,estropipate,C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O,3001028.0,Launched,estrogen receptor agonist,ESR1|ESR2,orthopedics|endocrinology|obstetrics/gynecology,osteoporosis|menopause|vaginal atrophy|hypoestrogenism,2099|2100
2434,BRD-K63630713,etacrynic-acid,CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl,3278.0,Launched,sodium/potassium/chloride transporter inhibitor,ATP1A1|SLC12A1,cardiology|gastroenterology|nephrology|rheumatology,hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome,476|6557
2438,BRD-K64755930,etazolate,CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C,3277.0,Phase 2,phosphodiesterase inhibitor,GABRB3|PDE4A,,,2562|5141
2439,BRD-K54264768,ETC-159,Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O,86280523.0,Phase 1,beta catenin inhibitor|porcupine inhibitor,PORCN,,,64840
2447,BRD-M75061779,ethanolamine-oleate,NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O,5282489.0,Launched,immunostimulant,F12|FABP4|FFAR1|FFAR4|PLD2,gastroenterology,esophageal varices,2864|2161|2167|5338|338557
2451,BRD-K48195008,ethinyl-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C,5991.0,Launched,estrogen receptor agonist|estrogenic hormone,ESR1|ESR2|NR1I2,endocrinology,contraceptive,8856|2099|2100
2453,BRD-K03981224,ethisterone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|,5284557.0,Launched,progestogen hormone,TYR,endocrinology,amenorrhea,7299
2455,BRD-A99633051,ethosuximide,"CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|",10630591.0,Launched,succinimide antiepileptic,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,epilepsy,8912|8913|150350
2456,BRD-A30205217,ethotoin,CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|,12309784.0,Launched,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures,6331
2458,BRD-K18131774,ethoxzolamide,CCOc1ccc2nc(sc2c1)S(N)(=O)=O,3295.0,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9,ophthalmology|gastroenterology,glaucoma|duodenal ulcer disease,768|771|11238|377677|23632|759|760|761|762|763|765|766
2465,BRD-K46331928,ethynodiol-diacetate,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|,9270.0,Launched,,ESR1|PGR,endocrinology,contraceptive,5241|2099
2467,BRD-K50417881,eticlopride,CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC,57267.0,Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4,,,1813|1814|1815
2468,BRD-K37949327,etidronic-acid,CC(O)(P(O)(O)=O)P(O)(O)=O,3305.0,Launched,bone resorption inhibitor,ATP6V1A|PTPRS,endocrinology|orthopedics,Paget's disease|heterotopic ossification,5802|523
2470,BRD-K01826330,etifoxine,"CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|",135564604.0,Launched,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA5,neurology/psychiatry,anxiety,2554|2555|2556|2558
2471,BRD-A09925278,etilefrine,CCNCC(O)c1cccc(O)c1,164652.0,Launched,adrenergic receptor agonist,ADRA1A|ADRB1,neurology/psychiatry|otolaryngology|endocrinology|pulmonary,headache|nasal congestion|fever|cough suppressant|common cold,153|146
2472,BRD-K90982969,etilevodopa,CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,170345.0,Phase 3,dopamine receptor agonist,DRD3,,,1814
2473,BRD-K68232413,etizolam,CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|,3307.0,Launched,benzodiazepine receptor agonist,GABRA1,neurology/psychiatry,insomnia|anxiety,2554
2474,BRD-A74667430,etodolac,"CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|",688461.0,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5743
2475,BRD-K73541271,etofenamate,OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,35375.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain,5742|5743
2476,BRD-K49338325,etofibrate,CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1,65777.0,Launched,PPAR receptor agonist,PPARA,endocrinology,hypertriglyceridemia,5465
2477,BRD-K83064458,etofylline,Cn1c2ncn(CCO)c2c(=O)n(C)c1=O,1892.0,Launched,adenosine receptor antagonist,ADORA1,pulmonary,asthma|bronchitis,134
2478,BRD-K49840922,etofylline-clofibrate,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,41109.0,Launched,platelet aggregation inhibitor,PPARA,endocrinology,hyperlipidemia,5465
2479,BRD-K55055802,etomidate,CCOC(=O)c1cncn1[C@H](C)c1ccccc1,667484.0,Launched,GABA receptor modulator,ADRA2B|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ,neurology/psychiatry,general anaesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|151|2554|2555|2556|2557|2558|2559
2480,BRD-K32405725,etomoxir,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,9840324.0,Phase 2,carnitine palmitoyltransferase inhibitor,CPT1A,,,1374
2481,BRD-K00003655,etonogestrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|,6917715.0,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive,5241|2099
2482,BRD-K37798499,etoposide,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,36462.0,Launched,topoisomerase inhibitor,TOP2A|TOP2B,oncology,non-small cell lung cancer (NSCLC),7153|7155
2483,BRD-K72533376,etoposide-phosphate,COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,6918092.0,Launched,topoisomerase inhibitor,TOP2A,oncology,testicular carcinoma|small cell lung cancer,7153
2484,BRD-K54770957,etoricoxib,Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O,123619.0,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis|psoriatic arthritis|osteoarthritis|gout|ankylosing spondylitis,5743
2487,BRD-K15858023,ETP-45658,Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1,25229608.0,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,5290|5291|5294|22883
2491,BRD-K74717603,etravirine,Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N,193962.0,Launched,non-nucleoside reverse transcriptase inhibitor,CYP2C19|CYP2C9|CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1576|1557|1559
2492,BRD-K49076555,etretinate,CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C,5282375.0,Withdrawn,protein synthesis inhibitor,RARA|RXRG,,,5914|6258
2493,BRD-K29996876,eucalyptol,CC12CCC(CC1)C(C)(C)O2,2758.0,Launched,acetylcholinesterase inhibitor,ACHE,dental,gingivitis,43
2495,BRD-K32977963,eugenol,COc1cc(CC=C)ccc1O,3314.0,Launched,androgen receptor antagonist,AR,dental,toothache,367
2496,BRD-K19741031,EUK-134,"COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|",,Preclinical,catalase stimulant,APP|SOD2,,,100129518|351
2498,BRD-K16551357,evacetrapib,Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1,,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,,1071
2499,BRD-K24548560,evans-blue,"Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|",6804600.0,Launched,glutamate receptor negative allosteric modulator,GRIA1|PTPN1,,,2890|5770
2500,BRD-K11452913,evatanepag,CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1,9890801.0,Phase 2,prostaglandin inhibitor,PTGER2|PTGER4,,,5732|5734
2502,BRD-K13514097,everolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|",,Launched,mTOR inhibitor,MTOR,oncology|neurology/psychiatry|genetics|urology,breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma,2475
2505,BRD-A68631409,evodiamine,"CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|",442088.0,Preclinical,ATPase inhibitor|TRPV agonist,TRPV1,,,7442
2506,BRD-K71603915,EVP-6124,Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2,46196517.0,Phase 3,acetylcholine receptor agonist,CHRNA7,,,89832
2508,BRD-K74396648,EW-7197,Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1,54766013.0,Phase 2,TGF beta receptor inhibitor,ACVR1B|TGFBR1,,,91|7046
2509,BRD-A73908300,EX-527,"NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|",707029.0,Phase 2,SIRT inhibitor,SIRT1,,,23411
2511,BRD-K35304636,examorelin,C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,6918297.0,Phase 2,growth hormone releasing factor agonist,GHRHR|GHSR,,,2692|2693
2512,BRD-K92150287,exatecan-mesylate,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45,151115.0,Phase 3,topoisomerase inhibitor,TOP1,,,7150
2513,BRD-K33425534,exemestane,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|",60198.0,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer,1588
2514,BRD-K00003559,exenatide,[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|,91935542.0,Launched,GLP receptor agonist,GLP1R,endocrinology,diabetes mellitus,2740
2515,BRD-K81795818,exherin,CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O,,Phase 2,cadherin antagonist,CDH2,,,1000
2516,BRD-K65716359,exifone,Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O,40399.0,Withdrawn,nootropic agent,TYR,,,7299
2517,BRD-K37708699,exisulind,CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|,5472495.0,Phase 3,phosphodiesterase inhibitor,PDE5A,,,8654
2519,BRD-K96155658,exo-IWR-1,O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|,1163034.0,Preclinical,WNT signaling inhibitor negative control,TNKS,,,8658
2520,BRD-K98963219,ezatiostat,CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,5310939.0,Phase 2,glutathione transferase inhibitor,GSTP1,,,2950
2521,BRD-K42260897,ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1,150311.0,Launched,cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist,ANPEP|NPC1L1|SOAT1,endocrinology|metabolism,hyperlipidemia|hypercholesterolemia|sitosterolemia,29881|290|6646
2522,BRD-K25570267,ezutromid,CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1,886736.0,Phase 2,utrophin enhancer,UTRN,,,7402
2523,BRD-K87948281,F-11440,Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O,208928.0,Phase 2,serotonin receptor agonist,HTR1A,,,3350
2525,BRD-K41267922,F351,Cc1ccc(=O)n(c1)-c1ccc(O)cc1,11217901.0,Phase 2,TGF beta receptor inhibitor,TGFB1,,,7040
2526,BRD-A25619068,fadrozole,N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|,9815923.0,Launched,aromatase inhibitor,CYP11B1|CYP19A1,oncology,breast cancer,1584|1588
2527,BRD-K61536264,fagomine,OC[C@H]1NCC[C@@H](O)[C@@H]1O,72259.0,Phase 2,glucosidase inhibitor,GLB1,,,2720
2528,BRD-K08251020,falecalcitriol,C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5282190.0,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,1594
2530,BRD-K00673382,famotidine,NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1,5702160.0,Launched,histamine receptor antagonist,HRH2,gastroenterology,heartburn,1665
2532,BRD-K08998509,fananserin,Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1,60785.0,Phase 2,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,,,3356
2536,BRD-K14590126,farnesyl-thiosalicylic-acid-amide,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O,25187973.0,Phase 1,Ras GTPase inhibitor,HRAS,,,3265
2540,BRD-K76617868,fasudil,O=S(=O)(N1CCCNCC1)c1cccc2cnccc12,3547.0,Launched,rho associated kinase inhibitor,PKIA|PRKACA|ROCK1|ROCK2,neurology/psychiatry,cerebral vasospasm,5569|5578|9475|6093
2545,BRD-K48367671,febuxostat,CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O,134018.0,Launched,xanthine oxidase inhibitor,XDH,nephrology,hyperuricemia,6652
2546,BRD-K12502280,fedratinib,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C,16722836.0,Launched,FLT3 inhibitor|JAK inhibitor,BRD4|JAK1|JAK2|JAK3|TYK2,hematologic malignancy,myelofibrosis,7297|3716|3717|3718|23476
2547,BRD-K99107520,felbamate,NC(=O)OCC(COC(N)=O)c1ccccc1,3331.0,Launched,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,neurology/psychiatry,epilepsy,114787|2903|2904|2905|2906|116443|116444
2548,BRD-K91740057,felbinac,OC(=O)Cc1ccc(cc1)-c1ccccc1,3332.0,Launched,cyclooxygenase inhibitor,CTSL,rheumatology|neurology/psychiatry,rheumatoid arthritis|muscle pain,1514
2549,BRD-K26404903,felbinac-ethyl,CCOC(=O)Cc1ccc(cc1)-c1ccccc1,26436.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,,5742|5743
2550,BRD-A30815329,felodipine,"CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|",941699.0,Launched,calcium channel blocker,CFTR,cardiology,hypertension,1080
2553,BRD-K51318897,fenbendazole,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1,3334.0,Launched,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites|gastrointestinal roundworms,7280
2554,BRD-K12513978,fenbufen,OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1,3335.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
2555,BRD-K01825694,fenclonine-(+/-),N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|,736190.0,Preclinical,tryptophan hydroxylase inhibitor,PAH|TPH1|TPH2,,,5053|7166|6999
2556,BRD-A71033472,fendiline,C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|,36687769.0,Preclinical,calcium channel blocker,HTR2B,,,106480180
2558,BRD-A66920069,fenigam,"NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|",685623.0,Launched,benzodiazepine receptor agonist,GABBR1|GABBR2,neurology/psychiatry,posttraumatic stress disorder|anxiety|depression,9568|10537
2560,BRD-K41160163,fenobam,CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|,135659063.0,Phase 2,glutamate receptor antagonist,GRM5,,,2915
2561,BRD-K50388907,fenofibrate,CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1,3339.0,Launched,PPAR receptor agonist,MMP25|PPARA,endocrinology,hypercholesterolemia|hypertriglyceridemia,5465|64386
2562,BRD-K30213273,fenofibric-acid,CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O,64929.0,Launched,cytochrome P450 inhibitor,CLCN1|PPARA,cardiology,dyslipidemia,5465|1180
2563,BRD-K01826790,fenoldopam,Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|,30026875.0,Launched,dopamine receptor agonist,DRD1|DRD4,cardiology,hypertension,1812|1815
2564,BRD-K01827286,fenoprofen,C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|,41097863.0,Launched,prostaglandin inhibitor,PTGS1|SLC5A8,rheumatology,rheumatoid arthritis|osteoarthritis,160728|5742
2565,BRD-K00003668,fenoterol,"C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|",688469.0,Withdrawn,adrenergic receptor agonist,ADRB2,,,154
2567,BRD-K44777569,fenoxaprop-p-ethyl,CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1,91707.0,Preclinical,,NOS3,,,342977
2568,BRD-K89085489,fenretinide,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|,5288209.0,Phase 3,apoptosis stimulant|retinoid receptor agonist,RARA,,,5914
2571,BRD-K16077845,fentiazac,OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1,28871.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology,muscle pain|joint pain,5742|5743
2573,BRD-K61642990,FERb-033,O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1,135931707.0,Preclinical,EGFR inhibitor,ERBB2,,,2064
2576,BRD-K66295376,ferulic-acid,COc1cc(\C=C\C(O)=O)ccc1O,445858.0,Phase 2,antioxidant,CA1|CA12|CA14|CA2|CA4|CA6|CA9,,,768|771|23632|759|760|762|765
2577,BRD-K46731503,fesoterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C,6918558.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence,1128|1129|1131|1132|1133
2579,BRD-K08864679,fexaramine,COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1,5326713.0,Preclinical,FXR agonist,NR1H4,,,9971
2581,BRD-A73368467,fexofenadine,CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|,6603853.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269
2583,BRD-K56807945,FG-2216,OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O,6914666.0,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1|EGLN2|HIF1A,,,100529264|3091|54583
2584,BRD-K14385366,FG-4592,Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12,11256664.0,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN1|EGLN2|EGLN3,,,100529264|112399|54583
2586,BRD-K09778810,FGIN-1-27,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1,132496.0,Preclinical,inositol monophosphatase inhibitor,TSPO,,,706
2587,BRD-K66093087,FGIN-1-43,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1,3995234.0,Preclinical,benzodiazepine receptor agonist,TSPO,,,706
2588,BRD-K48112880,FH-535,Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O,3463933.0,Preclinical,PPAR receptor antagonist|WNT signaling inhibitor,PPARD|PPARG,,,5467|5468
2591,BRD-A63752151,fidarestat,"NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|",449156.0,Phase 3,aldose reductase inhibitor,AKR1B1,,,231
2593,BRD-K37379014,filanesib,CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|,44224257.0,Phase 3,kinesin inhibitor|kinesin-like spindle protein inhibitor,KIF11,,,3832
2594,BRD-K16803204,filgotinib,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,49831257.0,Phase 3,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,,,7297|3716|3717|3718
2595,BRD-K21586122,fimasartan,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,9870652.0,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure,185
2597,BRD-K01095011,finasteride,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|,57363.0,Launched,5 alpha reductase inhibitor,AKR1D1|SRD5A1|SRD5A2,endocrinology,androgenetic alopecia,6715|6716|6718
2598,BRD-K88025533,fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,107970.0,Launched,immunosuppressant|sphingosine 1-phosphate receptor agonist,S1PR1|S1PR5,neurology/psychiatry,multiple sclerosis,1901|53637
2600,BRD-K61560897,FIPI,Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O,16739265.0,Preclinical,phospholipase inhibitor,PLD1|PLD2,,,5338|5589
2602,BRD-K17513304,firategrast,CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1,9935681.0,Phase 2,integrin antagonist,ITGA4,,,3676
2603,BRD-K09090523,firocoxib,CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|,208910.0,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,osteoarthritis,5743
2605,BRD-K31836715,fisetin,Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O,5281614.0,Preclinical,Aurora kinase inhibitor,CDK6|FASN,,,2194|1021
2607,BRD-K17896185,FIT,CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1,84008.0,Preclinical,opioid receptor agonist,OPRD1,,,4985
2608,BRD-A01907367,FK-33-824,"C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|",,Phase 2,opioid receptor agonist,OPRM1,,,4988
2609,BRD-K38350380,FK-3311,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,164009.0,Phase 2,cyclooxygenase inhibitor,PTGS2,,,5743
2611,BRD-K58550667,FK-866,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,6914657.0,Phase 2,niacinamide phosphoribosyltransferase inhibitor,NAMPT,,,10135
2612,BRD-K83508485,FK-888,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12,107967.0,Phase 2,tachykinin antagonist,TACR1|TACR2,,,6865|6869
2614,BRD-K01666925,flavin-adenine-dinucleotide,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15,17,19,32,34,35,37,&1:23,&2:27|",643975.0,Preclinical,,ACAD8|ACADM|ACADS|ACOX1|AIFM1|CYB5R1|CYB5R3|DAO|DLD|DPYD|ERO1LB|FDXR|GCDH|GFER|GSR|IL4I1|IVD|MAOA|MAOB|NOS1|NQO1|NQO2|POR|TXNRD1|XDH,,,3712|7296|1806|26|27034|56605|4128|4129|34|35|9131|51|2232|1727|1728|1738|2639|4835|259307|2671|340719|2936|7417|51706|6652
2615,BRD-K47639036,flavoxate,Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1,3354.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2,urology,urinary incontinence|interstitial cystitis (IC)|urethritis|prostatitis,1128|1129
2616,BRD-A09472452,flecainide,FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1,46864232.0,Launched,sodium channel blocker,KCNA5|KCNA7|SCN5A,cardiology,ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias,6331|3741|3743
2617,BRD-K61717546,fleroxacin,CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O,40466912.0,Launched,topoisomerase inhibitor,TOP2A,infectious disease|gastroenterology,gonorrhea|enteritis|diarrhea|respiratory tract infections,7153
2619,BRD-K33637378,flibanserin,FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1,6918248.0,Launched,serotonin receptor agonist,DRD4|HTR1A|HTR2A,neurology/psychiatry,hypoactive sexual desire disorder,3356|3350|1815
2620,BRD-K56740996,flindokalner,COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F,214350.0,Phase 3,potassium channel agonist,KCNMA1|KCNN4|KCNQ2|KCNQ4|KCNQ5,,,3778|3783|3785|9132|56479
2621,BRD-A23418262,floctafenine,"OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|",76958517.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
2622,BRD-K43383936,flopropione,CCC(=O)c1c(O)cc(O)cc1O,3362.0,Launched,serotonin receptor antagonist,HTR1A,neurology/psychiatry,spasms,3350
2626,BRD-K47832606,floxuridine,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O,5790.0,Launched,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,7298
2628,BRD-K86003836,flubendazole,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1,35802.0,Launched,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,7280
2630,BRD-K05977355,fluconazole,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,3365.0,Launched,sterol demethylase inhibitor,CYP51A1,infectious disease,esophageal candidiasis|meningitis,1595
2631,BRD-K82143716,flucytosine,Nc1nc(=O)[nH]cc1F,3366.0,Launched,other antifungal,DNMT1,infectious disease,bacterial septicemia|endocarditis|urinary tract infections|meningitis,1786
2632,BRD-K66788707,fludarabine,Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,657237.0,Launched,ribonucleotide reductase inhibitor,ADA|DCK|POLA1|RRM1|RRM2,hematologic malignancy,chronic lymphocytic leukemia (CLL),6240|1633|6241|100|5422
2633,BRD-K71106091,fludarabine-phosphate,Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O,30751.0,Launched,ribonucleotide reductase inhibitor,POLA1|POLD1|POLE|RRM1|RRM2|RRM2B,hematologic malignancy,chronic lymphocytic leukemia (CLL),6240|6241|5422|5424|5426|50484
2634,BRD-K06408664,fludrocortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|,225609.0,Launched,,NR3C2,endocrinology,Addison's disease|adrenogenital syndrome,4306
2635,BRD-K00824317,fludroxycortide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|,15209.0,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,infectious disease|dermatology,skin infections|psoriasis,866|2908
2636,BRD-K44067360,flufenamic-acid,OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,3371.0,Preclinical,chloride channel blocker,AKR1C3|ANO1|AR|GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|PANX1|PANX2|PANX3|PKD2L1|PTGS1|PTGS2|TRPC5|TRPM2|TRPM5,,,81025|2697|2700|2701|2702|2703|2705|2706|2707|2709|57369|29850|1191|127534|10804|125111|7224|55107|8644|9033|57165|24145|84694|56666|349149|375519|5742|367|5743|116337|219770
2637,BRD-K68870568,flumatinib,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,46848036.0,Phase 3,Bcr-Abl kinase inhibitor,ABL1|PDGFRB,,,25|5159
2638,BRD-K98769987,flumazenil,CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21,3373.0,Launched,benzodiazepine receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ,neurology/psychiatry,sedative,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|2554|2555|2556|2557|2558|2559
2641,BRD-K61496577,flumethasone,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|",16490.0,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,otolaryngology|infectious disease|dermatology,otitis|ear infections|corticosteroid-responsive dermatoses,2908|5319
2642,BRD-K00025599,flumethasone-pivalate,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|",443980.0,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,allergy,allergic rhinitis,866|2908
2644,BRD-K29582677,flunarizine,Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,941361.0,Launched,calcium channel blocker,CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1,neurology/psychiatry|cardiology,migraine headache|vertigo|peripheral artery disease (PAD),801|3269|150350|8912|8913
2645,BRD-K49577446,flunisolide,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|",82153.0,Launched,cytochrome P450 inhibitor,NR3C1,allergy,allergic rhinitis,2908
2647,BRD-K94353609,fluocinolone-acetonide,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|",6215.0,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,dermatology,seborrheic dermatitis,866|2908
2648,BRD-K57886322,fluocinonide,"CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|",9642.0,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6|SMO,dermatology,seborrheic dermatitis|eczema,54498|866|2908
2649,BRD-K21913543,fluorescein,Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1,16850.0,Launched,,SLC22A6,ophthalmology,ophthalmology diagnostic,9356
2650,BRD-K64862097,fluorometholone,"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|",9878.0,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,2908
2651,BRD-K02528732,fluorometholone-acetate,"C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|",240767.0,Launched,,NR3C1,ophthalmology,eye inflammation,2908
2653,BRD-A31159102,fluoxetine,CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1,657320.0,Launched,selective serotonin reuptake inhibitor (SSRI),ANO1|HTR2B|SLC6A4,neurology/psychiatry,depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder,6532|55107|106480180
2654,BRD-K70487031,flupentixol,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,5281881.0,Launched,dopamine receptor antagonist,ADRA1A|CHRM1|DRD1|DRD2|DRD3|DRD5|HTR2A,neurology/psychiatry,schizophrenia|depression,1128|146|1812|1813|1814|1816|3356
2655,BRD-K55127134,fluphenazine,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,3372.0,Launched,dopamine receptor antagonist,CALM1|DRD1|DRD2|DRD5|HRH1|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia,801|3362|3363|3269|1812|1813|1816|3356
2656,BRD-K27898013,fluphenazine-decanoate,CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,3388.0,Launched,dopamine receptor antagonist,DRD2|HTR1B|HTR4,neurology/psychiatry,schizophrenia,3360|1813|3351
2657,BRD-K50720187,flupirtine,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N,53276.0,Launched,glutamate receptor antagonist,ADRA2A|KCNQ1|KCNQ2,neurology/psychiatry,pain relief,3784|3785|150
2658,BRD-K44091134,fluprazine,NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F,71153.0,Phase 1,serotonin receptor agonist,HTR1A|HTR1B,,,3350|3351
2661,BRD-K69907333,flurbiprofen-(S)-(+),C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1,72099.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743
2663,BRD-K75410565,flurizan,C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1,92337.0,Phase 3,gamma secretase inhibitor,APH1B|BACE1|IKBKG|PSEN1|PSEN2|PTGS1|PTGS2,,,5664|8517|23621|83464|5742|5743|5663
2667,BRD-K77947974,fluspirilene,Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1,3396.0,Launched,dopamine receptor antagonist,CACNG1|DRD2|HRH1|HTR1A|HTR1D|HTR1E|HTR2A,neurology/psychiatry,schizophrenia,3269|786|1813|3350|3352|3354|3356
2668,BRD-K28307902,flutamide,CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,3397.0,Launched,androgen receptor antagonist,AHR|AR,oncology,prostate cancer,196|367
2669,BRD-K62310379,fluticasone-propionate,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|",444036.0,Launched,glucocorticoid receptor agonist,NR3C1|NR3C2|PGR|PLA2G4A,dermatology,corticosteroid-responsive dermatoses,5241|4306|5321|2908
2671,BRD-K66296774,fluvastatin,CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12,446155.0,Launched,HMGCR inhibitor,HMGCR,endocrinology|cardiology,hypercholesterolemia|congenital heart defects,3156
2672,BRD-K53517854,fluvoxamine,COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F,5324346.0,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A4,neurology/psychiatry,obsessive compulsive disorder (OCD),6532
2675,BRD-K18673820,folic-acid,Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1,6037.0,Launched,folate receptor ligand,FOLR2|FOLR3|SLC19A1|SLC46A1,hematology,megaloblastic anemia,2352|113235|6573|2350
2676,BRD-K56810756,fomepizole,Cc1cn[nH]c1,3406.0,Launched,alcohol dehydrogenase inhibitor,ADH1A|ADH1B|ADH1C|AKR1A1|CAT,critical care,poison antidote,847|10327|124|125|126
2678,BRD-K00003513,fondaparinux,[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O,5282448.0,Launched,coagulation factor inhibitor,F10|SERPINC1,hematology,deep vein thrombosis (DVT),462|2159
2679,BRD-K03449891,foretinib,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,42642645.0,Phase 2,VEGFR inhibitor,FLT1|FLT4|KDR|MET,,,2321|8731|2324|3791
2680,BRD-A26503646,formestane,"C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|",,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer,1588
2681,BRD-K55567017,formononetin,COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,5280378.0,Preclinical,alcohol dehydrogenase inhibitor,ADH1C|SLC5A2,,,6524|126
2682,BRD-K54006094,formoterol,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,3034756.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm,154
2683,BRD-K16505263,forodesine,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O,135409409.0,Launched,purinergic receptor antagonist,PNP,hematologic malignancy,peripheral T-cell lymphoma (PTCL),5539
2684,BRD-K57774929,foropafant,CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C,119368.0,Phase 3,platelet activating factor receptor antagonist,PTAFR,,,5724
2685,BRD-K09602097,forskolin,CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C,47936.0,Launched,adenylyl cyclase activator,ADCY2|ADCY5|GNAS,,,2778|108|111
2687,BRD-K23848629,fosaprepitant-dimeglumine,C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,135413538.0,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting,6869
2688,BRD-K06814349,fosbretabulin,COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O,5351387.0,Phase 3,tubulin polymerization inhibitor|VE-cadherin antagonist,CDH5,,,1003
2690,BRD-K20801936,fosfestrol,CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1,3032325.0,Launched,synthetic estrogen,ESR1|ESR2,oncology,prostate cancer,2099|2100
2693,BRD-K28687144,fosfosal,OC(=O)c1ccccc1OP(O)(O)=O,3418.0,Launched,phosphodiesterase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
2695,BRD-A51382177,fosinopril,"CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|",6708482.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure,1636
2696,BRD-A33506612,fosinoprilat,"OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3,5,&1:11|",62956.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636
2697,BRD-K53809807,fosphenytoin,OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1,56339.0,Launched,sodium channel blocker,SCN5A,neurology/psychiatry,epilepsy|seizures,6331
2698,BRD-K85178109,fostamatinib,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC,11671467.0,Launched,SYK inhibitor,SYK,hematology,chronic immune thrombocytopenia (ITP),6850
2701,BRD-K13005598,foxy-5,CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O,44628955.0,Phase 2,WNT5a peptide mimetic,WNT5A,,,7474
2707,BRD-K78959463,FPL-64176,COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1,3423.0,Preclinical,calcium channel activator,CACNA1C|CACNA1S,,,779|775
2708,BRD-K87691185,FPS-ZM1,Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1,24752728.0,Preclinical,RAGE receptor antagonist,AGER,,,177
2710,BRD-K19318328,FR-139317,CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O,107810.0,Phase 1,endothelin receptor antagonist,EDNRA,,,1909
2711,BRD-K68756823,FR-180204,Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1,53338808.0,Preclinical,MAP kinase inhibitor,MAPK1|MAPK3,,,5594|5595
2712,BRD-K57243773,FRAX486,CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O,68060125.0,Preclinical,serine/threonine kinase inhibitor,PAK1|PAK2|PAK3|PAK4,,,8874|5585|5586|10298
2714,BRD-K00004668,freselestat,CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C,46936829.0,Preclinical,elastase inhibitor,CELA1|ELANE,,,1990|1991
2715,BRD-K08255599,frovatriptan,CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O,77992.0,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D,neurology/psychiatry,migraine headache,3352|3350|3351
2716,BRD-K70504253,fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,44480399.0,Launched,VEGFR inhibitor,KDR,oncology,colorectal cancer,3791
2719,BRD-K99383816,ftorafur,Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O,288216.0,Launched,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,7298
2722,BRD-A85667082,fulvestrant,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|",57300161.0,Launched,estrogen receptor antagonist,ESR1|ESR2|GPER1,oncology,breast cancer,2099|2100|2852
2723,BRD-A99367815,fumagillin,"CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|",12015870.0,Launched,methionine aminopeptidase inhibitor,METAP2,infectious disease,microsporidiosis,10988
2724,BRD-K61915943,fumonisin-B1,CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O,2733487.0,Preclinical,,CERS1,,,2657
2728,BRD-K77758223,furamidine,NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N,126437.0,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT1,,,3276
2730,BRD-K55529781,furegrelate,OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1,3437.0,Phase 1,thromboxane synthase inhibitor,TBXAS1,,,6916
2731,BRD-K78010432,furosemide,NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl,3440.0,Launched,diuretic,CA2|GPR35|SLC12A1|SLC12A2,cardiology|rheumatology,edema|hypertension|congestive heart failure|nephrotic syndrome,760|2859|6557|6558
2736,BRD-K62696033,G-1,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|,5322399.0,Preclinical,G protein-coupled receptor agonist,GPER1,,,2852
2737,BRD-K00004290,G-15,"Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|",25727983.0,Preclinical,estrogen receptor antagonist,GPER1,,,2852
2739,BRD-K26878113,g-caryophyllene,C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|,5281515.0,Preclinical,acetylcholinesterase inhibitor,ACHE,,,43
2740,BRD-K12198961,G007-LK,CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl,67960134.0,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,,8658|80351
2742,BRD-K62737565,gabapentin,NCC1(CC(O)=O)CCCCC1,6919078.0,Launched,calcium channel blocker,ADORA1|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1E|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CACNG2|CACNG3|CACNG4|CACNG5|CACNG6|CACNG7|CACNG8|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,infectious disease|neurology/psychiatry,virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome,10368|10369|773|134|775|776|774|777|778|779|781|782|783|784|785|786|59283|59284|93589|59285|9254|150350|8912|8913|27091|27092|2903|2904|2905|2906|116443|116444|114787|55799
2743,BRD-A86665761,gabapentin-enacarbil,"CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|",66864580.0,Launched,adrenergic receptor agonist,CACNA1G,neurology/psychiatry,restless leg syndrome|postherpetic neuralgia,8913
2744,BRD-K79905821,gabazine,COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1,107896.0,Preclinical,GABA receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRG2,,,2566|2554|2555|2556|2557|2558|2559
2745,BRD-K59256312,gabexate,CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1,3447.0,Launched,serine protease inhibitor,PRSS1|TPSAB1,gastroenterology,pancreatitis,7177|136541
2746,BRD-K89104321,gaboxadol,O=c1[nH]oc2CNCCc12,3448.0,Phase 3,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3,,,2563|200959|2569|2570|2554|2555|2556|2557|2558|2559
2749,BRD-K25106841,gadopentetic-acid,OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2,6857474.0,Launched,contrast agent,PGD,radiology,contrast agent,26227
2753,BRD-K49481516,galantamine,COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|,9651.0,Launched,acetylcholinesterase inhibitor,ACHE|BCHE|CHRNA1|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB1|CHRNB2|CHRNB3|CHRNB4|CHRND|CHRNE|CHRNG,neurology/psychiatry,senile dementia,55584|89832|43|8973|1134|590|1135|1136|1137|1138|1140|1141|1142|1143|1144|1145|1146|57053
2754,BRD-K00004319,galeterone,"[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|",11188409.0,Phase 3,androgen receptor modulator,AR|CYP17A1,,,1586|367
2756,BRD-K43106192,gallamine-triethiodide,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,3450.0,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA1,neurology/psychiatry,muscle relaxant,1129|1134
2757,BRD-K77345217,gallic-acid,OC(=O)c1cc(O)c(O)c(O)c1,370.0,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,CA1|CA12|CA14|CA2|CA4|CA6|CA9|SELP,,,768|771|6414|23632|759|760|762|765
2759,BRD-A52922642,gallopamil,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|,1234.0,Launched,L-type calcium channel blocker,ATP2A2,cardiology,hypertension|cardiac arrythmia,488
2760,BRD-K08542803,gambogic-acid,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|",9852185.0,Phase 2,caspase activator,BCL2,,,596
2762,BRD-K77245796,gamma-aminobutyric-acid,NCCCC(O)=O,6992099.0,Preclinical,benzodiazepine receptor agonist,GABBR1|GABBR2|GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2|GATM|KCTD12|KCTD16|KCTD8|SLC6A1,,,9568|2561|6529|2628|2566|115207|10537|57528|386617|2554|2555|2556|2558
2763,BRD-K18059238,gamma-linolenic-acid,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O,5280933.0,Phase 2,cyclooxygenase inhibitor|prostanoid receptor agonist,PTGS1|PTGS2,,,5742|5743
2764,BRD-K28217197,ganaxolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,6918305.0,Phase 3,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6,,,2554|2555|2556|2557|2558|2559
2766,BRD-K38852836,ganetespib,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,135564985.0,Phase 3,HSP inhibitor,HSP90AA1,,,3320
2768,BRD-K64451768,GANT-58,c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1,253078.0,Preclinical,GLI antagonist,GLI1,,,2735
2769,BRD-K09485525,GANT-61,CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1,421610.0,Preclinical,GLI antagonist,GLI1|GLI2,,,2736|2735
2770,BRD-K77038618,garenoxacin,C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1,40461170.0,Launched,topoisomerase inhibitor,TOP2A,infectious disease,respiratory tract infections,7153
2773,BRD-K81981783,gavestinel,OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1,6450546.0,Phase 3,glutamate receptor antagonist,GLRB|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B,,,114787|2743|2903|2904|2905|2906|116443|116444
2775,BRD-K50135270,GBR-12935,C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1,3456.0,Preclinical,dopamine reuptake inhibitor,AGTR1|SLC6A3,,,185|6531
2776,BRD-K92577649,GBR-13069,Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,5974189.0,Preclinical,dopamine reuptake inhibitor,SLC6A3,,,6531
2777,BRD-K43002773,GDC-0068,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,24788740.0,Phase 3,AKT inhibitor,AKT1|AKT2|AKT3|PRKG1,,,208|10000|5592|207
2780,BRD-K68938568,GDC-0152,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,46940575.0,Phase 1,XIAP inhibitor,BIRC2|BIRC3|BIRC7|XIAP,,,329|330|331|79444
2781,BRD-K43187018,GDC-0349,CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1,59239165.0,Phase 1,Pim kinase inhibitor,PIK3CA,,,5290
2784,BRD-K61923022,GDC-0810,CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl,56941241.0,Phase 2,selective estrogen receptor destabilizer,ESR1,,,2099
2785,BRD-A30984645,GDC-0834,"CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|",25234917.0,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,695
2786,BRD-K67578145,GDC-0879,OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O,11717001.0,Preclinical,RAF inhibitor,BRAF,,,673
2788,BRD-K52911425,GDC-0941,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1,17755052.0,Phase 2,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,5290|5291|5294|22883
2789,BRD-K23228615,GDC-0980,C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1,25254071.0,Phase 2,mTOR inhibitor|PI3K inhibitor,FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK,,,6850|22883|4293|5290|2475|5291|5294|2268
2790,BRD-A20830788,GDC-0994,"Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|",124583908.0,Phase 1,MAP kinase inhibitor,MAPK1|MAPK3,,,5594|5595
2791,BRD-K02703275,gedunin,CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|,12004512.0,Preclinical,HSP inhibitor,HSP90AA1,,,3320
2793,BRD-K64052750,gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,123631.0,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),1956
2794,BRD-K43570081,geldanamycin,"CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|",,Preclinical,HSP inhibitor,HSP90AA1,,,3320
2796,BRD-K15108141,gemcitabine,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,60750.0,Launched,ribonucleotide reductase inhibitor,CMPK1|RRM1|RRM2|TYMS,oncology,ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer,6240|6241|7298|51727
2797,BRD-K09456915,gemcitabine-elaidate,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O,9828310.0,Phase 1,apoptosis inhibitor|DNA synthesis inhibitor,CMPK1|RRM1|TYMS,,,6240|7298|51727
2798,BRD-K11129031,gemfibrozil,Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1,3463.0,Launched,lipoprotein lipase activator,LPL|PPARA|SLCO1B1|SLCO1B3|SLCO2B1,endocrinology|cardiology,hyperlipidemia|coronary heart disease,3936|10599|28234|11309|5465
2802,BRD-K57275767,geniposide,"COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|",107848.0,Preclinical,GLP receptor agonist,GLP1R,,,2740
2804,BRD-K43797669,genistein,Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,5280961.0,Phase 2/Phase 3,tyrosine kinase inhibitor,CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5,,,10499|8648|2185|7224|7153|2099|2100|2101|2103|1080|2104|5468
2805,BRD-K97891829,gentamycin,CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1,72395.0,Launched,bacterial 50S ribosomal subunit inhibitor,HSPA8,infectious disease|critical care,bone and joint infections|endocarditis|pelvic inflammatory disease|meningitis|pneumonia|urinary tract infections|sepsis,3312
2806,BRD-K33131085,gentiopicrin,"OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|",88708.0,Phase 3,glutamate receptor downregulator,GRIN2B,,,2904
2807,BRD-K70693421,genz-123346,CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1,23652732.0,Preclinical,glucosylceramidase inhibitor,UGCG,,,7357
2808,BRD-K99475619,genz-644282,CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O,10294813.0,Phase 1,topoisomerase inhibitor,TOP1,,,7150
2814,BRD-K97472745,gestrinone,"CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|",27812.0,Launched,progesterone receptor antagonist,AR|ESR1|PGR,obstetrics/gynecology,endometriosis,5241|2099|367
2815,BRD-K31342827,GF109203X,CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|,2396.0,Preclinical,PKC inhibitor,PDPK1|PIM1|PRKCI|PRKCZ,,,5584|9361|5170|5590
2816,BRD-A25625670,GGsTop,"COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|",139340107.0,Preclinical,gamma glutamyltransferase Inhibitor,GGT1,,,2678
2817,BRD-K19669037,GGTI-298,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,9811606.0,Preclinical,GGTase inhibitor,CDKN1A,,,1026
2818,BRD-K72280606,gilteritinib,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,49803313.0,Launched,FLT3 inhibitor,FLT3,,,2322
2819,BRD-K35687421,gimeracil,Oc1cc(=O)[nH]cc1Cl,54679224.0,Launched,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,1806
2820,BRD-K42679315,ginkgolide-A,C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,,Preclinical,GABA receptor antagonist,GLRA1|GLRB,,,2741|2743
2821,BRD-K93816012,ginkgolide-B,C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,,Phase 3,platelet activating factor receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B,,,8001|2741|2742|2743|9177|3359
2822,BRD-K01942833,ginsenoside-C-K,CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C,9852086.0,Phase 1,NFkB pathway inhibitor|nitric oxide synthase inhibitor,PTGS2,,,5743
2825,BRD-A44511856,ginsenoside-RE3,"CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,12,14,15,18,19,23,25,27,30,32,34,36,38,41,43,45,50,53,&1:6|",46887680.0,Launched,angiogenesis inhibitor|apoptosis stimulant,KCNH2,,,3757
2826,BRD-K13810148,givinostat,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,9804992.0,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,,55869|9734|8841|3065|3066|10013|10014|9759
2827,BRD-K38272302,GK921,C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1,56682080.0,Preclinical,transglutaminase inhibitor,TGM2,,,7052
2828,BRD-K03827870,GKA-50,COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O,11340230.0,Preclinical,glucokinase activator,GCK,,,5871
2829,BRD-K79710622,GKT137831,CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12,58496428.0,Phase 2,NADPH oxidase inhibitor,NOX1|NOX4,,,50507|27035
2830,BRD-K01826515,glafenine,OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|,969495.0,Withdrawn,DeltaF508-CFTR Correctors,CFTR,,,1080
2831,BRD-K34341643,glasdegib,CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N,25166913.0,Launched,hedgehog pathway inhibitor,SMO,hematologic malignancy,acute myeloid leukemia (AML),54498
2835,BRD-K34776109,glimepiride,"CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|",,Launched,insulin secretagogue,ABCC8|KCNJ1|KCNJ11,endocrinology,diabetes mellitus,6833|3758|3767
2836,BRD-K12219985,glipizide,Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,3478.0,Launched,sulfonylurea,ABCC8|KCNJ10|KCNJ11|PPARG,endocrinology,diabetes mellitus|hyperglycemia,6833|5468|3766|3767
2837,BRD-K80396088,gliquidone,COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C,91610.0,Launched,sulfonylurea,ABCC8|KCNJ10|KCNJ8,endocrinology,diabetes mellitus,6833|3764|3766
2840,BRD-K15893360,GLPG0492,CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F,59317190.0,Phase 1,androgen receptor modulator,AR,,,367
2841,BRD-K04643927,GLPG0492-R-enantiomer,CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F,59317173.0,Phase 1,androgen receptor modulator,AR,,,367
2844,BRD-K04288422,gluconolactone,OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O,1549082.0,Launched,,LCT,,,3938
2845,BRD-K29918010,glucosamine,N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,441477.0,Launched,glycosylated protein precursor,IL1B,neurology/psychiatry|rheumatology,muscle pain|rheumatoid arthritis|joint pain|backache,3553
2846,BRD-K69346723,glutathione,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,25246407.0,Phase 3,antioxidant,ESD|GGT1|GLO1|GLRX|GLRX2|GPX1|GPX2|GPX3|GPX4|GPX5|GPX6|GPX7|GPX8|GSR|GSS|GSTA1|GSTA2|GSTA3|GSTA4|GSTA5|GSTK1|GSTM1|GSTM2|GSTM3|GSTM4|GSTM5|GSTO1|GSTO2|GSTP1|GSTT1|GSTZ1|HAGH|HPGDS|LTC4S|MGST1|MGST2|MGST3|TXNDC12,,,2944|2946|2947|2948|2949|2950|2952|2954|4257|4258|4259|373156|27306|493869|221357|2098|2739|2745|2876|2877|2878|2879|2880|2882|51022|3029|4056|119391|9446|51060|5621|2678|2936|2938|2939|2940|2941
2849,BRD-K36927236,glyburide,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,3488.0,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1,endocrinology,diabetes mellitus|hyperglycemia,8647|10060|11309|3758|6833|3762|19|3764|3767|1080|1374
2852,BRD-K78303961,glycitein,COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O,5317750.0,Phase 3,tumor necrosis factor release inhibitor,TNF,,,7124
2853,BRD-A81233518,glycopyrrolate,"C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|",9933193.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,gastroenterology,peptic ulcer disease (PUD),1128|1129|1131|1132|1133
2854,BRD-K00004613,GM-1485,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O,9837656.0,Preclinical,immunophilin ligand,FKBP1A,,,2280
2855,BRD-K69832040,GMX1778,Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1,148198.0,Phase 1/Phase 2,NAMPT inhibitor,NAMPT,,,10135
2857,BRD-K97056771,GNF-2,NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1,5311510.0,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,,25|106480993
2858,BRD-K87632963,GNF-5,OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1,44129660.0,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,,25|106480993
2859,BRD-K19975102,GNF-5837,Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1,59397065.0,Preclinical,growth factor receptor inhibitor,NTRK1|NTRK2|NTRK3,,,4914|4915|4916
2860,BRD-K69075588,GNF-7,CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C,11478363.0,Preclinical,glucokinase inhibitor|protein kinase inhibitor,GCK|TNK2,,,10188|5871
2861,BRD-K64748124,GNTI,NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O,9826034.0,Preclinical,opioid receptor antagonist,OPRK1|OPRM1,,,4986|4988
2862,BRD-K36984403,go-6983,COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|,3499.0,Preclinical,protein kinase inhibitor,PRKCA|PRKCB|PRKCD|PRKCG|PRKCZ,,,5578|5579|5580|5582|5590
2863,BRD-A57886255,golgicide-A,"Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|",1085377.0,Preclinical,ARF inhibitor,GBF1,,,80142
2864,BRD-K69001009,golvatinib,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,16118392.0,Phase 2,VEGFR inhibitor,KDR|MET,,,8731|3791
2865,BRD-K96874295,gonadorelin,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,638793.0,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,obstetrics/gynecology,cystic ovaries|reproductive synchrony,2798
2866,BRD-K99504665,goserelin-acetate,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,5311128.0,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR|LHCGR,oncology|obstetrics/gynecology,prostate cancer|breast cancer|endometriosis,3973|2798
2867,BRD-K19295594,gossypol,CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,3503.0,Phase 2,BCL inhibitor|MCL1 inhibitor,BCL2,,,596
2868,BRD-K65285700,GP1a,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1,10252734.0,Preclinical,cannabinoid receptor agonist,CNR2,,,56142
2869,BRD-K34608650,GP2a,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1,16094766.0,Preclinical,cannabinoid receptor agonist,CNR2,,,56142
2870,BRD-K67397687,GPBAR-A,Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12,11656002.0,Preclinical,G protein-coupled receptor agonist,GPBAR1,,,151306
2871,BRD-K44869961,GPI-1046,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1,445501.0,Preclinical,FKBP inhibitor,FKBP1A,,,2280
2873,BRD-K83289131,GPP-78,O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1,44819697.0,Preclinical,NAMPT inhibitor,NAMPT,,,10135
2874,BRD-K19409553,GPR120-modulator-1,Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O,25017320.0,Preclinical,G protein-coupled receptor modulator,FFAR4,,,338557
2875,BRD-K50891186,GR-103691,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1,4302960.0,Preclinical,dopamine receptor antagonist,DRD3,,,1814
2876,BRD-K49945136,GR-113808,Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12,119376.0,Preclinical,serotonin receptor antagonist,HTR4,,,3360
2877,BRD-K11911061,GR-127935,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1,107780.0,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6,,,3362|106480180|3350|3351|3352|3354|3355|3356|3358
2879,BRD-K12120659,GR-144053,NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1,173614.0,Preclinical,integrin antagonist,ITGA2B|ITGB3,,,3674|3690
2880,BRD-K52394958,GR-159897,COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1,9953599.0,Preclinical,tachykinin antagonist,TAC1|TACR2,,,6865|6863
2881,BRD-K00004242,GR-235,[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|,146898.0,Launched,estrogen receptor agonist|FXR antagonist|progesterone receptor agonist,NR1H4,,,9971
2882,BRD-K40578143,GR-79236,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12,9884817.0,Phase 1,adenosine receptor agonist,ADORA1|ADORA2A,,,134|135
2883,BRD-K62594868,GR125487,COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1,4284721.0,Preclinical,serotonin receptor antagonist,HTR4,,,3360
2884,BRD-K98155362,GR46611,COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1,6160690.0,Preclinical,serotonin receptor agonist,HTR1D,,,3352
2887,BRD-A10967948,granisetron,"CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|",,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting,3359
2888,BRD-K62050508,grapiprant,CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,11677589.0,Launched,prostaglandin inhibitor,PTGER4,rheumatology,osteoarthritis,5734
2890,BRD-K08273968,griseofulvin,COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|,441140.0,Launched,tubulin polymerization inhibitor,KRT12,infectious disease,ringworm|tinea pedis,3859
2891,BRD-K99916169,GS-143,OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|,121513876.0,Preclinical,ubiquitin ligase inhibitor,BTRC|NFKBIA,,,4792|8945
2892,BRD-K75478907,GS-39783,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,6604928.0,Preclinical,GABA receptor modulator,GABBR1,,,10537
2893,BRD-K68453341,GS-6201,CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1,11270783.0,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
2894,BRD-K73585091,GS-9620,CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1,46241268.0,Phase 2,toll-like receptor agonist,TLR7,,,51284
2896,BRD-K76719364,GS-9973,C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1,59473233.0,Phase 2,SYK inhibitor,SYK,,,6850
2897,BRD-K04923131,GSK-3-inhibitor-IX,O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12,,Preclinical,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,GSK3A|GSK3B,,,2931|2932
2898,BRD-K32847255,GSK-J1,OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1,56963315.0,Preclinical,histone demethylase inhibitor,KDM6B,,,23135
2900,BRD-K98203492,GSK-J4,CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1,71729975.0,Preclinical,histone lysine demethylase inhibitor,KDM6A|KDM6B,,,7403|23135
2902,BRD-K33521504,GSK-LSD-1,C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1,71522234.0,Preclinical,histone lysine demethylase inhibitor,KDM1A,,,23028
2903,BRD-K98684188,GSK0660,COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC,46233311.0,Preclinical,PPAR receptor antagonist,PPARD,,,5467
2904,BRD-K06750613,GSK1059615,O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1,23582824.0,Phase 1,PI3K inhibitor,PIK3CG,,,5294
2905,BRD-K36740062,GSK1070916,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,46885626.0,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC|CYP2D6|CYP3A4,,,6790|1576|6795|9212|1565
2906,BRD-K60341624,GSK1292263,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,24996872.0,Phase 2,glucose dependent insulinotropic receptor agonist,GRPR,,,2925
2907,BRD-K36697397,GSK1562590,CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12,46846503.0,Preclinical,urotensin receptor antagonist,UTS2R,,,2837
2908,BRD-K69669039,GSK163090,Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1,11292933.0,Phase 2,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D,,,3352|3350|3351
2909,BRD-K06749501,GSK1838705A,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12,25182616.0,Preclinical,insulin growth factor receptor inhibitor,ALK|IGF1R|INSR|RPS6KA1,,,3480|6195|3643|238
2911,BRD-K04833372,GSK1904529A,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,25124816.0,Preclinical,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,IGF1R|INSR,,,3480|3643
2912,BRD-K25412176,GSK2110183,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,46843057.0,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,,208|10000|207
2913,BRD-K07972848,GSK2126458,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,25167777.0,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,22883|5290|2475|5291|5294
2914,BRD-K15691453,GSK2190915,CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1,44473151.0,Phase 2,lipoxygenase inhibitor,ALOX5AP,,,241
2915,BRD-K90737788,GSK2193874,FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1,53464483.0,Preclinical,transient receptor potential channel antagonist,TRPV4,,,59341
2916,BRD-K95123482,GSK2194069,O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1,67376285.0,Preclinical,fatty acid synthase inhibitor,FASN,,,2194
2919,BRD-K62738477,GSK2256294A,CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1,59448236.0,Phase 1,epoxide hydolase inhibitor,EPHX2,,,2053
2920,BRD-K05858796,GSK2330672,CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1,53492727.0,Phase 2,bile acid transporter inhibitor,SLC10A2,,,6555
2921,BRD-K70642949,GSK2334470,CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1,46215815.0,Preclinical,phosphoinositide dependent kinase inhibitor,AURKA|AURKB|PDPK1,,,5170|9212|6790
2923,BRD-K37590257,GSK256066,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,9827968.0,Phase 2,phosphodiesterase inhibitor,PDE4A,,,5141
2924,BRD-K30185465,GSK2578215A,Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1,68107965.0,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,,120892
2925,BRD-K81689258,GSK2606414,Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12,53469448.0,Preclinical,protein kinase inhibitor,EIF2AK3|MYLK2,,,9451|85366
2926,BRD-K49215523,GSK2636771,Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O,56949517.0,Phase 2,PI3K inhibitor,PIK3CB,,,5291
2928,BRD-K89464729,GSK269962,CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N,16095342.0,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,,9475|6093
2929,BRD-K48062199,GSK2801,CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O,73010930.0,Preclinical,bromodomain inhibitor,BAZ2A|BAZ2B,,,11176|29994
2930,BRD-K21867462,GSK2816126,CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O,68210102.0,Phase 1,histone lysine methyltransferase inhibitor,EZH2,,,2146
2931,BRD-K17472821,GSK2830371,Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1,70983932.0,Preclinical,protein phosphatase inhibitor,PPM1D,,,8493
2932,BRD-K50679358,GSK2837808A,COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1,71533725.0,Preclinical,lactate dehydrogenase inhibitor,LDHA,,,3939
2934,BRD-K09223495,GSK2879552,OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1,66571643.0,Phase 1/Phase 2,histone lysine demethylase inhibitor,KDM1A,,,23028
2943,BRD-K26514105,GSK37647,COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C,743974.0,Preclinical,free fatty acid receptor agonist,FFAR4,,,338557
2944,BRD-K03155172,GSK3787,FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1,2800647.0,Preclinical,PPAR receptor antagonist,PPARD,,,5467
2945,BRD-A10523515,GSK429286A,"CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|",92472001.0,Preclinical,rho associated kinase inhibitor,ROCK1,,,6093
2946,BRD-K92428232,GSK461364,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,15983966.0,Phase 1,PLK inhibitor,PLK1,,,5347
2947,BRD-K72293620,GSK503,CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O,67469117.0,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,,2146
2948,BRD-K14991967,GSK650394,OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1,25022668.0,Preclinical,serum/glucocorticoid regulated kinase inhibitor,SGK1|SGK2,,,23678|6446
2950,BRD-K25325018,GSK690693,CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N,16725726.0,Phase 1,AKT inhibitor,AKT1|AKT2|AKT3|PAK4|PAK6|PAK7|PRKCQ|PRKG1|PRKX,,,106821730|5592|5613|207|208|10000|5588|57144|10298
2951,BRD-K29328421,GSK9027,Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F,24882669.0,Preclinical,glucocorticoid receptor agonist,NR3C1,,,2908
2952,BRD-K89015388,GSK923295,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,46898058.0,Phase 1,centromere associated protein inhibitor,CENPE,,,1062
2953,BRD-K16664969,GTP-14564,c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12,3385203.0,Preclinical,FLT3 inhibitor|tyrosine kinase inhibitor,CSF1R|FLT3|KIT|PDGFRB,,,2322|1436|5159|3815
2954,BRD-K14235254,GTS21,COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|,5310985.0,Phase 1/Phase 2,cholinergic receptor agonist,CHRNA7,,,89832
2957,BRD-K96282009,guaiacol,COc1ccccc1O,460.0,Launched,local anesthetic,CA2,pulmonary,cough suppressant,760
2959,BRD-K62736196,guanaben-acetate,NC(=N)N\N=C\c1c(Cl)cccc1Cl,5702063.0,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension,152|150|151
2962,BRD-K62676709,guanethidine,NC(=N)NCCN1CCCCCCC1,3518.0,Launched,adrenergic inhibitor,SLC6A2,cardiology,hypertension,6530
2963,BRD-K32830106,guanfacine,NC(=N)NC(=O)Cc1c(Cl)cccc1Cl,3519.0,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension,152|150|151
2964,BRD-K76037122,guanidine,NC(N)=N,3520.0,Launched,HSP inhibitor,ALDH2|DLG4|GAMT|RNASE1,neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),217|6035|3996|2593
2965,BRD-K69191882,guanidinoethyldisulfide-bicarbonate,NC(=N)NCCSSCCNC(N)=N,3521.0,Phase 2,nitric oxide synthase inhibitor,NOS2,,,339345
2966,BRD-K50781608,guanidinopropionic-acid,NC(=N)NCCC(O)=O,67701.0,Phase 2,creatine kinase inhibitor,CKM,,,1158
2967,BRD-K67644125,guanosine,Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,135398635.0,Preclinical,,PNP,,,5539
2968,BRD-K18745919,Gue-1654,CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1,5066134.0,Preclinical,oxoeicosanoid receptor modulator,OXER1,,,165140
2969,BRD-K01980392,guvacine,OC(=O)C1=CCCNC1 |t:3|,40468028.0,Preclinical,GABA uptake inhibitor,SLC6A1|SLC6A11|SLC6A12|SLC6A13,,,6529|6538|6539|6540
2970,BRD-K82983861,GW-0742,Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F,9934458.0,Preclinical,PPAR receptor agonist,PPARD,,,5467
2971,BRD-K23614267,GW-1100,CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1,11692123.0,Preclinical,G protein-coupled receptor agonist,FFAR1,,,2864
2972,BRD-K00004238,GW-1929,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1,6518171.0,Preclinical,PPAR receptor agonist,PPARG,,,5468
2973,BRD-K24242599,GW-2580,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,11617559.0,Preclinical,cFMS kinase inhibitor,CSF1R,,,1436
2974,BRD-K37864785,GW-311616,CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O,9800961.0,Phase 1,elastase inhibitor|leukocyte elastase inhibitor,ELANE,,,1991
2975,BRD-K33818169,GW-3965,OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1,72199895.0,Preclinical,LXR agonist,NR1H2|NR1H3,,,7376|10062
2976,BRD-K10705233,GW-405833,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,9911463.0,Preclinical,cannabinoid receptor agonist,CNR2,,,56142
2977,BRD-K88186167,GW-4064,CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl,9893571.0,Preclinical,FXR agonist,NR1H4,,,9971
2978,BRD-K13039700,GW-438014A,O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1,6918627.0,Preclinical,neuropeptide receptor antagonist,NPY5R,,,4889
2979,BRD-K41312087,GW-441756,Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12,9943465.0,Preclinical,growth factor receptor inhibitor,NTRK1,,,4914
2980,BRD-K14880289,GW-501516,Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F,9803963.0,Phase 2,PPAR receptor agonist,PPARA|PPARD,,,5465|5467
2981,BRD-K39520573,GW-5074,Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br,5034.0,Phase 1/Phase 2,leucine rich repeat kinase inhibitor|RAF inhibitor,NTRK1|RAF1,,,4914|6037
2982,BRD-K36485341,GW-542573X,COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C,24885053.0,Preclinical,calcium channel activator,KCNN1,,,3780
2983,BRD-K79930101,GW-583340,CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,5329480.0,Preclinical,EGFR inhibitor,EGFR|ERBB2,,,2064|1956
2984,BRD-K50005760,GW-627368,CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1,5312130.0,Preclinical,prostanoid receptor antagonist,PTGER4,,,5734
2985,BRD-K20828910,GW-6471,CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F,446738.0,Preclinical,PPAR receptor antagonist,PPARA,,,5465
2986,BRD-K96263742,GW-7647,CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O,3392731.0,Preclinical,PPAR receptor agonist,PPARA,,,5465
2987,BRD-K78086729,GW-788388,O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1,10202642.0,Preclinical,ALK tyrosine kinase receptor inhibitor,LCK|MAPK14|TGFBR1,,,1432|3932|7046
2988,BRD-K65576800,GW-803430,COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1,9826520.0,Phase 1,melanin inhibitor,KCNH2|MCHR1,,,3757|2847
2989,BRD-K26823213,GW-842166,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,10253143.0,Phase 2,cannabinoid receptor agonist,CNR2,,,56142
2990,BRD-K90382497,GW-843682X,COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC,9826308.0,Preclinical,PLK inhibitor,PLK1|PLK3,,,5347|1263
2991,BRD-K71534238,GW-9508,OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,11595431.0,Preclinical,free fatty acid receptor agonist|G protein-coupled receptor agonist,FFAR1|FFAR4,,,2864|338557
2992,BRD-K93258693,GW-9662,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1,644213.0,Preclinical,PPAR receptor antagonist,NCOA2|PPARG|RXRA,,,6256|10499|5468
2994,BRD-K24240364,GYKI-52466,"CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|",3538.0,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,,2890|2891|2892|2893
2996,BRD-K35329391,GZD824,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1,51038269.0,Preclinical,Bcr-Abl kinase inhibitor,ABL1|BCR,,,25|106480993
2998,BRD-K27737647,H-89,Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1,449241.0,Preclinical,PKA inhibitor,GSG2|PKIA|PRKACA,,,5569|5578|83903
2999,BRD-K26439554,H2L-5765834,OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1,1365686.0,Preclinical,lysophosphatidic acid receptor antagonist,LPAR1|LPAR3,,,1902|23566
3001,BRD-K64452997,HA-130,OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1,46911532.0,Preclinical,autotaxin inhibitor,ENPP2,,,5168
3002,BRD-K58046914,HA-966-(R)-(+),N[C@@H]1CCN(O)C1=O,6603720.0,Preclinical,glutamate receptor agonist,GRIA1,,,2890
3003,BRD-K41304947,HA-966-(S)-(-),N[C@H]1CCN(O)C1=O,183351.0,Preclinical,glutamate receptor antagonist,GRIA1,,,2890
3004,BRD-K18163608,HA14-1,"CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|",6976314.0,Preclinical,BCL inhibitor,BCL2,,,596
3006,BRD-K81709173,halcinonide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|,443943.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
3007,BRD-K71487404,halobetasol-propionate,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18,t:14|",6918178.0,Launched,glucocorticoid receptor agonist,NR3C1|PLA2G1B,dermatology,corticosteroid-responsive dermatoses,2908|5319
3008,BRD-A51964809,halofantrine,CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|,36688213.0,Launched,antimalarial agent,KCNN4,infectious disease,malaria,3783
3009,BRD-K54247840,halofuginone,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,456390.0,Launched,collagenase inhibitor,COL1A1|MMP2,rheumatology,scleroderma,4313|1277
3010,BRD-K50055394,halopemide,Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O,65490.0,Phase 2,phospholipase inhibitor,PLD1|PLD2,,,5338|5589
3011,BRD-K67783091,haloperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,3559.0,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|GRIN2B|HRH1|HTR1A|HTR1D|HTR2A|HTR2B|HTR7|KCNH1,neurology/psychiatry,schizophrenia|Tourette's disorder,3352|3363|3269|3756|2904|1812|1813|1814|1815|1816|3350|106480180|3356
3012,BRD-K80859331,haloperidol-decanoate,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,52919.0,Launched,psychoactive drug,DRD2|DRD3|DRD4|HTR2A,neurology/psychiatry,schizophrenia,3356|1813|1814|1815
3014,BRD-A20550616,halothane,"FC(F)(F)[C@@H](Cl)Br |&1:4,r|",4369439.0,Launched,glutamate receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK12|KCNK13|KCNK15|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,general anaesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|338567|2741|60598|2743|54207|3776|3777|55879|56659|56660|51305|2554|2555|2556|2557|2558|2559
3015,BRD-K12630395,harmane,Cc1nccc2c3ccccc3[nH]c12,5281404.0,Preclinical,monoamine oxidase inhibitor,MAOA|MAOB,,,4128|4129
3018,BRD-K73815512,HC-030031,CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1,1150897.0,Phase 1,TRPA1 channel blocker,TRPA1,,,8989
3019,BRD-K03391209,HC-067047,Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F,2742550.0,Preclinical,transient receptor potential channel antagonist,TRPV4,,,59341
3021,BRD-K49788188,heclin,CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1,7464118.0,Preclinical,ubiquitin ligase inhibitor,NEDD4|SMURF2|WWP1,,,64750|11059|4734
3022,BRD-K34672903,HEMADO,CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,10981286.0,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
3026,BRD-K15231341,hemomex-s,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C,11468733.0,Launched,,PPARG,,,5468
3030,BRD-K58122457,hesperadin,CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1,,Preclinical,Aurora kinase inhibitor,AURKB,,,9212
3031,BRD-K30553453,hesperetin,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1,72281.0,Launched,ACAT inhibitor,DGAT1|MTTP|SOAT1|SOAT2,,,4571|6646|8694|8435
3032,BRD-K38903228,hesperidin,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1,10621.0,Launched,flavanone glycoside,AURKB|CACNA1B,,,9212|774
3034,BRD-K99792991,hexachlorophene,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,3598.0,Launched,potassium channel activator,GLUD1|SDHD,infectious disease,gram-positive bacterial infections,6392|2746
3035,BRD-K10598093,hexamethonium,C[N+](C)(C)CCCCCC[N+](C)(C)C,3604.0,Preclinical,cholinergic receptor antagonist,CHRNA2|CHRNA3|CHRNA4|CHRNA6,,,1136|1137|8973|1135
3036,BRD-K04710043,hexamethylenebisacetamide,CC(=O)NCCCCCCNC(C)=O,3616.0,Phase 2,AKT inhibitor|differentiation inducer|NFKB pathway inhibitor,AKT1,,,207
3039,BRD-K69253806,hexestrol,CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1,192197.0,Launched,synthetic estrogen,AKR1C1|ESR1|ESR2,endocrinology,hypoestrogenism,2099|2100|1645
3042,BRD-A33894669,hexoprenaline,"O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1,&2:12|",24993924.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154
3043,BRD-A97730597,hexylcaine,C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|,6604266.0,Launched,sodium channel blocker,SCN5A,neurology/psychiatry,local anesthetic,6331
3044,BRD-A14234430,hexylene-glycol,"C[C@@H](O)CC(C)(C)O |&1:1,r|",5288845.0,Preclinical,,AKR1C3|CTPS1|DLG4|HSP90AA1|NOS3|PGF|PLA2G1B|PTPN1|SELP,,,342977|8644|5319|5770|5228|6414|3320|3996|1503
3045,BRD-K99946902,hexylresorcinol,CCCCCCc1ccc(O)cc1O,3610.0,Launched,local anesthetic,TYR,infectious disease,skin infections|first-aid antiseptic,7299
3046,BRD-A55204514,higenamine,Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|,440988.0,Phase 1,adrenergic receptor agonist,ADRB2,,,154
3048,BRD-K01674964,histamine,NCCc1cnc[nH]1,774.0,Launched,histamine receptor agonist,HRH1|HRH2|HRH3|HRH4,allergy,allergic rhinitis,1665|59340|3269|11255
3049,BRD-K34411045,HJC-0350,Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C,22200891.0,Preclinical,GTPase inhibitor,RAPGEF4,,,11069
3050,BRD-K58811567,HKI-357,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,11238512.0,Phase 1,EGFR inhibitor,EGFR,,,1956
3051,BRD-K73746696,HLCL-61,CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12,2250650.0,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT5,,,10419
3053,BRD-K70511574,HMN-214,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,9888590.0,Phase 1,PLK inhibitor,PLK1,,,5347
3055,BRD-K01826529,homatropine,"CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|",,Launched,acetylcholine receptor antagonist,CHRM1,ophthalmology,uveal tract inflammation|pupil dilation,1128
3056,BRD-A54234250,homatropine-methylbromide,"C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3,6,8,&1:13,THB:10:8:1:4.5|",,Launched,acetylcholine receptor antagonist,CHRM5,ophthalmology,uveal tract inflammation,1133
3058,BRD-K01826562,homochlorcyclizine,CN1CCCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:8|,5393145.0,Launched,antihistamine,HRH1,allergy,allergic rhinitis,3269
3059,BRD-K76674262,homoharringtonine,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|,285033.0,Launched,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),6122
3060,BRD-K30519779,homoquinolinic-acid,OC(=O)Cc1cccnc1C(O)=O,3080554.0,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,114787|2903|2904|2905|2906
3063,BRD-K98493452,honokiol,Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O,72303.0,Phase 3,AKT inhibitor,ALOX5|PTGS1|PTGS2,,,240|5742|5743
3071,BRD-K58726989,HTH-01-015,CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12,78357766.0,Preclinical,protein kinase inhibitor,NUAK1,,,9891
3073,BRD-K01825665,HTMT,C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|,6604743.0,Preclinical,histamine receptor agonist,HRH4,,,59340
3074,BRD-K62240499,huperzine-A,C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|,854026.0,Phase 2,acetylcholinesterase inhibitor,ACHE,,,43
3075,BRD-K59788572,hyaluronic-acid,CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O,6852395.0,Launched,,C1QBP|CD44|HABP2|HAPLN1|HAPLN3|HAPLN4|HMMR|ICAM1|NCAN|VCAN,rheumatology|urology,osteoarthritis|interstitial cystitis (IC),960|1463|708|404037|145864|3026|1462|3383|3161|1404
3081,BRD-K13078532,hydrochlorothiazide,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl,3639.0,Launched,thiazide diuretic,CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A3,cardiology,hypertension|congestive heart failure,768|3778|771|759|760|762|6559
3082,BRD-K93568044,hydrocortisone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|,5754.0,Launched,glucocorticoid receptor agonist,ANXA1|NOS2|NR3C1|NR3C2,dermatology|neurology/psychiatry,eczema|psoriasis|seborrheic dermatitis|itching,339345|4306|2908|301
3083,BRD-K11612998,hydrocortisone-acetate,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|,5744.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
3084,BRD-K99199077,hydrocortisone-butyrate,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|,26133.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses|eczema,2908
3087,BRD-K09968782,hydrocortisone-valerate,CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|,5282494.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
3088,BRD-K36862742,hydroflumethiazide,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,3647.0,Launched,sodium/potassium/chloride transporter inhibitor,ATP1A1|CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A1|SLC12A3,cardiology|gastroenterology|rheumatology|nephrology,edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension,768|3778|771|759|760|762|476|6557|6559
3090,BRD-K11227669,hydroquinone,Oc1ccc(O)cc1,785.0,Launched,melanin inhibitor,TYR,dermatology,dyschromia,7299
3092,BRD-A80871782,hydroxyamphetamine,C[C@@H](N)Cc1ccc(O)cc1 |&1:1|,12234986.0,Launched,trace amine associated receptor agonist,TAAR1,ophthalmology,mydriasis,134864
3093,BRD-A99117172,hydroxychloroquine,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,12947.0,Launched,antimalarial agent,TLR7|TLR9,infectious disease,malaria,54106|51284
3094,BRD-K77793136,hydroxyfasudil,O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1,3064778.0,Preclinical,rho associated kinase inhibitor,PKIA|PRKACA|ROCK1,,,5569|5578|6093
3095,BRD-K44932450,hydroxyprogesterone,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|,6238.0,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,spontaneous preterm birth,5241
3096,BRD-K92902018,hydroxyprogesterone-acetate,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|,10156152.0,Launched,progesterone receptor agonist,PGR,,,5241
3100,BRD-K01825165,"hydroxytacrine-maleate-(R,S)",Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|,667530.0,Preclinical,cholinesterase inhibitor,ACHE,,,43
3102,BRD-K51747290,hydroxyurea,NC(=O)NO,3657.0,Launched,ribonucleotide reductase inhibitor,RRM1|RRM2|RRM2B,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC),6240|6241|50484
3103,BRD-K01826510,hydroxyzine,OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|,1548976.0,Launched,antihistamine,HRH1,neurology/psychiatry|allergy|dermatology,anxiety|urticaria|itching|dermatosis,3269
3105,BRD-K46424862,hymecromone,Cc1cc(=O)oc2cc(O)ccc12,5280567.0,Phase 2,monoamine oxidase inhibitor,MAOA|MAOB,,,4128|4129
3107,BRD-K40530731,hyoscyamine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1,,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology|urology|neurology/psychiatry|allergy,peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis,1128|1129|1131|1132
3109,BRD-A63780829,hyperin,"OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|",5742688.0,Preclinical,aldose reductase inhibitor,ACE|AKR1B1,,,1636|231
3110,BRD-K13881745,hypoestoxide,CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C,11199742.0,Phase 1,IKK inhibitor,IKBKB|IL1B|TNF,,,3553|7124|3551
3111,BRD-K03739921,hypoxanthine,O=c1nc[nH]c2nc[nH]c12,790.0,Preclinical,PARP inhibitor,PNP,,,5539
3112,BRD-K08109215,I-BET-762,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|,46943432.0,Phase 2,bromodomain inhibitor,BRD2|BRD3|BRD4,,,8019|23476|6046
3113,BRD-K36363294,I-BET151,COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C,52912189.0,Preclinical,bromodomain inhibitor,BRD2|BRD3|BRD4,,,8019|23476|6046
3114,BRD-K04972057,I-BRD9,CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1,91668541.0,Preclinical,bromodomain inhibitor,BRD9,,,65980
3117,BRD-K57090026,I-CBP-112,CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1,90488984.0,Preclinical,bromodomain inhibitor,CREBBP|EP300,,,2033|1387
3119,BRD-K31135544,IB-MECA,CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12,123683.0,Phase 3,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
3120,BRD-K08681769,ibandronate,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O,60852.0,Launched,bone resorption inhibitor,FDPS,orthopedics,osteoporosis,2224
3121,BRD-K15196155,IBC-293,CC(C)n1nnc2cc(ccc12)C(O)=O,2736690.0,Preclinical,hydroxycarboxylic acid receptor agonist,HCAR3,,,8843
3124,BRD-K94979336,IBMX,CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O,3758.0,Preclinical,phosphodiesterase inhibitor,ADORA1|PDE2A|PDE3B|PDE4D|PDE5A|PDE6G|PDE7A|PDE8A|PDE9A,,,5152|134|8654|5138|5140|5144|5148|5150|5151
3125,BRD-A02971356,ibotenic-acid,"N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|",6971210.0,Preclinical,glutamate receptor agonist,GRIN1,,,114787
3126,BRD-K62490786,ibrolipim,CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC,131601.0,Phase 2,lipoprotein lipase activator,LPL,,,3936
3127,BRD-K70301465,ibrutinib,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C,24821094.0,Launched,Bruton's tyrosine kinase (BTK) inhibitor,BLK|BMX|BTK,hematologic malignancy,chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM),640|660|695
3128,BRD-K16444452,ibudilast,CC(C)C(=O)c1c(nn2ccccc12)C(C)C,3671.0,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A,pulmonary|neurology/psychiatry,asthma|stroke,3553|8654|3569|5139|5141|5142|5143|5144
3130,BRD-K14965640,ibuprofen-(S),CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O,39912.0,Launched,cyclooxygenase inhibitor,ASIC1|PTGS1|PTGS2|SLC5A8,neurology/psychiatry,pain relief,160728|41|5742|5743
3132,BRD-A75224450,ibuprofen-piconol,"CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|",76968625.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
3133,BRD-A40940854,ibuproxam,CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|,11458696.0,Launched,cyclooxygenase inhibitor|prostaglandin inhibitor,ALOX5,endocrinology|rheumatology|neurology/psychiatry,fever|joint inflammation|pain relief,240
3134,BRD-K44771174,ibutamoren,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1,178024.0,Phase 2,growth hormone secretagogue receptor agonist,GHR|GHSR,,,2690|2693
3135,BRD-A74391928,ibutilide,CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|,21149973.0,Launched,potassium channel blocker,CACNA1C|KCNH2,cardiology,atrial fibrillation (AF),3757|775
3136,BRD-K09638361,IC261,COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1,5288600.0,Preclinical,casein kinase inhibitor,CSNK1A1|CSNK1D|CSNK1E|CSNK1G2,,,1452|1453|1454|1455
3137,BRD-K59839632,ICA-069673,Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1,10149311.0,Preclinical,voltage-gated potassium channel activator,KCNQ2|KCNQ3,,,3785|3786
3138,BRD-K71686520,ICA-110381,Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1,4314115.0,Preclinical,voltage-gated potassium channel activator,KCNQ2,,,3785
3139,BRD-K03149601,ICA-121431,O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1,998021.0,Preclinical,sodium channel blocker,SCN1A|SCN3A,,,6328|6323
3140,BRD-K65639003,icariin,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,5318997.0,Phase 3,phosphodiesterase inhibitor,PDE5A,,,8654
3141,BRD-K24476327,icaritin,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O,5318980.0,Phase 3,PPAR receptor antagonist,PDE5A,,,8654
3142,BRD-K63772874,icatibant-acetate,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,6918173.0,Launched,bradykinin receptor antagonist,BDKRB2,cardiology,angioedema,623
3143,BRD-K73261812,ICG-001,Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,11238147.0,Preclinical,beta-catenin inhibitor,CTNNB1,,,1499
3144,BRD-K74603273,"ICI-118,551",CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12,5311179.0,Phase 2,adrenergic receptor antagonist,ADRB2|ADRB3,,,154|155
3145,BRD-K66782112,ICI-162846,NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1,134778.0,Phase 1,histamine receptor antagonist,HRH2,,,1665
3148,BRD-K59433843,ICI-192605,OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl,6604763.0,Phase 2,thromboxane receptor antagonist,TBXA2R,,,6915
3149,BRD-K73290745,ICI-199441,CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1,3082718.0,Preclinical,opioid receptor agonist,CYP2D6|OPRD1|OPRK1|OPRM1|UTS2R,,,2837|4985|4986|4988|1565
3150,BRD-K52487250,"ICI-215,001",O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1,164451.0,Preclinical,adrenergic receptor agonist,ADRB3,,,155
3152,BRD-A03359064,ICI-89406,"O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|",92211532.0,Phase 1,adrenergic receptor antagonist,ADRB1|ADRB2,,,153|154
3153,BRD-K48869804,icilin,Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|,161930.0,Phase 1,TRPV agonist,TRPA1|TRPM8,,,8989|79054
3155,BRD-K41234004,icomucret,CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O,5280724.0,Phase 3,mucin production enhancer,LTB4R2,,,56413
3156,BRD-K47192521,icosapent,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,446284.0,Launched,platelet aggregation inhibitor,ACSL3|ACSL4|FADS1|FFAR1|PPARD|PPARG|PTGS1|PTGS2|SLC8A1|TRPV1,endocrinology,hypertriglyceridemia,2181|2182|5742|5743|2864|4593|6546|7442|5467|5468
3157,BRD-K31698212,icotinib,C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,22024915.0,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),1956
3158,BRD-K18634484,iCRT-14,Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1,5967294.0,Preclinical,beta catenin inhibitor|WNT signaling inhibitor,CTNNB1|TCF4,,,1499|6934
3159,BRD-K90305467,ID-1101,C[C@H](O)[C@H](C)[C@H](N)C(O)=O,6918732.0,Phase 1,insulin sensitizer,INS,,,3630
3161,BRD-K79102359,idalopirdine,FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1,21071390.0,Phase 3,serotonin receptor antagonist,HTR6,,,3362
3162,BRD-K69650333,idarubicin,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O,42890.0,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),7153
3163,BRD-K62627508,idasanutlin,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,53358942.0,Phase 3,MDM inhibitor,MDM2|TP53,,,4193|7157
3164,BRD-A18696154,idazoxan,"C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|",12866829.0,Phase 3,adrenergic receptor antagonist,ADRA2A|PTGS2,,,150|5743
3166,BRD-K60866521,idelalisib,CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,11625818.0,Launched,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,hematologic malignancy,chronic lymphocytic leukemia (CLL),5290|5291|5294|22883
3169,BRD-K22356203,IDO5L,Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1,135424953.0,Preclinical,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,3620
3171,BRD-A14344385,IDRA-21,"C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|",7048549.0,Preclinical,glutamate receptor positive allosteric modulator,GRIA1|GRIA2|GRIA3|GRIA4,,,2890|2891|2892|2893
3173,BRD-K74671368,idronoxil,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|,219100.0,Phase 3,XIAP inhibitor,ENOX2|SPHK1,,,8877|10495
3174,BRD-K13829090,IEM1460,C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2,3248290.0,Preclinical,glutamate receptor antagonist,GRIA2,,,2891
3175,BRD-K80060353,IEM1754,NCCCCCNCC12CC3CC(CC(C3)C1)C2,9887868.0,Preclinical,glutamate receptor antagonist,GRIA1,,,2890
3176,BRD-K00004210,ifenprodil,"C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1,2|",6604117.0,Launched,adrenergic receptor antagonist|glutamate receptor antagonist,GRIN2B,,,2904
3177,BRD-A67097164,ifosfamide,ClCCN[P@@]1(=O)OCCCN1CCCl |r|,9588020.0,Launched,DNA alkylating agent,CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP3A4|CYP3A5|CYP3A7|PTGS1,oncology|urology,testicular carcinoma|hemorrhagic cystitis,100861540|1576|1577|1548|5742|1555|1557|1558|1559|1562
3178,BRD-A48376327,igmesine,CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|,6438340.0,Phase 2,sigma receptor agonist,SIGMAR1,,,10280
3179,BRD-K15426076,iguratimod,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,124246.0,Launched,cyclooxygenase inhibitor|NFkB pathway inhibitor,PTGS2,rheumatology,rheumatoid arthritis,5743
3180,BRD-K14618467,IKK-16,O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1,9549298.0,Preclinical,IKK inhibitor,IKBKB,,,3551
3181,BRD-K26373640,IKK-2-inhibitor,NC(=O)c1sc(cc1N)-c1ccsc1,2807869.0,Preclinical,IKK inhibitor|SYK inhibitor,IKBKB,,,3551
3182,BRD-K74305673,IKK-2-inhibitor-V,Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F,5081913.0,Phase 1,IKK inhibitor|NFkB pathway inhibitor,IKBKB,,,3551
3185,BRD-K51662849,ilomastat,CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO,132519.0,Phase 3,matrix metalloprotease inhibitor,ACAN|ADAM28|MMP1|MMP12|MMP13|MMP14|MMP2|MMP3|MMP8|MMP9,,,4321|4322|4323|10863|176|4312|4313|4314|4317|4318
3186,BRD-K48722833,iloperidone,COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O,71360.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR2A|HTR6|HTR7,neurology/psychiatry,schizophrenia,3362|3363|3269|146|1812|1813|1814|1815|152|3350|3356
3187,BRD-A45664787,iloprost,"CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|",51397006.0,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,PTGDR|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|PTGIR|TBXA2R,pulmonary,pulmonary arterial hypertension (PAH),5729|5731|5732|5733|5734|6915|5737|5739
3188,BRD-K92723993,imatinib,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,5291.0,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET,hematologic malignancy|oncology,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST),5156|3815|5159|780|4914|25|5979|1436
3191,BRD-K33183200,imetit,NC(=N)SCCc1cnc[nH]1,3692.0,Preclinical,histamine receptor agonist,HRH3|HRH4,,,59340|11255
3194,BRD-K29626940,imidafenacin,Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,6433090.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM3,neurology/psychiatry,spasms,1128|1131
3195,BRD-K11466259,imidapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O,5464343.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure,1636
3198,BRD-A10903566,imiloxan,CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|,76966048.0,Phase 1,adrenergic receptor antagonist,ADRA2A|ADRA2B,,,150|151
3200,BRD-K38436528,imipramine,CN(C)CCCN1c2ccccc2CCc2ccccc12,3696.0,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry|urology,depression|nocturnal enuresis,6530|6531|6532|146|147|1812|1813|3350|1816|3356|3358|3362|3363|3751|3752|3756|3757|3269|1128|1129|1131|1132|1133
3201,BRD-K26657438,imiquimod,CC(C)Cn1cnc2c(N)nc3ccccc3c12,57469.0,Launched,interferon inducer|toll-like receptor agonist,TLR7|TLR8,dermatology|infectious disease|oncology,actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC),51284|51311
3204,BRD-K25906698,immepip,C(C1CCNCC1)c1cnc[nH]1,3035842.0,Preclinical,histamine receptor agonist,HRH3|HRH4,,,59340|11255
3205,BRD-K49519092,immethridine,C(c1cnc[nH]1)c1ccncc1,9989505.0,Phase 1,histamine receptor agonist,HRH3,,,11255
3206,BRD-K20049318,impentamine,NCCCCCc1cnc[nH]1,9793868.0,Preclinical,histamine receptor antagonist,HRH3,,,11255
3210,BRD-K81016934,INC-280,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,25145656.0,Phase 3,c-Met inhibitor,MET,,,8731
3211,BRD-K33308633,INCA-6,"O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|",230748.0,Preclinical,calcineurin inhibitor,NFATC1,,,4772
3214,BRD-K67628093,INCB-3284,COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,,Phase 2,CC chemokine receptor antagonist,CCR2,,,729230
3216,BRD-K89208535,indacaterol,CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,6918554.0,Launched,adrenergic receptor agonist,ADRB1|ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD),153|154
3217,BRD-K64973364,indalpine,C(Cc1c[nH]c2ccccc12)C1CCNCC1,44668.0,Withdrawn,selective serotonin reuptake inhibitor (SSRI),SLC6A4,,,6532
3218,BRD-A95869247,indapamide,"C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|",12598931.0,Launched,thiazide diuretic,CA2|HTR3A|KCNQ1,cardiology,hypertension|congestive heart failure,760|3784|3359
3219,BRD-K01649396,indatraline,CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1,126280.0,Preclinical,norepinephrine transporter inhibitor,MAOA|MAOB,,,4128|4129
3220,BRD-K00003177,indeglitazar,COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12,11395145.0,Phase 2,PPAR receptor agonist,NCOA1|PPARA|PPARD|PPARG,,,8648|5465|5467|5468
3223,BRD-K33226500,indinavir,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12,5362440.0,Launched,HIV protease inhibitor,CYP3A4|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1),1576|1577|100861540
3224,BRD-K90948141,indiplon,CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1,6450813.0,Phase 3,benzodiazepine receptor agonist,GABRA1,,,2554
3225,BRD-K17894950,indirubin,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,,Phase 2/Phase 3,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK5|GSK3A,,,2931|1020|983
3226,BRD-K19136521,indirubin-3-monoxime,O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12,,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CDK1|CDK2|CDK5|CDK5R1|GSK3B,,,8851|2932|983|1017|1020
3227,BRD-K17610631,indisulam,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,216468.0,Phase 2,CDK inhibitor,CA1|CA12|CA14|CA2|CA6|CA7|CA9,,,768|771|23632|759|760|765|766
3230,BRD-A16296925,indobufen,"CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|",189556.0,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor,PTGS1|PTGS2,hematology,thrombosis,5742|5743
3231,BRD-K80762071,indocyanine-green,CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|,9919342.0,Launched,contrast agent,SLCO1B1,cardiology,vascular imaging agent,10599
3232,BRD-K01815685,indole-3-carbinol,OCc1c[nH]c2ccccc12,3712.0,Phase 2/Phase 3,"aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor",AHR,,,196
3234,BRD-K57222227,indomethacin,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1,3715.0,Launched,cyclooxygenase inhibitor,GLO1|PLA2G2A|PPARA|PPARG|PTGDR2|PTGR2|PTGS1|PTGS2|SLC46A1,rheumatology|orthopedics,rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis,5320|145482|5742|5743|2739|11251|113235|5465|5468
3235,BRD-A44090213,indoprofen,"C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|",93283.0,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,CXCR1|CXCR2|PTGS1|PTGS2,,,3577|3579|5742|5743
3236,BRD-K76953762,indoramin,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,33625.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2B|ADRA2C,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension,152|146|147|151
3237,BRD-K93255255,indoximod,Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12,6920151.0,Phase 2,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,3620
3238,BRD-K00003329,ingenol,"[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13,t:2|",442042.0,Launched,PKC activator,PRKCD|PRKCE,dermatology,keratosis,5580|5581
3239,BRD-K93779381,ingenol-mebutate,"C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|",6918670.0,Launched,PKC activator,PRKCA|PRKCB|PRKCD|PRKCE|PRKCG,dermatology,actinic keratosis (AK),5578|5579|5580|5581|5582
3240,BRD-K70177501,INH1,Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1,959043.0,Preclinical,Hec1 inhibitor,NDC80,,,10403
3242,BRD-K11153516,iniparib,NC(=O)c1ccc(I)c(c1)[N+]([O-])=O,9796068.0,Phase 3,PARP inhibitor,PARP1,,,142
3243,BRD-K79612754,inosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O,135398641.0,Launched,neurotrophic agent,PARP1|PNP,,,5539|142
3244,BRD-K52618540,inositol,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,,Launched,insulin sensitizer,CDIPT,obstetrics/gynecology,polycystic ovary syndrom (PCOS),10423
3248,BRD-K33067152,INT-767,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12,23642339.0,Phase 1,FXR agonist,GPBAR1,,,151306
3249,BRD-K88165431,integrin-antagonist-1,Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O,86272865.0,Phase 1,integrin antagonist,ITGAV|ITGB6,,,3685|3694
3253,BRD-K67261995,iodipamide,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,3739.0,Launched,radiopaque medium,ALB,radiology,contrast agent,213
3257,BRD-K51918615,iodophenpropit,Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1,3035746.0,Preclinical,histamine receptor antagonist,HRH3|HRH4,,,59340|11255
3266,BRD-K84892605,IOWH032,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,135565181.0,Phase 2,CFTR channel antagonist,CFTR,,,1080
3267,BRD-K70751730,IOX1,OC(=O)c1ccc(O)c2ncccc12,459617.0,Preclinical,histone demethylase inhibitor,EGLN1|KDM3A|KDM4C|KDM6B,,,23081|55818|23135|54583
3268,BRD-K98251413,IOX2,OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O,54685215.0,Preclinical,hypoxia inducible factor inhibitor,EGLN1|KDM2A|KDM5C,,,22992|8242|54583
3271,BRD-K38727704,IPA-3,Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12,521106.0,Preclinical,p21 activated kinase inhibitor,PAK1,,,5585
3274,BRD-K66896231,ipidacrine,Nc1c2CCCc2nc2CCCCc12,604519.0,Phase 3,acetylcholinesterase inhibitor,ACHE,,,43
3275,BRD-K51247865,ipragliflozin-L-proline,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1,10453870.0,Launched,sodium/glucose cotransporter inhibitor,SLC5A2,endocrinology,diabetes mellitus,6524
3276,BRD-K01826778,ipratropium,"CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5,8,10,&1:3,&2:15,TLB:4:3:6.7:9.10.11,THB:1:3:6.7:9.10.11,12:10:3:6.7|",,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,pulmonary,bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema,1128|1129|1131|1132|1133
3278,BRD-K88568253,iproniazid,CC(C)NNC(=O)c1ccncc1,3748.0,Withdrawn,monoamine oxidase inhibitor,MAOA|MAOB,,,4128|4129
3279,BRD-K90574421,ipsapirone,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,56971.0,Phase 3,serotonin receptor agonist,HTR1A,,,3350
3280,BRD-K60038276,irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|,3749.0,Launched,angiotensin receptor antagonist,AGTR1|JUN|SLC10A1,cardiology|nephrology,hypertension|diabetic nephropathy,185|6554|3725
3283,BRD-K08547377,irinotecan,CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12,60838.0,Launched,topoisomerase inhibitor,TOP1|TOP1MT,oncology,colorectal cancer,7150|116447
3284,BRD-K98357249,IRL-2500,CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1,5311192.0,Preclinical,endothelin receptor antagonist,EDNRB,,,1910
3285,BRD-K87777313,irosustat,NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1,5287541.0,Phase 2,steroid sulfatase inhibitor,CA2|STS,,,760|412
3286,BRD-K74195153,irsogladine,Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl,3752.0,Launched,phosphodiesterase inhibitor,PDE4A,gastroenterology,peptic ulcer disease (PUD),5141
3287,BRD-K01825673,isamoltane,CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|,6604790.0,Phase 1,adrenergic receptor antagonist,HTR1A|HTR1B,,,3350|3351
3288,BRD-A17009129,isavuconazole,"C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1,&1:15|",92043107.0,Phase 3,cytochrome P450 inhibitor,CYP3A4,,,1576
3292,BRD-A94055480,ISO-1,"COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|",5288525.0,Preclinical,macrophage migration inhibiting factor inhibitor,MIF,,,4282
3294,BRD-K54057105,isobutyramide,CC(C)C(N)=O,68424.0,Phase 2,gene expression stimulant,HBE1|HBG1,,,3046|3047
3295,BRD-K93332168,isocarboxazid,Cc1cc(no1)C(=O)NNCc1ccccc1,3759.0,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression,4128|4129
3296,BRD-K01825590,isoconazole,Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|,25273632.0,Launched,fungal lanosterol demethylase inhibitor,CYP17A1,infectious disease,gram-positive bacterial infections,1586
3300,BRD-K29173907,isoflupredone-acetate,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|",224246.0,Preclinical,,NR3C1,,,2908
3301,BRD-A31564021,isoflurane,"FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|",4369440.0,Launched,inhaled anaesthetic,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9,neurology/psychiatry,general anaesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|338567|2741|2743|54207|3776|3777|55879|51305|2554|2555|2556|2557|2558|2559
3302,BRD-K56575995,isoflurophate,CC(C)OP(F)(=O)OC(C)C,5936.0,Launched,cholinesterase inhibitor,ACHE|BCHE,ophthalmology,glaucoma,43|590
3303,BRD-K66480997,isoguvacine,OC(=O)C1=CCNCC1 |t:3|,7059534.0,Preclinical,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3,,,200959|2569|2570|2554|2555|2556|2557|2558|2559
3305,BRD-K33583600,isoliquiritigenin,Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1,638278.0,Preclinical,guanylate cyclase activator,GABBR1,,,10537
3307,BRD-K87202646,isoniazid,NNC(=O)c1ccncc1,3767.0,Launched,FABI inhibitor,CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4,infectious disease,tuberculosis,1571|1544|1576|1557|1558
3309,BRD-A04322457,isoprenaline,CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|,5808.0,Launched,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,cardiology|pulmonary,bradycardia|heart block|asthma,153|154|155
3310,BRD-K14127446,isopropamide-iodide,CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,3775.0,Launched,acetylcholine receptor antagonist,CHRM3|CHRM4,gastroenterology,peptic ulcer disease (PUD)|gastrointestinal acidosis,1131|1132
3316,BRD-K55853390,isosorbide-dinitrate,[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O,6883.0,Launched,nitric oxide stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3|NPR1,cardiology,angina pectoris|coronary artery disease (CAD),2977|2982|2983|4881|2974
3317,BRD-K82225283,isosorbide-mononitrate,O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O,27661.0,Launched,nitric oxide stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3,cardiology,angina pectoris|coronary artery disease (CAD),2977|2974|2982|2983
3320,BRD-K76723084,isotretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|,5282379.0,Launched,retinoid receptor agonist,RARA|RARB|RARG,dermatology,acne vulgaris (AV),5914|5915|5916
3323,BRD-A75552914,isoxicam,CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|,54677972.0,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,,,5742|5743
3324,BRD-K00003690,isoxsuprine,"C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|",42066885.0,Launched,adrenergic receptor agonist,ADRB2,rheumatology|cardiology,Raynaud's disease|arteriosclerosis|Buerger's disease,154
3325,BRD-K64881305,ispinesib,CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1,6851740.0,Phase 2,kinesin inhibitor,KIF11,,,3832
3326,BRD-A90799790,isradipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|",13773524.0,Launched,calcium channel blocker,CACNA1D|CACNA1F|CACNA2D1,cardiology,hypertension,776|778|781
3327,BRD-K12826175,ISRIB,Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|,,Preclinical,eukaryotic translation initiation factor inhibitor|PERK inhibitor,EIF2A|EIF2AK3,,,9451|1965
3328,BRD-K95412502,istaroxime,C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O,9841834.0,Phase 2,ATPase inhibitor,ATP1A1,,,476
3329,BRD-K87774949,istradefylline,CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O,5311037.0,Launched,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,neurology/psychiatry,Parkinson's Disease|dyskinesia,136|140|134|135
3330,BRD-K53903639,ISX-9,O=C(NC1CC1)c1cc(on1)-c1cccs1,19582717.0,Preclinical,neural stem cell inducer,NEUROD1,,,4760
3331,BRD-K73499906,IT1t,"CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|",25147749.0,Preclinical,CC chemokine receptor antagonist,CXCR4,,,7852
3332,BRD-K67482377,itacitinib,Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,53380437.0,Phase 3,JAK inhibitor,JAK1,,,3716
3333,BRD-A56690687,ITD-1,"CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|",71512660.0,Preclinical,TGF beta receptor inhibitor,TGFBR2,,,7048
3334,BRD-K60298136,ITE,COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12,4668801.0,Preclinical,aryl hydrocarbon receptor agonist,AHR,,,196
3335,BRD-K77987496,ITI214,CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|,42639643.0,Phase 1/Phase 2,phosphodiesterase inhibitor,PDE1A,,,5136
3336,BRD-K96740444,itopride,COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,3792.0,Launched,dopamine receptor antagonist,CHRM3|DRD2,gastroenterology|neurology/psychiatry,dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia,1131|1813
3338,BRD-K36515744,ITX3,Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1,1362865.0,Preclinical,GEF inhibitor,TRIO,,,7204
3340,BRD-K45841694,IU1,Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1,675434.0,Preclinical,ubiquitin C-terminal hydrolase inhibitor,USP14,,,9097
3341,BRD-K33972682,ivabradine,COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC,132999.0,Launched,HCN channel blocker|potassium channel blocker|sodium channel blocker,HCN1|HCN3|HCN4,cardiology,angina pectoris,57657|348980|10021
3342,BRD-K52818472,ivacaftor,CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C,16220172.0,Launched,CFTR channel potentiator,CFTR,pulmonary,cystic fibrosis,1080
3343,BRD-K85554912,ivermectin,"CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|",6321424.0,Launched,benzodiazepine receptor agonist,CHRNA7|P2RX7,infectious disease,gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies,89832|5027
3344,BRD-K93073858,ivosidenib,Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N,71657455.0,Launched,isocitrate dehydrogenase inhibitor,IDH1,hematologic malignancy,acute myeloid leukemia (AML),3417
3345,BRD-K53234107,IWP-L6,O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1,71601111.0,Preclinical,porcupine inhibitor,PORCN,,,64840
3346,BRD-K03601870,ixabepilone,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,,Launched,microtubule stabilizing agent,TUBB,oncology,breast cancer,7280
3350,BRD-K95676198,JAK3-inhibitor-V,C=CC(=O)c1ccc2ccccc2c1,3799.0,Preclinical,JAK inhibitor,JAK3,,,3718
3352,BRD-K95837862,JDTic,CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1,9956146.0,Phase 1,opioid receptor antagonist,OPRK1,,,4986
3353,BRD-K32892871,JHW-007,CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1,,Preclinical,dopamine reuptake inhibitor,SLC6A3,,,6531
3355,BRD-K76180386,JIB04,Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1,6519698.0,Preclinical,histone lysine demethylase inhibitor,KDM4E,,,390245
3357,BRD-K22010301,JLK-6,COc1oc(=O)c2cc(N)ccc2c1Cl,3803.0,Preclinical,gamma secretase inhibitor,PSEN1,,,5663
3358,BRD-K15086322,JNJ-10191584,CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1,10446295.0,Preclinical,histamine receptor antagonist,HRH4,,,59340
3359,BRD-K61721596,JNJ-10397049,CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1,9869934.0,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,,131450|3061
3360,BRD-K25596805,JNJ-16259685,CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|,,Preclinical,glutamate receptor antagonist,GRM1,,,2911
3361,BRD-K47376733,JNJ-1661010,O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1,2809273.0,Preclinical,FAAH inhibitor,FAAH,,,79152
3362,BRD-K51770398,JNJ-17203212,FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1,11339118.0,Preclinical,TRPV antagonist,TRPV1,,,7442
3363,BRD-K83837640,JNJ-26481585,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,11538455.0,Phase 2,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9|MDM2,,,4193|55869|9734|8841|10013|79885|3065|3066|83933|10014|9759
3365,BRD-K41895652,JNJ-27141491,CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1,11703589.0,Preclinical,CC chemokine receptor antagonist,CCR2,,,729230
3366,BRD-K31802667,JNJ-37822681,Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F,16058752.0,Phase 2,dopamine receptor antagonist,DRD2,,,1813
3367,BRD-K02123250,JNJ-38877605,Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1,46911863.0,Phase 1,tyrosine kinase inhibitor,MET,,,8731
3370,BRD-K55029398,JNJ-40411813,CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O,25195461.0,Phase 2,glutamate receptor positive allosteric modulator,GRM2,,,2912
3371,BRD-K01036220,JNJ-42041935,OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1,45102710.0,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,PDK2,,,5164
3372,BRD-K70330032,JNJ-42165279,FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1,54576693.0,Phase 2,FAAH inhibitor,FAAH,,,79152
3373,BRD-K83547600,JNJ-47965567,O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1,66553218.0,Preclinical,purinergic receptor antagonist,P2RX7,,,5027
3375,BRD-K19482962,JNJ-63533054,C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1,2548547.0,Preclinical,G protein-coupled receptor agonist,GPR139,,,124274
3378,BRD-K11636097,JNJ-7706621,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,5330790.0,Preclinical,CDK inhibitor,AURKA|AURKB|CDK1|CDK2,,,1017|9212|6790|983
3379,BRD-K17774839,JNJ-7777120,CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1,4908365.0,Preclinical,histamine receptor antagonist,HRH4,,,59340
3382,BRD-K54606188,JQ1-(+),Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|,46907787.0,Preclinical,bromodomain inhibitor,BRD4|BRDT,,,676|23476
3383,BRD-K17705806,JTC-801,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1,5311340.0,Phase 2,opioid receptor antagonist,OPRL1,,,4987
3384,BRD-K43330982,JTE-013,CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12,10223146.0,Preclinical,lysophospholipid receptor antagonist,P2RY10|S1PR2,,,9294|27334
3385,BRD-K81405859,JTE-607,CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O,9938545.0,Phase 2,cytokine production inhibitor,IL10|IL1B|IL6|TNF,,,3553|3586|7124|3569
3386,BRD-K63150726,JTE-907,CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12,9867770.0,Phase 1,cannabinoid receptor inverse agonist,CNR2,,,56142
3387,BRD-K53328210,JW-55,COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1,2946601.0,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,,8658|80351
3388,BRD-K48424871,JW-642,FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F,71656520.0,Preclinical,monoacylglycerol lipase inhibitor,MGLL,,,11343
3389,BRD-K24554037,JW-67,O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12,644733.0,Preclinical,WNT pathway inhibitor,APC|AXIN1|GSK3B,,,5624|2932|8312
3390,BRD-K75664313,JW-74,COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1,16013152.0,Preclinical,tankyrase inhibitor|WNT signaling inhibitor,TNKS|TNKS2,,,8658|80351
3391,BRD-K05464208,JX-401,COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1,1126109.0,Preclinical,p38 MAPK inhibitor,MAPK14,,,1432
3392,BRD-K45446451,JZL-184,OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1,25021165.0,Preclinical,monoacylglucerol lipase inhibitor,MGLL,,,11343
3393,BRD-K38875233,JZL-195,[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1,46232606.0,Preclinical,FAAH inhibitor|monoacylglycerol lipase inhibitor,FAAH|MGLL,,,79152|11343
3395,BRD-A67748489,K-858,"CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|",686905.0,Preclinical,kinesin-like spindle protein inhibitor,KIF11,,,3832
3397,BRD-K90756851,K-Ras(G12C)-inhibitor-12,Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C,73555129.0,Preclinical,K-Ras inhibitor,KRAS,,,3265
3399,BRD-K84595254,K-strophanthidin,C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|,6185.0,Phase 2,ATPase inhibitor,ATP1A1,,,476
3400,BRD-K58568447,K02288,COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1,46173038.0,Preclinical,bone morphogenic protein inhibitor,BMP1,,,649
3401,BRD-K12106308,K145,CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1,71714682.0,Preclinical,sphingosine kinase inhibitor,SPHK2,,,56848
3402,BRD-K12807006,kaempferol,Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O,5280863.0,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1,,,231|1545|367|240|2739|247|133688|3292
3404,BRD-K52459018,kainic-acid,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O,44338126.0,Preclinical,kainate receptor agonist,GRIA1|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5,,,2890|2897|2899|2900|2901
3407,BRD-K00003176,karenitecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O,148202.0,Phase 3,topoisomerase inhibitor,TOP1,,,7150
3408,BRD-K27584835,kartogenin,OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1,2826191.0,Preclinical,chondrocyte differentiation stimulator,FLNA,,,2316
3410,BRD-K17743697,KB-R7943,NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1,4534086.0,Preclinical,sodium/calcium exchange inhibitor,SLC8A1|TRPC3|TRPC5|TRPC6,,,7224|7225|6546|7222
3411,BRD-K88154110,KB-SRC-4,Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1,73349077.0,Preclinical,SRC inhibitor,SRC,,,6714
3412,BRD-A00376169,KBG,"O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|",92461199.0,Phase 2,neprilysin inhibitor,MME,,,4321
3413,BRD-K71164191,KD-023,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,115175.0,Phase 2,ACAT inhibitor,ACACA|ACACB,,,32|31
3414,BRD-K88506063,KD025,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1,11950170.0,Phase 2,rho associated kinase inhibitor,ROCK2,,,9475
3415,BRD-K37312348,kenpaullone,Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1,3820.0,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,CCNB1|CDK1|CDK5|GSK3B,,,2932|891|1020|983
3416,BRD-K49671696,ketanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,3822.0,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2,cardiology,hypertension,3352|3361|3363|6570|6571|146|147|1812|106480180|3350|3351|1816|3356|3358
3417,BRD-K29113274,ketoconazole,"CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|",47576.0,Launched,sterol demethylase inhibitor,KCNA10,dermatology,seborrheic dermatitis,3744
3419,BRD-A97739905,ketoprofen,"C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|",180540.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2|SLC5A8,rheumatology,rheumatoid arthritis|osteoarthritis,160728|5742|5743
3420,BRD-K01825750,ketorolac,"OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|",181817.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
3421,BRD-K28936863,ketotifen,CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|,57392700.0,Launched,histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor,HRH1,neurology/psychiatry,itching,3269
3423,BRD-A54927599,KF-38789,"COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|",135565372.0,Preclinical,P selectin inhibitor,SELP,,,6414
3424,BRD-K90747162,KG-5,CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1,53328059.0,Preclinical,RAF inhibitor,BRAF|FLT3|KIT|PDGFRB,,,673|2322|5159|3815
3425,BRD-K66430217,KH-CB19,CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C,91899919.0,Preclinical,CDC inhibitor,CLK1|CLK3|DYRK1A,,,1859|1195|1198
3427,BRD-K84605263,KHK-IN-1,CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1,53348216.0,Preclinical,hexokinase inhibitor,KHK,,,3795
3428,BRD-K78978711,KHS-101,CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1,71304818.0,Preclinical,neural stem cell inducer,TACC3,,,10460
3429,BRD-A25569250,KI-16425,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|",40467027.0,Preclinical,lysophosphatidic acid receptor antagonist,LPAR1|LPAR3,,,1902|23566
3430,BRD-A88787317,KI-20227,"COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|",57881591.0,Preclinical,c-Fms inhibitor,CSF1R|KDR|KIT|PDGFRB,,,3815|1436|5159|3791
3431,BRD-K47150025,KI-8751,COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,11317348.0,Preclinical,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,,,3791
3432,BRD-A94323479,ki16198,"COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|",92461210.0,Preclinical,lipoprotein antagonist,LPA,,,4018
3433,BRD-K02898090,kifunensine,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,130611.0,Phase 1,mannosidase inhibitor,MAN1B1|MAN2A1,,,4124|11253
3435,BRD-A94580299,KL-001,"CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|",1367681.0,Preclinical,proteasome inhibitor,CRY1|CRY2,,,1408|1407
3438,BRD-K46734292,KML29,OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1,71656212.0,Preclinical,monoacylglucerol lipase inhibitor,MGLL,,,11343
3439,BRD-A81177136,KN-62,"CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|",5312126.0,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,AKT1|CAMK2A|CHEK1|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|P2RX7|PRKCA|ROCK1|RPS6KB1|SGK1,,,5600|5027|5578|6093|6446|815|207|6300|6198|1111|1432|5594|3932|5599
3440,BRD-K93480852,KN-93,COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1,5312122.0,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,CAMK2A,,,815
3441,BRD-K64642496,Ko143,COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O,10322450.0,Preclinical,BCRP inhibitor,ABCB1|ABCC1,,,4363|5243
3443,BRD-K71467466,KPT-185,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,53495165.0,Preclinical,exportin antagonist,XPO1,,,7514
3444,BRD-K75352575,KPT-276,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1,71496742.0,Preclinical,exportin antagonist,XPO1,,,7514
3447,BRD-K40604024,KRCA-0008,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O,72547474.0,Preclinical,ALK inihibitor,ALK,,,238
3448,BRD-K90993449,KRN-633,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,9549295.0,Preclinical,VEGFR inhibitor,FLT1|FLT4|KDR,,,2321|2324|3791
3449,BRD-K81053848,KS-176,OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1,49779726.0,Preclinical,BCRP inhibitor,ABCG2,,,9429
3451,BRD-K67566344,KU-0063794,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1,16736978.0,Preclinical,mTOR inhibitor,MTOR,,,2475
3452,BRD-K25311561,KU-55933,O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1,5278396.0,Preclinical,ATM kinase inhibitor,ATM|PRKDC,,,472|5591
3453,BRD-K36016295,KU-60019,C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1,15953870.0,Preclinical,ATM kinase inhibitor,ATM,,,472
3455,BRD-K51337109,kuromanin,OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O,441667.0,Preclinical,ribosyl cyclase inhibitor,CD38,,,952
3456,BRD-K21718444,KW-2449,O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1,11427553.0,Phase 1,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,ABL1|AURKA|AURKB|FLT3,,,25|2322|9212|6790
3458,BRD-A95683721,KW-3902,"CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|",,Phase 3,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
3459,BRD-K29968218,KX2-391,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,23635314.0,Phase 3,SRC inhibitor|tubulin polymerization inhibitor,SRC,,,6714
3460,BRD-K13302470,KY02111,COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC,8582409.0,Preclinical,WNT pathway inhibitor,DKK1,,,22943
3461,BRD-K85872723,kynurenic-acid,OC(=O)c1cc(=O)c2ccccc2[nH]1,3845.0,Phase 1,glutamate receptor antagonist,GPR35|GRIN1|GRIN2A|GRIN2B,,,114787|2904|2859|2903
3463,BRD-K01827100,L-152804,"CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|",969478.0,Preclinical,neuropeptide receptor antagonist,NPY5R,,,4889
3464,BRD-K39733634,L-161982,CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C,9961192.0,Preclinical,prostanoid receptor antagonist,PTGER4,,,5734
3465,BRD-K98372770,L-165041,CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O,6603901.0,Preclinical,PPAR receptor agonist,PPARD,,,5467
3466,BRD-K18036262,L-168049,CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1,5311276.0,Preclinical,glucagon receptor antagonist,GCGR,,,2642
3467,BRD-K34277641,L-365260,CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|,5311201.0,Phase 2,CCK receptor antagonist,CCKAR|CCKBR|KCNQ1,,,3784|886|887
3468,BRD-K00004282,L-368899,Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C,9872389.0,Phase 1,oxytocin receptor antagonist,AVPR1A|AVPR2|OXTR,,,552|554|5021
3469,BRD-K13474508,"L-655,708",CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21,5311203.0,Preclinical,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRG2,,,2566|2554|2555|2556|2558
3470,BRD-K89402695,L-655240,Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12,122070.0,Phase 1,thromboxane receptor antagonist,PTGES,,,9536
3472,BRD-K74284736,L-689560,OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1,6604749.0,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,114787|2903|2904|2905|2906
3473,BRD-K28470988,L-690330,CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O,132449.0,Preclinical,inositol monophosphatase inhibitor,IMPA1,,,3612
3474,BRD-K83322645,L-693403,C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1,4687238.0,Preclinical,sigma receptor agonist|sigma receptor antagonist,DRD2|SIGMAR1,,,10280|1813
3475,BRD-K18816859,L-694247,CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1,132059.0,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D,,,3352|3350|3351
3476,BRD-K10176267,L-701252,Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12,54687453.0,Preclinical,glutamate receptor antagonist,GRIN1,,,114787
3477,BRD-K08109516,L-701324,Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12,54682505.0,Preclinical,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,114787|2903|2904|2905|2906
3478,BRD-K37952347,"L-732,138",CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F,44396853.0,Preclinical,tachykinin antagonist,TACR1|TACR2,,,6865|6869
3479,BRD-K15791587,L-733060,FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F,132846.0,Preclinical,tachykinin antagonist,TACR1,,,6869
3480,BRD-K13211965,L-741742,Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1,133008.0,Preclinical,dopamine receptor antagonist,DRD3|DRD4|SCN1A|SCN3A,,,6328|6323|1814|1815
3481,BRD-K05528470,L-745870,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,5311200.0,Preclinical,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR6|HTR7,,,3362|3363|1815|1812|1813|3350|1814|3356
3482,BRD-K39359968,L-755507,CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1,9829836.0,Preclinical,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,,,153|154|155
3483,BRD-K30425481,L-760735,C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,9809077.0,Preclinical,tachykinin antagonist,TACR1,,,6869
3484,BRD-K10958118,L-778123,Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O,216454.0,Phase 1,farnesyltransferase inhibitor,FNTA|FNTB|PGGT1B,,,2339|100529261|5229
3485,BRD-K43905307,L-798106,COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1,15551229.0,Preclinical,prostanoid receptor antagonist,PTGER3,,,5733
3486,BRD-K46647427,L-838417,Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F,9908880.0,Preclinical,GABA receptor partial agonist,GABRA1|GABRA2|GABRA3|GABRA5,,,2554|2555|2556|2558
3487,BRD-K25125382,L-alanine,C[C@H](N)C(O)=O,7311724.0,Launched,,AARS|AARS2|ABAT|AGXT|AGXT2|GPRC6A|GPT|GPT2|KYNU|NFS1|PHYKPL|SLC1A4|SLC36A1|SLC7A8,,,57505|84706|23428|64902|1798|6509|8942|85007|16|222545|18|206358|189|9054
3488,BRD-K06033833,L-arginine,N[C@@H](CCCNC(N)=N)C(O)=O,6322.0,Launched,nitric oxide precursor,ARG2|ASL|ASS1|AZIN2|GPRC6A|NOS2|NOS3|SLC7A1|SLC7A3|SLC7A4,cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology,congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold,384|342977|113451|6541|222545|339345|6545|84889|445|158
3490,BRD-K06665116,L-asparagine,N[C@@H](CC(N)=O)C(O)=O,6992089.0,Phase 3,,ASNS|ASRGL1|NARS|NARS2|SLC1A5|SLC38A3,,,4677|6510|10991|79731|80150|440
3492,BRD-K97163964,L-aspartic-acid,N[C@@H](CC(O)=O)C(O)=O,5960.0,Launched,metallic radical formation stimulant,ACY1|ACY3|ADSS|ADSSL1|ASNS|ASPA|ASPH|ASRGL1|ASS1|CAD|DARS|DARS2|GOT1|GOT2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|LYZ|PAICS|RNASE1|SLC1A1|SLC25A12|SLC25A13,,,6035|80150|790|8604|159|10165|91703|440|443|444|445|1615|2903|2904|2905|2906|95|114787|4069|6505|10606|55157|2806|2805|122622
3493,BRD-A12237696,L-citrulline,"N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|",9750.0,Launched,nitric oxide stimulant,ASS1|DDAH1|DDAH2|GPRC6A|NOS1|NOS2|NOS3|OTC|PADI1|PADI2|PADI3|PADI4|PADI6,cardiology|urology,hypertension|erectile dysfunction,342977|11240|23564|340719|222545|339345|5009|23569|51702|29943|23576|353238|445
3494,BRD-K00795468,L-cysteine,N[C@@H](CS)C(O)=O,6419722.0,Launched,,CARS|CARS2|CBS|CDO-1|CDO1|CSAD|CTH|GCLC|GCLM|GOT1|GSS|MGMT|NFS1|SLC19A3,rheumatology,osteoarthritis|rheumatoid arthritis,23584|833|80704|79587|2729|2730|1036|102724560|51380|2805|5621|9054|4255
3495,BRD-A25800195,L-cysteinesulfinic-acid,"N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|",28167170.0,Preclinical,glutamate receptor agonist,GRM1|GRM5|GSR|HMGCS2|PAPOLA|PRDX2,,,10914|2915|3158|2936|7001|2911
3496,BRD-K99679910,L-cystine,N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O,6992103.0,Launched,,CTNS|SLC3A1|SLC7A11|SLC7A9,,,11136|1497|682|6519
3498,BRD-K62309135,L-glutamic-acid,N[C@@H](CCC(O)=O)C(O)=O,88747398.0,Launched,glutamate receptor agonist,AADAT|AASS|ABAT|ALDH18A1|ASNS|BCAT1|BCAT2|CCBL2|DNPEP|EARS2|ENPEP|EPRS|FOLH1|FPGS|FTCD|GAD1|GAD2|GATB|GCLC|GCLM|GGCX|GLS|GLS2|GLUD1|GLUD2|GLUL|GMPS|GOT1|GOT2|GPT|GPT2|GRIA1|GRIA2|GRIA3|GRIA4|GRID1|GRID2|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM1|GRM2|GRM3|GRM4|GRM6|GRM7|GRM8|LGSN|NADSYN1|NAGS|OPLAH|PFAS|PGCP|PSAT1|SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7|SLC25A18|SLC25A22|SLC7A11|TAT,,,8833|1798|79751|2058|2571|2572|29968|18|83733|55191|27165|10404|124454|2729|2346|2730|5198|10157|682|79969|2356|440|2746|2747|2752|5188|5832|586|587|56267|2890|2891|2892|2893|2894|2895|2897|2899|2901|2900|2903|2904|10841|2905|2906|116443|116444|51166|2911|2912|2913|84706|114787|2914|2916|2917|2918|51557|6505|6506|6507|2028|6511|6512|162417|2677|2805|2806|26873|23549
3499,BRD-K83896451,L-glutamine,N[C@@H](CCC(N)=O)C(O)=O,6992086.0,Launched,,CTPS1|GLUL|GPRC6A|PPAT,gastroenterology|dental|neurology/psychiatry|rheumatology,diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia,2752|222545|80347|1503
3502,BRD-K12853841,L-leucine,CC(C)C[C@H](N)C(O)=O,7045798.0,Phase 3,,BCAT1|BCAT2|LARS|LARS2|LCMT1|LCMT2,,,51520|23395|586|587|9836|51451
3503,BRD-K86016185,L-lysine,NCCCC[C@H](N)C(O)=O,71774817.0,Phase 2,serotonin receptor agonist,GPRC6A|KARS|SLC7A1|SLC7A2|SLC7A3|SLC7A4,,,6541|6542|222545|6545|3735|84889
3504,BRD-K06502269,L-methionine,CSCC[C@H](N)C(O)=O,6992087.0,Launched,voltage-gated calcium channel ligand,BHMT|BHMT2|METAP2|MTR|MTRR,pulmonary|allergy|neurology/psychiatry,asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia,4548|4552|10988|635|23743
3505,BRD-K00004529,L-mimosine,N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|,129010056.0,Preclinical,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,DBH|EIF5A,,,143244|1621
3506,BRD-K20946707,L-monomethylarginine,CN[C@@H](CCCNC(N)=N)C(O)=O,73046.0,Phase 3,nitric oxide synthase inhibitor,NOS1|NOS2,,,339345|340719
3507,BRD-K33141550,L-NAME,COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O,39836.0,Phase 2/Phase 3,nitric oxide synthase inhibitor,NOS3,,,342977
3508,BRD-K60036103,L-NIL,CC(=N)NCCCC[C@H](N)C(O)=O,2733506.0,Preclinical,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,,339345|342977|340719
3510,BRD-K01666412,L-proline,OC(=O)[C@@H]1CCCN1,6971047.0,Launched,glutamate receptor agonist,EPRS|L3HYPDH|P3H1|P3H2|P3H3|P4HA1|P4HA2|PARS2|PPIA|PPIB|PPIC|PPIF|PPIG|PPIH|PRODH|PROSC|PYCR1|PYCR2|PYCRL|SLC6A14|SLC6A7,,,6534|2058|8974|9360|10105|10536|5033|55214|64175|5831|11212|112849|29920|10465|5478|5479|5480|65263|25973|11254|5625
3511,BRD-K92404805,L-quisqualic-acid,N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O,6971145.0,Preclinical,glutamate receptor agonist,FOLH1|GRIA2|GRIK1|GRIK2|GRM1|GRM2|GRM3|GRM5|GRM7|GRM8,,,2912|2913|2915|2917|2918|2346|2891|2897|2901|2911
3513,BRD-K75508643,L-threonine,C[C@@H](O)[C@H](N)C(O)=O,6971019.0,Phase 2,,TARS|TARS2|THNSL1,,,79896|6897|80222
3515,BRD-K01825098,labetalol,"C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|",134043.0,Launched,adrenergic receptor antagonist,ADRA1D|ADRB1|ADRB2,cardiology,hypertension,153|146|154
3516,BRD-K43586850,lacidipine,"CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|",5311217.0,Launched,calcium channel blocker,CACNA1C,cardiology,hypertension,775
3519,BRD-K00003615,lafutidine,O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|,40490609.0,Launched,histamine receptor antagonist,HRH2,gastroenterology,duodenal ulcer disease|peptic ulcer disease (PUD),1665
3521,BRD-K93460210,lamotrigine,Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl,3878.0,Launched,serotonin receptor antagonist|sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|bipolar disorder,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335
3524,BRD-K86436199,landiolol,CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1,114905.0,Launched,adrenergic receptor antagonist,ADRB1,cardiology,cardiac arrythmia,153
3527,BRD-K00004280,lansoprazole,"Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14,r|",9578005.0,Launched,ATPase inhibitor,ATP4A|ATP4B,gastroenterology,heartburn,496|495
3528,BRD-K19687926,lapatinib,CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,208908.0,Launched,EGFR inhibitor,EGFR|ERBB2,oncology,breast cancer,2064|1956
3530,BRD-K60918217,laquinimod,CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,54677946.0,Phase 3,immunosuppressant,CXCL2,,,2920
3532,BRD-K48894757,laropiprant,CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12,9867642.0,Launched,prostanoid receptor antagonist,PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGFR|PTGIR|TBXA2R,cardiology,cholesterol,5729|5731|5732|5733|6915|5737|5739|11251
3533,BRD-K36574127,larotrectinib,O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F,46188928.0,Launched,tropomyosin receptor kinase inhibitor,NTRK1|NTRK2|NTRK3,,,4914|4915|4916
3536,BRD-M93148412,lasofoxifene,O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1,3081919.0,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer,2099|2100
3537,BRD-K10961822,latanoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,5311221.0,Launched,prostanoid receptor agonist,PTGFR,ophthalmology,ocular hypertension|glaucoma,5737
3538,BRD-K55703048,latrepirdine,CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1,197033.0,Phase 3,glutamate receptor antagonist,HRH1|HTR6,,,3362|3269
3539,BRD-K61292460,latrunculin-B,"C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|",6436219.0,Phase 1,actin polymerization inhibitor,ACTA1|MKL1|SPIRE2,,,58|84501|57591
3540,BRD-K67375056,lauric-acid,CCCCCCCCCCCC(O)=O,3893.0,Phase 3,bacterial permeability inducer,GPR84|HNF4A|LTF|LY96|PLA2G2A|TLR4,,,7099|53831|5320|6927|4057|23643
3543,BRD-K51486818,lazabemide,NCCNC(=O)c1ccc(Cl)cn1,71307.0,Phase 3,monoamine oxidase inhibitor,MAOB,,,4129
3547,BRD-K08248804,LCL-161,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,24737642.0,Phase 2,XIAP inhibitor,BIRC2|XIAP,,,329|331
3548,BRD-K20008181,LCQ908,OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|,,Phase 3,diacylglycerol O acyltransferase inhibitor,DGAT1,,,8694
3550,BRD-K44715996,LDC1267,CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C,56847486.0,Preclinical,protein tyrosine kinase inhibitor,AXL|MERTK|TYRO3,,,10461|558|7301
3551,BRD-K61795638,LDN-209929,COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1,46871867.0,Preclinical,haspin kinase inhibitor,GSG2,,,83903
3552,BRD-K59831625,LDN-212854,C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,60182388.0,Preclinical,bone morphogenic protein inhibitor,ABL1|ACVR1|RIPK2,,,25|90|8767
3553,BRD-K51485109,LDN-27219,NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1,1150683.0,Preclinical,tissue transglutaminase inhibitor,TGM2,,,7052
3555,BRD-K04853698,LDN193189,C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12,25195294.0,Preclinical,bone morphogenic protein inhibitor,ACVR1|BMPR1A,,,657|90
3556,BRD-K06593056,LE-135,CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|,10410894.0,Preclinical,retinoid receptor agonist,RARB,,,5915
3558,BRD-K78692225,leflunomide,Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F,3899.0,Launched,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,AHR|DHODH|PTK2B,rheumatology,rheumatoid arthritis,2185|1723|196
3559,BRD-K78666663,lemborexant,Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1,56944144.0,Launched,orexin receptor antagonist,HCRTR1|HCRTR2,,,131450|3061
3560,BRD-A17883755,lenalidomide,"Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|",12044976.0,Launched,anticancer agent,TNF,hematologic malignancy,multiple myeloma|mantle cell lymphoma (MCL)|myelodysplastic diseases (MDS),7124
3562,BRD-K39974922,lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,9823820.0,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT4|KDR,oncology,thyroid cancer,2324|3791
3565,BRD-A18992208,lercanidipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|",9809926.0,Launched,calcium channel blocker,CACNA2D1,cardiology,hypertension,781
3566,BRD-K62398570,lerisetron,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,65997.0,Phase 3,serotonin receptor antagonist,HTR3A,,,3359
3568,BRD-K75024268,lesinurad,OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,53465279.0,Launched,uric acid diuretic,SLC22A12,rheumatology,gout,116085
3569,BRD-A27376179,lestaurtinib,"C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|",9932888.0,Phase 3,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,FLT3|NTRK1,,,2322|4914
3574,BRD-K88789588,letrozole,N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1,3902.0,Launched,aromatase inhibitor,CYP19A1,oncology,breast cancer,1588
3575,BRD-K27460187,leucomethylene-blue,CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C,164695.0,Phase 3,nitric oxide production inhibitor|tau aggregation inhibitor,MAPT,,,4137
3578,BRD-K45300898,leuprolide,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,657181.0,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology,prostate cancer,2798
3579,BRD-K34469523,levalbuterol,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,123600.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm,154
3580,BRD-K30634073,levallorphan,Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1,5359371.0,Launched,opioid receptor antagonist,CHRNA2|OPRM1,pulmonary,respiratory depression,4988|1135
3581,BRD-K73107279,levamisole,C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|,26879.0,Withdrawn,acetylcholine receptor agonist,ALPL,,,249
3583,BRD-K24526313,levcromakalim,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N,93504.0,Phase 3,potassium channel activator,KCNJ5,,,3762
3584,BRD-K49404994,levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,5284583.0,Launched,calcium channel blocker,CACNA1B|SCN1A|SV2A,neurology/psychiatry,seizures,6323|9900|774
3585,BRD-A64698388,levo-phencynonate,"CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7,&2:3,&3:9,&4:13|",,Launched,acetylcholine receptor antagonist,CHRM1,,,1128
3586,BRD-K43883465,levobetaxolol,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,60657.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,intraocular pressure|glaucoma,153|154
3587,BRD-K31812033,levobunolol,CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12,39468.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,ophthalmology,glaucoma|ocular hypertension,153|154|155
3590,BRD-K33453211,levocabastine,C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1,,Launched,histamine receptor antagonist,HRH1|NTSR2,ophthalmology,conjunctivitis,23620|3269
3591,BRD-K59647213,levocarnitine,C[N+](C)(C)C[C@H](O)CC(O)=O,10918.0,Launched,,CRAT|CROT,endocrinology,carnitine deficiency,1384|54677
3592,BRD-K84366268,levocarnitine-propionate,CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C,157837.0,Launched,carnitine palmitoyltransferase inhibitor,CRAT,neurology/psychiatry|endocrinology,peripheral neuropathy|carnitine deficiency,1384
3593,BRD-K27184429,levocetirizine,OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,28145931.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269
3594,BRD-K34730807,levodopa,N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O,6971033.0,Launched,dopamine precursor,DRD1|DRD2|DRD3|DRD4|DRD5|GPR143,neurology/psychiatry,Parkinson's Disease,4935|1812|1813|1814|1815|1816
3596,BRD-K09471561,levofloxacin,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,6956357.0,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|otolaryngology|pulmonary|urology,pneumonia|sinusitis|bronchitis|skin infections|prostatitis|urinary tract infections|pyelonephritis|anthrax|plague,7153
3598,BRD-K50329370,levomenthol,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,16666.0,Launched,,OPRK1|TRPA1|TRPM8|TRPV3,neurology/psychiatry,pain relief,162514|4986|8989|79054
3599,BRD-K35559145,levomepromazine,COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1,72287.0,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR2A|HTR2C,neurology/psychiatry|gastroenterology,psychosis|schizophrenia|bipolar disorder|nausea|insomnia,3269|1128|1129|1131|1132|1133|1815|1816|146|147|1812|1813|150|151|152|1814|3356|3358
3600,BRD-A67616246,levomequitazine,"C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|",3246605.0,Phase 2,histamine receptor antagonist,HRH1,,,3269
3601,BRD-K02976377,levonordefrin,C[C@H](N)[C@H](O)c1ccc(O)c(O)c1,164739.0,Launched,vasodilator,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|SLC6A2,hematology,hemorrhage,6530|146|147|150|151|152
3602,BRD-K35189033,levonorgestrel,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|,13109.0,Launched,estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist,PGR,endocrinology,contraceptive,5241
3604,BRD-K03095347,levosimendan,C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|,3033825.0,Launched,calcium sensitizer,KCNJ11|KCNJ8|PDE3A|TNNC1,cardiology,congestive heart failure,7137|5139|3764|3767
3605,BRD-K51671335,levosulpiride,CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O,688272.0,Launched,dopamine receptor antagonist,CA1|CA12|CA7|DRD2|DRD3,neurology/psychiatry|gastroenterology|urology,schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE),771|1813|1814|759|766
3606,BRD-K30685142,levothyroxine,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O,5819.0,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,myxedema coma,7067|7068
3607,BRD-A30655177,LFM-A13,"CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|",,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,695
3609,BRD-K16810791,LGK-974,Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C,46926973.0,Phase 2,porcupine inhibitor,PORCN,,,64840
3610,BRD-K47409078,LH846,Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl,851474.0,Preclinical,casein kinase inhibitor,CSNK1D,,,1453
3611,BRD-K00004284,liarozole,"Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|",76956376.0,Phase 2/Phase 3,cytochrome P450 inhibitor,CYP19A1|CYP26A1,,,1592|1588
3612,BRD-A22642447,licarbazepine,"NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|",9816485.0,Phase 3,voltage-gated sodium channel blocker,SCN5A,,,6331
3613,BRD-K99667445,licochalcone-A,COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C,5318998.0,Phase 3,topoisomerase inhibitor,PTPN1,,,5770
3614,BRD-K08439945,licofelone,CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1,133021.0,Phase 3,cyclooxygenase inhibitor|lipoxygenase inhibitor,ALOX5|PLA2G2E|PTGS2,,,240|30814|5743
3618,BRD-K52662033,lidocaine,CCN(CC)CC(=O)Nc1c(C)cccc1C,3676.0,Launched,histamine receptor agonist,EGFR|SCN10A|SCN5A|SCN9A,neurology/psychiatry|dermatology|hematology,itching|eczema|hemorrhage,6336|6331|1956|6335
3619,BRD-K62996583,lidoflazine,Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,3926.0,Launched,calcium channel blocker,SCN1A|SCN3A|SLC29A1,cardiology,coronary artery disease (CAD),6328|6323|2030
3622,BRD-K48875051,ligustilide,"CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|",5319022.0,Preclinical,tumor necrosis factor production inhibitor,TNF,,,7124
3623,BRD-K25015158,limaprost-alfadex,CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O,6438378.0,Launched,prostanoid receptor agonist,PTGER1,cardiology,claudication,5731
3624,BRD-K75373031,LIMKi-3,CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F,56965901.0,Preclinical,LIM kinase inhibitor,LIMK1,,,3984
3626,BRD-K00003592,linaclotide,[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O,16158208.0,Launched,guanylate cyclase activator,GUCY2C,gastroenterology,irritable bowel syndrome|constipation,2984
3627,BRD-K96550715,linagliptin,CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1,10096344.0,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
3631,BRD-K93814253,lindane,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,,Launched,,GABRB1|GLRA1|GLRA2|GLRA3|GLRB,infectious disease,scabies,2560|8001|2741|2742|2743
3632,BRD-K66876909,linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1,441401.0,Launched,bacterial 50S ribosomal subunit inhibitor,MAOA|MAOB,infectious disease,pneumonia|skin infections,4128|4129
3633,BRD-K99749624,linifanib,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1,11485656.0,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1|CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RET|TEK,,,5979|7010|3815|5159|3791|2321|2322|2324|1435|1436
3634,BRD-K08973992,linoleic-acid,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O,5280450.0,Phase 3,oxidative stress inducer,FABP4|FFAR1|FFAR4|HNF4A|KCNB1|PPARG|TRPM8,,,3745|79054|6927|2864|2167|5468|338557
3635,BRD-K59332007,linopirdine,O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1,3932.0,Phase 3,potassium channel blocker,KCNQ2|KCNQ3|KCNQ4|KCNQ5,,,3785|3786|9132|56479
3637,BRD-K86118762,linsitinib,C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|,,Phase 3,IGF-1 inhibitor,IGF1R|INSR|INSRR,,,3480|3643|3645
3639,BRD-K89152108,liothyronine,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O,7048703.0,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,hypothyroidism|myxedema coma,7067|7068
3643,BRD-K00003717,liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,16153050.0,Launched,GLP receptor agonist,GLP1R,endocrinology,weight-loss aid|diabetes mellitus,2740
3647,BRD-K67966701,lisinopril,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,5362119.0,Launched,angiotensin converting enzyme inhibitor,ACE|ACE2,cardiology|endocrinology,hypertension|congestive heart failure|diabetes mellitus,59272|1636
3649,BRD-K67943528,lisuride,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|,28864.0,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6,neurology/psychiatry,Parkinson's Disease,3352|3362|1815|1816|146|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358
3650,BRD-K73234506,lithium-acetoacetate,CC(=O)CC(O)=O,96.0,Preclinical,,FAH,,,2175
3652,BRD-K20986251,lithocholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,9903.0,Preclinical,FXR antagonist|vitamin D receptor agonist,GPBAR1|NR1H4|NR1I2|VDR,,,8856|151306|9971|1594
3653,BRD-K83029223,litronesib,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|,25167017.0,Phase 2,kinesin-like spindle protein inhibitor,KIF11,,,3832
3654,BRD-K59391348,lixivaptan,Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1,172997.0,Phase 3,vasopressin receptor antagonist,AVPR2,,,554
3655,BRD-K70404782,LM-22A4,OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO,2054170.0,Preclinical,tropomyosin receptor kinase inhibitor,NTRK2,,,4915
3656,BRD-A04649065,LM11A-31,"CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|",28174760.0,Phase 1,neurotrophic agent,NGFR,,,4804
3657,BRD-K08532119,LMI070,CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1,135565042.0,Phase 1/Phase 2,survival motor neuron protein modulator,SMN1,,,6606
3658,BRD-K49921286,LMK-235,Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO,71520717.0,Preclinical,HDAC inhibitor,HDAC4|HDAC5,,,10014|9759
3659,BRD-K66206289,lobeline,CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1,101616.0,Launched,acetylcholine receptor antagonist,CHRNA10|CHRNA9|SLC18A2,neurology/psychiatry,smoking cessation,55584|6571|57053
3665,BRD-K82147103,lofepramine,CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1,3947.0,Launched,norepinephrine reuptake inhibitor|serotoninânorepinephrine reuptake inhibitor (SNRI),HTR1A|SLC6A2|SLC6A4,neurology/psychiatry,depression,6530|6532|3350
3668,BRD-K27955832,lomeguatrib,Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1,3025944.0,Phase 2,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,,4255
3669,BRD-K62858456,lomerizine,COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC,3949.0,Launched,calcium channel blocker,CACNA1B|SCN5A,neurology/psychiatry,migraine headache,6331|774
3670,BRD-K66036108,lometrexol,Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1,135413518.0,Phase 2,glycinamide ribonucleotide formyltransferase inhibitor,GART,,,2618
3671,BRD-K92213669,lomitapide,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,9853053.0,Launched,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,4571
3673,BRD-K41599323,lonafarnib,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,148195.0,Phase 3,farnesyltransferase inhibitor,FNTA|HRAS|KRAS|NRAS,,,3265|2339|4893
3674,BRD-K78513633,lonidamine,OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12,39562.0,Launched,glucokinase inhibitor,GCK,,,5871
3675,BRD-K61250553,loperamide,CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1,3955.0,Launched,opioid receptor agonist,CACNA1A|CALM1|OPRD1|OPRK1|OPRM1|POMC,gastroenterology,diarrhea,801|5443|773|4985|4986|4988
3678,BRD-K82795137,loratadine,CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12,3957.0,Launched,histamine receptor antagonist,HRH1,allergy|neurology/psychiatry,allergic rhinitis|itching,3269
3679,BRD-K09659835,loreclezole,Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl,3034012.0,Phase 2,benzodiazepine receptor agonist,GABRB2|GABRB3,,,2561|2562
3680,BRD-K42066335,lorediplon,CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1,12004146.0,Phase 2,GABA receptor modulator,GABRA1,,,2554
3681,BRD-K01825818,lorglumide,"CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|",13605417.0,Phase 1,CCK receptor antagonist,CCKAR|CCKBR,,,886|887
3682,BRD-K99879819,lorlatinib,C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N,78162481.0,Launched,ALK tyrosine kinase receptor inhibitor,ALK,oncology,non-small cell lung cancer (NSCLC),238
3683,BRD-A90551241,lornoxicam,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|,54690031.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|neurology/psychiatry,osteoarthritis|sciata,5742|5743
3684,BRD-K76205745,losartan,CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,3961.0,Launched,angiotensin receptor antagonist,AGTR1,cardiology|nephrology,hypertension|diabetic nephropathy|hypertension,185
3685,BRD-K56195681,losmapimod,Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1,11552706.0,Phase 3,p38 MAPK inhibitor,MAPK14,,,1432
3687,BRD-K39983086,loteprednol,"CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|",444025.0,Launched,glucocorticoid receptor agonist|phospholipase inhibitor,NR3C1,ophthalmology,conjunctivitis,2908
3688,BRD-K09416995,lovastatin,"CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|",53232.0,Launched,HMGCR inhibitor,HDAC2|HMGCR|ITGAL|NR1I2,cardiology|endocrinology,coronary heart disease|myocardial infarction|hypercholesterolemia,8856|3066|3683|3156
3689,BRD-K39915878,loxapine,CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|,3964.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,schizophrenia,1665|6530|6531|6532|146|147|1812|1813|150|1815|1816|151|152|153|1814|3350|3351|3352|3354|3356|3358|3359|3361|3362|3363|3269|59340|1128|1129|1131|1132|1133
3690,BRD-K21937671,loxistatin-acid,CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O,123664.0,Preclinical,cysteine peptidase inhibitor,CTSB,,,1508
3691,BRD-K01825691,loxoprofen,"C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|",13049027.0,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGS2,neurology/psychiatry,pain relief,5743
3693,BRD-K32322923,LPA2-antagonist-1,C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12,24882686.0,Preclinical,lysophosphatidic acid receptor antagonist,LPAR2,,,9170
3694,BRD-K01436366,LRRK2-IN-1,COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1,46843906.0,Preclinical,leucine rich repeat kinase inhibitor,LRRK2,,,120892
3695,BRD-K79337272,LSN-2463359,CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1,72551298.0,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,,2915
3698,BRD-K53124401,LTB4,CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O,5280492.0,Phase 2,leukocyte activator,LTB4R|LTB4R2,,,1241|56413
3700,BRD-K83970940,Lu-AA-47070,CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O,,Phase 2,adenosine receptor antagonist,ADORA2A,,,135
3701,BRD-K33814251,lubiprostone,CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,9800568.0,Launched,chloride channel activator,CLCN2,gastroenterology,constipation|irritable bowel syndrome,1181
3702,BRD-K00003521,lucanthone,CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12,10180.0,Phase 2,endonuclease inhibitor,APEX1|TOP1|TOP2A,,,328|7153|7150
3703,BRD-K31309378,lucitanib,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,25031915.0,Phase 2,FGFR inhibitor|VEGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,,,5156|3815|5159|3791|2321|2260|5979
3704,BRD-K67079690,LUF-5834,Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N,135543624.0,Preclinical,adenosine receptor agonist,ADORA2A|ADORA2B,,,136|135
3707,BRD-K69236721,lumacaftor,Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O,16678941.0,Launched,CFTR channel agonist,CFTR,pulmonary,cystic fibrosis,1080
3708,BRD-K10031916,lumateperone,CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23,21302490.0,Launched,dopamine receptor modulator|serotonin receptor antagonist,DRD2|HTR2A,,,3356|1813
3709,BRD-A05926236,lumefantrine,"CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|",73416445.0,Launched,antimalarial agent,ATP1A1,infectious disease,malaria,476
3710,BRD-K26901728,lumiracoxib,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1,151166.0,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,,,5742|5743
3711,BRD-K00004532,lupanine,[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H],91471.0,Phase 1,sodium channel blocker,INS,,,3630
3712,BRD-K51143828,lurasidone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,213046.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2A|ADRA2C|DRD2|HTR1A|HTR2A|HTR7,neurology/psychiatry,schizophrenia,3363|1813|150|3350|152|3356
3717,BRD-K05236810,luteolin,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1,5280445.0,Phase 2,glucosidase inhibitor,TOP1,,,7150
3718,BRD-K67013324,luzindole,CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,122162.0,Preclinical,melatonin receptor antagonist,MTNR1A|MTNR1B,,,4544|4543
3719,BRD-K32101625,LX1031,COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,23633604.0,Phase 2,tryptophan hydroxylase inhibitor,TPH1,,,7166
3720,BRD-K21038058,LX7101,CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1,56962369.0,Phase 1/Phase 2,LIM kinase inhibitor|rho associated kinase inhibitor,LIMK2|ROCK1|ROCK2,,,3985|9475|6093
3722,BRD-K54520417,LXR-623,Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F,16734800.0,Phase 1,LXR agonist,AR|NR1H2|NR1H3|NR1I2|NR3C1,,,10062|367|7376|8856|2908
3724,BRD-K78055238,LY2090314,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|,10029385.0,Phase 2,glycogen synthase kinase inhibitor,GSK3B,,,2932
3725,BRD-K47557313,LY2109761,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1,11655119.0,Preclinical,TGF beta receptor inhibitor,TGFBR1|TGFBR2,,,7048|7046
3726,BRD-K49519144,LY2140023,N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,9834591.0,Phase 3,glutamate receptor agonist,GRM3,,,2913
3727,BRD-K34313798,LY215490,OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,127894.0,Phase 1,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4|GRIK1,,,2890|2891|2892|2893|2897
3728,BRD-K78118466,LY2157299,Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O,10090485.0,Phase 2/Phase 3,TGF beta receptor inhibitor,TGFBR1,,,7046
3729,BRD-K37865504,LY2183240,CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1,11507802.0,Preclinical,FAAH inhibitor|FAAH reuptake inhibitor,FAAH,,,79152
3730,BRD-K59227464,LY2228820,CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C,11539025.0,Phase 2,p38 MAPK inhibitor,MAPK14,,,1432
3731,BRD-K35367061,LY223982,COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1,6444688.0,Phase 2,leukotriene receptor antagonist,LTB4R,,,1241
3732,BRD-K33864865,LY225910,CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O,4355450.0,Preclinical,CCK receptor antagonist,CCKBR,,,887
3735,BRD-K13888115,LY2365109,CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O,11552757.0,Preclinical,glycine transporter inhibitor,SLC6A9,,,6536
3736,BRD-K90171280,LY2452473,CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N,24963749.0,Phase 2,androgen receptor modulator,AR,,,367
3738,BRD-K92492521,LY255283,CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1,122023.0,Preclinical,leukotriene receptor antagonist,LTB4R|LTB4R2,,,1241|56413
3739,BRD-K21833260,LY2584702,Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F,25118925.0,Phase 1,ribosomal protein inhibitor,RPS6KB1,,,6198
3740,BRD-K14109347,LY2603618,Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,11955855.0,Phase 2,CHK inhibitor,CHEK1,,,1111
3741,BRD-K20463415,LY2606368,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1,46700756.0,Phase 2,CHK inhibitor,CHEK1,,,1111
3742,BRD-K12068470,LY2608204,O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1,46832368.0,Phase 2,glucokinase activator,GCK,,,5871
3743,BRD-A64004759,LY266097,COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|,92845961.0,Preclinical,serotonin receptor antagonist,HTR2B,,,106480180
3744,BRD-K25630527,LY2784544,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,46213929.0,Phase 2,JAK inhibitor,JAK2|JAK3,,,3717|3718
3746,BRD-K18961567,LY2801653,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,44603533.0,Phase 2,MET inhibitor,MET,,,8731
3747,BRD-K94534639,LY2811376,C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|,44251605.0,Phase 1,beta-secretase inhibitor,BACE1,,,23621
3749,BRD-K15382985,LY2857785,CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|,,Preclinical,CDK inhibitor,CDK9,,,1025
3750,BRD-K17203476,LY2874455,C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,46944259.0,Phase 1,FGFR antagonist,FGFR1|FGFR2|FGFR3|FGFR4|KDR,,,3791|2260|2261|2263|2264
3751,BRD-K24675965,LY288513,Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1,2802894.0,Preclinical,CCK receptor antagonist,CCKBR,,,887
3752,BRD-K51258098,LY2886721,NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|,49837968.0,Phase 1/Phase 2,beta-secretase inhibitor,BACE1,,,23621
3753,BRD-K27305650,LY294002,O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1,3973.0,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1,,,9361|1432|6300|5290|2475|5291|5294|6446|6198|5578|6093|207|5591|1111|5594|3932|5599|5600|22883|5347|2932
3754,BRD-K68220839,LY2979165,C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,53246986.0,Phase 1,glutamate receptor agonist,GRM2,,,2912
3755,BRD-K21070437,LY3000328,CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1,67475270.0,Phase 1,cathepsin inhibitor,CTSS,,,1520
3756,BRD-K38385169,LY3009120,CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C,71721540.0,Phase 1,RAF inhibitor,BRAF|RAF1,,,673|6037
3757,BRD-K82967180,LY3023414,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,57519748.0,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR,,,2475
3758,BRD-K22385716,LY303511,O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1,3971.0,Preclinical,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,BRD2|BRD3|BRD4,,,8019|23476|6046
3759,BRD-K41194171,LY310762,CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12,4282258.0,Preclinical,serotonin receptor antagonist,HTR1D,,,3352
3762,BRD-K78637815,LY320135,COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N,5311257.0,Preclinical,cannabinoid receptor antagonist,CNR1,,,1268
3766,BRD-K95899059,LY344864,CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1,5311097.0,Preclinical,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR7,,,3363|106480180|3350|3351|3352|3354|3355|3356|3358
3767,BRD-K06234293,LY364947,c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1,447966.0,Preclinical,p38 MAPK inhibitor|TGF beta receptor inhibitor,TGFBR1,,,7046
3768,BRD-K08534264,LY393558,CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|,10347428.0,Preclinical,serotonin receptor antagonist,HTR1B|HTR1D|HTR2A|HTR2B,,,3352|3356|106480180|3351
3769,BRD-A50062753,LY404187,"CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|",66857735.0,Preclinical,glutamate receptor positive allosteric modulator,GRIA1|GRIA2|GRIA3|GRIA4,,,2890|2891|2892|2893
3772,BRD-K87696786,LY456236,COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1,9926999.0,Preclinical,glutamate receptor antagonist,GRM1,,,2911
3774,BRD-K62289640,lylamine,CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1,62034.0,Preclinical,cannabinoid receptor agonist,CNR1,,,1268
3777,BRD-K93331255,lypressin,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,133588927.0,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2,endocrinology,central diabetes insipidus,552|553|554
3778,BRD-A96977263,M-14157,CCCCCC(O)CCCC(O)=O,1825.0,Phase 2,ATP-sensitive potassium channel antagonist,KCNQ1,,,3784
3779,BRD-K51265828,M-25,CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC,44250034.0,Preclinical,smoothened receptor antagonist,DHH|IHH|SMO,,,54498|3549|50846
3780,BRD-K45528773,M-344,CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO,3994.0,Preclinical,HDAC inhibitor,HDAC8,,,55869
3781,BRD-K09635314,m-3M3FBS,Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F,761523.0,Preclinical,phospholipase activator,PLCB2|PLCB3|PLCD1|PLCG1|PLCG2,,,5330|5331|5333|5335|5336
3782,BRD-K36965586,m-chlorophenylbiguanide,NC(N)=NC(=N)Nc1cccc(Cl)c1,1354.0,Preclinical,serotonin receptor agonist,HTR3A|HTR3B,,,9177|3359
3784,BRD-K90410034,M8-B,COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1,11675630.0,Preclinical,transient receptor potential channel antagonist,TRPM8,,,79054
3786,BRD-A13116749,mabuterol,CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|,11551355.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154
3788,BRD-K48812570,macitentan,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,16004692.0,Launched,endothelin receptor antagonist,EDNRA|EDNRB,endocrinology,contraceptive,1909|1910
3793,BRD-K30649484,mafenide,NCc1ccc(cc1)S(N)(=O)=O,3998.0,Launched,carbonic anhydrase inhibitor,CA12|CA14|CA2|CA4|CA6|CA9,infectious disease,first-aid antibiotic|skin infections,768|771|23632|760|762|765
3794,BRD-K26168087,magnolol,Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O,72300.0,Preclinical,PPAR receptor agonist,GABRA1|PPARG,,,2554|5468
3795,BRD-A01976766,malathion,"CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|",12358970.0,Launched,cholinesterase inhibitor,ACHE,infectious disease,lice,43
3796,BRD-A18396475,malic-acid,"O[C@@H](CC(O)=O)C(O)=O |&1:1,r|",222656.0,Launched,,PKD2L1,,,9033
3801,BRD-K01825587,manidipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|",13632719.0,Launched,calcium channel blocker,CACNA1C|CACNA1D,cardiology,hypertension,776|775
3804,BRD-K03319035,maprotiline,CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|,,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A2,neurology/psychiatry,depression|dysthymic disorder,6530
3805,BRD-K00004293,maraviroc,CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,,Launched,CC chemokine receptor antagonist,CCR5,infectious disease,human immunodeficiency virus (HIV-1),1234
3807,BRD-K59524082,maribavir,CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O,471161.0,Phase 3,cytomegalovirus inhibitor|protein kinase inhibitor,PYGM,,,5837
3808,BRD-K21396683,marimastat,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,119031.0,Phase 3,matrix metalloprotease inhibitor,MMP1|MMP10|MMP11|MMP12|MMP13|MMP14|MMP15|MMP16|MMP17|MMP19|MMP2|MMP20|MMP21|MMP23A|MMP24|MMP25|MMP26|MMP27|MMP28|MMP3|MMP7|MMP8|MMP9,,,64386|10893|79148|8510|8511|64066|4312|4313|4314|4316|4317|4318|4319|4320|4321|4322|4323|4324|4325|4326|4327|56547
3809,BRD-K76594255,maropitant,COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C,204108.0,Launched,neurokinin receptor antagonist,TACR1,gastroenterology,vomiting,6869
3810,BRD-K71035033,masitinib,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1,10074640.0,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,FGFR3|KIT|PDGFRA|PDGFRB,dermatology,mastocytoma,5159|5156|2261|3815
3811,BRD-A87130939,masoprocol,"C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|",688035.0,Launched,lipoxygenase inhibitor,ALOX5,dermatology,actinic keratosis (AK),240
3812,BRD-K08623988,matrine,O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34,91466.0,Phase 2,opioid receptor agonist,OPRK1,,,4986
3815,BRD-K07790550,mavoglurant,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1,9926832.0,Phase 2,glutamate receptor antagonist,GRM5,,,2915
3816,BRD-K47318833,maxacalcitol,C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,6398761.0,Launched,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,1594
3818,BRD-K32218650,MBX-2982,CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1,25025505.0,Phase 2,glucose dependent insulinotropic receptor agonist,GPR119,,,139760
3819,BRD-K50712474,MC-1,Cc1ncc(COP(O)(O)=O)c(C=O)c1O,1051.0,Phase 3,,AADAT|ABAT|AGXT|AGXT2|ALAS1|AZIN2|BCAT1|BCAT2|CBS|CCBL1|CCBL2|CSAD|CTH|DDC|FTCD|GAD1|GAD2|GADL1|GCAT|GLDC|GOT1|GOT2|GPT|GPT2|HDC|IGSF10|KYNU|MOCOS|NFS1|OAT|ODC1|PDXDC1|PDXP|PHYKPL|PNPO|PROSC|PSAT1|PYGB|PYGL|PYGM|SCLY|SDS|SDSL|SEPSECS|SGPL1|SHMT1|SHMT2|SPTLC1|SPTLC2|SPTLC3|SRR|TAT|THNSL1,,,285313|23042|64902|1798|55304|2571|2572|113675|85007|29968|18|89874|51091|79896|23584|23464|113451|2731|9517|51119|8879|51380|339896|189|10558|57026|6470|6472|586|587|56267|11212|4942|5834|102724560|5836|5837|211|51540|63826|10841|51166|9054|79969|84706|1644|8942|51696|883|2805|2806|55034|55163
3820,BRD-K24031866,MC1568,Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1,71311876.0,Preclinical,HDAC inhibitor,HDAC2,,,3066
3821,BRD-K55418700,MCC950,CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12,9910393.0,Preclinical,NOD like receptor inhibitor,NLRP3,,,114548
3823,BRD-K73276278,MCOPPB,CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1,24800108.0,Preclinical,nociceptin/orphanin FQ receptor agonist,OPRL1,,,4987
3824,BRD-K75844781,mCPP,Clc1cccc(c1)N1CCNCC1,1355.0,Phase 2,serotonin receptor agonist,HTR1A|HTR1D|HTR1E|HTR2A|HTR2B|HTR2C|HTR6,,,3362|106480180|3350|3352|3354|3356|3358
3825,BRD-K92758126,MD-920,C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|,6466.0,Phase 1,NFkB pathway inhibitor,AADACL2,,,344752
3826,BRD-K61128465,mdivi-1,COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O,3825829.0,Preclinical,dynamin inhibitor,DNM1,,,1759
3827,BRD-A62057054,MDL-11939,"O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|",76958673.0,Phase 2,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
3829,BRD-K59753853,MDL-29951,OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O,446916.0,Preclinical,glutamate receptor antagonist,FBP1,,,2203
3830,BRD-K01825683,MDL-72832,O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|,6604720.0,Preclinical,serotonin receptor agonist,HTR1A,,,3350
3831,BRD-K01826803,MDL-73005EF,O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|,6604719.0,Phase 1,serotonin receptor antagonist,HTR1A,,,3350
3833,BRD-K24283677,ME-0328,C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1,135566764.0,Preclinical,PPAR receptor antagonist,PARP3,,,10039
3834,BRD-A63444178,ME0328,"C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|",136229577.0,Preclinical,PARP inhibitor,PARP3,,,10039
3835,BRD-K77987382,mebendazole,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,4030.0,Launched,tubulin polymerization inhibitor,TUBA1A|TUBB|TUBB4B,infectious disease,pinworm|whipworm|hookworm|ascariasis,7280|7846|10383
3836,BRD-A09467419,mebeverine,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|,6604311.0,Launched,acetylcholine receptor antagonist,CHRM1,gastroenterology,irritable bowel syndrome,1128
3840,BRD-A20119038,mecamylamine,CNC1(C)C2CCC(C2)C1(C)C,46912050.0,Launched,acetylcholine receptor antagonist,CHRNA1|CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB4,cardiology,hypertension,89832|8973|1134|1135|1136|1137|1143
3842,BRD-K25075681,meclinertant,COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,119192.0,Phase 2/Phase 3,neurotensin receptor antagonist,NTSR1|NTSR2,,,4923|23620
3843,BRD-K01826560,meclizine,Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|,6604289.0,Launched,constitutive androstane receptor (CAR) agonist,NR1I3,gastroenterology|neurology/psychiatry,nausea|vomiting|motion sickness,9970
3845,BRD-K50398167,meclofenamic-acid,Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl,4037.0,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,ALOX5|CNR1|KCNQ2|KCNQ3|PTGS1|PTGS2,rheumatology|neurology/psychiatry|endocrinology,joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD),3785|3786|5742|5743|240|1268
3848,BRD-A66563878,medetomidine,C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|,60612.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,sedative,146|147|150|151|152
3849,BRD-K92908289,medica-16,CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O,121871.0,Phase 2,ATP citrase lyase inhibitor,FFAR1,,,2864
3852,BRD-K99615199,medroxyprogesterone,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|,10631.0,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive,5241
3853,BRD-K82216340,medroxyprogesterone-acetate,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|,6279.0,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive,5241|2099
3854,BRD-K56515112,medrysone,C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|,247839.0,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology,conjunctivitis|episcleritis,2908
3855,BRD-K92778217,mefenamic-acid,Cc1cccc(Nc2ccccc2C(O)=O)c1C,4044.0,Launched,cyclooxygenase inhibitor,KCNQ1|PTGS1|PTGS2|TRPM3,endocrinology,primary dysmenorrhea (PD),3784|80036|5742|5743
3859,BRD-K19507340,megestrol-acetate,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|",11683.0,Launched,progesterone receptor agonist,NR3C1|PGR,neurology/psychiatry|endocrinology,anorexia|cachexia,5241|2908
3860,BRD-K51324732,meglitinide,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,41214.0,Phase 2,potassium channel blocker,CCR2,,,729230
3862,BRD-K00495673,meglutol,CC(O)(CC(O)=O)CC(O)=O,1662.0,Launched,HMGCR inhibitor,HMGCR,,,3156
3863,BRD-K14529030,meisoindigo,CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12,,Phase 3,STAT inhibitor,STAT3,,,6774
3864,BRD-K12244279,MEK1-2-inhibitor,Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1,54483521.0,Preclinical,MEK inhibitor,MAP2K2,,,5605
3866,BRD-K97530723,melatonin,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,896.0,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB,neurology/psychiatry,sleep cycle support,8288|801|4353|4544|4835|811|6096|2099|106480180|438|4543
3867,BRD-K79392608,meldonium,C[N+](C)(C)NCCC(O)=O,123869.0,Launched,gamma butyrobetaine hydroxylase inhibitor,BBOX1,cardiology,coronary artery disease (CAD),8424
3869,BRD-K18749874,melevodopa,COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,23497.0,Launched,dopamine precursor|dopamine receptor agonist,DDC,neurology/psychiatry,Parkinson's Disease,1644
3870,BRD-K01826742,meloxicam,CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|,54677470.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5742|5743
3871,BRD-K92984783,melperone,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,15387.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,psychosis,3356|1813
3873,BRD-K36394566,melphalan-n-oxide,N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O,11234795.0,Phase 1,hypoxia inducible factor inhibitor,HIF1A,,,3091
3876,BRD-K78126613,menadione,CC1=CC(=O)c2ccccc2C1=O |t:1|,4055.0,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1,gastroenterology|neurology/psychiatry|dermatology|rheumatology,ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis,1728|2147|4835|5624|2155|2158|2159|2677|154807|632|79001|8858|5627|316
3877,BRD-K01826025,menadione-bisulfite,C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|,1711949.0,Phase 2,vitamin K,GGCX|VKORC1|VKORC1L1,,,79001|2677|154807
3880,BRD-A45889380,mepacrine,CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|,446536.0,Launched,cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator,PLA2G1B,infectious disease,giardiasis,5319
3882,BRD-K01825575,mepazine,"CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|",7047378.0,Phase 2,MALT1 inhibitor (JH),MALT1,,,10892
3885,BRD-K18194590,mephentermine,CNC(C)(C)Cc1ccccc1,3677.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3,cardiology,hypotension,146|147|150|151|152|153|154|155
3886,BRD-A83937277,mephenytoin,"CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|",107921.0,Launched,hydantoin antiepileptic,SCN5A,neurology/psychiatry,seizures,6331
3889,BRD-K18207669,meprednisone,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|",5284587.0,Launched,,NR3C1,,,2908
3891,BRD-A02710418,meptazinol,CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|,25271754.0,Launched,opioid receptor agonist,BCHE,neurology/psychiatry,pain relief,590
3892,BRD-K97564742,mepyramine,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,4992.0,Launched,histamine receptor antagonist,HRH1,otolaryngology|obstetrics/gynecology,common cold|menstrual pain,3269
3893,BRD-K45216060,mequinol,COc1ccc(O)cc1,9015.0,Launched,,TYR,dermatology,skin depigmentation,7299
3894,BRD-K45152786,merbarone,Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1,3000671.0,Phase 2,topoisomerase inhibitor,TOP2A,,,7153
3896,BRD-K91601245,mercaptopurine,S=c1nc[nH]c2nc[nH]c12,667490.0,Launched,immunosuppressant|protein synthesis inhibitor|purine antagonist,HPRT1|IMPDH1|IMPDH2|PPAT,hematologic malignancy,acute lymphoblastic leukemia (ALL),727833|3251|80347|3615
3898,BRD-K04466929,Merck60,CC(=O)Nc1ccc(cc1)C(=O)Nc1cc(ccc1N)-c1cccs1,6918878.0,Preclinical,HDAC inhibitor,HDAC1|HDAC2,,,3065|3066
3900,BRD-K09372874,merimepodib,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,153241.0,Phase 2,inosine monophosphate dehydrogenase inhibitor,IMPDH1,,,727833
3903,BRD-K28849549,mesalazine,Nc1ccc(O)c(c1)C(O)=O,4075.0,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2,gastroenterology,ulcerative colitis|inflammatory bowel disease,4353|5742|5743|240|1147|5468|3551
3905,BRD-K01827307,mesoridazine,"CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|",57146948.0,Launched,dopamine receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia,3356|1813
3906,BRD-K69688083,mestinon,CN(C)C(=O)Oc1ccc[n+](C)c1,4991.0,Launched,cholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,myasthenia gravis,43|590
3907,BRD-K31920458,mestranol,COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1,6291.0,Launched,estrogen receptor agonist,ESR1,endocrinology,contraceptive,2099
3908,BRD-K91336023,mesulergine,CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1,68848.0,Phase 2,dopamine receptor agonist,HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|HTR7,,,3362|3363|106480180|9177|3356|3358|3359
3911,BRD-K22518984,metacresol,Cc1cccc(O)c1,342.0,Launched,,INS,,,3630
3913,BRD-K76812510,metamizole,CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O,3111.0,Withdrawn,cyclooxygenase inhibitor|opioid receptor agonist,PTGS1,,,5742
3915,BRD-K01826731,metaproterenol,CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|,25271693.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm|asthma|bronchitis|emphysema,154
3916,BRD-K96253961,metaraminol,C[C@H](N)[C@H](O)c1cccc(O)c1,5906.0,Launched,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,146
3917,BRD-K27182532,metatinib,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,44155856.0,Phase 1,Bcr-Abl kinase inhibitor,ABL1|BCR,,,25|106480993
3919,BRD-A78277353,metazosin,"CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|",51057264.0,Phase 2,adrenergic receptor antagonist,ADRA1A,,,146
3920,BRD-A38218502,metenkephalin,"CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|",73265283.0,Phase 2,immunostimulant,OPRD1,,,4985
3921,BRD-K56699285,metergoline,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13,28693.0,Launched,dopamine receptor agonist|serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry|endocrinology,seasonal affective disorder|anxiety|hyperprolactinemia,3361|3362|3363|106480180|3350|3351|3352|3354|3355|3356|3358
3922,BRD-K79602928,metformin,CN(C)C(=N)N=C(N)N,4091.0,Launched,insulin sensitizer,ACACB|PRKAB1,endocrinology,diabetes mellitus,32|5564
3923,BRD-A18056626,methacholine,C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|,6603706.0,Launched,acetylcholine receptor agonist,CHRM2|CHRM4,pulmonary,bronchial hyperresponsiveness diagnostic,1129|1132
3925,BRD-K53896891,methanesulfonyl-fluoride,CS(F)(=O)=O,11207.0,Phase 2,acetylcholinesterase inhibitor,ACHE,,,43
3926,BRD-K09859624,methantheline,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12,4097.0,Launched,acetylcholine receptor antagonist,CHRM1|HRH2,gastroenterology|neurology/psychiatry|urology,peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder,1128|1665
3927,BRD-K47323024,methapyrilene,CN(C)CCN(Cc1cccs1)c1ccccn1,4098.0,Withdrawn,histamine receptor antagonist,HRH1,,,3269
3928,BRD-K88143662,metharbital,CCC1(CC)C(=O)NC(=O)N(C)C1=O,4099.0,Launched,GABA receptor modulator,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2,neurology/psychiatry,epilepsy,2560|2561|2562|2563|2564|2565|2566|2567|2568|55879|2891|2901|89832|1137|2554|2555|2556|2557|2558|2559
3929,BRD-K00002562,methazolamide,CC(=O)N=c1sc(nn1C)S(N)(=O)=O,4100.0,Launched,carbonic anhydrase inhibitor,CA1|CA12|CA14|CA2|CA4|CA7,ophthalmology,glaucoma|intraocular pressure,771|23632|759|760|762|766
3933,BRD-K54416256,methimazole,Cn1cc[nH]c1=S,1349907.0,Launched,antithyroid agent,TPO,endocrinology,hyperthyroidism,7066
3934,BRD-A39515206,methionine,"CSCC[C@@H](N)C(O)=O |&1:4,r|",84815.0,Launched,,METAP2,,,10988
3935,BRD-K00004541,methiopril,"C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|",667560.0,Phase 2,angiotensin converting enzyme inhibitor,ACE,,,1636
3936,BRD-A31521121,methocarbamol,"COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|",688484.0,Launched,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,759
3938,BRD-K59456551,methotrexate,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,126941.0,Launched,dihydrofolate reductase inhibitor,DHFR,oncology|hematologic malignancy|dermatology|rheumatology,gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis,1719
3939,BRD-A39189014,methoxamine,COc1ccc(OC)c(c1)C(O)C(C)N,657286.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,cardiology,hypotension,146|147
3940,BRD-K63430059,methoxsalen,COc1c2occc2cc2ccc(=O)oc12,4114.0,Launched,DNA synthesis inhibitor,CYP1A1|CYP1A2|CYP2A13|CYP2A6|CYP3A4,dermatology,psoriasis,1543|1544|1576|1548|1553
3941,BRD-K79277568,methoxyamine,CON,4113.0,Phase 2,DNA repair enzyme inhibitor,APEX1,,,328
3942,BRD-K06152156,methoxyflurane,COC(F)(F)C(Cl)Cl,4116.0,Launched,membrane permeability inhibitor,ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|MT-ND1,neurology/psychiatry,general anaesthetic,2560|513|2561|2562|2563|2564|2565|2566|2567|2568|27032|3736|2741|2743|55879|2890|2554|2555|2556|2557|2558|2559
3944,BRD-K48619321,methscopolamine,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,gastroenterology,peptic ulcer disease (PUD),1128|1129|1131
3945,BRD-A57592049,methsuximide,"CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|",25271978.0,Launched,T-type calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,seizures,8912|8913|150350
3946,BRD-A95340155,methyclothiazide,"CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|",12309469.0,Launched,chloride reabsorption inhibitor,SLC12A1|SLC12A3,cardiology,hypertension|edema,6557|6559
3948,BRD-K01292611,methyl-aminolevulinate,COC(=O)CCC(=O)CN,157922.0,Launched,oxidizing agent,FCGR1A|FECH,dermatology,actinic keratosis (AK),2210|2235
3951,BRD-K00004543,methylatropine-nitrate,"C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|",,Preclinical,acetylcholine receptor antagonist,CHRM1,,,1128
3955,BRD-K48578705,methyldopa,C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O,6919173.0,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C|DDC,cardiology,hypertension,152|1644|150|151
3957,BRD-K54770538,methylene-blue,CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C,4139.0,Launched,guanylyl cyclase inhibitor|nitric oxide production inhibitor,ACHE,hematology,methemoglobinemia,43
3958,BRD-K34685430,methylergometrine,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|,8226.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C,hematology|neurology/psychiatry,postpartum hemorrhage (PPH)|migraine headache,1812|106480180|3354|3355|3356|3358
3959,BRD-K43192255,methyllycaconitine,CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14,5288811.0,Preclinical,acetylcholine receptor antagonist,CHRNA7,,,89832
3960,BRD-K00003599,methylnaltrexone,[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O,16089915.0,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,gastroenterology,constipation,4985|4986|4988
3962,BRD-K35240538,methylprednisolone,"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|",6741.0,Launched,glucocorticoid receptor agonist,NR3C1,endocrinology|rheumatology|dermatology|infectious disease|allergy|hematology|neurology/psychiatry|gastroenterology,hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis,2908
3963,BRD-K24452555,methylprednisolone-aceponate,"CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|",63019.0,Launched,anti-inflammatory agent|glucocorticoid receptor agonist,NR3C1,endocrinology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|dermatology|neurology/psychiatry|hematology,congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia,2908
3966,BRD-K35941380,methysergide,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|,9681.0,Launched,serotonin receptor antagonist,HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,neurology/psychiatry,headache,3361|3362|3363|106480180|3351|3352|3354|3355|3356|3358
3969,BRD-K83766205,metirosine,C[C@](N)(Cc1ccc(O)cc1)C(O)=O,6918925.0,Launched,tyrosine hydroxylase inhibitor,TH,cardiology,hypertension,7054
3970,BRD-K01826545,metitepine,"CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|",969502.0,Preclinical,anti-HCVE2,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,,3361|3362|3363|106480180|3350|3351|3352|3354|3355|3356|3358
3971,BRD-K01826531,metixene,CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|,6604302.0,Launched,acetylcholine receptor antagonist,CHRM5,neurology/psychiatry,Parkinson's Disease,1133
3972,BRD-K75641298,metoclopramide,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,4168.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,CHRM1|DRD2|HTR3A|HTR3B|HTR4,gastroenterology,gastroparesis|nausea|vomiting,3360|1128|1813|9177|3359
3973,BRD-K16484091,metocurine,COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3,21233.0,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA2,neurology/psychiatry,muscle relaxant,1129|1135
3974,BRD-A61793559,metolazone,"C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|",28125490.0,Launched,carbonic anhydrase inhibitor,SLC12A3,cardiology,edema|hypertension,6559
3975,BRD-K01826568,metoprolol,COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|,157716.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology,hypertension|angina pectoris|myocardial infarction,153|154
3976,BRD-A71725768,metoxibutropate,"COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|",836891.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,,5742|5743
3977,BRD-A22101059,metrifonate,"COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|",6604183.0,Phase 3,acetylcholinesterase inhibitor,ACHE,,,43
3980,BRD-K52020312,metronidazole,Cc1ncc(n1CCO)[N+]([O-])=O,4173.0,Launched,DNA inhibitor,CYP2C9|CYP3A4,dermatology,rosacea,1576|1559
3981,BRD-K46862739,metyrapone,CC(C)(C(=O)c1cccnc1)c1cccnc1,4174.0,Launched,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,1584
3982,BRD-K94441233,mevastatin,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|",64715.0,Preclinical,HMGCR inhibitor,HMGCR,,,3156
3984,BRD-A64092382,mexiletine,C[C@@H](N)COc1c(C)cccc1C |&1:1|,180621.0,Launched,sodium channel blocker,PLAU|SCN4A|SCN5A,cardiology,ventricular arrhythmias|ventricular tachycardia (VT),5328|6329|6331
3986,BRD-K34328244,MF-101,Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1,114829.0,Phase 3,estrogen receptor agonist,CYP19A1|XDH,,,6652|1588
3987,BRD-K60230970,MG-132,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O,462382.0,Preclinical,proteasome inhibitor,PSMB1,,,5689
3988,BRD-K03128577,MG-624,CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1,5824382.0,Preclinical,acetylcholine receptor antagonist,CHRNA7,,,89832
3989,BRD-K56277358,MGCD-265,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,24901704.0,Preclinical,VEGFR inhibitor,AXL|MET,,,8731|558
3990,BRD-K26726854,MI-14,CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12,91758319.0,Preclinical,PI4K inhibitor,PI4KB,,,5298
3991,BRD-A19661776,mianserin,CN1CCN2C(C1)c1ccccc1Cc1ccccc21,68551.0,Launched,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7,neurology/psychiatry,depression,1665|3362|3363|3269|146|147|106480180|3356|3358
3992,BRD-K42981054,mibampator,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,9889366.0,Phase 2,glutamate receptor modulator,GRIA1,,,2890
3993,BRD-K09549677,mibefradil,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,60663.0,Withdrawn,T-type calcium channel blocker,ANO1|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CATSPER1|CATSPER2|CATSPER3|CATSPER4,,,55107|117155|775|776|778|779|150350|782|8912|8913|783|784|785|347732|378807|117144
3995,BRD-K01826511,miconazole,"Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|",1150344.0,Launched,bacterial cell wall synthesis inhibitor,TRPM2|TRPV5,infectious disease|neurology/psychiatry,yeast infection|itching,56302|1191
3997,BRD-K45163704,midafotel,OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1,6435801.0,Phase 3,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,2904|2905|2906|2903
4000,BRD-K13646352,midostaurin,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,9829523.0,Launched,FLT3 inhibitor|KIT inhibitor|PKC inhibitor,FLT3|PRKCG,hematologic malignancy,acute myeloid leukemia (AML),2322|5582
4001,BRD-K37270826,mifepristone,"CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|",55245.0,Launched,glucocorticoid receptor antagonist|progesterone receptor antagonist,AR|NR1I2|NR3C1|PGR,endocrinology,hyperglycemia|diabetes mellitus,8856|5241|2908|367
4002,BRD-K00004244,mifobate,"COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|",76958126.0,Phase 2,PPAR receptor antagonist,PPARG,,,5468
4003,BRD-K44779798,miglitol,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,441314.0,Launched,glucosidase inhibitor,GAA|GANAB|GANC|MGAM,endocrinology,diabetes mellitus,23193|2595|2548|8972
4004,BRD-K33251802,miglustat,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,51634.0,Launched,glycosyl transferase inhibitor,UGCG,hematology,Gaucher disease,7357
4005,BRD-K64338723,milacemide,CCCCCNCC(N)=O,53569.0,Phase 3,monoamine oxidase inhibitor,MAOB,,,4129
4007,BRD-K00004287,milnacipran,CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|,6917779.0,Launched,serotoninânorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A4,rheumatology,fibromyalgia,6530|6532
4008,BRD-K67080878,milrinone,Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N,4197.0,Launched,phosphodiesterase inhibitor,PDE2A|PDE3A|PDE3B|PDE5A,cardiology,congestive heart failure,5138|5139|5140|8654
4009,BRD-K01824991,miltefosine,CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|,3600.0,Launched,membrane integrity inhibitor,PLA2G1B,infectious disease,leishmaniasis,5319
4010,BRD-K67642028,mimosine,N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O,6971294.0,Preclinical,DNA replication inhibitor,CCL2|SHMT1|SHMT2|TYR,,,6472|6347|7299|6470
4011,BRD-K02867583,minaprine,Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1,4199.0,Withdrawn,serotonin reuptake inhibitor,ACHE|CHRM1|DRD1|DRD2|HTR2A|HTR2B|HTR2C|MAOA|SLC6A4,,,4128|6532|1128|43|1812|1813|106480180|3356|3358
4014,BRD-K89337853,minodronic-acid,OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O,130956.0,Launched,bone resorption inhibitor,FDPS|GGPS1,orthopedics,osteoporosis,2224|9453
4015,BRD-K06902185,minoxidil,Nc1cc(nc(N)[n+]1[O-])N1CCCCC1,,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1,endocrinology,androgenetic alopecia,10060|3758|5742|3764|3766|3767
4018,BRD-K47949423,mirabegron,Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,9865528.0,Launched,adrenergic receptor agonist,ADRB1|ADRB2|ADRB3,urology,urinary incontinence,153|154|155
4020,BRD-K55420858,mirin,NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|,137319711.0,Preclinical,MRE11A exonuclease inhibitor,MRE11A,,,4361
4022,BRD-K82967685,mirodenafil,CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1,135497803.0,Launched,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,8654
4024,BRD-A64977602,mirtazapine,"CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|",3085219.0,Launched,adrenergic receptor antagonist|serotonin receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C,neurology/psychiatry,depression,150|151|152|3356|3358
4026,BRD-A72351335,misoprostol,"CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10,11,16,&1:4|",5282381.0,Launched,prostanoid receptor agonist,PTGER2|PTGER3|PTGER4|PTGIR,gastroenterology,duodenal ulcer disease,5739|5732|5733|5734
4028,BRD-K52959329,mitiglinide,OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,121891.0,Launched,insulin secretagogue,ABCC8|KCNJ10|PPARG,endocrinology,diabetes mellitus,6833|5468|3766
4029,BRD-K35882976,mitoflaxone,OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1,55748.0,Phase 2,antitumor agent,VWF,,,7450
4032,BRD-A31204924,mitotane,"ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|",6603772.0,Launched,antineoplastic agent,CYP11A1|CYP11B1|ESR1,oncology,adrenal cortical carcinoma,1584|2099|1583
4033,BRD-K21680192,mitoxantrone,OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12,4212.0,Launched,topoisomerase inhibitor,TOP2A,neurology/psychiatry|oncology|hematologic malignancy,multiple sclerosis|prostate cancer|acute myeloid leukemia (AML),7153
4034,BRD-A48465967,mivacurium,"COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55,&1:7,&2:27|",22839211.0,Launched,acetylcholine receptor antagonist,CHRNA2,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant,1135
4038,BRD-K21884483,mizolastine,CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1,65906.0,Launched,histamine receptor antagonist,HRH1,allergy,urticaria|allergic rhinitis,3269
4039,BRD-K88061624,mizoribine,NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|,11949547.0,Launched,immunosuppressant|inosine monophosphate dehydrogenase inhibitor,IMPDH1,transplant|rheumatology,organ rejection|nephrotic syndrome,727833
4040,BRD-K71315565,MJ-15,Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1,59377482.0,Preclinical,cannabinoid receptor antagonist,CNR1,,,1268
4041,BRD-K91405252,MK-0354,C1Cc2[nH]nc(-c3nn[nH]n3)c2C1,11159621.0,Phase 2,niacin receptor agonist,HCAR2|HCAR3,,,338442|8843
4045,BRD-K38868394,MK-0773,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|,11950726.0,Phase 2,androgen receptor modulator,AR,,,367
4046,BRD-K14175878,MK-0812,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,11180808.0,Phase 2,CC chemokine receptor antagonist,CCR2,,,729230
4047,BRD-K16732600,MK-0893,COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1,11570626.0,Phase 2,glucagon receptor antagonist,GCGR,,,2642
4049,BRD-K54256913,MK-1775,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,24856436.0,Phase 2,WEE1 kinase inhibitor,WEE1,,,7465
4052,BRD-K68065987,MK-2206,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,24964624.0,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,,208|10000|207
4053,BRD-K43316319,MK-2295,FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1,11247522.0,Phase 2,TRPV antagonist,TRPV1,,,7442
4054,BRD-K56405753,MK-2461,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,44137946.0,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|KDR|MERTK|MET|MST1R|NTRK1|NTRK2|PDGFRB,,,4486|5159|3791|2321|2322|4914|2260|2261|2324|2263|4915|8731|10461
4055,BRD-K27983781,MK-2894,Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F,24952929.0,Preclinical,prostaglandin inhibitor,PTGER4,,,5734
4056,BRD-K66911501,MK-3207,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,25019940.0,Phase 2,calcitonin antagonist,CALCA,,,796
4057,BRD-K95828359,MK-3697,COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC,46190695.0,Phase 2,orexin receptor antagonist,HCRTR2,,,131450
4059,BRD-K03886848,MK-5046,O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F,49871766.0,Preclinical,bombesin receptor agonist,BRS3|GRPR|NMBR,,,680|4829|2925
4060,BRD-K53665955,MK-5108,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|,,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,,6795|9212|6790
4061,BRD-A73679382,MK-571,CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|,14325224.0,Phase 2,leukotriene receptor antagonist,ABCC2|CYSLTR1,,,10800|1244
4062,BRD-K03894385,MK-6096,C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1,25128145.0,Phase 2,orexin receptor antagonist,HCRTR1|HCRTR2,,,131450|3061
4065,BRD-K55512740,MK-8033,Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1,45142457.0,Phase 1,c-Met inhibitor,MET,,,8731
4066,BRD-K29656036,MK-8245,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,24988881.0,Phase 2,stearoyl-CoA desaturase inhibitor,SCD,,,6319
4068,BRD-K25279140,MK-8745,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,11676373.0,Preclinical,Aurora kinase inhibitor,AURKA,,,6790
4071,BRD-K90316462,MK2-IN-1,Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1,53475321.0,Preclinical,MAP kinase inhibitor,MAPKAPK2,,,9261
4073,BRD-K69343602,ML10302,COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1,5311299.0,Preclinical,serotonin receptor partial agonist,HTR3A|HTR3B|HTR4,,,3360|9177|3359
4076,BRD-A28422330,ML141,"COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|",7454812.0,Preclinical,GTPase inhibitor,CDC42,,,998
4078,BRD-K64835161,ML167,Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1,44968231.0,Preclinical,CLK inhibitor|DYRK inhibitor,CLK4|DYRK1B,,,57396|9149
4079,BRD-K77547509,ML179,FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1,45100448.0,Preclinical,liver receptor homolog inverse agonist,NR5A2,,,2494
4080,BRD-K27539181,ML193,Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C,1261822.0,Preclinical,G protein-coupled receptor antagonist,GPR55,,,9290
4081,BRD-K80021413,ML204,Cc1cc(nc2ccccc12)N1CCCCC1,230710.0,Preclinical,transient receptor potential channel antagonist,TRPC4|TRPC5,,,7224|7223
4082,BRD-K00004301,ML213,"Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|",1219187.0,Preclinical,potassium channel activator,KCNQ4,,,9132
4083,BRD-K92995792,ML218,CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1,,Preclinical,T-type calcium channel blocker,CACNA1G|CACNA1H|CACNA1I,,,8912|8913|150350
4084,BRD-K44432556,ML228,C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1,46742353.0,Preclinical,hypoxia inducible factor activator,HIF1A,,,3091
4085,BRD-K60020910,ML277,COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1,53347902.0,Preclinical,potassium channel activator,KCNQ1,,,3784
4086,BRD-K48188942,ML281,CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O,53377448.0,Preclinical,serine/threonine kinase inhibitor,STK33,,,65975
4087,BRD-K51137250,ML297,Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1,56642816.0,Preclinical,inward rectifier potassium channel activator,KCNJ3,,,3760
4088,BRD-K24600306,ML298,Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1,53393916.0,Preclinical,phospholipase inhibitor,PLD2,,,5338
4089,BRD-K92606079,ML314,COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1,53245590.0,Preclinical,neurotensin agonist,NTSR1,,,4923
4090,BRD-K93942811,ML323,CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1,60167849.0,Preclinical,ubiquitin specific protease inhibitor,USP1,,,7398
4091,BRD-K25611237,ML324,CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1,44143209.0,Preclinical,histone lysine demethylase inhibitor,KDM4A,,,9682
4092,BRD-A29014990,ML3403,"CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|",10938334.0,Preclinical,MAP kinase inhibitor,CYP3A4|MAPK11|MAPK12|MAPK14,,,1576|6300|1432|5600
4093,BRD-K33892651,ML347,COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,44577753.0,Preclinical,ALK tyrosine kinase receptor inhibitor,ACVR1|ACVRL1|BMPR1A,,,657|90|94
4094,BRD-K81044214,ML348,FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1,3238952.0,Preclinical,lysophospholipase inhibitor,LYPLA1,,,10434
4095,BRD-K02160913,ML365,COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1,46785920.0,Preclinical,potassium channel blocker,KCNK3|KCNK9,,,51305|3777
4096,BRD-K52644305,ML786,CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1,50992247.0,Preclinical,RAF inhibitor,BRAF|RAF1,,,673|6037
4097,BRD-K68402494,ML9,Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1,4217.0,Preclinical,myosin light chain kinase inhibitor,TRPC6,,,7225
4098,BRD-K59317601,MLN0128,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,45375953.0,Phase 2,mTOR inhibitor,MTOR|PIK3CA|PIK3CD|PIK3CG,,,5290|2475|5294|22883
4099,BRD-K73877023,MLN1117,Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1,70798655.0,Phase 2,PI3K inhibitor,PIK3CA,,,5290
4101,BRD-K83963101,MLN8054,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|,11712649.0,Phase 1,Aurora kinase inhibitor,AURKA,,,6790
4104,BRD-K98353094,MM-11253,CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O,10389639.0,Preclinical,retinoid receptor antagonist,RARG,,,5916
4106,BRD-K50293352,MM77,COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1,3994476.0,Preclinical,serotonin receptor antagonist,HTR1A,,,3350
4109,BRD-K16183658,MN-64,CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1,2802462.0,Preclinical,tankyrase inhibitor,TNKS,,,8658
4111,BRD-K16485616,mocetinostat,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1,9865515.0,Phase 2,HDAC inhibitor,HDAC1|HDAC11|HDAC2|HDAC3,,,3065|3066|8841|79885
4112,BRD-K07237224,moclobemide,Clc1ccc(cc1)C(=O)NCCN1CCOCC1,4235.0,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression|anxiety,4128|4129
4114,BRD-K34441861,moexipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O,91270.0,Launched,angiotensin converting enzyme inhibitor,ACE|ACE2,cardiology,hypertension,59272|1636
4115,BRD-K52598503,mofegiline,NC\C(CCc1ccc(F)cc1)=C\F,6437850.0,Phase 1,monoamine oxidase inhibitor,MAOA|MAOB,,,4128|4129
4116,BRD-K49372556,mofezolac,COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1,4237.0,Launched,cyclooxygenase inhibitor,PTGS1,rheumatology|orthopedics,rheumatoid arthritis|osteoporosis,5742
4118,BRD-K01291782,molidustat,O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1,59603622.0,Phase 3,hypoxia inducible factor inhibitor,EGLN2,,,100529264
4119,BRD-A65280694,molindone,CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|,6604347.0,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR2A,neurology/psychiatry,schizophrenia,3269|3356|1813
4120,BRD-K63861289,molsidomine,CCOC(=O)Nc1c[n+](no1)N1CCOCC1,4239.0,Launched,guanylate cyclase stimulant,GUCY1A3,cardiology,coronary artery disease (CAD),2982
4121,BRD-K50265942,mometasone,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11,t:7|",441335.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
4122,BRD-K60640630,mometasone-furoate,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|",441336.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
4123,BRD-A78377521,monastrol,"CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|",794325.0,Preclinical,kinesin inhibitor,KIF11,,,3832
4126,BRD-K54262262,monobenzone,Oc1ccc(OCc2ccccc2)cc1,7638.0,Launched,melanin inhibitor,TYR,dermatology,skin depigmentation,7299
4132,BRD-K69470111,montelukast,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1,5281040.0,Launched,leukotriene receptor antagonist,ALOX5|CYSLTR1,pulmonary|allergy,asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB),240|10800
4134,BRD-K21548250,moracizine,CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1,34633.0,Withdrawn,sodium channel blocker,SCN5A,cardiology,ventricular arrhythmias,6331
4136,BRD-K11590034,morin,Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O,5281670.0,Preclinical,cytochrome P450 inhibitor,ADORA2A|ESR2|FASN|MCL1|SLC22A12,,,135|4170|2194|2100|116085
4137,BRD-A40546373,morinidazole,"Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|",102486242.0,Launched,other antibiotic,CYP51A1,,,1595
4141,BRD-A39052811,mosapride,CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|,9979608.0,Launched,serotonin receptor agonist,HTR4,gastroenterology,hypertrophic gastritis (GHG)|gastroesophageal reflux disease (GERD)|dyspepsia|irritable bowel syndrome,3360
4143,BRD-K99616396,motesanib,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12,11667893.0,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FLT1|FLT4|KDR|KIT,,,2321|3815|2324|3791
4144,BRD-K11785681,motolimod,"CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|",16049404.0,Phase 2,toll-like receptor agonist,TLR8,,,51311
4148,BRD-K66615216,moxifloxacin,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1,40467042.0,Launched,bacterial DNA gyrase inhibitor,TOP2A,otolaryngology|pulmonary|infectious disease,sinusitis|bronchitis|pneumonia|skin infections|intra-abdominal infections,7153
4150,BRD-K77771411,moxonidine,COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|,4810.0,Launched,imidazoline receptor agonist,ADRA2A|ADRA2B|ADRA2C,cardiology,hypertension,152|150|151
4151,BRD-A31095847,mozavaptan,"CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|",11441742.0,Launched,vasopressin receptor antagonist,AVPR1A|AVPR1B|AVPR2,endocrinology,hyponatremia,552|553|554
4152,BRD-K60690191,MPEP,Cc1cccc(n1)C#Cc1ccccc1,3025961.0,Preclinical,glutamate receptor antagonist,GRM1|GRM4|GRM5,,,2914|2915|2911
4153,BRD-K45551181,MPI-0479605,Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1,46909588.0,Preclinical,mitotic kinase inhibitor,TTK,,,7272
4154,BRD-K18530250,Mps-BAY-2a,CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12,57381882.0,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,,7272
4155,BRD-K94853001,Mps1-IN-1,COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1,25195352.0,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,,7272
4158,BRD-K84883208,MR-948,OCCc1ccc(OCCn2ccnc2)cc1,10443938.0,Phase 1,thromboxane synthase inhibitor,TBXAS1,,,6916
4159,BRD-K44022883,MRK-016,Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C,6918583.0,Phase 1,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,,2554|2555|2556|2558
4161,BRD-K68795758,MRK-560,Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|,,Preclinical,gamma secretase inhibitor,APP,,,351
4162,BRD-K37618799,MRS-1220,Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1,393595.0,Preclinical,adenosine receptor antagonist,ADORA2B|ADORA3,,,136|140
4163,BRD-A06784547,MRS-1334,"CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|",6604859.0,Preclinical,adenosine receptor antagonist,ADORA3,,,140
4165,BRD-K91135178,MRS-2578,S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1,16078986.0,Preclinical,purinergic receptor antagonist,P2RY6,,,5031
4166,BRD-K10575656,MRS-3777,C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12,,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
4167,BRD-K10575656,MRS-3777,C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12,11771279.0,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
4172,BRD-K25143390,MSX-122,C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1,11687907.0,Phase 2,CC chemokine receptor antagonist,CXCR4,,,7852
4173,BRD-A28329383,MTPG,C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|,10752093.0,Preclinical,glutamate receptor antagonist,GRM2|GRM3,,,2912|2913
4174,BRD-K19061412,mubritinib,FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,6444692.0,Phase 1,protein tyrosine kinase inhibitor,EGFR|ERBB2,,,2064|1956
4176,BRD-K60441002,muscimol,NCc1cc(=O)[nH]o1,4266.0,Phase 1,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3,,,200959|2569|2570|2554|2555|2556|2557|2558|2559
4178,BRD-K90524085,MY-5445,Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1,1348.0,Preclinical,phosphodiesterase inhibitor|platelet aggregation inhibitor,PDE5A,,,8654
4179,BRD-K92428153,mycophenolate-mofetil,COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1,5281078.0,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection,727833|3615
4180,BRD-K63750851,mycophenolic-acid,COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O,446541.0,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,IMPDH1|IMPDH2,transplant,organ rejection,727833|3615
4181,BRD-K43149758,myricetin,Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O,5281672.0,Preclinical,androgen receptor agonist|cytochrome P450 inhibitor,PIK3CG,,,5294
4182,BRD-K48388905,myricitrin,C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O,5281673.0,Preclinical,PKC inhibitor,NOS1|PRKCA,,,5578|340719
4187,BRD-K80653534,N-acetyl-D-glucosamine,CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO,1738118.0,Phase 2/Phase 3,,B4GALT1|B4GALT2|B4GALT3|B4GALT4|NAGK|NAGLU|NAGPA|RENBP,,,8704|51172|5973|55577|2683|4669|8702|8703
4193,BRD-K75390981,N-alpha-methylhistamine-dihydrochloride,CNCCc1cnc[nH]1,912.0,Phase 3,histamine receptor agonist,HRH4,,,59340
4206,BRD-K60150510,N6-cyclopentyladenosine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12,657378.0,Preclinical,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3|SLC29A1,,,134|135|136|140|2030
4208,BRD-K82522873,N6022,Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O,44623946.0,Phase 1/Phase 2,alcohol dehydrogenase inhibitor,ADH5,,,128
4209,BRD-K36804890,NAB-2,Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl,82017756.0,Preclinical,ubiquitin ligase transport promoter,NEDD4,,,4734
4210,BRD-K65146499,nabumetone,COc1ccc2cc(CCC(C)=O)ccc2c1,4409.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743
4211,BRD-K01824972,nadide,"NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|",5893.0,Launched,free radical scavenger,AHCY|AKR1A1|ALDH2|BLVRA|DHPS|DLD|GALE|HMGCR|HSD17B1|HSD17B4|IMPDH2|MGAM|P2RY11|SORD|TRPM2,,,3295|644|1191|1738|3615|8972|6652|3156|2582|10327|692312|217|3292|1725|191
4213,BRD-A87606379,nadolol,"CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|",7048578.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,cardiology,angina pectoris|hypertension,153|154|155
4214,BRD-M06409173,NADPH,"NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:37,39,51,53,54,60,72,74,&1:42,&2:46,c:34,t:31|",71312102.0,Preclinical,,DRD2|DRD3|DRD4|GHSR|HTR2A|HTR2C,,,2693|1813|1814|1815|3356|3358
4215,BRD-A71262238,nafadotride,"CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|",6604854.0,Preclinical,dopamine receptor antagonist,DRD2|DRD3|HTR1A,,,1813|1814|3350
4216,BRD-K06674495,nafamostat,NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N,4413.0,Launched,serine protease inhibitor,ASIC1|ASIC2|ASIC3|C1R|PRSS1|TPSAB1|TRPM7,cardiology,anticoagulent,54822|40|41|7177|715|136541|9311
4217,BRD-K18574842,nafcillin,CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,8982.0,Launched,bacterial cell wall synthesis inhibitor,CYP1A2|CYP3A4|SLC22A6,infectious disease,gram-positive bacterial infections,1544|1576|9356
4220,BRD-K01826561,naftopidil,COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|,6603939.0,Launched,adrenergic receptor antagonist,ADRA1A,urology,benign prostatic hyperplasia (BPH),146
4221,BRD-K66404838,nalbuphine,O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45,5311304.0,Launched,opioid receptor agonist|opioid receptor antagonist,OPRD1|OPRK1|OPRM1,neurology/psychiatry,pain relief,4985|4986|4988
4222,BRD-K89272869,nalfurafine,CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1,6445230.0,Launched,opioid receptor agonist,OPRK1|OPRM1,nephrology,uremic pruritus,4986|4988
4224,BRD-K68407436,nalmefene,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O,5284594.0,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,pulmonary,respiratory depression,4985|4986|4988
4225,BRD-K41458421,naloxegol,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45,56959087.0,Launched,opioid receptor antagonist,OPRM1,gastroenterology,constipation,4988
4226,BRD-K67511046,naloxone,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,5284596.0,Launched,opioid receptor antagonist,CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4,pulmonary,respiratory depression,1385|2099|4985|4986|7099|4988
4227,BRD-K70898774,naloxone-benzoylhydrazone,Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1,9601084.0,Preclinical,opioid receptor antagonist,OPRK1|OPRM1,,,4986|4988
4228,BRD-K88172511,naltrexone,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,5360515.0,Launched,opioid receptor antagonist,OPRD1|OPRK1|OPRM1|SIGMAR1,neurology/psychiatry,abstinence from alcohol,10280|4985|4986|4988
4229,BRD-K81275354,naltriben,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O,5486827.0,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,,4985|4986|4988
4230,BRD-K34088084,naltrindole,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O,5497186.0,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,,4985|4986|4988
4232,BRD-K69195780,NAN-190,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,4431.0,Preclinical,serotonin receptor agonist,ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1F,,,3355|146|147|3350
4234,BRD-K22064724,napabucasin,CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,10331844.0,Phase 3,STAT inhibitor,STAT3,,,6774
4236,BRD-K77641333,naphazoline,C(C1=NCCN1)c1cccc2ccccc12 |t:1|,4436.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA2A,ophthalmology,eye irritation,146|150
4239,BRD-K59197931,naproxen,COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O,156391.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology,pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever,5742|5743
4242,BRD-K61337602,naratriptan,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,4440.0,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache,3350|3351|3352|3354|3355
4243,BRD-K08832567,naringenin,Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1,439246.0,Phase 1,aromatase inhibitor|TRPV antagonist,CYP19A1|CYP1B1|ESR2|GLO1|HSD17B1,,,1545|2739|1588|2100|3292
4244,BRD-K87122641,naringeninic-acid,OC(=O)\C=C\c1ccc(O)cc1,637542.0,Phase 1,,HCAR2|PTGR1,,,338442|22949
4245,BRD-K02953697,naringin,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O,442428.0,Preclinical,cytochrome P450 inhibitor,SLCO1A2,,,6579
4248,BRD-K00004235,NAS-181,C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|,9955015.0,Preclinical,serotonin receptor antagonist,HTR1B,,,3351
4249,BRD-K17295893,nastorazepide,CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1,9872609.0,Phase 2,CCK receptor antagonist,CCKBR,,,887
4251,BRD-K44353683,nateglinide,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O,,Launched,insulin secretagogue,ABCC8|KCNJ10|KCNJ11|PPARG,endocrinology,diabetes mellitus,6833|5468|3766|3767
4252,BRD-A84202322,NAV-26,"FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|",60201418.0,Preclinical,voltage-gated sodium channel blocker,SCN9A,,,6335
4253,BRD-K82850175,navarixin,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,9865554.0,Phase 2,CC chemokine receptor antagonist,CXCR1|CXCR2,,,3577|3579
4254,BRD-K82746043,navitoclax,CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|,24978538.0,Phase 2,BCL inhibitor,BCL2|BCL2L1|BCL2L2,,,596|598|599
4257,BRD-K61177364,NBI-27914,CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl,176157.0,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,,1394
4258,BRD-A86523169,NBI-74330-(+/-),"CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|",45784923.0,Preclinical,CC chemokine receptor antagonist,CXCR3,,,2833
4260,BRD-K11796549,NBQX,NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O,3272524.0,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B,,,114787|2890|2891|2892|2893|2897|2903|2904
4261,BRD-K01826782,NCS-382,O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|,6604757.0,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|SLC52A2,,,9568|10537|79581
4264,BRD-K17539220,NDT-9513727,CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1,10210160.0,Preclinical,complement antagonist,C5AR1,,,728
4265,BRD-K11443721,NE-100,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,9841596.0,Phase 2,sigma receptor antagonist,SIGMAR1,,,10280
4266,BRD-K00003617,nebivolol,"O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|",189562.0,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,153
4267,BRD-A51355958,nebracetam,NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|,25136943.0,Phase 3,acetylcholine receptor agonist,CHRM1,,,1128
4268,BRD-K14395568,NECA,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,448222.0,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
4269,BRD-K01825019,necrostatin-1,CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|,738301.0,Preclinical,RIPK inhibitor,RIPK1,,,8737
4270,BRD-K68851986,necrostatin-2,CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O,11288934.0,Preclinical,necroptosis inhibitor|RIPK inhibitor,RIPK2,,,8767
4272,BRD-K64716392,nedocromil,CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O,50294.0,Launched,histamine receptor antagonist,CYSLTR1|CYSLTR2|FPR1|HSP90AA1|PTGDR,neurology/psychiatry|ophthalmology,itching|conjunctivitis,5729|10800|57105|2357|3320
4273,BRD-K90789829,nefazodone,CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1,4449.0,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4,,,6530|6531|6532|1576|146|147|150|3350|3356|3358
4274,BRD-K65678996,nefiracetam,Cc1cccc(C)c1NC(=O)CN1CCCC1=O,71157.0,Phase 3,acetylcholine receptor agonist|benzodiazepine receptor agonist,CHRM1,,,1128
4276,BRD-K84466663,nelarabine,COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,3011155.0,Launched,DNA synthesis inhibitor|T cell inhibitor,POLA1,hematologic malignancy,acute lymphoblastic leukemia (ALL),5422
4277,BRD-K74117820,nelfinavir,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,64143.0,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1),100861540|1544|1576|1555|1557|1559|1565
4282,BRD-K47289124,nemonapride,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14,25|",156333.0,Launched,dopamine receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia,1813|1814|1815
4284,BRD-K51911221,nemorubicin,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,65907.0,Phase 2,topoisomerase inhibitor,TOP1|TOP2A,,,7153|7150
4288,BRD-K71013094,neomycin,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,8378.0,Launched,bacterial 30S ribosomal subunit inhibitor,CXCR4,infectious disease|gastroenterology,first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections,7852
4289,BRD-K18922609,neostigmine,CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C,4456.0,Launched,acetylcholinesterase inhibitor,ACHE,neurology/psychiatry,myasthenia gravis,43
4290,BRD-K04112579,nepafenac,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,151075.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,ophthalmology,eye inflammation,5742|5743
4291,BRD-K09126848,nepicastat,NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1,9796181.0,Phase 2,dopamine beta hydroxylase inhibitor,DBH,,,1621
4292,BRD-K85606544,neratinib,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,9915743.0,Launched,EGFR inhibitor,EGFR|ERBB2|KDR,oncology,breast cancer,2064|1956|3791
4294,BRD-K60212747,neridronic-acid,NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O,71237.0,Launched,bone resorption inhibitor,FDPS,endocrinology,brittle bone disease|Paget's disease,2224
4297,BRD-K97428065,netupitant,CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1,6451149.0,Launched,tachykinin antagonist,TACR1,gastroenterology,nausea|vomiting,6869
4300,BRD-K28567778,neuropathiazol,CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1,11667240.0,Preclinical,neural stem cell inducer,BMP2|LIF,,,3976|650
4301,BRD-K15502390,nevirapine,Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12,4463.0,Launched,non-nucleoside reverse transcriptase inhibitor,CYP1A2|CYP2A6|CYP2B6|CYP2C9|CYP2D6|CYP3A4|CYP3A5,infectious disease,human immunodeficiency virus (HIV-1),1544|1576|1577|1548|1555|1559|1565
4302,BRD-K70402238,nexturastat-A,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,71462653.0,Preclinical,HDAC inhibitor,HDAC1|HDAC6,,,3065|10013
4303,BRD-K83354763,NFKB-activation-inhibitor-II,Cc1ccc(NCCCc2ccccc2)c(N)c1,16760588.0,Preclinical,NFkB pathway inhibitor,RELA,,,5970
4304,BRD-K89223384,NG-nitro-arginine,N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O,440005.0,Phase 1,nitric oxide synthase inhibitor,NOS1|NOS2|NOS3,,,339345|342977|340719
4305,BRD-K05181084,NGB-2904,Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl,9891901.0,Preclinical,dopamine receptor antagonist,DRD3,,,1814
4306,BRD-K28639661,NGD-94-1,C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1,188942.0,Phase 1,dopamine receptor antagonist,DRD4,,,1815
4307,BRD-K81779590,NGD-98-2,CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC,9822241.0,Preclinical,corticotropin releasing factor receptor antagonist,CRHR1,,,1394
4310,BRD-K05653025,NHI-2,COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F,51355147.0,Preclinical,lactate dehydrogenase inhibitor,LDHA,,,3939
4311,BRD-K03042257,NI-57,COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N,91827373.0,Preclinical,bromodomain inhibitor,BRD1|BRPF1|BRPF3,,,27154|23774
4312,BRD-K60237333,niacin,OC(=O)c1cccnc1,938.0,Launched,NAD precursor|vitamin B,DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT,endocrinology,hypertriglyceridemia,4837|84649|338442|8843|23475|27198
4313,BRD-K12102668,nialamide,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,4472.0,Withdrawn,monoamine oxidase inhibitor,COMT|MAOA|MAOB,,,1312|4129|4128
4317,BRD-A26711594,nicardipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|",6603948.0,Launched,calcium channel blocker,ADORA3,cardiology,chronic stable angina|hypertension,140
4318,BRD-K76810206,nicergoline,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,34040.0,Launched,adrenergic receptor antagonist,ADRA1A,rheumatology|neurology/psychiatry|cardiology|hematology,Raynaud's disease|migraine headache|atherosclerosis|thrombosis,146
4320,BRD-K35960502,niclosamide,Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O,4477.0,Launched,DNA replication inhibitor|STAT inhibitor,STAT3,infectious disease,tapeworm,6774
4322,BRD-K97752965,nicorandil,[O-][N+](=O)OCCNC(=O)c1cccnc1,47528.0,Launched,nitric oxide donor|potassium channel activator,KCNJ11,cardiology,angina pectoris,3767
4323,BRD-K28912512,nicotinamide,NC(=O)c1cccnc1,936.0,Launched,protein synthesis stimulant,BST1|LDHA|PARP1|SIRT5,dermatology,acne vulgaris (AV),3939|683|23408|142
4324,BRD-K05395900,nicotine,CN1CCC[C@H]1c1cccnc1,89594.0,Launched,acetylcholine receptor agonist,CHAT|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB2|CHRNB3|CHRNB4|CYP19A1|TBXAS1|TRPA1,neurology/psychiatry,smoking cessation,55584|6916|89832|8989|8973|1135|1136|1137|1138|1588|1141|1142|1143|10044|57053
4326,BRD-K17617556,NIDA-41020,COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,11037861.0,Preclinical,cannabinoid receptor antagonist,CNR1,,,1268
4327,BRD-K96354014,nifedipine,"COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|",4485.0,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3,cardiology,vasospastic angina|chronic stable angina,801|8001|80036|775|776|778|779|781|8856|783|8912|2741|2743|3736|3741
4329,BRD-A21280314,nifenalol,"CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5,r|",202035.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,,,153|154
4331,BRD-K98763141,niflumic-acid,OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F,4488.0,Launched,cyclooxygenase inhibitor,ANO1|CLCN1|CLCNKA|CLCNKB|KCNQ1|PLA2G1B|PLA2G4A|PTGS1|PTGS2|UGT1A9,rheumatology|neurology/psychiatry,joint pain|muscle pain,55107|1188|1187|5319|3784|5321|54600|5742|5743|1180
4336,BRD-K59333713,niguldipine-(S)-(+),"COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|",60602.0,Preclinical,adrenergic receptor antagonist,ADRA1A,,,146
4338,BRD-K81528515,nilotinib,Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,644241.0,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor,ABL1|KIT,hematologic malignancy,chronic myeloid leukemia (CML),25|3815
4339,BRD-K23566484,nilutamide,CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,4493.0,Launched,androgen receptor antagonist,AR,oncology,prostate cancer,367
4340,BRD-A84687895,nilvadipine,"COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|",10340038.0,Launched,calcium channel blocker,CACNA1C|CACNA1D,cardiology,hypertension|cerebral artery occlusion,776|775
4342,BRD-K76775527,nimesulide,CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O,4495.0,Launched,cyclooxygenase inhibitor,LTF|PLA2G2E|PTGS1|PTGS2,rheumatology|obstetrics/gynecology,osteoarthritis|menstrual pain,4057|5742|30814|5743
4343,BRD-A58048407,nimodipine,"COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|",157132.0,Launched,calcium channel blocker,CFTR|NR3C2,hematology,hemorrhage,1080|4306
4347,BRD-K49075727,nintedanib,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1,,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,pulmonary,idiopathic pulmonary fibrosis (IPF),5156|5159|3791|2321|2260|2261|2324|2263|2264
4348,BRD-K54955827,niraparib,NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1,24958200.0,Launched,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),142
4351,BRD-A84465106,nisoldipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|",28248400.0,Launched,calcium channel blocker,CACNA1C|CACNA1D|CACNA1F|CACNA1S,cardiology,hypertension,776|778|779|775
4352,BRD-K01825513,nisoxetine,"CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|",10107248.0,Phase 1,norepinephrine reuptake inhibitor,SLC6A2|SLC6A3|SLC6A4,,,6530|6531|6532
4355,BRD-K75551531,nitecapone,CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O,5464105.0,Phase 2,catechol O methyltransferase inhibitor,COMT,,,1312
4359,BRD-A02006392,nitrendipine,"CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|",157702.0,Launched,calcium channel blocker,CACNA1D|CACNA2D1|KCNN4,cardiology,hypertension,776|781|3783
4360,BRD-K28453807,nitrocaramiphen,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,3941250.0,Preclinical,cholinergic receptor antagonist,CHRM1,,,1128
4366,BRD-K97534525,nitroxoline,Oc1ccc([N+]([O-])=O)c2cccnc12,19910.0,Launched,cathepsin inhibitor,METAP2,infectious disease,urinary tract infections,10988
4367,BRD-K73589491,nizatidine,CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O,3033637.0,Launched,histamine receptor antagonist,HRH2,gastroenterology,duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD),1665
4369,BRD-K47441935,NK-252,O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1,71618700.0,Preclinical,nuclear factor erythroid derived|like (NRF2) activator,NFE2L2,,,4780
4371,BRD-A75015151,NKY-80,"Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|",777417.0,Preclinical,adenylyl cyclase inhibitor,ADCY5,,,111
4372,BRD-A62133859,NLG919,"O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|",70874604.0,Phase 1,"indoleamine 2,3-dioxygenase inhibitor",IDO1,,,3620
4374,BRD-K62414032,NMDA,CN[C@H](CC(O)=O)C(O)=O,22880.0,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,114787|2903|2904|2905|2906
4375,BRD-K83699324,NMS-1286937,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,49792852.0,Phase 2,PLK inhibitor,FLT3|PLK1|PLK2|PLK3,,,10769|2322|5347|1263
4376,BRD-K26253904,NMS-873,Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O,71521142.0,Preclinical,ATPase inhibitor,VCP,,,7415
4379,BRD-K00004640,NN-DNJ,CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,501640.0,Preclinical,glucosidase inhibitor,GBA,,,2630
4380,BRD-K85015012,NNC-05-2090,COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1,9888030.0,Preclinical,GABA uptake inhibitor|GAT inhibitor,SLC6A12,,,6539
4381,BRD-K78122587,NNC-55-0396,CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1,9957280.0,Preclinical,T-type calcium channel blocker,CATSPER1|CATSPER2|CATSPER3|CATSPER4,,,117144|117155|347732|378807
4382,BRD-K72904818,NNC-63-0532,COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O,9803475.0,Preclinical,opioid receptor agonist,OPRL1,,,4987
4383,BRD-K42221274,NNC-711,OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|,4515.0,Preclinical,GABA uptake inhibitor,SIGMAR1|SLC6A1,,,10280|6529
4384,BRD-K08807999,NO-ASA,CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1,119032.0,Phase 2,cyclooxygenase inhibitor,PTGS2,,,5743
4385,BRD-K06753942,nobiletin,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,72344.0,Preclinical,MEK inhibitor,MAP2K1,,,5604
4386,BRD-K12539581,nocodazole,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1,4122.0,Preclinical,tubulin polymerization inhibitor,HPGDS,,,27306
4387,BRD-K36636143,nolatrexed,Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1,135400184.0,Phase 3,thymidylate synthase inhibitor,TYMS,,,7298
4388,BRD-K27351809,nomegestrol-acetate,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|",91668.0,Launched,progesterone receptor agonist,PGR,endocrinology,contraceptive,5241
4389,BRD-A29644307,nomifensine,CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|,55993.0,Withdrawn,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,DRD2|SLC6A2|SLC6A3,,,6530|6531|1813
4390,BRD-K05907307,nonivamide,CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,2998.0,Launched,TRPV agonist,TRPV1,rheumatology|neurology/psychiatry,rheumatoid arthritis|muscle pain,7442
4392,BRD-K36381762,nor-binaltorphimine,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O,5480230.0,Preclinical,opioid receptor antagonist,OPRD1|OPRK1|OPRM1,,,4985|4986|4988
4394,BRD-K42504537,norelgestromin,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C |t:9|,9568628.0,Launched,,PGR,endocrinology,contraceptive,5241
4395,BRD-K87349682,norepinephrine,NC[C@H](O)c1ccc(O)c(O)c1,439260.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2,cardiology|allergy|neurology/psychiatry,hypertension|urticaria|headache|seasonal affective disorder,6570|6571|146|147|150|151|152|153|154|155|5053
4396,BRD-K92073408,norethindrone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|,6230.0,Launched,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,5241
4397,BRD-K96037667,norethindrone-acetate,CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|,5832.0,Launched,progesterone receptor agonist,PGR,endocrinology|orthopedics|obstetrics/gynecology,menopause|osteoporosis|vaginal atrophy,5241
4399,BRD-A00758722,noretynodrel,"C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|",6231.0,Launched,progestogen hormone,PGR,endocrinology,contraceptive,5241
4400,BRD-K11196887,norfloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1,6919051.0,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|urology,urinary tract infections|gonorrhea|prostatitis,7153
4401,BRD-A79769222,norfluoxetine,"NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|",9797657.0,Phase 1,selective serotonin reuptake inhibitor (SSRI),HTR2B,,,106480180
4402,BRD-K38041788,norgestimate,CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|,6540478.0,Launched,progesterone receptor agonist,ESR1|PGR,endocrinology,contraceptive,5241|2099
4403,BRD-A14886633,norgestrel,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|",13109.0,Launched,progesterone receptor agonist,AR|ESR1|PGR|SRD5A1,endocrinology,contraceptive,5241|2099|6715|367
4405,BRD-K91263825,nortriptyline,CNCCC=C1c2ccccc2CCc2ccccc12,4543.0,Launched,tricyclic antidepressant,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|HTR6|KCNJ10|PGRMC1|SIGMAR1|SLC6A2|SLC6A4,neurology/psychiatry,depression,6530|6532|146|147|1813|150|151|152|153|154|155|3350|3356|3358|3362|10280|3766|3269|1128|1129|10857|1131|1132|1133
4407,BRD-K89237706,noscapine,COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12,275196.0,Launched,bradykinin receptor antagonist|tubulin polymerization inhibitor,SIGMAR1,pulmonary,cough suppressant,10280
4408,BRD-K11411329,NOV-002,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O,16401161.0,Phase 3,,GSR,,,2936
4411,BRD-K65275554,NPC-15199,CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O,1549477.0,Phase 2,ICAM1 antagonist,PPARG,,,5468
4412,BRD-K89272762,NPPB,OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O,4549.0,Preclinical,chloride channel blocker,ANO1|CLCN2|CLCN7|TRPA1,,,8989|1186|55107|1181
4413,BRD-K75506300,NPS-2143,CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,6918446.0,Preclinical,calcium receptor antagonist,CASR,,,846
4415,BRD-K95600043,NPY-5RA972,CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12,9884833.0,Preclinical,neuropeptide receptor antagonist,NPY5R,,,4889
4416,BRD-K61918008,NQDI-1,CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23,5522952.0,Preclinical,caspase inhibitor,CASP3,,,836
4417,BRD-K21865955,NS-018,C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1,46866319.0,Phase 1/Phase 2,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,,,7297|3716|3717|3718
4418,BRD-K94342292,NS-11021,FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F,24825677.0,Preclinical,calcium-activated potassium channel activator,KCNMA1,,,3778
4420,BRD-K73738482,NS-1643,Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F,10177784.0,Preclinical,voltage-gated potassium channel activator,KCNH2|KCNH6|KCNMA1,,,81033|3778|3757
4421,BRD-K03808106,NS-19504,Nc1ncc(Cc2ccc(Br)cc2)s1,727750.0,Preclinical,calcium-activated potassium channel activator,KCNMA1,,,3778
4422,BRD-K00004295,NS-309,O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl,,Preclinical,calcium-activated potassium channel activator,KCNN1|KCNN2|KCNN3|KCNN4,,,3780|3781|3782|3783
4423,BRD-K24434292,NS-3623,FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1,9954236.0,Preclinical,voltage-gated potassium channel activator,KCNH2,,,3757
4424,BRD-K00004309,NS-3861,"CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|",,Preclinical,acetylcholine receptor agonist,CHRNA3|CHRNB4,,,1136|1143
4425,BRD-K93314017,NS-5806,FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F,11642685.0,Preclinical,voltage-gated potassium channel activator,KCND3,,,3752
4426,BRD-K22667752,NS-8,Cc1c([nH]c(N)c1C#N)-c1ccccc1F,10176749.0,Phase 2,potassium channel agonist,KCNMA1,,,3778
4427,BRD-K34624869,NS-8593,C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1,11587013.0,Preclinical,calcium-activated potassium channel modulator,KCNN1|KCNN2|KCNN3,,,3780|3781|3782
4428,BRD-K40176866,NS-9283,N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1,11998180.0,Preclinical,acetylcholine receptor allosteric modulator,CHRNA4,,,1137
4431,BRD-K13169950,NSC-3852,Oc1ccc(N=O)c2cccnc12,19103.0,Preclinical,HDAC inhibitor,HDAC1,,,3065
4432,BRD-A67975844,NSC-405020,"CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|",879610.0,Preclinical,matrix metalloprotease inhibitor,MMP1,,,4312
4433,BRD-K64874225,NSC-4644,CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12,72326.0,Phase 2,ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor,PYGM,,,5837
4434,BRD-K73799155,NSC-5844,Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1,221354.0,Preclinical,CC chemokine receptor agonist,CCR1,,,1230
4435,BRD-K62949423,NSC-625987,COc1ccc(OC)c2c1[nH]c1ccccc1c2=S,3004085.0,Preclinical,CDK inhibitor,CDK2|CDK4,,,1017|1019
4436,BRD-K81197548,NSC-632839,Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1,5351363.0,Preclinical,ubiquitin specific protease inhibitor,SENP2|USP1|USP2|USP7,,,7874|9099|7341|7398
4437,BRD-K61120504,NSC-636819,[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O,6288112.0,Preclinical,histone demethylase inhibitor,KDM4A|KDM4B,,,9682|23030
4438,BRD-K03109492,NSC-663284,ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|,379077.0,Preclinical,CDC inhibitor,CDC25A|CDC25B|CDC25C,,,993|994|995
4439,BRD-K20605374,NSC-697923,Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O,394449.0,Preclinical,ubiquitin-conjugating enzyme inhibitor,UBE2N,,,7334
4440,BRD-K68143200,NSC-95397,OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|,262093.0,Preclinical,CDC inhibitor,CDC25A|CDC25B,,,993|994
4441,BRD-K49811169,NSC-9965,"CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|",31762.0,Preclinical,acetylcholine receptor antagonist,CHRNA4|CHRNB2,,,1137|1141
4444,BRD-K54098378,NT157,Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O,135398520.0,Preclinical,IGF-1 inhibitor,IGF1R,,,3480
4445,BRD-A40413915,NTNCB,"[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|",,Preclinical,neuropeptide receptor antagonist,NPY5R,,,4889
4446,BRD-K07788774,NTRC-824,CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O,101873359.0,Preclinical,neurotensin receptor antagonist,NTSR2,,,23620
4447,BRD-K54708045,nTZDpa,OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1,9954280.0,Preclinical,PPAR receptor agonist,PPARG,,,5468
4448,BRD-K48692744,NU-1025,Cc1nc(=O)c2cccc(O)c2[nH]1,135398517.0,Preclinical,PARP inhibitor,PARP1,,,142
4449,BRD-K20976221,NU-2058,Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1,4564.0,Preclinical,cyclin D inhibitor,CCNA2|CDK2,,,1017|890
4450,BRD-K03294269,NU-6027,Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1,398148.0,Preclinical,CDK inhibitor,CCNA2|CDK2,,,1017|890
4451,BRD-K09537769,NU-7026,O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1,9860529.0,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,PRKDC,,,5591
4452,BRD-K00337317,NU-7441,O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1,11327430.0,Preclinical,DNA dependent protein kinase inhibitor,PRKDC,,,5591
4454,BRD-K00002882,nutlin-3,"COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|",11433190.0,Preclinical,MDM inhibitor,MDM2|TP53,,,4193|7157
4456,BRD-K01573278,NVP-231,O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1,4096211.0,Preclinical,ceramidase inhibitor,CERK,,,64781
4457,BRD-K15179513,NVP-ADW742,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|,,Preclinical,insulin growth factor receptor inhibitor,IGF1R,,,3480
4458,BRD-K24696047,NVP-AEW541,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|,,Preclinical,IGF-1 inhibitor,IGF1R|INSR,,,3480|3643
4459,BRD-K41859756,NVP-AUY922,CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O,135539077.0,Phase 2,HSP inhibitor,HSP90AA1|HSP90AB1,,,3320|3326
4460,BRD-K12184916,NVP-BEZ235,Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1,11977753.0,Phase 3,mTOR inhibitor|PI3K inhibitor,ATR|MTOR|PIK3CA|PIK3CD|PIK3CG,,,545|22883|5290|2475|5294
4461,BRD-K42728290,NVP-BGJ398,CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1,53235510.0,Phase 3,FGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|KDR,,,3791|2260|2261|2263|2264
4462,BRD-K79259477,NVP-BHG712,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,16747388.0,Preclinical,ephrin inhibitor,EPHB4,,,2050
4463,BRD-K02017404,NVP-BSK805,Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1,46398810.0,Preclinical,JAK inhibitor,JAK2,,,3717
4464,BRD-K77943374,NVP-BVU972,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,44206063.0,Preclinical,MET inhibitor,MET,,,8731
4465,BRD-K77396579,NVP-DPP728,O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N,9796290.0,Phase 2,dipeptidyl peptidase inhibitor,DPP4,,,1803
4466,BRD-K67915505,NVP-HSP990,COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1,46216556.0,Phase 1,HSP inhibitor,HSP90AA1|HSP90AB1,,,3320|3326
4467,BRD-K21025364,NVP-TAE226,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl,9934347.0,Preclinical,protein tyrosine kinase inhibitor,PTK2,,,5747
4468,BRD-K50140147,NVP-TAE684,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,16038120.0,Preclinical,ALK tyrosine kinase receptor inhibitor,ALK|INSR,,,3643|238
4469,BRD-K87454346,NVP-TNKS656,COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1,136237316.0,Preclinical,tankyrase inhibitor,TNKS2,,,80351
4470,BRD-K28132190,NVS-PAK1-1,CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|,137125241.0,Preclinical,p21 activated kinase inhibitor,PAK1,,,5585
4476,BRD-K63247785,O-acetyl-L-serine,CC(=O)OC[C@H](N)C(O)=O,99478.0,Preclinical,,PTGS1,,,5742
4478,BRD-K53849769,O4I1,COc1ccc(COc2ccc(CC#N)cc2)cc1,2774690.0,Preclinical,Oct inducer,POU5F1,,,5460
4479,BRD-K92041145,O6-benzylguanine,Nc1nc(OCc2ccccc2)c2[nH]cnc2n1,4578.0,Phase 3,O6-alkylguanine-DNA alkyltransferase inhibitor,MGMT,,,4255
4481,BRD-K18305454,OAC2,O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1,2814138.0,Preclinical,Oct activator,POU5F1,,,5460
4482,BRD-K15600710,obatoclax,"COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|",,Phase 3,BCL inhibitor,BCL2,,,596
4483,BRD-A75838038,obeticholic-acid,"CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2,&2:3,&3:5,&4:6,&5:9,&6:10,&7:17,&8:21,&9:22,&10:26,&11:29,r|",,Launched,FXR agonist,NR1H4,gastroenterology,primary biliary cholangitis,9971
4484,BRD-K33588785,obidoxime,O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1,8251.0,Launched,cholinesterase reactivator,ACHE,critical care|neurology/psychiatry,poison antidote|nerve gas poisoning,43
4485,BRD-K36463073,OC000459,Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O,11462174.0,Phase 2,CRTH receptor antagonist,PTGDR2,,,11251
4487,BRD-K92524032,ochromycinone,C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21,11808929.0,Phase 1,STAT inhibitor,STAT3,,,6774
4488,BRD-K92581468,ocinaplon,O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1,216456.0,Phase 3,GABA receptor modulator,GABRA1|GABRA2|GABRA3|GABRA5,,,2554|2555|2556|2558
4497,BRD-A14240607,octopamine,NCC(O)c1ccc(O)cc1,657354.0,Preclinical,trace amine associated receptor agonist,F10|TAAR1,,,134864|2159
4498,BRD-A64173453,octreotide,"C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|",,Launched,somatostatin receptor agonist,SSTR2|SSTR3|SSTR5,gastroenterology|endocrinology|oncology,diarrhea|acromegaly|carcinoid tumors,6752|6753|6755
4499,BRD-K22822991,odanacatib,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,10152654.0,Phase 3,cathepsin inhibitor,CTSK,,,1513
4500,BRD-K26015241,ODQ,O=c1onc2cnc3ccccc3n12,1456.0,Preclinical,guanylyl cyclase inhibitor,GUCY1A2|GUCY1A3|GUCY1B3,,,2977|2982|2983
4501,BRD-K92658264,OF-1,COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C,35397514.0,Preclinical,bromodomain inhibitor,BRD1,,,23774
4503,BRD-K26349472,OG-L002,N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1,56639570.0,Preclinical,histone lysine demethylase inhibitor,KDM1A,,,23028
4507,BRD-K94083718,OICR-9429,CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1,91623360.0,Preclinical,WDR5/MLL interaction inhibitor,WDR5,,,11091
4508,BRD-K18895904,olanzapine,CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|,135398745.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder,2560|2561|2562|2563|2564|2565|2566|2567|2568|1665|146|147|1812|1813|150|1815|1816|151|152|153|154|155|1814|3350|3351|3352|3354|3355|3356|3358|3359|3361|3362|3363|106480180|3269|55879|59340|1128|1129|1131|1132|1133|2554|2555|2556|2557|2558|2559
4509,BRD-K02113016,olaparib,Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1,23725625.0,Launched,PARP inhibitor,PARP1|PARP2,oncology,ovarian cancer,10038|142
4510,BRD-K95523387,OLDA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,5282106.0,Preclinical,TRPV agonist,GPR119,,,139760
4511,BRD-K06644925,oleamide,CCCCCCCC\C=C/CCCCCCCC(N)=O,5283387.0,Preclinical,cannabinoid receptor agonist,HTR7|PLA2G2A,,,5320|3363
4513,BRD-K90647725,oleanolic-acid,CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|,10494.0,Preclinical,G protein-coupled receptor agonist,GPBAR1,,,151306
4514,BRD-K66956375,oleoylethanolamide,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,5283454.0,Preclinical,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,CNR1|GPR119|GPR55|PPARA,,,139760|5465|9290|1268
4516,BRD-A00842753,oleuropein,"COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|",,Phase 2,estrogen receptor agonist,GPER1,,,2852
4517,BRD-K00003580,oligomycin-A,"[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|",133268482.0,Preclinical,ATP synthase inhibitor|ATPase inhibitor,ATP5A1,,,498
4518,BRD-K83144676,olmesartan,CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O,158781.0,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,185
4519,BRD-K78485176,olmesartan-medoxomil,CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O,130881.0,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,185
4520,BRD-K60421517,olmutinib,CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1,54758501.0,Launched,Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor,BTK|EGFR,oncology,non-small cell lung cancer (NSCLC),1956|695
4522,BRD-K82731415,olomoucine,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12,4592.0,Preclinical,CDK inhibitor,CDK1|CDK2|CDK5|MAPK1,,,1017|5594|1020|983
4523,BRD-K67637637,olopatadine,CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12,5281071.0,Launched,histamine receptor antagonist,HRH1|S100A1|S100A12|S100A13|S100A2|S100B,ophthalmology,conjunctivitis,6273|3269|6283|6284|6285|6271
4524,BRD-K20745393,olprinone,Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N,4593.0,Launched,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,5139
4525,BRD-K57853941,olsalazine,OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O,,Launched,cyclooxygenase inhibitor,IFNG|TPMT,gastroenterology,ulcerative colitis,3458|7172
4526,BRD-K86972824,oltipraz,Cc1c(ssc1=S)-c1cnccn1,47318.0,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,ANG,,,283
4528,BRD-K31560319,olvanil,CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1,5311093.0,Preclinical,TRPV agonist,CNR1|GPR119|TRPV1,,,139760|7442|1268
4530,BRD-K00003265,omapatrilat,[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O,656629.0,Preclinical,metalloproteinase inhibitor,ACE|MME,,,4321|1636
4531,BRD-K14171291,omarigliptin,CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F,46209133.0,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
4534,BRD-K48830578,OMDM-2,CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1,6604915.0,Preclinical,FAAH inhibitor,GPR119,,,139760
4535,BRD-K36680103,omecamtiv-mecarbil,COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,11689883.0,Phase 3,cardiac myosin activator,MYBPC3,,,4607
4538,BRD-A55962179,omeprazole,COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|,9568614.0,Launched,ATPase inhibitor,ATP4A|CLCN2,gastroenterology,heartburn,1181|495
4539,BRD-A56892734,omeprazole-magnesium,COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|,9601083.0,Launched,proton pump inhibitor,ATP4A|ATP4B,gastroenterology,gastroesophageal reflux disease (GERD)|heartburn,496|495
4543,BRD-K88554883,ON123300,CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1,56649281.0,Preclinical,CDK inhibitor,CDK4|NUAK1|PDGFRB,,,1019|9891|5159
4544,BRD-K58529924,ONC201,"Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|",73777259.0,Phase 2,AKT inhibitor|MAP kinase inhibitor,TNFSF10,,,8743
4546,BRD-K01826546,ondansetron,Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|,667538.0,Launched,serotonin receptor antagonist,HTR3A|HTR3B,gastroenterology,nausea|vomiting,9177|3359
4547,BRD-K00003197,ONO-4059,CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O,54755438.0,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,695
4548,BRD-K58894520,ONO-4817,CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1,9888141.0,Phase 1,matrix metalloprotease inhibitor,MMP8,,,4317
4549,BRD-K76725781,ONO-8130,CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1,9827317.0,Preclinical,prostanoid receptor antagonist,PTGER1,,,5731
4550,BRD-A80567330,ONO-AE3-208,"C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|",92978378.0,Preclinical,prostanoid receptor antagonist,PTGER4,,,5734
4553,BRD-K19426040,OPC-21268,CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12,114904.0,Phase 1,vasopressin receptor antagonist,AVPR1A|AVPR2|OXTR,,,552|554|5021
4554,BRD-K66192203,opicapone,Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O,135565903.0,Phase 3,catechol O methyltransferase inhibitor,COMT,,,1312
4557,BRD-K18602506,OR-486,Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O,3870203.0,Preclinical,catechol O methyltransferase inhibitor,COMT,,,1312
4558,BRD-K55966568,orantinib,Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O,5329099.0,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB,,,1956|5156|6790|5159|3791|2260|2263|9212
4560,BRD-K67068943,ORE1001,CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O,448281.0,Phase 1/Phase 2,angiotensin converting enzyme inhibitor,ACE2,,,59272
4561,BRD-K07409305,ORG-12962,FC(F)(F)c1ccc(nc1Cl)N1CCNCC1,9796408.0,Phase 2,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
4562,BRD-K32853922,ORG-25543,COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C,5311287.0,Preclinical,glycine transporter inhibitor,GLRB|SLC6A5,,,6530|2743
4564,BRD-K57597776,ORG-27569,CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1,44828492.0,Preclinical,cannabinoid receptor modulator,CNR1,,,1268
4565,BRD-K41434598,ORG-9768,CC1(CN)Cc2ccccc2C1,22152353.0,Phase 1,adrenergic receptor antagonist,ADRA2A,,,150
4566,BRD-K00003710,oridonin,[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O,5321010.0,Preclinical,BCL inhibitor,BCL2,,,596
4568,BRD-K63343048,orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,3034010.0,Launched,lipase inhibitor,CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP,endocrinology,weight-loss aid,8513|221955|747|2194|1268|5406
4572,BRD-K01825132,ornithine,"Cl.NCCC[C@@H](N)C(O)=O |&1:5,r|",74765349.0,Launched,NFkB pathway modulator,GPRC6A,,,222545
4573,BRD-K32572029,orotic-acid,OC(=O)c1cc(=O)[nH]c(=O)[nH]1,967.0,Phase 2,,DHODH,,,1723
4574,BRD-K05717154,orphanin-fq,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O,56947112.0,Phase 1,opioid receptor agonist,OPRL1|OPRM1,,,4987|4988
4576,BRD-K00674894,orteronel,CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12,10335364.0,Phase 3,androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor,CYP17A1,,,1586
4577,BRD-K59711701,ORY-1001,NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1,71543365.0,Phase 1/Phase 2,histone lysine demethylase inhibitor,KDM1A,,,23028
4579,BRD-K76011241,oseltamivir-phosphate,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|,65028.0,Launched,neuraminidase inhibitor,CES1|NEU1|NEU2,infectious disease,influenza A virus infection,51162|1066|4759
4580,BRD-K60371362,osemozotan,C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1,198747.0,Phase 2/Phase 3,serotonin receptor agonist,HTR1A,,,3350
4581,BRD-K87124298,OSI-027,COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|,,Phase 1,mTOR inhibitor,MTOR,,,2475
4582,BRD-K73309154,OSI-420,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,10317566.0,Preclinical,EGFR inhibitor,EGFR,,,1956
4583,BRD-K25340465,OSI-930,FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1,9868037.0,Phase 1,KIT inhibitor|VEGFR inhibitor,FLT1|KDR|KIT,,,2321|3815|3791
4585,BRD-K42805893,osimertinib,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,71496458.0,Launched,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),1956
4586,BRD-K44184170,ospemifene,OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1,3036505.0,Launched,selective estrogen receptor modulator (SERM),ESR1|ESR2,obstetrics/gynecology|endocrinology,vaginal atrophy|dyspareunia|menopause,2099|2100
4587,BRD-K29735307,ostarine,C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F,11326715.0,Phase 3,androgen receptor modulator,AR,,,367
4589,BRD-K42009284,OT-R-antagonist-1,CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1,9690136.0,Preclinical,oxytocin receptor antagonist,AVPR1A|OXTR,,,552|5021
4590,BRD-K80082640,otamixaban,COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1,5496659.0,Phase 3,coagulation factor inhibitor,F10,,,2159
4591,BRD-A00520476,otenzepad,"CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|",76966449.0,Phase 3,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,,,1128|1129|1131|1132|1133
4592,BRD-K85337334,otilonium,CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC,72093.0,Launched,acetylcholine receptor antagonist,CACNA1C,gastroenterology,irritable bowel syndrome,775
4593,BRD-K53417444,OTS167,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|,,Phase 1/Phase 2,maternal embryonic leucine zipper kinase inhibitor,MELK,,,9833
4595,BRD-K43471985,OTX015,Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|,9936746.0,Phase 1/Phase 2,bromodomain inhibitor,BRD2|BRD3|BRD4,,,8019|23476|6046
4596,BRD-K33277808,ouabain,C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|,11527152.0,Launched,ATPase inhibitor,ATP1A1,cardiology,hypertension|cardiac arrythmia,476
4597,BRD-K98736329,OXA-06,Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12,24857242.0,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,,9475|6093
4604,BRD-K25394294,oxaprozin,OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1,4614.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5742|5743
4605,BRD-K22556255,oxatomide,O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,4615.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269
4606,BRD-K04196797,oxcarbazepine,NC(=O)N1c2ccccc2CC(=O)c2ccccc12,34312.0,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335
4609,BRD-A73891132,OXF-BD-02,"Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|",70699441.0,Preclinical,bromodomain inhibitor,BRD4,,,23476
4611,BRD-K30373577,oxfenicine,N[C@@H](C(O)=O)c1ccc(O)cc1,89853.0,Phase 1,carnitine palmitoyltransferase inhibitor,CPT1A|CPT1B,,,386593|1374
4612,BRD-K52075715,oxibendazole,CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1,4622.0,Launched,tubulin polymerization inhibitor,TUBB|TUBB4B,infectious disease,strongyles,7280|10383
4621,BRD-K01942991,oxotremorine-M,C[N+](C)(C)CC#CCN1CCCC1=O,4629.0,Preclinical,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,,1128|1129|1131|1132
4622,BRD-K21936341,oxotremorine-sesquifumarate,O=C1CCCN1CC#CCN1CCCC1,4630.0,Preclinical,cholinergic receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4,,,1128|1129|1131|1132
4623,BRD-A43671941,oxprenolol,CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|,94423.0,Launched,adrenergic receptor antagonist,ADRB1,cardiology,angina pectoris|hypertension|cardiac arrythmia,153
4624,BRD-K59037100,oxybenzone,COc1ccc(C(=O)c2ccccc2)c(O)c1,4632.0,Launched,lipase inhibitor,LIPE,dermatology,sunscreen lotion,3991
4625,BRD-K04185004,oxybuprocaine,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,4633.0,Launched,local anesthetic,SCN10A,neurology/psychiatry,local anesthetic,6336
4626,BRD-K01825580,oxybutynin,"CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|",6098167.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,urology,urinary incontinence,1128|1129|1131
4630,BRD-K16195444,oxymetazoline,Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|,4636.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR2C,otolaryngology,nasal congestion,3352|146|147|150|151|152|3351|3358
4633,BRD-A14208071,oxyphenonium,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,5748.0,Launched,cholinergic receptor antagonist,CHRM1|CHRM3,gastroenterology,peptic ulcer disease (PUD),1128|1131
4634,BRD-K31841515,oxypurinol,O=c1nc2[nH][nH]cc2c(=O)[nH]1,135398752.0,Phase 2/Phase 3,xanthine oxidase inhibitor,XDH,,,6652
4635,BRD-K66808046,oxyquinoline,Oc1cccc2cccnc12,1923.0,Launched,chelating agent,METAP2,dermatology,cosmetic,10988
4637,BRD-K25243230,oxytocin,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O,133698923.0,Launched,oxytocin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,obstetrics/gynecology,labor induction,552|553|554|5021
4638,BRD-K53061490,ozagrel,OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1,5282440.0,Launched,thromboxane synthase inhibitor,TBXAS1,neurology/psychiatry,stroke,6916
4639,BRD-K46625559,ozanimod,CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO,52938427.0,Phase 3,sphingosine 1-phosphate receptor agonist,S1PR1,,,1901
4643,BRD-K97714174,P22077,CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O,46931953.0,Preclinical,ubiquitin specific protease inhibitor,USP7,,,7874
4644,BRD-K51791723,P276-00,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,23643976.0,Phase 2,CDK inhibitor,CDK1|CDK4|CDK9,,,1025|1019|983
4645,BRD-K13606314,P5091,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,2819993.0,Preclinical,ubiquitin specific protease inhibitor,USP7,,,7874
4646,BRD-A09487507,P7C3,"O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|",981442.0,Preclinical,NAMPT inhibitor,NAMPT,,,10135
4647,BRD-K11428250,PA-452,CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C,9803242.0,Preclinical,retinoid receptor antagonist,RXRA,,,6256
4648,BRD-K92991072,PAC-1,Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1,9675990.0,Phase 1,caspase activator,CASP3,,,836
4649,BRD-K62008436,paclitaxel,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|,36314.0,Launched,tubulin polymerization inhibitor,BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC),10376|84617|10381|10382|10383|8856|4134|7846|347688|4137|113457|84790|7099|203068|112714|596|347733|10988|7277|7278|7280
4650,BRD-K05677083,PACOCF3,CCCCCCCCCCCCCCCC(=O)C(F)(F)F,4670.0,Preclinical,phospholipase inhibitor,PLA2G4A,,,5321
4651,BRD-K19034817,pacritinib,C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|,46216796.0,Phase 3,FLT3 inhibitor|JAK inhibitor,FLT3|JAK1|JAK2|JAK3,,,2322|3716|3717|3718
4657,BRD-K51313569,palbociclib,CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O,5330286.0,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer,1019|1021
4659,BRD-A99888680,paliperidone,"Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|",9823781.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|HTR2A,neurology/psychiatry,schizophrenia,3356|1813
4660,BRD-K58466253,palmatine-chloride,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,19009.0,Preclinical,dopamine synthesis inhibitor,CYP3A4,,,1576
4663,BRD-K68095457,palmitoylethanolamide,CCCCCCCCCCCCCCCC(=O)NCCO,4671.0,Launched,cannabinoid receptor agonist,CNR2|GPR119|GPR55,,,139760|9290|56142
4664,BRD-A50998626,palomid-529,"COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|",86324425.0,Phase 1,AKT inhibitor|mTOR inhibitor,MTOR,,,2475
4665,BRD-K08924299,palonosetron,O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2,6337614.0,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting,3359
4666,BRD-K07682953,palosuran,Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1,10173280.0,Phase 2,urotensin receptor antagonist,UTS2R,,,2837
4667,BRD-K83794243,palovarotene,CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12,10295295.0,Phase 3,retinoid receptor agonist,RARG,,,5916
4669,BRD-K58513245,pamidronate,NCCC(O)(P(O)(O)=O)P(O)(O)=O,4674.0,Launched,bone resorption inhibitor,FDPS,endocrinology|oncology|hematologic malignancy,hypercalcemia|Paget's disease|breast cancer|multiple myeloma,2224
4671,BRD-K50817623,pancuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,441289.0,Launched,acetylcholine receptor antagonist,CHRM2|CHRM3|CHRNA1|CHRNA2,critical care|neurology/psychiatry,endotracheal intubation|muscle relaxant,1129|1131|1134|1135
4673,BRD-K02130563,panobinostat,Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1,6918837.0,Launched,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,multiple myeloma,55869|9734|8841|3065|3066|10013|9759
4675,BRD-K00003243,pantoprazole,COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|,11181988.0,Launched,ATPase inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)|Zollinger-Ellison syndrome,495
4677,BRD-K18573821,PAOPA,NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O,44281634.0,Preclinical,dopamine receptor modulator,DRD2,,,1813
4678,BRD-K15567136,papaverine,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,4680.0,Launched,phosphodiesterase inhibitor,PDE10A|PDE4B|PDE5A,cardiology|hematology|gastroenterology,myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm,8654|10846|5142
4680,BRD-K62412084,para-toluenesulfonamide,Cc1ccc(cc1)S(N)(=O)=O,6269.0,Phase 3,,CA12|CA2|CA6|CA9,,,760|768|771|765
4681,BRD-K41524689,paracetamol,CC(=O)Nc1ccc(O)cc1,1983.0,Launched,cyclooxygenase inhibitor,FAAH|PTGS1|PTGS2|TRPV1,neurology/psychiatry|endocrinology,pain relief|fever,79152|7442|5742|5743
4683,BRD-A22128695,paramethadione,"CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|",51380897.0,Launched,anticonvulsant,CACNA1G,neurology/psychiatry,seizures,8913
4685,BRD-K02407574,parbendazole,CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1,26596.0,Preclinical,tubulin polymerization inhibitor,TUBB,,,7280
4687,BRD-K11851476,pardoprunox,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,6918525.0,Phase 3,dopamine receptor agonist|serotonin receptor agonist,DRD2|DRD3|DRD4|HTR1A|HTR7,,,3363|1815|1813|3350|1814
4688,BRD-K13800121,parecoxib,CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1,119828.0,Launched,cyclooxygenase inhibitor,LTF,neurology/psychiatry,pain relief,4057
4690,BRD-K83597974,pargyline,CN(CC#C)Cc1ccccc1,4688.0,Launched,monoamine oxidase inhibitor,MAOA|MAOB,cardiology,hypertension,4128|4129
4691,BRD-K60585088,paricalcitol,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1,5281104.0,Launched,vitamin D receptor agonist,VDR,nephrology|endocrinology,chronic kidney disease (CKD)|hyperthyroidism,1594
4694,BRD-K37991163,paroxetine,Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1,43815.0,Launched,selective serotonin reuptake inhibitor (SSRI),CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR2A|SLC6A2|SLC6A4,neurology/psychiatry,depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder,6530|6532|1128|1129|1131|1132|1133|3356
4698,BRD-K34851558,parthenolide-(-),C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|,5420805.0,Preclinical,NFkB pathway inhibitor,HDAC1,,,3065
4699,BRD-K28120222,parthenolide-(alternate-stereo),C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|,7251185.0,Preclinical,NFkB pathway inhibitor,IKBKB|RELA,,,5970|3551
4700,BRD-K59715032,pasireotide,NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1,9941444.0,Launched,somatostatin receptor agonist,SSTR1|SSTR2|SSTR3|SSTR5,endocrinology,Cushing's syndrome|acromegaly,6752|6753|6755|6751
4703,BRD-K74514084,pazopanib,CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1,10113978.0,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3,oncology,renal cell carcinoma (RCC)|soft tissue sarcoma (STS),10019|5156|2246|3815|5159|3791|2321|2260|2261|2324|3702|1436
4707,BRD-A29289453,PCA-4248,"COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|",6604734.0,Phase 1,platelet activating factor receptor antagonist,PTAFR,,,5724
4708,BRD-K12867552,PCI-24781,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,11749858.0,Phase 3,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC6,,,3065|3066|8841|10013
4710,BRD-K71223042,PCI-29732,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1,22347110.0,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,695
4711,BRD-K88742110,PCI-34051,COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1,24753719.0,Preclinical,HDAC inhibitor,HDAC1|HDAC10|HDAC6|HDAC8,,,3065|10013|55869|83933
4712,BRD-K52721684,PCO-400,CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|,129348.0,Phase 1,potassium channel activator,KCNJ8,,,3764
4713,BRD-K49865102,PD-0325901,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,9826528.0,Phase 2,MEK inhibitor,MAP2K1,,,5604
4714,BRD-A89337244,PD-102807,"CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|",92845316.0,Preclinical,acetylcholine receptor antagonist,CHRM4,,,1132
4715,BRD-K34657753,PD-118057,OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1,9864959.0,Preclinical,potassium channel activator,KCNH2,,,3757
4716,BRD-K34713073,PD-123319,CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C,5311345.0,Phase 1,angiotensin antagonist,AGTR2,,,186
4717,BRD-K62456038,PD-128907,CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21,5311346.0,Preclinical,dopamine receptor agonist,DRD2|DRD3,,,1813|1814
4718,BRD-K26603252,PD-153035,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,4705.0,Phase 1,EGFR inhibitor,EGFR|KDR,,,1956|3791
4719,BRD-K13826399,PD-156707,COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1,9871594.0,Preclinical,endothelin receptor antagonist,EDNRA|EDNRB,,,1909|1910
4720,BRD-K48735772,PD-158780,CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,4707.0,Preclinical,EGFR inhibitor,EGFR,,,1956
4721,BRD-K12079898,PD-160170,CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O,9820766.0,Preclinical,neuropeptide receptor antagonist,NPY1R,,,4886
4722,BRD-K97152684,PD-161570,CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl,5328135.0,Preclinical,FGFR inhibitor,FGFR1,,,2260
4723,BRD-K93217218,PD-166285,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,5311382.0,Preclinical,SRC inhibitor,EGFR|FGFR1|PDGFRB|PKMYT1|SRC|WEE1,,,9088|1956|5159|7465|2260|6714
4724,BRD-K60984070,PD-166793,CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O,9887870.0,Preclinical,collagenase inhibitor|metalloproteinase inhibitor,MMP13|MMP2|MMP3,,,4313|4322|4314
4725,BRD-K47761761,PD-168077,Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N,3645619.0,Preclinical,dopamine receptor agonist,DRD2,,,1813
4726,BRD-K17702546,PD-168393,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,4708.0,Preclinical,EGFR inhibitor,EGFR|ERBB2|SRC,,,2064|6714|1956
4727,BRD-A82013137,PD-168568,Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|,9928335.0,Preclinical,dopamine receptor antagonist,DRD2|DRD4,,,1813|1815
4728,BRD-K97764662,PD-173074,CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1,1401.0,Preclinical,FGFR inhibitor|VEGFR inhibitor,FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB,,,5156|5159|3791|2321|2260|2261|2324|2263|2264
4729,BRD-K04426574,PD-173212,CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C,9916734.0,Preclinical,calcium channel blocker,CACNA1B,,,774
4730,BRD-K05104363,PD-184352,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,6918454.0,Phase 2,MEK inhibitor,MAP2K1|MAP3K1|MAP3K2,,,10746|5604|4214
4731,BRD-K88677950,PD-198306,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,9956637.0,Preclinical,MAP kinase inhibitor|MEK inhibitor,MAP2K1|MAP2K2,,,5604|5605
4733,BRD-K82823804,PD-407824,Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1,4369491.0,Preclinical,PKC inhibitor,WEE1,,,7465
4734,BRD-K77951111,PD-81723,Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C,122028.0,Preclinical,adenosine receptor agonist,ADORA1,,,134
4735,BRD-K62810658,PD-98059,COc1cccc(c1N)-c1cc(=O)c2ccccc2o1,4713.0,Preclinical,MEK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1,,,5600|5604|5578|6093|6446|207|6300|2932|6037|6198|1111|1432|5594|3932|5599
4736,BRD-K04032780,PD1-PDL-inhibitor-1,COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O,91663303.0,Preclinical,programmed death ligand inhibitor,CD274,,,29126
4738,BRD-K38145871,PDE10-IN-1,Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1,72709059.0,Preclinical,phosphodiesterase inhibitor,PDE10A,,,10846
4739,BRD-K26358347,PDP-EA,CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1,69724031.0,Preclinical,FAAH activator,FAAH,,,79152
4740,BRD-A14577621,peficitinib,"NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|",,Launched,JAK inhibitor,JAK1|JAK2|JAK3,rheumatology,rheumatoid arthritis,3716|3717|3718
4741,BRD-K55034111,pefloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1,6919009.0,Launched,bacterial DNA gyrase inhibitor,TOP2A,infectious disease|urology,gastrointestinal infections|urethritis|gonorrhea|urinary tract infections,7153
4742,BRD-K96436774,pelanserin,O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1,65435.0,Phase 2,serotonin receptor antagonist,HTR2A,,,3356
4743,BRD-K08799216,pelitinib,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,6445562.0,Phase 2,EGFR inhibitor,EGFR,,,1956
4746,BRD-K32842773,pemetrexed,Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1,135410875.0,Launched,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,ATIC|DHFR|GART|TYMS,oncology,non-small cell lung cancer (NSCLC)|mesothelioma,1719|2618|7298|471
4747,BRD-K31731454,pemirolast,Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O,57697.0,Launched,mediator release inhibitor,HRH1,pulmonary,asthma,3269
4749,BRD-K55705469,penbutolol,CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1,37464.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|HTR1A|HTR1B,cardiology,hypertension,153|154|3350|3351
4751,BRD-K15409150,penfluridol,OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F,33630.0,Launched,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,8913
4756,BRD-K78789465,pentagastrin,CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,9853654.0,Launched,CCK receptor agonist,CCKBR,gastroenterology,anacidity diagnostic|gastric hypersecretion diagnostic,887
4757,BRD-K13183738,pentamidine,NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1,4735.0,Launched,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,1787
4759,BRD-K44942604,pentolinium,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,5850.0,Launched,cholinergic receptor antagonist,CHRNA10|CHRNA3|CHRNA4|CHRNB4,cardiology,hypertension,1136|1137|57053|1143
4760,BRD-K91543828,pentostatin,OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|,439693.0,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,ADA,hematologic malignancy,hairy cell leukemia,100
4761,BRD-K57569181,pentoxifylline,CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O,4740.0,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|ADORA2B|ADRA2B|NT5E|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|TNF,cardiology,claudication,134|135|136|5136|5137|5138|5139|5140|5141|5142|151|5143|5144|5145|5146|5147|5148|5149|5150|5151|5153|5152|5158|4907|8622|8654|7124|10846|27115
4764,BRD-K13571841,pepstatin,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,5478883.0,Preclinical,aspartic protease inhibitor,CTSB|CTSD|CTSL|REN,,,147040|1514|1508|1509
4767,BRD-K99431849,peretinoin,CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O,6437836.0,Phase 3,retinoid receptor agonist,RXRA,,,6256
4772,BRD-K60770992,pergolide,CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13,47811.0,Withdrawn,dopamine receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,,,3352|1815|1816|146|147|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358
4773,BRD-A19633847,perhexiline,C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|,38988177.0,Launched,carnitine palmitoyltransferase inhibitor,CPT1A,cardiology,angina pectoris,1374
4774,BRD-A89082344,perifosine,CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|,148178.0,Phase 3,AKT inhibitor,AKT1,,,207
4775,BRD-A13323580,perillyl-alcohol,"CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|",369312.0,Phase 2,apoptosis stimulant|farnesyltransferase inhibitor,FNTA,,,2339
4776,BRD-K92731339,perindopril,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC,40466996.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|myocardial infarction|coronary artery disease (CAD),1636
4777,BRD-K00768353,perindoprilat,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O,72022.0,Phase 2,angiotensin converting enzyme inhibitor,ACE,,,1636
4779,BRD-K85503079,perospirone,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12,115368.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD2|DRD3|DRD4,neurology/psychiatry,schizophrenia|bipolar disorder,1813|1814|1815
4780,BRD-K10995081,perphenazine,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,4748.0,Launched,dopamine receptor antagonist,CALM1|DRD1|DRD2|HRH1|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry|gastroenterology,schizophrenia|nausea|vomiting,801|3362|3363|3269|1812|1813|3356|3358
4782,BRD-K04643877,perzinfotel,OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O,6918236.0,Phase 2,glutamate receptor antagonist,GRIN1|GRIN2A|GRIN2B,,,2904|114787|2903
4783,BRD-A93477898,PETCM,"O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|",736879.0,Preclinical,caspase activator,CASP3,,,836
4784,BRD-K67844266,pevonedistat,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,16720766.0,Phase 3,nedd activating enzyme inhibitor,NAE1|UBA3,,,8883|9039
4785,BRD-K54519451,pexidartinib,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,25151352.0,Launched,tyrosine kinase inhibitor,CSF1R|FLT3|KIT,,,2322|1436|3815
4786,BRD-K53405000,pexmetinib,Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C,24765037.0,Phase 1,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,MAPK14|TEK,,,1432|7010
4788,BRD-K31519811,PF-02545920,Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1,11581936.0,Phase 2,phosphodiesterase inhibitor,PDE10A,,,10846
4789,BRD-K07070922,PF-03049423,CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1,24963293.0,Phase 2,phosphodiesterase inhibitor,PDE5A,,,8654
4791,BRD-K37764012,PF-03758309,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1,25227462.0,Phase 1,p21 activated kinase inhibitor,PAK4,,,10298
4792,BRD-K68747584,PF-03814735,CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21,51346455.0,Phase 1,Aurora kinase inhibitor,AURKA|AURKB,,,9212|6790
4795,BRD-K73319509,PF-04217903,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,17754438.0,Phase 1,c-Met inhibitor,MET,,,8731
4796,BRD-K54871792,PF-04418948,COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1,25114442.0,Phase 1,prostaglandin inhibitor,PTGER2,,,5732
4797,BRD-K50031829,PF-04447943,C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1,135564558.0,Phase 2,phosphodiesterase inhibitor,PDE9A,,,5152
4798,BRD-K86816506,PF-04457845,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,24771824.0,Phase 2,FAAH inhibitor,FAAH,,,79152
4799,BRD-K30550578,PF-04620110,Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|,,Phase 1,diacylglycerol O acyltransferase inhibitor,DGAT1,,,8694
4800,BRD-K07310275,PF-04691502,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|,,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,,,5290|2475
4801,BRD-K92435527,PF-04885614,CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1,65459349.0,Preclinical,voltage-gated sodium channel blocker,SCN10A,,,6336
4802,BRD-K27755542,PF-04937319,CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1,46916694.0,Phase 2,glucokinase activator,GCK,,,5871
4807,BRD-K02554563,PF-05190457,Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1,58438464.0,Phase 2,growth hormone secretagogue receptor inverse agonist,GHSR,,,2693
4808,BRD-K07955840,PF-05212384,CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1,44516953.0,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,,,5290|2475
4815,BRD-K83114366,PF-06447475,N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12,72706840.0,Preclinical,serine/threonine kinase inhibitor,LRRK2,,,120892
4817,BRD-A23124853,PF-06463922,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1,r|",78162481.0,Launched,ALK tyrosine kinase receptor inhibitor,ALK|FES|ROS1,oncology,non-small cell lung cancer (NSCLC),6098|2242|238
4825,BRD-K31417912,PF-3274167,COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1,11683187.0,Phase 2,oxytocin receptor antagonist,AVPR1A|OXTR,,,552|5021
4826,BRD-K68997413,PF-3845,FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1,25154867.0,Preclinical,FAAH inhibitor,FAAH,,,79152
4828,BRD-K11821338,PF-429242,CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1,23661637.0,Preclinical,SREBP inhibitor,MBTPS1,,,8720
4829,BRD-K93788137,PF-431396,CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O,11598628.0,Preclinical,focal adhesion kinase inhibitor,PTK2|PTK2B,,,2185|5747
4830,BRD-K14711741,PF-4708671,CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1,51371303.0,Preclinical,ribosomal protein inhibitor,RPS6KB1,,,6198
4831,BRD-K03063480,PF-477736,Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O,135565545.0,Phase 1,CHK inhibitor,CHEK1|CHEK2,,,11200|1111
4832,BRD-K43428468,PF-4800567,Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1,53472153.0,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E,,,1453|1454
4833,BRD-K78318619,PF-4981517,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,71315139.0,Preclinical,cytochrome P450 inhibitor,CYP3A4,,,1576
4835,BRD-K40302533,PF-5274857,Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O,56956240.0,Preclinical,smoothened receptor antagonist,SMO,,,54498
4836,BRD-K99545815,PF-562271,CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O,11713159.0,Phase 1,focal adhesion kinase inhibitor,PTK2|PTK2B,,,2185|5747
4837,BRD-K79239947,PF-573228,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1,11612883.0,Preclinical,focal adhesion kinase inhibitor,CDK1|CDK2|CDK7|GSK3B|IKBKB,,,2932|983|1017|1022|3551
4838,BRD-K96295391,PF-670462,Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1,11681588.0,Preclinical,casein kinase inhibitor,CSNK1D|CSNK1E,,,1453|1454
4839,BRD-K83213911,PF-750,O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1,25154868.0,Preclinical,FAAH inhibitor,FAAH,,,79152
4840,BRD-K50865540,PF-8380,Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1,25265312.0,Preclinical,autotaxin inhibitor,ENPP2,,,5168
4841,BRD-K18289362,PF-915275,Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1,23725123.0,Phase 1,11-beta hydroxysteroid dehydrogenase inhibitor,HSD11B1,,,3290
4842,BRD-K13094524,PFI-1,COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1,71271629.0,Preclinical,bromodomain inhibitor,BRD4,,,23476
4843,BRD-K61524559,PFI-3,Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1,78243717.0,Preclinical,bromodomain inhibitor,PBRM1|SMARCA4,,,55193|6597
4844,BRD-K13106865,PFI-4,COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1,40642506.0,Preclinical,bromodomain inhibitor,BRPF1,,,23774
4845,BRD-K95573441,PFK-015,O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1,25142799.0,Phase 1,phosphofructokinase inhibitor,PFKFB3,,,5209
4846,BRD-K28010364,PFK-158,FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1,71730058.0,Phase 1,phosphofructokinase inhibitor,PFKFB3,,,5209
4848,BRD-A53813595,PGL5001,"N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|",76969933.0,Phase 2,JNK inhibitor,MAPK10|MAPK8|MAPK9,,,5601|5602|5599
4849,BRD-K95880107,PH-797804,CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O,22049997.0,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK14,,,5600|1432
4851,BRD-K48053228,PHA-568487,O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1,9932000.0,Preclinical,nicotinic receptor agonist,CHRNA7,,,89832
4852,BRD-K95435023,PHA-665752,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,10461815.0,Preclinical,c-Met inhibitor,MET,,,8731
4853,BRD-K09443272,PHA-680632,CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,11249084.0,Preclinical,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,,6795|9212|6790
4854,BRD-K50000283,PHA-767491,O=C1NCCc2[nH]c(cc12)-c1ccncc1,11715767.0,Preclinical,CDC inhibitor,CDK1|RPS6KB1,,,6198|983
4855,BRD-K64800655,PHA-793887,CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,46191454.0,Phase 1,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CDK7|CDK9,,,1025|983|1017|1019|1020|1022
4856,BRD-K60997853,PHA-848125,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,16718576.0,Phase 2,CDK inhibitor|growth factor receptor inhibitor,CDK2|CDK4|CDK7|NTRK1,,,1017|4914|1019|1022
4857,BRD-K00004222,PHCCC,"O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|",44572113.0,Preclinical,glutamate receptor agonist,GRM1|GRM4,,,2914|2911
4859,BRD-K40905133,phenacemide,NC(=O)NC(=O)Cc1ccccc1,4753.0,Launched,sodium channel blocker,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335
4860,BRD-K38323065,phenacetin,CCOc1ccc(NC(C)=O)cc1,4754.0,Withdrawn,cyclooxygenase inhibitor,PTGS1,,,5742
4861,BRD-K46937689,phenazone,Cc1cc(=O)n(-c2ccccc2)n1C,2206.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
4862,BRD-K76304753,phenazopyridine,Nc1ccc(\N=N\c2ccccc2)c(N)n1,,Launched,local anesthetic,SCN1A,infectious disease,urinary tract infections,6323
4863,BRD-K87024524,phenelzine,NNCCc1ccccc1,3675.0,Launched,monoamine oxidase inhibitor,ABAT|AOC3|GAD2|GPT|GPT2|MAOA|MAOB|SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,4128|4129|84706|6530|6531|6532|1798|2572|18|8639
4865,BRD-K56700933,phenethyl-isothiocyanate,S=C=NCCc1ccccc1,16741.0,Phase 2,anticancer agent,CYP2E1,,,1571
4866,BRD-K11399644,phenformin,NC(N)=NC(=N)NCCc1ccccc1,8249.0,Withdrawn,AMPK activator,KCNJ8|PRKAA1,,,5562|3764
4867,BRD-A33178345,phenindamine,"CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|",57086802.0,Launched,histamine receptor antagonist,HRH1,allergy|otolaryngology,allergic rhinitis|common cold,3269
4868,BRD-K70592963,phenindione,O=C1C(C(=O)c2ccccc12)c1ccccc1,4760.0,Launched,vitamin K antagonist,VKORC1,hematology,deep vein thrombosis (DVT),79001
4869,BRD-A23072235,pheniramine,CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|,667440.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis|urticaria,3269
4870,BRD-K76549667,phenol,Oc1ccccc1,996.0,Preclinical,,CA1|CA12|CA14|CA2|CA4|CA9,otolaryngology,pharyngitis,768|771|23632|759|760|762
4871,BRD-K19227686,phenolphthalein,Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1,4764.0,Withdrawn,indicator dye,UGT1A9,,,54600
4875,BRD-A67799922,phenoxybenzamine,CC(COc1ccccc1)N(CCCl)Cc1ccccc1,657233.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,cardiology|endocrinology,hypertension|pheochromocytoma,146|147|150|151|152
4877,BRD-A49838158,phenprocoumon,"CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|",54681533.0,Launched,vitamin K antagonist,VKORC1,hematology,thrombosis|pulmonary embolism (PE),79001
4878,BRD-K46580984,phenserine,CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21,192706.0,Phase 3,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,ACHE|BCHE,,,43|590
4880,BRD-K90333595,phentolamine,Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|,5775.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,endocrinology|cardiology,pheochromocytoma|hypertension,146|147|150|151|152
4885,BRD-K10843433,phenylbutazone,CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,4781.0,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,PTGIS|PTGS1|PTGS2,,,5740|5742|5743
4886,BRD-K67102207,phenylbutyrate,OC(=O)CCCc1ccccc1,4775.0,Launched,HDAC inhibitor,HDAC1,metabolism,urea cycle disorders,3065
4887,BRD-K73381542,phenylephrine,CNC[C@H](O)c1cccc(O)c1,6041.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D,otolaryngology|gastroenterology|cardiology,nasal congestion|hemorrhoids|hypotension,146|147
4892,BRD-K55930204,phenytoin,O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1,1775.0,Launched,hydantoin antiepileptic,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335
4893,BRD-K44400149,PhiKan-083,CCn1c2ccccc2c2cc(CNC)ccc12,4722579.0,Preclinical,p53 stabilizing agent,TP53,,,7157
4894,BRD-K15563106,phloretin,Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1,4788.0,Launched,sodium/glucose cotransporter inhibitor,AQP9|CLCN3|SLC23A1,,,9962|1182|366
4895,BRD-K73756878,phlorizin,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,6072.0,Preclinical,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A11|SLC5A2|SLC5A3,,,115584|6523|6524|6526
4897,BRD-K74558903,phortress,Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1,399465.0,Phase 1,aryl hydrocarbon receptor ligand,AHR,,,196
4899,BRD-K07460388,PHP-501,On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1,46204221.0,Preclinical,GABA receptor antagonist,GABRA1|GABRB2|GABRG2,,,2561|2554|2566
4900,BRD-K59745944,PHT-427,CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1,44240850.0,Preclinical,AKT inhibitor|pyruvate dehydrogenase inhibitor,AKT2|PDPK1,,,208|5170
4903,BRD-K76568384,PHTPP,Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1,11201035.0,Preclinical,estrogen receptor antagonist,ESR2,,,2100
4904,BRD-K25650355,physostigmine,CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1,5983.0,Launched,acetylcholinesterase inhibitor|cholinesterase inhibitor,ACHE|BCHE,cardiology|neurology/psychiatry|ophthalmology|gastroenterology,hypotension|Alzheimer's disease|glaucoma|gastroparesis,43|590
4905,BRD-K76661572,phytonadione,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|,5284607.0,Launched,,BGLAP|GGCX,hematology,vitamin K deficiency|anticoagulation reversal,632|2677
4907,BRD-K67868012,PI-103,Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,9884685.0,Preclinical,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,,,22883|5290|2475|5291|5294|5591
4911,BRD-K75528696,PI4KIII-beta-inhibitor-1,COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C,71549093.0,Preclinical,PI4K inhibitor,PI4K2B,,,55300
4913,BRD-K02750403,piboserod,CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1,177336.0,Phase 2,serotonin receptor antagonist,HTR2B|HTR4,,,3360|106480180
4914,BRD-A71765060,picartamide,"CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|",76960918.0,Phase 2,H+/K+-ATPase inhibitor,ATP4A,,,495
4915,BRD-K91509126,piceatannol,Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1,667639.0,Preclinical,SYK inhibitor,ATP5A1|ATP5B|ATP5C1|IRF3,,,498|506|3661|509
4916,BRD-K47642186,piclamilast,COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl,154575.0,Phase 2,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,,,5144|5141|5142|5143
4920,BRD-K67277431,picotamide,COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1,4814.0,Launched,thromboxane receptor antagonist|thromboxane synthase inhibitor,TBXA2R,hematology,thrombosis,6915
4921,BRD-A91822151,picrotin,"CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|",,Phase 2,GABA receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB,,,8001|2741|2742|2743
4922,BRD-K36461289,picrotoxinin,CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C,7098683.0,Preclinical,GABA receptor antagonist,GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B,,,8001|2741|2742|2743|9177|3359
4923,BRD-K57313110,pidolic-acid,OC(=O)[C@@H]1CCC(=O)N1,7405.0,Launched,,ADAM28|AMY1A|AMY2A|AMY2B|ANG|CCL8|HCRT|IGLC1|KRTAP5-2|TFF2|VEGFA,dermatology,xerosis cutis,57830|10863|3537|6355|276|3060|7032|279|280|283|7422
4925,BRD-K66874953,pifithrin-alpha,Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N,4817.0,Preclinical,TP53 inhibitor,TP53,,,7157
4926,BRD-K31792052,pifithrin-cyclic,Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1,443278.0,Preclinical,TP53 inhibitor,TP53,,,7157
4927,BRD-K96799727,pifithrin-mu,NS(=O)(=O)C#Cc1ccccc1,327653.0,Preclinical,HSP inhibitor,HSPA1A|TP53,,,7157|3303
4928,BRD-K30977212,PIK-293,Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O,53245636.0,Preclinical,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,5290|5291|5294|22883
4929,BRD-K50631926,PIK-294,Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O,24905149.0,Preclinical,PI3K inhibitor,PIK3CB|PIK3CD|PIK3CG,,,5291|5294|22883
4930,BRD-K49371609,PIK-75,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,10275789.0,Preclinical,DNA protein kinase inhibitor|PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC,,,22883|5290|5291|5294|5591
4931,BRD-K29395450,PIK-93,CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO,6852167.0,Preclinical,PI3K inhibitor,PI4KB|PIK3C3|PIK3CG,,,5289|5298|5294
4935,BRD-K85090592,pilocarpine,CC[C@H]1[C@@H](Cc2cncn2C)COC1=O,5910.0,Launched,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,ophthalmology|cardiology,glaucoma|hypertension,1128|1129|1131|1132|1133
4936,BRD-K83245588,pilsicainide,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,4820.0,Launched,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,6331
4937,BRD-K48832421,PIM-1-Inhibitor-2,Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1,2765355.0,Preclinical,Pim kinase inhibitor,PIM1,,,9361
4939,BRD-K83405785,pimavanserin,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,10071196.0,Launched,serotonin receptor inverse agonist,DRD2|HTR2A,neurology/psychiatry,Parkinson's Disease,3356|1813
4942,BRD-K01826269,pimobendan,"COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|",7120080.0,Launched,calcium sensitizer|phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,5139
4945,BRD-K01292756,pimozide,Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1,16362.0,Launched,dopamine receptor antagonist,CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2,neurology/psychiatry,Tourette's disorder,3744|801|3269|3757|150350|1812|1813|1814|1815|1816|3350|3356
4946,BRD-A43882281,pinacidil,"C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|",12428581.0,Launched,ATP channel activator|potassium channel activator,ABCC8|ABCC9,cardiology,hypertension,6833|10060
4948,BRD-A13175897,pinaverium,"COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17,19,&2:14,r|",73416161.0,Launched,T-type calcium channel blocker,CACNA1C,gastroenterology,irritable bowel syndrome,775
4950,BRD-A97701745,pindolol,"CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|",155030.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|HTR1A|HTR2A|HTR2B,cardiology,hypertension,106480180|3350|153|154|3356
4951,BRD-K95598440,pindolol-(-),CC(C)NC[C@H](O)COc1cccc2[nH]ccc12,688095.0,Phase 2,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A,,,3350
4953,BRD-K94689771,pinocembrin,Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1,68071.0,Phase 2,cytochrome P450 inhibitor,CYP1B1,,,1545
4954,BRD-K01826904,pioglitazone,CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|,29010894.0,Launched,insulin sensitizer|PPAR receptor agonist,PPARG|TRPM3,endocrinology,diabetes mellitus,80036|5468
4955,BRD-K26801045,pipamperone,NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1,4830.0,Launched,dopamine receptor antagonist,DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR2A,neurology/psychiatry,schizophrenia,3269|1813|3350|3351|3352|3356
4956,BRD-A21544762,pipecuronium,"CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1 |a:5,7,8,11,13,18,20,22,25,&1:4|",50192.0,Launched,neuromuscular blocker,CHRM2|CHRM3|CHRNA2,neurology/psychiatry,anesthetic,1129|1131|1135
4958,BRD-A53561827,pipenzolate,"CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|",16048561.0,Launched,cholinergic receptor antagonist,CHRM1,neurology/psychiatry,spasms,1128
4962,BRD-K13249881,piperazine,C1CNCCN1,4837.0,Launched,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,2562
4964,BRD-A97479839,piperidolate,CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|,688565.0,Launched,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,spasms,1128
4965,BRD-K59522102,piperine,O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1,638024.0,Phase 1,monoamine oxidase inhibitor,MAOA|MAOB|TRPV1,,,4128|4129|7442
4969,BRD-K00004560,pipotiazine,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,62867.0,Launched,dopamine receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia,3356|1812|1813|3350
4970,BRD-K48429278,pipotiazine-palmitate,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1,37767.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia,3356|1812|1813|3350
4971,BRD-K19456237,piracetam,NC(=O)CN1CCCC1=O,4843.0,Launched,acetylcholine receptor agonist,GRIA1|GRIA2|GRIA3|GRIA4,neurology/psychiatry,senile dementia,2890|2891|2892|2893
4972,BRD-K83794624,pirarubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,11296583.0,Launched,topoisomerase inhibitor,TOP2A,oncology,breast cancer,7153
4974,BRD-K25224017,pirenperone,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,4847.0,Preclinical,serotonin receptor antagonist,HTR2A|HTR7,,,3363|3356
4975,BRD-K89375097,pirenzepine,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,4848.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,gastroenterology,peptic ulcer disease (PUD),1128|1129|1131|1132|1133
4976,BRD-K87990216,piretanide,NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,4849.0,Launched,glucocorticoid receptor agonist,SLC12A1|SLC12A2,cardiology,hypertension|edema,6557|6558
4977,BRD-K96862998,pirfenidone,Cc1ccc(=O)n(c1)-c1ccccc1,40632.0,Launched,TGF beta receptor inhibitor,FURIN|TNF,pulmonary,idiopathic pulmonary fibrosis (IPF),7124|5045
4978,BRD-K47936004,piribedil,C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1,4850.0,Launched,dopamine receptor agonist,ADRA1A|ADRA2A|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR2B,neurology/psychiatry,Parkinson's Disease|dizziness,1815|146|106480180|1813|150|1814|152|3350
4979,BRD-K00004544,piricapiron,"CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|",5545745.0,Phase 2,dopamine receptor antagonist|serotonin receptor antagonist,HTR2A,,,3356
4980,BRD-K01902415,pirinixic-acid,Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C,5694.0,Preclinical,PPAR receptor agonist,PPARA,,,5465
4981,BRD-K01826702,pirlindole,Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|,667444.0,Launched,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,4128
4986,BRD-K01826746,piroxicam,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|,54676228.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5742|5743
4987,BRD-K71977764,piroximone,CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1,55263.0,Phase 2,phosphodiesterase inhibitor,PDE3A,,,5139
4990,BRD-K43978949,PIT,[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|,124334.0,Preclinical,purinergic receptor antagonist,P2RY1,,,5028
4991,BRD-K75958547,pitavastatin,O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O,5282452.0,Launched,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,3156
4992,BRD-K21673112,pitolisant,Clc1ccc(CCCOCCCN2CCCCC2)cc1,9948102.0,Launched,histamine receptor antagonist,HRH3,,,11255
4993,BRD-K62264492,pivagabine,CC(C)(C)C(=O)NCCCC(O)=O,68888.0,Launched,corticotropin releasing factor receptor antagonist,CRHR1|CRHR2,neurology/psychiatry,depression,1394|1395
4995,BRD-K20504455,pivanex,CCCC(=O)OCOC(=O)C(C)(C)C,60748.0,Phase 2,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,,3065|3066|8841|55869
4997,BRD-K48304345,pixantrone,NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12,134019.0,Launched,topoisomerase inhibitor,TOP2A,hematologic malignancy,non-Hodgkin lymphoma (NHL),7153
4998,BRD-K75958195,pizotifen,CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12,27400.0,Launched,serotonin receptor antagonist,HTR1A|HTR2A|HTR2C,neurology/psychiatry,migraine headache,3356|3350|3358
4999,BRD-K11853856,PJ-34,CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,4858.0,Preclinical,PARP inhibitor,EEF2|PARP1|PARP15|PARP3,,,1938|10039|142|165631
5000,BRD-A41451487,PK-11195,"CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|",24839733.0,Phase 1,benzodiazepine receptor antagonist,TSPO,,,706
5001,BRD-K04035716,PK-44,N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12,46208486.0,Preclinical,dipeptidyl peptidase inhibitor,DPP4,,,1803
5002,BRD-K44043890,PK-THPP,CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1,53464059.0,Preclinical,potassium channel blocker,KCNK9,,,51305
5003,BRD-K10115470,PKI-166,C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1,6918403.0,Phase 1,EGFR inhibitor,EGFR,,,1956
5004,BRD-A28467416,PKI-179,"O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|",76958312.0,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR,,,2475
5006,BRD-K33240821,plerixafor,C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1,65015.0,Launched,CC chemokine receptor antagonist,ACKR3|CCR4|CXCR4,hematologic malignancy,non-Hodgkin lymphoma (NHL)|multiple myeloma,57472|7852|57007
5009,BRD-A20781140,plovamer-acetate,"N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|",6942100.0,Phase 2,,TAT|TH|YARS|YARS2,,,79969|51067|8565|7054
5011,BRD-K99149715,plurisin-1,O=C(NNc1ccccc1)c1ccncc1,225362.0,Preclinical,stearoyl-CoA desaturase inhibitor,SCD,,,6319
5012,BRD-K16478699,PLX4720,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,24180719.0,Preclinical,RAF inhibitor,BRAF|KDR,,,673|3791
5014,BRD-K79294107,PLX647,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1,11545419.0,Preclinical,receptor tyrosine protein kinase inhibitor,CSF1R|KIT,,,1436|3815
5015,BRD-K53723268,PLX8394,F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F,90116675.0,Phase 1/Phase 2,serine/threonine kinase inhibitor,BRAF,,,673
5016,BRD-A74387232,PMPA,"OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|",11031538.0,Preclinical,glutamate receptor antagonist,FOLH1,,,2346
5017,BRD-K71731651,PNU-120596,COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl,311434.0,Preclinical,acetylcholine receptor agonist,CHRNA7,,,89832
5018,BRD-K81616657,PNU-142633,CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1,9845148.0,Phase 2,serotonin receptor agonist,HTR1D,,,3352
5019,BRD-K04635846,PNU-177864,CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1,9887351.0,Preclinical,dopamine receptor antagonist,DRD3,,,1814
5020,BRD-K16551401,PNU-22394,Cn1c2CCNCCc2c2ccccc12,27559.0,Phase 2,serotonin receptor agonist,HTR2A|HTR2B|HTR2C|MAOA|MAOB,,,4128|4129|106480180|3356|3358
5021,BRD-K28863208,PNU-282987,Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2,9795278.0,Preclinical,cholinergic receptor agonist,CHRNA7,,,89832
5023,BRD-K30707190,PNU-74654,Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1,9836739.0,Preclinical,beta-catenin inhibitor,CTNNB1|TCF4,,,1499|6934
5024,BRD-K84507776,PNU-89843,Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1,154689.0,Preclinical,benzodiazepine receptor agonist,GABBR1,,,10537
5026,BRD-K47869605,podophyllotoxin,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,10607.0,Launched,microtubule inhibitor|tubulin polymerization inhibitor,IGF1R|TOP2A|TUBA4A|TUBB,infectious disease,genital warts,3480|7153|7280|7277
5029,BRD-K43236057,polydatin,OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,5281718.0,Phase 2,ICAM1 expression inhibitor,ICAM1,,,3383
5030,BRD-A67531813,polyinosine,"O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|",138454308.0,Preclinical,immunostimulant,HPRT1|IMPDH2|PYGM,,,3251|5837|3615
5032,BRD-A15739803,polythiazide,"CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|",12876779.0,Launched,sodium/chloride cotransporter inhibitor,SLC12A3,cardiology|gastroenterology|rheumatology|nephrology,edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure|hypertension,6559
5034,BRD-K44227013,ponatinib,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1,24826799.0,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK,hematologic malignancy,chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL),106480993|7010|4067|5156|3815|3791|2322|2260|2261|2263|2264|25|6714|5979|3932
5035,BRD-K44030614,ponesimod,CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,,Phase 3,sphingosine 1-phosphate receptor agonist,S1PR1,,,1901
5036,BRD-K06222852,posaconazole,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O,468595.0,Launched,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,1576
5037,BRD-K46556543,potassium-canrenoate,"C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|",656615.0,Launched,mineralocorticoid receptor antagonist,NR3C2,cardiology,edema,4306
5040,BRD-K79803033,pozanicline,Cc1ncccc1OC[C@@H]1CCCN1,178052.0,Phase 2,acetylcholine receptor antagonist,CHRNA4|CHRNB2,,,1137|1141
5041,BRD-K50010139,poziotinib,COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C,25127713.0,Phase 2,EGFR inhibitor,EGFR|ERBB2|ERBB4,,,2064|2066|1956
5042,BRD-K47598052,PP-1,Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C,1400.0,Preclinical,SRC inhibitor,HCK|RET,,,5979|3055
5043,BRD-K81801188,PP-121,Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1,24905142.0,Preclinical,protein tyrosine kinase inhibitor,ABL1|EGFR|HCK|KDR|MTOR|PDGFRA|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC|SRC,,,22883|1956|5156|5290|2475|5291|5294|3791|3055|5591|25|6714
5044,BRD-K95785537,PP-2,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12,4878.0,Preclinical,SRC inhibitor,ABL1|LCK|RIPK2|SRC,,,25|6714|3932|8767
5045,BRD-K87112191,PP242,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12,135565635.0,Preclinical,mTOR inhibitor,MTOR|PASK,,,2475|27347
5046,BRD-K00312224,PPT,CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1,5040063.0,Preclinical,estrogen receptor agonist,ESR1,,,2099
5047,BRD-K72514671,PPY-A,COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C,16750094.0,Preclinical,Abl kinase inhibitor,ABL1|BCR,,,25|106480993
5048,BRD-K67537649,PQ-401,COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12,9549305.0,Preclinical,IGF-1 inhibitor,IGF1R,,,3480
5050,BRD-A41304429,practolol,"CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|",6918924.0,Withdrawn,adrenergic receptor antagonist,ADRB1,,,153
5052,BRD-A74914197,pralatrexate,"Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|",11155808.0,Launched,dihydrofolate reductase inhibitor,DHFR,hematologic malignancy,peripheral T-cell lymphoma (PTCL),1719
5053,BRD-K84281997,pralidoxime,C[n+]1ccccc1\C=N\O,4884.0,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,critical care,organophosphate poisoning,43|590
5054,BRD-K24221957,pralidoxime-chloride,C[n+]1ccccc1CN=O,54072659.0,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,pulmonary,respiratory depression,43|590
5056,BRD-K06388322,pramipexole,CCCN[C@H]1CCc2nc(N)sc2C1,119570.0,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease,3352|1815|1816|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358
5059,BRD-A68083442,pranidipine,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|",29986494.0,Phase 2,calcium channel blocker,CACNA1C,,,775
5060,BRD-K97045029,pranlukast,O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1,4887.0,Launched,leukotriene receptor antagonist,CYSLTR1|CYSLTR2|IL5|MUC2|NFKB1|RNASE3|TNF,pulmonary,bronchospasm|asthma,4583|3567|10800|57105|7124|6037|4790
5063,BRD-A83029242,prasugrel,"CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|",51698431.0,Launched,purinergic receptor antagonist,P2RY12,cardiology,myocardial infarction|acute coronary syndrome (ACS),64805
5064,BRD-K46209126,pravadoline,COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12,56463.0,Preclinical,cyclooxygenase inhibitor,CNR1|CNR2,,,1268|56142
5065,BRD-K60511616,pravastatin,"CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|",54687.0,Launched,HMGCR inhibitor,HMGCR|SLCO1B1,endocrinology|cardiology,hypercholesterolemia|myocardial infarction|hyperlipidemia,3156|10599
5067,BRD-K49111258,prazosin,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1,4893.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7,cardiology,hypertension,81033|3757|146|147|150|151|152|90134
5068,BRD-K57304726,PRE-084,O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1,126402.0,Preclinical,sigma receptor agonist,SIGMAR1,,,10280
5069,BRD-K02908048,preclamol,CCCN1CCC[C@@H](C1)c1cccc(O)c1,202478.0,Phase 2,dopamine receptor agonist,DRD2,,,1813
5070,BRD-A93963402,prednicarbate,"CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6,19,22,25,&1:9,&2:10,&3:21,c:17,t:13|",,Launched,phospholipase activator,PLA2G1B,dermatology|ophthalmology|neurology/psychiatry,eczema|contact dermatitis|itching,5319
5071,BRD-A27887842,prednisolone,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|",5755.0,Launched,glucocorticoid receptor agonist,NR3C1|NR3C2|SERPINA6,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis,4306|2908|866
5072,BRD-K45664306,prednisolone-acetate,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|",5834.0,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis,2908
5073,BRD-A01643550,prednisolone-acetate,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:7,24,27,&1:11,&2:12,&3:21,&4:23,c:19,t:15|",11865455.0,Launched,glucocorticoid receptor agonist,NR3C1,ophthalmology|dermatology|infectious disease,conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis,2908
5074,BRD-A78391468,prednisolone-hemisuccinate,"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|",656804.0,Preclinical,glucocorticoid receptor agonist,NR3C1,,,2908
5075,BRD-K00003654,prednisolone-sodium-phosphate,"[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31,t:27|",72078.0,Launched,glucocorticoid receptor agonist,NR3C1,allergy|pulmonary|ophthalmology|infectious disease|rheumatology|endocrinology|neurology/psychiatry|gastroenterology|hematology,allergic rhinitis|asthma|contact dermatitis|mycosis|lupus|hypercalcemia|thyroiditis|congenital adrenal hyperplasia|multiple sclerosis|ulcerative colitis|enteritis|thrombocythemia|pneumonia|meningitis|psoriatic arthritis|rheumatoid arthritis,2908
5077,BRD-K85883481,prednisone,"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|",5865.0,Launched,glucocorticoid receptor agonist,HSD11B1|NR3C1,endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry,congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis,3290|2908
5078,BRD-K43880410,pregnenolone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|,8955.0,Launched,glutamate receptor modulator,SULT2B1,rheumatology,rheumatoid arthritis,6820
5079,BRD-A35912562,pregnenolone-succinate,"CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|",,Preclinical,GABA receptor negative allosteric modulator,CYP17A1,,,1586
5080,BRD-K46290096,preladenant,COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1,10117987.0,Phase 3,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
5083,BRD-K96671969,pretomanid,[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1,456199.0,Launched,nitric oxide donor,FASN,,,2194
5086,BRD-K01825595,prilocaine,"CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|",6603976.0,Launched,local anesthetic,SCN5A,neurology/psychiatry,anesthetic,6331
5087,BRD-K15318909,PRIMA1,OCC1(CO)N2CCC(CC2)C1=O,322968.0,Preclinical,TP53 inhibitor,ACHE,,,43
5089,BRD-K32247306,primidone,CCC1(C(=O)NCNC1=O)c1ccccc1,4909.0,Launched,GABA receptor antagonist,CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,2560|2561|2562|2563|2564|2565|2566|2567|2568|11280|6323|6326|6328|6329|6331|6332|6334|6335|6336|55879|2891|2901|89832|1137|2554|2555|2556|2557|2558|2559
5090,BRD-K87316765,prinaberel,Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1,656954.0,Phase 2,estrogen receptor agonist,ESR2|NCOA1,,,8648|2100
5092,BRD-K01662324,priralfinamide,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,5745207.0,Phase 3,sodium channel blocker,CACNA1B,,,774
5099,BRD-K46317332,proadifen,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,4910.0,Preclinical,nitric oxide synthase inhibitor,NOS1,,,340719
5100,BRD-K95237249,probenecid,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O,4911.0,Launched,uricosuric blocker,PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1,nephrology|rheumatology,hyperuricemia|gout,9376|9356|24145|55867|53919
5101,BRD-K72029282,probucol,CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,4912.0,Launched,atherogenesis inhibitor,ABCA1|ABCB11|CES1,cardiology,coronary artery disease (CAD),1066|19|8647
5102,BRD-K75089421,procainamide,CCN(CC)CCNC(=O)c1ccc(N)cc1,4913.0,Launched,sodium channel blocker,DNMT1|SCN5A,cardiology,ventricular arrhythmias|ventricular tachycardia (VT),1786|6331
5103,BRD-K24616672,procaine,CCN(CC)CCOC(=O)c1ccc(N)cc1,4914.0,Launched,HMGCR inhibitor,CHRNA2|GRIN3A|HTR3A|KCNMA1|KCNMB1|KCNMB2|KCNMB3|KCNMB4|KCNN1|KCNN2|KCNN3|KCNN4|MAOA|MAOB|RYR1|RYR2|SCN10A|SLC6A3,neurology/psychiatry,anesthetic,4128|4129|3778|3779|3780|3781|3782|3783|6336|6531|1135|27345|6261|27094|6262|116443|3359
5105,BRD-K78666826,procaterol,CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,688561.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154
5106,BRD-K19352500,prochlorperazine,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,4917.0,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4,gastroenterology,nausea|vomiting,1812|1813|1814|1815
5111,BRD-A16311756,profenamine,CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|,667534.0,Launched,butyrylcholinesterase inhibitor|cholinergic receptor antagonist,CHRM1,neurology/psychiatry,Parkinson's Disease,1128
5112,BRD-K68408467,proflavine-hemisulfate,Nc1ccc2cc3ccc(N)cc3nc2c1,7099.0,Phase 2,topical anesthetic,F2,,,2147
5113,BRD-K64994968,progesterone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|,5994.0,Launched,progesterone receptor agonist,CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ESR1|NR3C2|OPRK1|PGR|TRPC5,obstetrics/gynecology|endocrinology,infertility|amenorrhea,117155|7224|1586|2099|347732|4306|378807|117144|5241|4986
5114,BRD-A19458515,proglumetacin,"CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9,r|",76965948.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
5115,BRD-K01826553,proglumide,CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|,6603906.0,Withdrawn,CCK receptor antagonist,CCKAR|CCKBR,,,886|887
5116,BRD-K28183345,proguanil,CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1,6178111.0,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,malaria,1719
5118,BRD-K06980535,promazine,CN(C)CCCN1c2ccccc2Sc2ccccc12,4926.0,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|HRH1|HTR2A|HTR2C,neurology/psychiatry,schizophrenia,3269|1128|1129|1131|1132|1133|146|147|1812|1813|1814|1815|3356|3358
5119,BRD-K75097983,promestriene,CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC,9883915.0,Launched,estrogen receptor agonist,ESR1,endocrinology,androgenetic alopecia,2099
5120,BRD-A46335897,promethazine,CC(CN1c2ccccc2Sc2ccccc12)N(C)C,89044377.0,Launched,histamine receptor antagonist,HRH1,neurology/psychiatry|allergy,sedative|allergic rhinitis,3269
5122,BRD-K54496168,propacetamol,CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1,68865.0,Launched,cyclooxygenase inhibitor,PTGS2,endocrinology|neurology/psychiatry,fever|pain relief,5743
5123,BRD-K01826541,propafenone,"CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|",184819.0,Launched,antiarrhythmic,ADRB1|ADRB2|KCNA5|KCNH2,cardiology,atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias,153|154|3741|3757
5124,BRD-K53382462,propagermanium,OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O,83030.0,Launched,CCR agonist|interferon receptor agonist,CCR2,infectious disease,hepatitis B,729230
5125,BRD-K90885812,propantheline,CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C,4934.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology,peptic ulcer disease (PUD),1128|1129|1131|1132
5127,BRD-K59273480,propentofylline,CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12,4938.0,Launched,adenosine reuptake inhibitor|phosphodiesterase inhibitor,PDE1A,neurology/psychiatry,stroke,5136
5128,BRD-K14821965,propidium-iodide,CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12,4939.0,Preclinical,,ACHE,,,43
5130,BRD-K91244729,propiverine,CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,4942.0,Launched,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence,1128
5131,BRD-K82255054,propofol,CC(C)c1cccc(C(C)C)c1O,4943.0,Launched,benzodiazepine receptor agonist,FAAH|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|SCN2A|SCN4A,neurology/psychiatry,anesthetic,2560|2561|2562|2563|2564|2565|2566|2567|2568|79152|6326|6329|55879|2554|2555|2556|2557|2558|2559
5134,BRD-A10070317,propranolol,CC(C)NCC(O)COc1cccc2ccccc12,62882.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,cardiology|neurology/psychiatry,hypertension|angina pectoris|migraine headache,153|154
5135,BRD-K92830582,propranolol-(R),CC(C)NC[C@@H](O)COc1cccc2ccccc12,21138.0,Preclinical,adrenergic receptor antagonist,ADRB2|ADRB3,,,154|155
5136,BRD-K13994703,propranolol-(S),CC(C)NC[C@H](O)COc1cccc2ccccc12,91536.0,Preclinical,adrenergic receptor antagonist,ADRB1|HTR1A|HTR5A|SLC10A1,,,153|6554|3350|3361
5141,BRD-K48168960,propylthiouracil,CCCc1cc(=O)[nH]c(=S)[nH]1,657298.0,Launched,thyroid peroxidase inhibitor,DIO1|TPO,endocrinology,hyperthyroidism|Grave's disease|goiter,7066|11083
5143,BRD-K54339150,proquazone,CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1,31508.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,neurology/psychiatry,pain relief,5742|5743
5146,BRD-K00003716,protirelin,NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,638678.0,Launched,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,7201
5147,BRD-K26813314,protoporphyrin-IX,Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C,,Preclinical,heme oxygenase inhibitor,HMOX1,,,3162
5148,BRD-K42098891,protriptyline,CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|,4976.0,Launched,tricyclic antidepressant,SLC6A2|SLC6A4,neurology/psychiatry,depression,6530|6532
5150,BRD-K77171813,proxyfan,C(COCc1ccccc1)Cc1cnc[nH]1,6421522.0,Preclinical,histamine receptor modulator,HRH3,,,11255
5151,BRD-K79116891,proxymetacaine,CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC,4935.0,Launched,sodium channel blocker,SCN10A|SCN5A,neurology/psychiatry,anesthetic,6336|6331
5153,BRD-K25835157,PRT062070,CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1,44595079.0,Phase 2/Phase 3,JAK inhibitor|SYK inhibitor,SYK,,,6850
5154,BRD-K53734668,PRT062607,N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1,44462758.0,Phase 2,SYK inhibitor,FGR|MAP3K9|SYK,,,6850|2268|4293
5155,BRD-K32456483,PRT4165,O=C1C(=Cc2cccnc2)C(=O)c2ccccc12,207893.0,Preclinical,polycomb repressive complex inhibitor,PRC1,,,9055
5156,BRD-K33681278,prucalopride,COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12,3052762.0,Launched,serotonin receptor agonist,HTR4,gastroenterology,constipation,3360
5158,BRD-K43837174,pruvanserin,Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1,6433122.0,Phase 2,serotonin receptor antagonist,HTR2A|HTR2C,,,3356|3358
5160,BRD-K16757695,PRX-08066,Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N,11502243.0,Phase 2,serotonin receptor antagonist,HTR2B,,,106480180
5161,BRD-K99092662,PS178990,Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N,9882972.0,Phase 1,androgen receptor modulator,AR,,,367
5162,BRD-K71266197,PSB-06126,Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O,25124826.0,Preclinical,NTPDase inhibitor,ENTPD3,,,956
5163,BRD-K10177585,PSB-11,CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|,,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA3,,,140|134|135
5164,BRD-K49027941,PSB-1115,CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O,5311479.0,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2B|ADORA3,,,136|140|134
5165,BRD-K00004243,PSB-36,"[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r,THB:9:1:4:7.8|",,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
5166,BRD-K05419687,PSB-603,CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1,44185871.0,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
5170,BRD-K25524093,PSN-375963,CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1,2875918.0,Preclinical,glucose dependent insulinotropic receptor agonist,GPR119,,,139760
5171,BRD-K33502629,PSNCBAM-1,Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1,11560249.0,Preclinical,cannabinoid receptor modulator,CNR1,,,1268
5172,BRD-K47264279,psoralen,O=c1ccc2cc3ccoc3cc2o1,6199.0,Launched,,MAOA|MAOB,dermatology,psoriasis|eczema|vitiligo,4128|4129
5173,BRD-K20850787,PT-2385,CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12,91754484.0,Phase 1,hypoxia inducible factor inhibitor,EPAS1,,,2034
5176,BRD-K92870997,pterostilbene,COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1,5281727.0,Phase 2/Phase 3,cyclooxygenase inhibitor|PPAR receptor agonist,PTGS2,,,5743
5177,BRD-K36529613,PU-H71,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,9549213.0,Phase 1,HSP inhibitor,HSP90AA1,,,3320
5179,BRD-K44164034,pumosetrag,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O,154104.0,Phase 2,serotonin receptor agonist,HTR3A|HTR4,,,3360|3359
5180,BRD-K73397362,purmorphamine,C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12,5284329.0,Preclinical,smoothened receptor agonist,SMO,,,54498
5181,BRD-K36007650,puromycin,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,439530.0,Preclinical,protein synthesis inhibitor,NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1,,,23521|140801|6147|9349|4809|6122|51121|51187|6167|6132|6135|6138|6143
5182,BRD-K50836978,purvalanol-A,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,456214.0,Preclinical,CDK inhibitor,CDK1|CDK2|CDK4|CDK5|CSNK1G3|RPS6KA1|SRC,,,1456|6195|983|1017|6714|1019|1020
5183,BRD-K41564320,purvalanol-B,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1,448991.0,Preclinical,tyrosine kinase inhibitor,CDK2|CDK4|CDK5|MAPK1|MAPK3|SRPK2,,,6733|5595|1017|5594|1019|1020
5184,BRD-K75282878,putrescine,NCCCCN,1045.0,Phase 2,tissue transglutaminase inhibitor,AMD1|KCNJ4|ODC1,,,3761|89874|262
5185,BRD-A56592690,PX-12,"CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|",86308851.0,Phase 2,thioredoxin inhibitor,CNR1|TXN,,,1268|25828
5191,BRD-K28667793,pyrazinamide,NC(=O)c1cnccn1,1046.0,Launched,fatty acid synthase inhibitor,FASN,infectious disease,tuberculosis,2194
5193,BRD-K01567962,pyrazolanthrone,O=C1c2ccccc2-c2[nH]nc3cccc1c23,8515.0,Preclinical,JNK inhibitor,MAPK10|MAPK8|MAPK8IP1|MAPK9|TTK,,,5601|5602|9479|7272|5599
5194,BRD-K42607789,pyrazoloacridine,COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O,,Phase 2,topoisomerase inhibitor,TOP1|TOP2A,,,7153|7150
5196,BRD-K76204040,pyridoxal,Cc1ncc(CO)c(C=O)c1O,1050.0,Launched,,PDXK,neurology/psychiatry,epilepsy,8566
5199,BRD-K14349461,pyridoxine,Cc1ncc(CO)c(CO)c1O,1054.0,Launched,vitamin B,DDC|PDXK,metabolism,vitamin B6 deficiency,1644|8566
5200,BRD-K88429204,pyrimethamine,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,4993.0,Launched,dihydrofolate reductase inhibitor,DHFR|SLC47A1,infectious disease,malaria,55244|1719
5202,BRD-K16136380,pyrithione-zinc,O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1,,Launched,ATP synthase inhibitor,KCNQ1|KCNQ2|KCNQ4|KCNQ5,dermatology,dandruff|cosmetic,3784|3785|9132|56479
5207,BRD-K11663430,pyroxamide,ONC(=O)CCCCCCC(=O)Nc1cccnc1,4996.0,Phase 1,HDAC inhibitor,HDAC1,,,3065
5208,BRD-K80970344,pyrrolidine-dithiocarbamate,SC(=S)N1CCCC1,65351.0,Preclinical,NFkB pathway inhibitor,HSD11B1|RELA,,,3290|5970
5209,BRD-K39479472,pyrvinium-pamoate,CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1,5281035.0,Launched,androgen receptor antagonist,AR,infectious disease,pinworm,367
5212,BRD-K63631219,quazinone,CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|,135511466.0,Phase 2,phosphodiesterase inhibitor,PDE3A|PDE3B,,,5139|5140
5213,BRD-K97399794,quercetin,Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O,5280343.0,Launched,polar auxin transport inhibitor,ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1,neurology/psychiatry|allergy,fatigue|allergic rhinitis|drowsiness,26275|5294|3055|9262|9361|498|133688|506|509
5214,BRD-K68867920,quetiapine,OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|,5002.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2,neurology/psychiatry,schizophrenia|bipolar disorder,6530|146|147|1812|1813|150|1815|3352|1816|151|152|1814|3350|3351|3354|3355|3356|3358|3359|3362|3363|3269|1128|1129|1131|1132|1133
5215,BRD-K39503511,quiflapon,CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,60923.0,Phase 2,leukotriene synthesis inhibitor,ALOX5|ALOX5AP,,,240|241
5216,BRD-K02995728,quinagolide,CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC,3086401.0,Launched,dopamine receptor agonist,DRD2,endocrinology,hyperprolactinemia,1813
5217,BRD-K72222507,quinapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O,54892.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|congestive heart failure|angioedema,1636
5218,BRD-K42317111,quinaprilat,C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O,107994.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|angioedema,1636
5219,BRD-K13261168,quinelorane,CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12,57242.0,Phase 3,dopamine receptor agonist,DRD2|DRD3,,,1813|1814
5220,BRD-K63794707,quinestrol,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C,9046.0,Launched,estrogen receptor agonist,ESR1|ESR2,endocrinology,menopause,2099|2100
5222,BRD-K59632282,quinidine,COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,441074.0,Launched,sodium channel blocker,KCNA5|KCNA7|KCNH1|KCNH2|KCNH5|KCNK1|KCNK6|SCN5A|SLC29A4,infectious disease|cardiology,malaria|atrial fibrillation (AF)|ventricular arrhythmias,3741|3756|3757|9424|3775|222962|6331|27133|3743
5223,BRD-K07940445,quinine,COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,3034034.0,Launched,hemozoin biocrystallization inhibitor,GP9|KCNB2|KCNN4|SLC29A4,infectious disease,malaria,9312|3783|222962|2815
5226,BRD-K26548821,quinpirol-(-),CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12,54562.0,Phase 2,dopamine receptor agonist,DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR2B|HTR2C,,,1815|1812|1813|3350|1814|106480180|3356|3358
5227,BRD-K77925998,quipazine,C1CN(CCN1)c1ccc2ccccc2n1,5011.0,Preclinical,serotonin receptor agonist,HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4,,,3362|6532|106480180|3350|3352|9177|3356|3358|3359
5228,BRD-K93918653,quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,24889392.0,Phase 3,FLT3 inhibitor,CSF1R|FLT3|KIT|PDGFRA|PDGFRB|RET,,,5156|5159|3815|2322|5979|1436
5230,BRD-K56596464,QX-314,CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C,3925.0,Preclinical,sodium channel blocker,MAPK14|TGFBR1,,,1432|7046
5233,BRD-K96418224,R-1485,Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1,11689373.0,Phase 1,serotonin receptor antagonist,HTR6,,,3362
5235,BRD-K83904070,R-268712,Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1,11703284.0,Preclinical,serine/threonine kinase inhibitor,TGFBR1,,,7046
5236,BRD-K14870255,R-428,Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1,46215462.0,Phase 2,AXL kinase inhibitor,AXL,,,558
5237,BRD-K54665485,R-59022,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1,3012.0,Preclinical,diacylglycerol kinase inhibitor|protein kinase inhibitor,DGKA,,,1606
5238,BRD-K15588452,R-96544,COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1,10668211.0,Preclinical,serotonin receptor antagonist,HTR2A,,,3356
5239,BRD-K23902832,R112,Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1,9904854.0,Phase 1,SYK inhibitor,SYK,,,6850
5241,BRD-K20285085,R406,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC,11213558.0,Phase 1,SYK inhibitor,RET|SYK,,,6850|5979
5242,BRD-K52233191,R547,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,6918852.0,Phase 1,CDK inhibitor,CDK1|CDK2|CDK4|CDK7,,,1017|1019|1022|983
5243,BRD-K01826765,rabeprazole,COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|,9906855.0,Launched,ATPase inhibitor|gastrin inhibitor,ATP4A,gastroenterology,gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome,495
5244,BRD-A11069678,rac-BHFF,"CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|",7023847.0,Preclinical,GABA receptor positive allosteric modulator,GABBR1,,,10537
5245,BRD-A08187463,racecadotril,"CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|",60561.0,Launched,enkephalinase inhibitor,MME,gastroenterology,diarrhea,4321
5246,BRD-K04111260,raclopride,CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,3033769.0,Launched,dopamine receptor antagonist,DRD2|DRD3|HTR1A,,,1813|1814|3350
5249,BRD-K13394247,radafaxine,C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1,9795056.0,Phase 2,dopamine-norepinephrine reuptake inhibitor,SLC6A3,,,6531
5253,BRD-K93123848,RAF265,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,11656518.0,Phase 2,RAF inhibitor|VEGFR inhibitor,BRAF,,,673
5256,BRD-K63828191,raloxifene,Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1,5035.0,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1|ESR2,orthopedics|oncology,osteoporosis|breast cancer,2099|2100
5258,BRD-K08151102,raltitrexed,CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,135400182.0,Launched,thymidylate synthase inhibitor,FPGS|TYMS,oncology,mesothelioma,7298|2356
5259,BRD-K08586861,ramatroban,OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,123879.0,Launched,prostanoid receptor antagonist,PTGDR2|TBXA2R,cardiology|pulmonary,coronary artery disease (CAD)|asthma,6915|11251
5260,BRD-K28761891,ramelteon,CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12,208902.0,Launched,melatonin receptor agonist,MTNR1A|MTNR1B,neurology/psychiatry,insomnia,4544|4543
5262,BRD-K89348303,ramipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O,6992028.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636
5263,BRD-K85046107,ramosetron,Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12,135418340.0,Launched,serotonin receptor antagonist,HTR3A,gastroenterology,nausea|vomiting|irritable bowel syndrome,3359
5264,BRD-K50489389,ranirestat,Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O,153948.0,Phase 3,aldose reductase inhibitor,AKR1B1,,,231
5265,BRD-K30816563,ranitidine,CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1,9883333.0,Launched,histamine receptor antagonist,HRH2,gastroenterology,heartburn,1665
5266,BRD-K01825102,ranolazine,COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|,13560750.0,Launched,sodium channel blocker,SCN10A|SCN9A,cardiology,chronic stable angina,6336|6335
5268,BRD-K58114536,rasagiline,C#CCN[C@@H]1CCc2ccccc12,3052776.0,Launched,monoamine oxidase inhibitor,BCL2|MAOB,neurology/psychiatry,Parkinson's Disease,4129|596
5269,BRD-K77474816,rauwolscine,COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,643606.0,Preclinical,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR1E|HTR2B,,,3352|106480180|150|3351|152|151|3354
5270,BRD-K86309810,ravoxertinib,Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1,71727581.0,Phase 1,ERK1 and ERK2 phosphorylation inhibitor,MAPK1|MAPK3,,,5594|5595
5272,BRD-A67036568,RBC8,"COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|",,Preclinical,Ral GTPase inhibitor,RALA|RALB,,,5898|5899
5273,BRD-A15909516,rebamipide,"OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|",969464.0,Launched,free radical scavenger,FPR1,gastroenterology,peptic ulcer disease (PUD)|gastritis,2357
5274,BRD-K76694128,rebastinib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1,25066467.0,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,ABL1|BCR|FGR|FLT3|HCK|LYN|SRC,,,106480993|4067|3055|2322|25|6714|2268
5275,BRD-K77224738,reboxetine,"CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|",127151.0,Launched,adrenergic receptor antagonist,SLC6A2,neurology/psychiatry,depression,6530
5276,BRD-K84924479,Rec-15/2615,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C,9891980.0,Phase 2,adrenergic receptor antagonist,ADRA1A,,,146
5277,BRD-K85751432,refametinib,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,44182295.0,Phase 2,MEK inhibitor,MAP2K1|MAP2K2,,,5604|5605
5278,BRD-K00003609,regadenoson,CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,219024.0,Launched,adenosine receptor agonist,ADORA1|ADORA2A|ADORA2B|ADORA3,radiology,myocardial perfusion imaging (MPI),136|140|134|135
5279,BRD-K16730910,regorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,11167602.0,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK,oncology,colorectal cancer|gastrointestinal stromal tumors (GIST),5600|673|7010|5156|3815|5159|2444|3791|1969|2321|4914|2260|2324|6037|4921|25|2263|5979
5280,BRD-K96720755,relcovaptan,COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl,60943.0,Phase 2,vasopressin receptor antagonist,AVPR1A|AVPR1B|AVPR2|OXTR,,,552|553|554|5021
5283,BRD-A36074203,remacemide,C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|,760423.0,Phase 3,glutamate receptor antagonist,GRIN1,,,114787
5285,BRD-K89413285,remimazolam,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|,9867812.0,Phase 3,benzodiazepine receptor agonist,GABBR1,,,10537
5286,BRD-K75349868,remodelin,N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1,44442376.0,Preclinical,transferase inhibitor,NAT10,,,55226
5287,BRD-K54094468,remoxipride,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,54477.0,Withdrawn,dopamine receptor antagonist,DRD2|DRD3|DRD4|HTR2A|SIGMAR1,,,10280|1813|1814|1815|3356
5288,BRD-K82846253,repaglinide,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O,65981.0,Launched,insulin secretagogue,ABCC8|KCNJ11|PPARG,endocrinology,diabetes mellitus,6833|5468|3767
5289,BRD-K58486055,reparixin,CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O,9838712.0,Phase 3,CC chemokine receptor antagonist,CXCR1|CXCR2,,,3577|3579
5291,BRD-K80480517,repsox,Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1,449054.0,Preclinical,TGF beta receptor inhibitor,TGFBR1,,,7046
5292,BRD-K61567297,resatorvid,CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|,11703255.0,Phase 3,toll-like receptor inhibitor,TLR4,,,7099
5293,BRD-K95921201,reserpine,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1,5770.0,Launched,vesicular monoamine transporter inhibitor,SLC18A1|SLC18A2,cardiology,hypertension,6570|6571
5295,BRD-K76210423,resiquimod,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,159603.0,Phase 3,toll-like receptor agonist,TLR7|TLR8,,,51284|51311
5297,BRD-K28822270,resminostat,CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1,11609955.0,Phase 2,HDAC inhibitor,HDAC1|HDAC3|HDAC6|HDAC8,,,3065|8841|55869|10013
5298,BRD-K74190368,resorcinol,Oc1cccc(O)c1,5054.0,Launched,phosphodiesterase inhibitor,CA12|CA14|CA2|PTGS1,dermatology,acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis,23632|760|771|5742
5300,BRD-K80738081,resveratrol,Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1,445154.0,Launched,cytochrome P450 inhibitor|SIRT activator,CSNK2A1|NQO2|PTGS1|PTGS2,,,5743|1459|5742|4835
5303,BRD-K67935717,retaspimycin,"CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|",25169033.0,Phase 3,HSP inhibitor,HSP90AA1,,,3320
5305,BRD-K22429181,retinol,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|,445354.0,Launched,retinoid receptor ligand,ALDH1A1|ALDH1A2|ALDH1A3|DHRS3|DHRS4|LRAT|NR2C2|RBP1|RBP3|RDH11|RDH12|RDH13|RDH14|RDH5|RDH8|RETSAT|RHO|RLBP1|RXRA|RXRB|RXRG,dermatology,cosmetic|acne vulgaris (AV)|keratosis,6017|9227|50700|7182|10901|8854|9249|51109|5926|57665|5959|145226|1869|112724|216|220|54884|6256|6257|6258|6010
5308,BRD-A68281735,REV-5901,"CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|",40428144.0,Phase 2,leukotriene receptor antagonist|lipoxygenase inhibitor,ALOX5,,,240
5309,BRD-A51497544,revaprazan,"C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1,r|",40462255.0,Launched,potassium-competitive acid antagonist,ATP4A,gastroenterology,gastritis,495
5311,BRD-K79700588,reversan,O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1,2298706.0,Preclinical,MRP inhibitor,ABCC1,,,4363
5312,BRD-K77286328,reversine,C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12,210332.0,Preclinical,Aurora kinase inhibitor,AURKB|INCENP|MAP2K1,,,5604|3619|9212
5314,BRD-K89391146,RG108,OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O,702558.0,Preclinical,DNA methyltransferase inhibitor,DNMT1|DNMT3B,,,1786|1789
5315,BRD-K32942258,RG1530,"COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|",,Phase 1,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,FGFR1|FGFR2,,,2260|2263
5316,BRD-K02389548,RG2833,Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N,56654642.0,Phase 1,HDAC inhibitor,HDAC1|HDAC3,,,3065|8841
5317,BRD-K22024824,RG4733,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O,49867930.0,Phase 2,gamma secretase inhibitor,PSEN1,,,5663
5318,BRD-K13178532,RG7112,CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|,57406853.0,Phase 1,MDM inhibitor,MDM2,,,4193
5321,BRD-K20986415,RGB-286638,COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1,11285002.0,Phase 1,CDK inhibitor,CDK1|CDK2|CDK3|CDK4|CDK5|CDK6|CDK7|CDK9|FLT3|GSK3B|JAK2|MAP3K7|MAPK9,,,1025|5601|3717|6885|2322|2932|983|1017|1018|1019|1020|1021|1022
5322,BRD-K61688984,RGFP966,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,56650312.0,Preclinical,HDAC inhibitor,HDAC3,,,8841
5324,BRD-K56047318,RHC-80267,O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1,5063.0,Preclinical,triacylglycerol lipase inhibitor,DAGLA|DAGLB,,,221955|747
5325,BRD-K27335680,rhein,OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,10168.0,Phase 1,,HSP90AA1,,,3320
5326,BRD-K67772619,rheochrysidin,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,10639.0,Preclinical,protein tyrosine kinase inhibitor,PTPN1,,,5770
5328,BRD-K79555887,RI-1,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|,1074953.0,Preclinical,,RAD51,,,5888
5329,BRD-K60369935,ribavirin,NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,37542.0,Launched,antiviral,ADK|ENPP1|IMPDH1|IMPDH2|NT5C2,infectious disease,hepatitis C,22978|132|5167|727833|3615
5331,BRD-K36788280,ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1,44631912.0,Launched,CDK inhibitor,CDK4|CDK6,oncology,breast cancer,1019|1021
5332,BRD-K92760278,riboflavin,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,493570.0,Launched,vitamin B,BLVRB|RFK,gastroenterology,jaundice,55312|645
5333,BRD-K09229706,riboflavin-5-phosphate-sodium,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C,643976.0,Launched,,BLVRB|DHODH|DPYD|HAO1|HAO2|MT-ND1|NOS1|PNPO|POR|PPCDC|RFK|RPS6KA4|SGK1,,,55163|645|60490|51179|1806|340719|55312|6446|7417|8986|54363|1723
5335,BRD-K55188888,ribostamycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,33042.0,Launched,bacterial 30S ribosomal subunit inhibitor,P4HB,infectious disease,human immunodeficiency virus (HIV-1),5034
5337,BRD-K33682646,ricinoleic-acid,CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O,643684.0,Launched,prostanoid receptor agonist,PTGER3,,,5733
5340,BRD-K01507359,rifampin,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|",135925261.0,Launched,RNA polymerase inhibitor,NR1I2|SLCO1A2|SLCO1B1|SLCO1B3,infectious disease,tuberculosis|meningitis,8856|28234|6579|10599
5341,BRD-K38512030,rifamycin,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|",5282048.0,Launched,DNA directed RNA polymerase inhibitor,SLCO1A2|SLCO1B1|SLCO1B3|SLCO2B1,infectious disease,tuberculosis|leprosy,28234|6579|11309|10599
5343,BRD-K28346421,rifapentine,"CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|",136238508.0,Launched,RNA polymerase inhibitor,CYP2C8|CYP2C9|CYP3A4,infectious disease,tuberculosis,1576|1558|1559
5345,BRD-K55187425,rigosertib,COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1,6918736.0,Phase 3,cell cycle inhibitor|PLK inhibitor,PLK1,,,5347
5347,BRD-K01638814,rilmenidine,C1CC1C(NC1=NCCO1)C1CC1 |t:6|,68712.0,Launched,adrenergic receptor agonist|imidazoline receptor agonist,ADRA2A,cardiology,hypertension,150
5348,BRD-K06240250,rilpivirine,Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1,6451164.0,Launched,non-nucleoside reverse transcriptase inhibitor,NR1I2|SCN10A,infectious disease,human immunodeficiency virus (HIV-1),8856|6336
5349,BRD-K21283037,riluzole,Nc1nc2ccc(OC(F)(F)F)cc2s1,5070.0,Launched,glutamate inhibitor,KCNK10|KCNK2|KCNK4|KCNN4|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A|SLC7A11,neurology/psychiatry,amyotrophic lateral sclerosis (ALS),3776|6336|6335|3783|682|11280|50801|6323|6326|6328|6329|6331|6332|6334|54207
5351,BRD-K70490179,rimcazole,C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1,53389.0,Phase 1,sigma receptor antagonist,SIGMAR1,,,10280
5352,BRD-K55781385,rimegepant,N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F,51049968.0,Launched,calcitonin antagonist,CALCA,,,796
5354,BRD-K31627533,rimexolone,"CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|",5311412.0,Launched,glucocorticoid receptor agonist,NR3C1|SERPINA6,ophthalmology,anterior uveitis,866|2908
5355,BRD-K13296708,rimonabant,Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,104850.0,Withdrawn,cannabinoid receptor antagonist,CNR1|GPR55,,,9290|1268
5356,BRD-K84783599,riociguat,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,11304743.0,Launched,guanylate cyclase stimulant,GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3,cardiology,hypertension,2977|2974|2982|2983
5359,BRD-K53814070,ripasudil,C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,9863672.0,Launched,rho associated kinase inhibitor,ROCK1|ROCK2,ophthalmology,glaucoma|ocular hypertension,9475|6093
5360,BRD-K57427145,ripazepam,CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|,33474.0,Phase 2,benzodiazepine receptor agonist,GABRA1,,,2554
5363,BRD-K05185389,risedronate,OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O,5245.0,Launched,osteoclast inhibitor,FDPS,orthopedics|endocrinology,osteoporosis|Paget's disease,2224
5365,BRD-K53857191,risperidone,Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12,5073.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia|bipolar disorder|irritability,146|147|1812|1813|150|1815|3352|151|3354|152|1814|3350|3355|3351|3356|3358|3362|3363|3269
5366,BRD-K00317371,RITA,OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1,374536.0,Preclinical,MDM inhibitor,MDM2,,,4193
5367,BRD-K40887525,ritanserin,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1,5074.0,Phase 3,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7,,,3361|3362|3363|146|147|106480180|3350|3351|3352|3356|3358
5369,BRD-K51485625,ritonavir,CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,392622.0,Launched,HIV protease inhibitor,CYP1A2|CYP2B6|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP2E1|CYP3A4|CYP3A5|CYP3A7,infectious disease,human immunodeficiency virus (HIV-1),1571|100861540|1544|1576|1577|1555|1557|1558|1559|1565
5370,BRD-K79966802,rivanicline,CNCC\C=C\c1cccnc1,5310967.0,Phase 2,acetylcholine receptor agonist,CHRNA4|CHRNB2|CXCL8,,,3576|1137|1141
5371,BRD-K37130656,rivaroxaban,Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O,9875401.0,Launched,coagulation factor inhibitor,F10,neurology/psychiatry|hematology|cardiology,stroke|systemic embolism|atrial fibrillation (AF)|deep vein thrombosis (DVT)|pulmonary embolism (PE),2159
5372,BRD-K10706131,rivastigmine,CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,77991.0,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,Alzheimer's disease|Parkinson's Disease|senile dementia,43|590
5373,BRD-K75699339,rizatriptan,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,5078.0,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache,3350|3351|3352|3354|3355
5374,BRD-K19333160,RKI-1447,Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1,60138149.0,Preclinical,rho associated kinase inhibitor,CDC42BPA|DMPK|LIMK1|MYLK|PAK1|PKN1|ROCK1|ROCK2,,,1760|9475|6093|3984|5585|8476|4638
5377,BRD-K41415459,RN-1,CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1,45376076.0,Preclinical,histone demethylase inhibitor,KDM1A,,,23028
5378,BRD-K95581532,RN-1734,CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl,3601086.0,Preclinical,TRPV antagonist,TRPV4,,,59341
5379,BRD-K45519571,RN-1747,[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1,5068295.0,Preclinical,TRPV agonist,TRPV4,,,59341
5380,BRD-A63546914,Ro-04-5595,COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|,92169474.0,Preclinical,glutamate receptor antagonist,GRIN2B,,,2904
5381,BRD-K00486786,Ro-08-2750,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O,17756791.0,Preclinical,NGF binding inhibitor,NGF|NGFR,,,4803|4804
5382,BRD-K79684402,Ro-10-5824,Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|,16759175.0,Preclinical,dopamine receptor agonist,DRD4,,,1815
5384,BRD-K77220725,Ro-1138452,CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|,9839644.0,Preclinical,prostanoid receptor antagonist,PTGIR,,,5739
5385,BRD-K82823076,Ro-15-4513,CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-],5081.0,Preclinical,GABA benzodiazepine site receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2,,,2561|2566|2554|2555|2556|2557|2558|2559
5386,BRD-K80778372,Ro-19-4605,CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C,127382.0,Preclinical,GABA benzodiazepine site receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,,2554|2555|2556|2558
5387,BRD-A07207424,Ro-20-1724,"CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|",6998998.0,Preclinical,phosphodiesterase inhibitor,PDE3A|PDE4A|PDE4B|PDE4C|PDE4D,,,5139|5141|5142|5143|5144
5388,BRD-K51541829,Ro-25-6981,C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1,6604887.0,Preclinical,glutamate receptor antagonist|monamine transporter modulator,GRIN2B,,,2904
5389,BRD-K21672174,Ro-28-1675,CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1,9886086.0,Preclinical,glucokinase activator,GCK,,,5871
5390,BRD-K00354853,Ro-3,COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C,11289644.0,Preclinical,purinergic receptor antagonist,P2RX3,,,5024
5391,BRD-K78373679,Ro-3306,O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|,135400873.0,Preclinical,CDK inhibitor,CDK1,,,983
5393,BRD-K55192287,Ro-48-8071,CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C,1949.0,Preclinical,oxidosqualene cyclase inhibitor,LSS,,,64327
5394,BRD-K64538373,Ro-4987655,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,11548630.0,Phase 1,MEK inhibitor,MAP2K1,,,5604
5396,BRD-K82804538,Ro-5126766,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,16719221.0,Phase 1,MEK inhibitor|RAF inhibitor,BRAF|MAP2K1|MAP2K2|RAF1,,,673|5604|5605|6037
5398,BRD-K28007504,Ro-60-0175,C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12,3045227.0,Preclinical,serotonin receptor agonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
5399,BRD-K12639498,Ro-61-8048,COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O,5282337.0,Preclinical,kynurenine 3-monooxygenase inhibitor,KMO,,,8564
5400,BRD-K91333421,Ro-67-7476,Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1,32681978.0,Preclinical,glutamate receptor positive allosteric modulator,GRM1,,,2911
5401,BRD-K58299615,Ro-90-7501,Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1,824226.0,Preclinical,beta amyloid protein neurotoxicity inhibitor,APP,,,351
5403,BRD-K26169680,robalzotan,NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1,3055171.0,Phase 2,serotonin receptor antagonist,HTR1A,,,3350
5405,BRD-K33610132,rociletinib,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,57335384.0,Phase 3,EGFR inhibitor,EGFR,,,1956
5406,BRD-K43305603,rocuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1,441290.0,Launched,acetylcholine receptor antagonist,CHRM2|CHRNA2|HTR3A,neurology/psychiatry,anesthetic,1129|3359|1135
5407,BRD-K21733600,rofecoxib,CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|,5090.0,Withdrawn,cyclooxygenase inhibitor,ELN|PTGS2,,,100130933|5743
5408,BRD-K03194791,roflumilast,FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl,449193.0,Launched,phosphodiesterase inhibitor,PDE4A|PDE4B|PDE4C|PDE4D,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis,5144|5141|5142|5143
5415,BRD-K61397605,romidepsin,C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|,56840936.0,Launched,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,hematologic malignancy,cutaneous T-cell lymphoma (CTCL),55869|9734|8841|3065|3066|10013|10014|9759
5417,BRD-K15933101,ropinirole,CCCN(CCC)CCc1cccc2NC(=O)Cc12,5095.0,Launched,dopamine receptor agonist,ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease|restless leg syndrome,3352|1815|1816|1812|1813|150|151|152|1814|3350|3356|3351|106480180|3358
5418,BRD-K50938786,ropivacaine,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,175805.0,Launched,sodium channel blocker,SCN10A,neurology/psychiatry,anesthetic,6336
5421,BRD-K07691486,roscovitine,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,160355.0,Phase 2,CDK inhibitor,CDK2|CDK9,,,1017|1025
5424,BRD-K01826734,rosiglitazone,CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|,10021239.0,Withdrawn,insulin sensitizer|PPAR receptor agonist,FFAR1|PPARG|TRPC5|TRPM3,,,2864|80036|7224|5468
5426,BRD-K20313525,rosmarinic-acid,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1,5281792.0,Launched,GABA transaminase inhibitor,MCL1|TYR,,,4170|7299
5428,BRD-K11672787,rostafuroxine,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1,153976.0,Phase 2,ATPase inhibitor,ATP1A1,,,476
5429,BRD-K82941592,rosuvastatin,CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O,446157.0,Launched,HMGCR inhibitor,HMGCR,endocrinology|cardiology,hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis,3156
5430,BRD-K91111634,rotigotine,CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,59227.0,Launched,dopamine receptor agonist,ADRA2B|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A,neurology/psychiatry,Parkinson's Disease|restless leg syndrome,1816|1812|1813|1814|1815|151|3350
5431,BRD-K35719256,rotundine,COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC,72301.0,Launched,serotonin receptor agonist,DRD1|DRD2|DRD3|HTR1A,neurology/psychiatry,anxiety|sedative,1812|1813|1814|3350
5434,BRD-K81855038,roxatidine-acetate,CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1,5105.0,Launched,histamine receptor antagonist,HRH2,gastroenterology,Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis,1665
5435,BRD-K38684403,roxithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,,Launched,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,respiratory tract infections|urinary tract infections|skin infections,2862
5436,BRD-A29148886,RP-001,CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|,58344861.0,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,,1901
5438,BRD-K87973152,RQ-00203078,OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F,49783953.0,Preclinical,transient receptor potential channel antagonist,TRPM8,,,79054
5439,BRD-K06894065,RRx-001,[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O,15950826.0,Phase 3,glucose 6-phosphate dehydrogenase inhibitor,G6PD,,,8266
5441,BRD-K08640512,RS-100329,Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O,3567002.0,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1D,,,146
5442,BRD-K87048468,RS-102221,COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O,3693566.0,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
5443,BRD-K83063356,RS-102895,FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1,10000456.0,Preclinical,CCR antagonist,CCR2,,,729230
5444,BRD-K90825648,RS-127445,CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12,196968.0,Phase 1,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
5446,BRD-K76840893,RS-17053,CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1,3894573.0,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1D,,,146
5447,BRD-K01868942,RS-23597-190,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,182593.0,Preclinical,serotonin receptor antagonist,HTR4,,,3360
5448,BRD-K20742498,RS-39604,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,5145950.0,Preclinical,serotonin receptor antagonist,HTR4,,,3360
5450,BRD-K87510569,RS-504393,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,9953769.0,Preclinical,CC chemokine receptor antagonist,CCL2|CCR2,,,6347|729230
5451,BRD-K00004219,RS-56812,Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12,6604789.0,Preclinical,serotonin receptor partial agonist,HTR3A,,,3359
5452,BRD-K46142322,RS-67333,CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1,183782.0,Preclinical,serotonin receptor partial agonist,HTR4,,,3360
5453,BRD-K50018155,RS-67506,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,133076.0,Preclinical,serotonin receptor partial agonist,HTR4,,,3360
5454,BRD-K86600316,RS-79948,CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12,9908992.0,Preclinical,adrenergic receptor antagonist,ADRA2A,,,150
5456,BRD-K56211775,RTA-408,"CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|",71811910.0,Phase 2,nitric oxide production inhibitor,NFE2L2,,,4780
5457,BRD-K00234327,RU-24969,COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|,108029.0,Phase 1,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6,,,3361|3362|106480180|3350|3351|3352|3356|3358
5458,BRD-K37687387,RU-28318,CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|,3034004.0,Phase 2,cytochrome P450 inhibitor,NR3C2,,,4306
5459,BRD-K85285268,RU-42173,CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O,3086576.0,Phase 2,adrenergic receptor agonist,ADRB2,,,154
5460,BRD-K62762455,RU-58841,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,132981.0,Phase 2,androgen receptor antagonist,AR,,,367
5461,BRD-A33603104,RU-SKI-43,"CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|",93160320.0,Preclinical,hedgehog pathway inhibitor,HHAT,,,55733
5462,BRD-K79821389,rubitecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,472335.0,Phase 3,topoisomerase inhibitor,TOP1,,,7150
5464,BRD-K88560311,rucaparib,CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23,9931954.0,Phase 3,PARP inhibitor,PARP1|PARP2,,,10038|142
5465,BRD-K61036791,rucinol,CCCCc1ccc(O)cc1O,205912.0,Phase 1,tyrosinase inhibitor,TYR,,,7299
5466,BRD-K20079257,rufinamide,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,129228.0,Launched,voltage-gated sodium channel blocker,GRM5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures,6336|2915|11280|6323|6326|6328|6329|6331|6332|6334|6335
5468,BRD-K98004573,rupatadine,Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1,133017.0,Launched,histamine receptor antagonist|platelet activating factor receptor antagonist,HRH1|PTAFR,allergy,allergic rhinitis|urticaria,5724|3269
5469,BRD-K94723713,rutaecarpine,O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12,65752.0,Preclinical,cyclooxygenase inhibitor,PTGS2,,,5743
5470,BRD-K20482099,rutin,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,5280805.0,Launched,antioxidant|capillary stabilizing agent|nitric oxide scavenger,AKR1C3,rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy,joint pain|nasal congestion|constipation|irritability|allergic rhinitis,8644
5471,BRD-K53972329,ruxolitinib,N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,25126798.0,Launched,JAK inhibitor,JAK1|JAK2|JAK3|TYK2,hematologic malignancy|hematology,myelofibrosis|polycythemia vera,7297|3716|3717|3718
5472,BRD-K19601669,ruxolitinib-(S),N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,50878566.0,Preclinical,JAK inhibitor,JAK1|JAK2,,,3716|3717
5474,BRD-K00091711,RWJ-21757,Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1,135410906.0,Phase 2,toll-like receptor agonist,TLR7,,,51284
5475,BRD-K94623186,RWJ-50271,Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO,9953357.0,Preclinical,integrin inhibitor,ICAM1,,,3383
5476,BRD-K07074923,RWJ-67657,OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1,3008319.0,Phase 1,MAP kinase inhibitor,MAPK14|PTGS2,,,1432|5743
5477,BRD-K66213167,RX-3117,Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|,11242315.0,Phase 1/Phase 2,CDK inhibitor|DNA synthesis inhibitor,CDK2|DNMT1,,,1017|1786
5478,BRD-A65597028,RX-821002,"CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|",67743720.0,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,,,146|147|150|151|152
5479,BRD-K06426971,ryuvidine,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|,481747.0,Preclinical,histone lysine methyltransferase inhibitor,CDK2|CDK4,,,1017|1019
5480,BRD-K37635256,S-07662,Cc1oc2ccccc2c1CNC(=O)NCc1cccs1,2732040.0,Preclinical,CAR antagonist,NR1I3,,,9970
5481,BRD-K60005752,S-111,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C,11213350.0,Phase 2,PARP inhibitor,PARP1,,,142
5482,BRD-K46766488,S-14506,COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1,131906.0,Preclinical,serotonin receptor agonist,HTR1A,,,3350
5486,BRD-K10673031,S-isopropylisothiourea,CC(C)SC(N)=N,445319.0,Preclinical,nitric oxide synthase inhibitor,NOS3,,,342977
5487,BRD-K63123526,S-methylcysteine,CSC[C@H](N)C(O)=O,7058174.0,Phase 1,,CTSD|MGMT,,,1509|4255
5488,BRD-K00024724,S-nitrosoglutathione,N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O,104858.0,Phase 1,nitric oxide stimulant,PTPN1,,,5770
5492,BRD-K02501528,S18986,O=S1(=O)N[C@H]2CCCN2c2ccccc12,637863.0,Phase 2,glutamate receptor modulator,GRIA1|GRIA2|GRIA3|GRIA4,,,2890|2891|2892|2893
5493,BRD-K12745498,S1P1-agonist-III,COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F,54764919.0,Preclinical,sphingosine kinase inhibitor,S1PR1,,,1901
5494,BRD-K48826825,S26948,COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC,9958279.0,Preclinical,PPAR receptor agonist,PPARG,,,5468
5495,BRD-K96798615,S4,Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1,53342705.0,Preclinical,carbonic anhydrase inhibitor,CA12|CA9,,,768|771
5498,BRD-K99819791,SA-47,CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1,9840648.0,Preclinical,FAAH inhibitor,FAAH,,,79152
5499,BRD-K46493214,saccharin,O=C1NS(=O)(=O)c2ccccc12,5143.0,Launched,DNA polymerase inhibitor,CA1|CA12|CA2|CA9,,,760|768|771|759
5500,BRD-A24122750,saclofen,"NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|",57453816.0,Preclinical,GABA receptor antagonist,GABBR1|GABBR2|KCTD12|KCTD16|KCTD8,,,9568|115207|10537|57528|386617
5501,BRD-K91456750,sacubitril,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O,9811834.0,Launched,neprilysin inhibitor,MME,cardiology,congestive heart failure,4321
5504,BRD-K92613113,safinamide,C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,131682.0,Launched,dopamine reuptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor,MAOB,neurology/psychiatry,Parkinson's Disease,4129
5505,BRD-K93944989,safingol,CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO,91486.0,Phase 1,PKC inhibitor,TRPM3,,,80036
5506,BRD-K90582192,safranal,"CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|",61041.0,Phase 2,benzodiazepine receptor agonist,GABBR1,,,10537
5507,BRD-K99433989,SAG,CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|,,Preclinical,smoothened receptor agonist,SMO|TRPC6,,,7225|54498
5508,BRD-K01828772,sal003,"Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|",2252542.0,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2A,,,1965
5514,BRD-K93632104,salicylic-acid,OC(=O)c1ccccc1O,338.0,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,AKR1C1|ASIC3|PTGS1|PTGS2,dermatology|endocrinology|neurology/psychiatry,acne vulgaris (AV)|fever|pain relief,5743|1645|5742|9311
5515,BRD-K66030860,salidroside,OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,159278.0,Preclinical,beta amyloid protein neurotoxicity inhibitor,APP,,,351
5517,BRD-K98453471,salirasib,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O,5469318.0,Phase 2,mTOR inhibitor,TRPA1,,,8989
5518,BRD-K01826763,salmeterol,OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|,6604001.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm,154
5520,BRD-A45107007,salubrinal,"ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|",2305942.0,Preclinical,eukaryotic translation initiation factor inhibitor,EIF2S1,,,1965
5522,BRD-K18898553,salvianolic-acid-B,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,11629084.0,Phase 2,EGFR inhibitor|metalloproteinase inhibitor,MMP9,,,4318
5523,BRD-K19284129,salvinorin-A,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,128563.0,Phase 1,opioid receptor agonist,OPRD1|OPRK1|OPRM1,,,4985|4986|4988
5529,BRD-K66898851,sanguinarium-chloride,C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12,5154.0,Phase 1,apoptosis stimulant,CASP3,,,836
5530,BRD-K99741577,SANT-1,Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1,6878030.0,Preclinical,smoothened receptor antagonist,SHH|SMO,,,54498|6469
5531,BRD-K35781423,SANT-2,CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1,1367095.0,Preclinical,smoothened receptor antagonist,SHH|SMO,,,54498|6469
5533,BRD-K36859431,sapropterin,C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1,135398654.0,Launched,phenylalanine 4-hydroxylase stimulant,NOS3|PAH|TH|TPH1,metabolism,hyperphenylalaninemia (HPA),342977|7166|5053|7054
5534,BRD-K09963420,saquinavir,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,441243.0,Launched,HIV protease inhibitor,CYP3A4,infectious disease,human immunodeficiency virus (HIV-1),1576
5535,BRD-K75308783,SAR-245409,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1,49867926.0,Phase 1/Phase 2,PI3K inhibitor,MTOR|PIK3CG,,,2475|5294
5536,BRD-K38904395,SAR131675,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,71295845.0,Preclinical,VEGFR inhibitor,FLT4,,,2324
5537,BRD-K72868067,SAR405,C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F,72709209.0,Preclinical,PI3K inhibitor,PIK3C3,,,5289
5538,BRD-K45349653,SAR405838,CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1,,Phase 1,MDM inhibitor,MDM2,,,4193
5539,BRD-K56912469,SAR407899,O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,15604510.0,Phase 2,rho associated kinase inhibitor,ROCK1,,,6093
5540,BRD-K19540840,saracatinib,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,10302451.0,Phase 2/Phase 3,SRC inhibitor,ABL1|LCK|SRC|YES1,,,25|6714|3932|7525
5542,BRD-K51263939,sarcosine,CNCC(O)=O,7311726.0,Phase 2,glycine transporter inhibitor,SLC6A9,,,6536
5545,BRD-K79878800,saroglitazar,CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O,60151560.0,Launched,PPAR receptor agonist,PPARA|PPARG,endocrinology|cardiology|gastroenterology,diabetes mellitus|dyslipidemia|non-alcoholic steatohepatitis (NASH),5465|5468
5546,BRD-A34358106,sarpogrelate,COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|,40468125.0,Launched,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,endocrinology|cardiology|rheumatology,diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease,3356|106480180|3358
5547,BRD-K48892307,sasapyrine,OC(=O)c1ccccc1OC(=O)c1ccccc1O,5161.0,Launched,NFkB pathway inhibitor,PTGS1|PTGS2,rheumatology,osteoarthritis|rheumatoid arthritis,5742|5743
5549,BRD-K98028353,savolitinib,C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1,68289010.0,Phase 3,c-Met inhibitor,MET,,,8731
5550,BRD-K00003546,saxagliptin,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2,,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
5551,BRD-K77677632,SB-200646,Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12,126769.0,Preclinical,serotonin receptor antagonist,HTR2B|HTR2C,,,106480180|3358
5552,BRD-K54330070,SB-202190,Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1,5169.0,Preclinical,p38 MAPK inhibitor,AKT1|ALOX5|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1,,,5600|5578|6093|6446|207|240|6300|2932|6198|1111|1432|5594|3932|5599
5553,BRD-K27141178,SB-203186,O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,3272300.0,Preclinical,serotonin receptor antagonist,HTR4,,,3360
5554,BRD-K01826796,SB-203580,C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|,40467016.0,Preclinical,p38 MAPK inhibitor,AKT1|ALOX5|CHEK1|CYP2D6|CYP3A4|GAK|GSK3B|LCK|MAPK1|MAPK10|MAPK11|MAPK12|MAPK14|MAPK8|MAPK9|PRKCA|RAF1|RIPK2|ROCK1|RPS6KB1|SGK1|SRC|TNF,,,2580|6037|1432|6300|1565|1576|6446|6198|6714|8767|5578|6093|207|7124|1111|5594|3932|5599|5600|5601|5602|240|2932
5555,BRD-A22707317,SB-205384,"CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|",15991599.0,Preclinical,GABA receptor modulator,GABRA3|GABRA5|GABRA6,,,2556|2558|2559
5556,BRD-K36395411,SB-206553,Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1,5163.0,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
5557,BRD-K30867024,SB-216641,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,3292447.0,Preclinical,serotonin receptor antagonist,HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,,,106480180|3350|3351|3352|3356|3358
5558,BRD-K59184148,SB-216763,Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|,176158.0,Preclinical,glycogen synthase kinase inhibitor,CCNA2|CDK2|GSK3A|GSK3B,,,1017|890|2931|2932
5559,BRD-A06352508,SB-218078,"O=C1NC(=O)c2c1c1c3ccccc3n3[C@H]4CC[C@@H](O4)n4c5ccccc5c2c4c13 |&1:15,&2:18,r|",3387354.0,Preclinical,CHK inhibitor,CHEK1,,,1111
5560,BRD-K61097567,SB-218795,COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1,6604858.0,Preclinical,tachykinin antagonist,TACR3,,,6870
5561,BRD-K14807180,SB-221284,CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F,443389.0,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
5562,BRD-K04414442,SB-222200,CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1,6604009.0,Preclinical,tachykinin antagonist,TACR3,,,6870
5563,BRD-K61323504,SB-225002,Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O,3854666.0,Preclinical,CC chemokine receptor antagonist,CXCR2,,,3579
5564,BRD-K15424032,SB-228357,COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F,443390.0,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
5565,BRD-K98795921,SB-2343,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,46912230.0,Phase 1,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,22883|5290|2475|5291|5294
5566,BRD-K82091397,SB-239063,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|,,Preclinical,p38 MAPK inhibitor,MAPK11|MAPK14|PTGS2,,,5600|1432|5743
5567,BRD-K19412355,SB-242235,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,9863367.0,Phase 1,p38 MAPK inhibitor,HSPB1|MAPK14,,,1432|3315
5568,BRD-K99968849,SB-243213,Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F,443391.0,Phase 1,serotonin receptor inverse agonist,HTR2A|HTR2B|HTR2C|HTR6,,,3362|3356|106480180|3358
5569,BRD-K80639402,SB-258585,COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1,3248571.0,Preclinical,serotonin receptor antagonist,HTR6,,,3362
5570,BRD-A91031770,SB-268262,"CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|",93475590.0,Preclinical,calcitonin antagonist,CALCA,,,796
5571,BRD-K24201553,SB-269970,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1,6604889.0,Preclinical,serotonin receptor antagonist,HTR7,,,3363
5572,BRD-K82467063,SB-271046,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1,5312149.0,Phase 1,serotonin receptor antagonist,HTR6,,,3362
5573,BRD-K16107558,SB-297006,CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1,9840971.0,Preclinical,CC chemokine receptor antagonist,CCR3,,,1232
5575,BRD-K41567364,SB-334867,Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1,6604926.0,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,,131450|3061
5576,BRD-K61536336,SB-366791,COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1,667594.0,Preclinical,TRPV antagonist,TRPV1,,,7442
5577,BRD-K03988082,SB-399885,COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC,6918649.0,Preclinical,serotonin receptor antagonist,HTR6,,,3362
5578,BRD-K53913732,SB-408124,CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1,4331799.0,Preclinical,orexin receptor antagonist,HCRTR1|HCRTR2,,,131450|3061
5579,BRD-K76805682,SB-415286,Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|,4210951.0,Preclinical,glycogen synthase kinase inhibitor,GSK3A|GSK3B|RPS6KB1,,,2931|2932|6198
5580,BRD-K67298865,SB-431542,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1,4521392.0,Preclinical,TGF beta receptor inhibitor,ACVR1C|TGFBR1,,,7046|130399
5581,BRD-K03665769,SB-452533,CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1,9842609.0,Preclinical,TRPV antagonist,TRPV1,,,7442
5582,BRD-K40109029,SB-505124,Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C,9858940.0,Preclinical,ALK tyrosine kinase receptor inhibitor,TGFBR1,,,7046
5583,BRD-K37720887,SB-525334,Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C,9967941.0,Preclinical,TGF beta receptor inhibitor,TGFBR1,,,7046
5584,BRD-K78809024,SB-590885,CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1,135421339.0,Preclinical,RAF inhibitor,BRAF,,,673
5585,BRD-K08333979,SB-612111,Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12,10047612.0,Preclinical,nociceptin/orphanin FQ receptor antagonist,OPRL1,,,4987
5587,BRD-K95292280,SB-657510,COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1,11272107.0,Preclinical,urotensin receptor antagonist,UTS2R,,,2837
5588,BRD-K24968862,SB-683698,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1,9912743.0,Phase 1,integrin antagonist,ITGA4|ITGAV|ITGB1|ITGB7,,,3688|3676|3685|3695
5589,BRD-K65991129,SB-705498,FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br,9910486.0,Phase 2,TRPV antagonist,TRPV1,,,7442
5590,BRD-K68633027,SB-706375,COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F,21023902.0,Preclinical,urotensin receptor antagonist,UTS2R,,,2837
5591,BRD-K78941306,SB-742457,O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1,11256720.0,Phase 3,serotonin receptor antagonist,HTR6,,,3362
5592,BRD-K68532323,SB-743921,CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1,9936388.0,Phase 1/Phase 2,kinesin-like spindle protein inhibitor,KIF11,,,3832
5593,BRD-K49597925,SB-747651A,CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N,11393719.0,Preclinical,kinase inhibitor,AKT1|AKT3|ROCK1|RPS6KA5|RPS6KB1,,,9252|6093|207|10000|6198
5594,BRD-K45168550,SB-756050,COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1,1520267.0,Phase 1,G protein-coupled receptor agonist,GPBAR1,,,151306
5595,BRD-K49110935,SB-772077B,CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N,16095343.0,Preclinical,rho associated kinase inhibitor,ROCK1|ROCK2,,,9475|6093
5596,BRD-K86797399,SB-939,CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC,49855250.0,Phase 3,HDAC inhibitor,HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC9,,,9734|8841|10013|3065|3066|83933|10014|9759
5597,BRD-K71667152,SBE-13,COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC,4719406.0,Preclinical,PLK inhibitor,PLK1,,,5347
5598,BRD-K54729176,SBHA,ONC(=O)CCCCCCC(=O)NO,5173.0,Preclinical,HDAC inhibitor,HDAC1|HDAC3,,,3065|8841
5600,BRD-K05361803,SC-10,CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,5175.0,Preclinical,protein kinase activator,PRKCA,,,5578
5601,BRD-K40797222,SC-12267,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|,9820008.0,Phase 2,dihydroorotate dehydrogenase inhibitor,IL17A,,,3605
5603,BRD-K52512893,SC-19220,CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12,4336830.0,Preclinical,prostanoid receptor antagonist,PTGER1,,,5731
5604,BRD-K76365178,SC-236,NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F,9865808.0,Preclinical,cyclooxygenase inhibitor,PTGS2,,,5743
5605,BRD-K62715847,SC-51089,Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1,132749.0,Preclinical,prostanoid receptor antagonist,PTGER1,,,5731
5606,BRD-K14767410,SC-560,COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F,4306515.0,Preclinical,cyclooxygenase inhibitor,PTGS1,,,5742
5607,BRD-K25875056,SC-9,Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1,124172.0,Preclinical,protein tyrosine kinase activator,PRKCA,,,5578
5609,BRD-K29562203,SCH-202676,CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1,682802.0,Preclinical,G protein-coupled receptor modulator,CHRM1|CHRM2|DRD1|DRD2,,,1128|1129|1812|1813
5610,BRD-K00004286,SCH-221510,"Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|",,Preclinical,nociceptin/orphanin FQ receptor agonist,OPRL1,,,4987
5611,BRD-K45435259,SCH-23390,CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1,3036864.0,Preclinical,dopamine receptor antagonist,DRD1|DRD5|HTR2C|KCNJ4|KCNJ6,,,3761|3763|1812|1816|3358
5612,BRD-K55748775,SCH-28080,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,108137.0,Phase 1,ATPase inhibitor,ATP4A,,,495
5613,BRD-K02460719,SCH-51344,COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1,9995890.0,Preclinical,MTH1 inhibitor,NUDT1,,,4521
5614,BRD-K81225797,SCH-58261,Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1,176408.0,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
5615,BRD-K75009076,SCH-900776,Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1,46239015.0,Phase 2,CHK inhibitor,CDK2|CHEK1,,,1017|1111
5616,BRD-K00003711,schisandrin-B,COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|,174277.0,Preclinical,antioxidant,ATR,,,545
5620,BRD-K33809398,SCMC-Lys,N[C@@H](CSCC(O)=O)C(O)=O,193653.0,Launched,mucolytic agent,GSTP1,pulmonary,chronic obstructive pulmonary disease (COPD),2950
5622,BRD-K89923877,scopolamine,CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI,neurology/psychiatry|gastroenterology,motion sickness|vomiting|nausea,1128|1129|1131|1132|1133|6490
5623,BRD-A49906757,scopolamine-N-oxide,"C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|",,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,,,1128|1129|1131|1132
5625,BRD-K22503835,scriptaid,ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23,5186.0,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,,55869|9734|8841|3065|3066|10013|10014|9759
5628,BRD-K91904471,SD-169,NC(=O)c1ccc2[nH]ccc2c1,14973220.0,Preclinical,p38 MAPK inhibitor,MAPK14,,,1432
5629,BRD-K24566386,SD-208,Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1,10316032.0,Preclinical,TGF beta receptor inhibitor,TGFBR1,,,7046
5630,BRD-K51102532,SD-2590,COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1,9892815.0,Preclinical,matrix metalloprotease inhibitor,MMP1|MMP13|MMP2,,,4312|4313|4322
5631,BRD-K01826797,SDM25N,"CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|",9931601.0,Preclinical,opioid receptor antagonist,OPRD1,,,4985
5632,BRD-K15868788,SDZ-205-557,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC,5191.0,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,,9177|3359
5633,BRD-A15530910,SDZ-21009,"CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|",6604875.0,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,HTR1A|HTR1B,,,3350|3351
5634,BRD-K82266792,SDZ-220-040,N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O,6604839.0,Preclinical,glutamate receptor antagonist,GRIN1,,,114787
5635,BRD-K27168049,SDZ-220-581,N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O,128019.0,Preclinical,glutamate receptor antagonist,GRIN1,,,114787
5636,BRD-K65820248,SDZ-NKT-343,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O,9851211.0,Phase 1,tachykinin antagonist,TACR1,,,6869
5637,BRD-K31339597,SDZ-SER-082,CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34,9859407.0,Preclinical,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C,,,3356|106480180|3358
5638,BRD-K39558284,SDZ-WAG-994,CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12,164305.0,Phase 2,adenosine receptor agonist,ADORA1,,,134
5640,BRD-K02965577,secalciferol,C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,5283748.0,Launched,vitamin D receptor agonist,VDR,critical care,bone fracture,1594
5646,BRD-K49071277,securinine,"O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|",442872.0,Preclinical,GABA receptor antagonist|TP53 activator,GABRA1,,,2554
5647,BRD-K00003150,segesterone-acetate,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|,108059.0,Launched,progesterone receptor agonist,PGR,,,5241
5650,BRD-K86434416,selegiline,C[C@H](Cc1ccccc1)N(C)CC#C,26757.0,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,Parkinson's Disease,4128|4129
5653,BRD-K21191422,selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1,9913767.0,Launched,IP1 prostacyclin receptor agonist|platelet aggregation inhibitor,PTGIR,pulmonary,pulmonary arterial hypertension (PAH),5739
5654,BRD-K48738253,selfotel,OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1,6604838.0,Phase 3,glutamate receptor antagonist,GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,2904|2905|2906|2903
5655,BRD-K21361524,selinexor,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,71481097.0,Launched,exportin antagonist,XPO1,hematologic malignancy,multiple myeloma,7514
5658,BRD-K57080016,selumetinib,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,10127622.0,Phase 3,MEK inhibitor,MAP2K1,,,5604
5659,BRD-K65592642,semagacestat,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O,9843750.0,Phase 3,gamma secretase inhibitor,PSEN1,,,5663
5660,BRD-K21237892,semapimod,CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N,492132.0,Phase 2,cytokine production inhibitor|p38 MAPK inhibitor,MAPK14,,,1432
5661,BRD-K63504947,semaxanib,Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1,5329098.0,Phase 3,VEGFR inhibitor,FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET,,,5156|3815|5159|3791|2321|2260|5979
5663,BRD-K70614402,SEN-1269,CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1,46835756.0,Preclinical,beta amyloid inhibitor,APP,,,351
5664,BRD-K21295289,senicapoc,NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1,216327.0,Phase 3,intermediate conductance potassium channel blocker,KCNN4,,,3783
5667,BRD-K28456624,seocalcitol,CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5288149.0,Phase 3,vitamin D receptor agonist,VDR,,,1594
5668,BRD-K49504902,SEP-227900,OC(=O)c1cc2occc2[nH]1,7141881.0,Phase 1,D-amino acid oxidase Inhibitor,DAO,,,26
5669,BRD-A60765580,seratrodast,"CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|",73346713.0,Launched,prostanoid receptor antagonist,TBXA2R,pulmonary,asthma,6915
5670,BRD-K65924316,serdemetan,C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1,11609586.0,Phase 1,MDM inhibitor,MDM2,,,4193
5671,BRD-K38580127,serotonin,NCCc1c[nH]c2ccc(O)cc12,5202.0,Launched,growth factor receptor activator,DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR4|HTR5A|HTR6|HTR7|SLC36A1,neurology/psychiatry,anxiety|depression|sleeplessness,3360|3352|3361|3362|3363|1812|106480180|3350|3351|1816|9177|3354|3355|3356|206358|3358|3359
5673,BRD-K69116396,sertindole,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,60149.0,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|KCNH2,,,3352|3362|3269|3757|146|147|1813|1814|1815|3350|3356|3354|3355|3351|3358
5674,BRD-K82036761,sertraline,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12,68617.0,Launched,selective serotonin reuptake inhibitor (SSRI),SLC6A3|SLC6A4,neurology/psychiatry|obstetrics/gynecology,depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder,6531|6532
5676,BRD-K24497734,setipiprant,OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12,49843471.0,Phase 3,prostaglandin inhibitor,PTGDR2,,,11251
5677,BRD-K36732695,setiptiline,CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|,5205.0,Launched,adrenergic receptor antagonist,HRH1|HTR2A|HTR2C,neurology/psychiatry,depression,3356|3269|3358
5679,BRD-K05638300,sevoflurane,FCOC(C(F)(F)F)C(F)(F)F,5206.0,Launched,membrane integrity inhibitor,ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9|MT-ND1,neurology/psychiatry,anesthetic,2560|513|2561|2562|2563|2564|2565|2566|2567|2568|338567|27032|3736|2741|2743|54207|3776|3777|55879|2890|51305|2554|2555|2556|2557|2558|2559
5680,BRD-K15601958,SEW-2871,FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F,4077460.0,Preclinical,lysophospholipid receptor agonist,S1PR1,,,1901
5681,BRD-K42629487,SF-11,CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1,2936384.0,Preclinical,neuropeptide receptor antagonist,MCOLN3|NPY2R,,,55283|4887
5683,BRD-K86718786,SGC-707,O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1,90642938.0,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT3,,,10196
5684,BRD-K24821794,SGC-CBP30,COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl,72201027.0,Preclinical,bromodomain inhibitor,CREBBP|EP300,,,2033|1387
5685,BRD-K61228301,SGI-1027,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,24858111.0,Preclinical,DNA methyltransferase inhibitor,DNMT1|DNMT3A|DNMT3B,,,1786|1788|1789
5686,BRD-K80700417,SGI-1776,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,24795070.0,Phase 1,Pim kinase inhibitor,FLT3|PIM1|PIM2|PIM3,,,11040|9361|2322|415116
5687,BRD-K00004650,SGS-742,CCCCP(O)(=O)CCCN,130021.0,Preclinical,GABA receptor antagonist,GABBR1|GABBR2,,,9568|10537
5688,BRD-K19477839,SGX523,Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1,24779724.0,Phase 1,hepatocyte growth factor receptor inhibitor,MET,,,8731
5689,BRD-A63344375,SHA-68,"Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|",52951680.0,Preclinical,neuropeptide receptor antagonist,NPSR1,,,387129
5691,BRD-K00818915,SHP099,CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl,118238298.0,Preclinical,protein tyrosine kinase inhibitor,PTPN11,,,5781
5692,BRD-K01826006,SIB-1553A,CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|,10609936.0,Phase 2,acetylcholine receptor agonist,CHRNB4,,,1143
5693,BRD-K98157055,SIB-1757,C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|,132466061.0,Preclinical,glutamate receptor antagonist,GRM5,,,2915
5694,BRD-K14561059,SIB-1893,Cc1cccc(\C=C\c2ccccc2)n1,5311432.0,Preclinical,glutamate receptor antagonist,GRM4|GRM5,,,2914|2915
5695,BRD-A43885598,SID-7969543,"CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|",2149494.0,Preclinical,steroidogenic factor antagonist,NR5A1,,,2516
5696,BRD-A62071884,siguazodan,"CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|",6604007.0,Phase 1,phosphodiesterase inhibitor,PDE3A,,,5139
5697,BRD-K79759585,sildenafil,CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1,135398744.0,Launched,phosphodiesterase inhibitor,PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3,urology,erectile dysfunction,10599|28234|8654|5148|5149
5698,BRD-K80353138,silibinin,COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O,31553.0,Launched,cytochrome P450 inhibitor,ALOX5,gastroenterology,hepatic cirrhosis,240
5699,BRD-K10906636,silodosin,C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F,5312125.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology,benign prostatic hyperplasia (BPH),146|147
5702,BRD-K00003545,simeprevir,COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|,24873435.0,Launched,HCV inhibitor,CYP1A2|CYP3A4,infectious disease,hepatitis C,1544|1576
5704,BRD-K22134346,simvastatin,"CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|",54454.0,Launched,HMGCR inhibitor,HMGCR|ITGB2,endocrinology|cardiology|neurology/psychiatry,hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia,3689|3156
5706,BRD-K91100918,sinefungin,N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,65482.0,Preclinical,DNA methyltransferase inhibitor|RNA synthesis inhibitor,CARM1,,,10498
5708,BRD-K53195974,sipatrigine,CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl,60803.0,Phase 2,voltage-gated sodium channel blocker,CACNA1D|SCN10A|SCN1A|SCN3A|SCN4A|SCN5A|SCN9A,,,6336|776|6323|6328|6329|6331|6335
5709,BRD-K62384160,siponimod,CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F,44599207.0,Launched,sphingosine 1-phosphate receptor modulator,S1PR1,neurology/psychiatry,multiple sclerosis,1901
5710,BRD-K51333959,siramesine,Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12,9829526.0,Phase 2,sigma receptor antagonist,ADRA1A|ADRA1B|ADRA1D,,,146|147
5712,BRD-K84937637,sirolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|",134812764.0,Launched,mTOR inhibitor,FKBP1A|MTOR,transplant|pulmonary,organ rejection|lymphangioleiomyomatosis,2280|2475
5713,BRD-K16472653,SirReal-2,Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1,1096292.0,Preclinical,SIRT inhibitor,SIRT2,,,22933
5714,BRD-A23747351,sirtinol,"C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|",,Preclinical,SIRT inhibitor,SIRT1|SIRT2,,,23411|22933
5715,BRD-K38905597,SIS3,COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12,10138988.0,Preclinical,serine/threonine kinase inhibitor,SMAD3|TGFBR1,,,4088|7046
5719,BRD-K19416115,sitagliptin,N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F,4369359.0,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
5720,BRD-K63806092,sitaxentan,Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl,216235.0,Withdrawn,endothelin receptor antagonist,EDNRA|EDNRB,,,1909|1910
5723,BRD-K02152879,sivelestat,CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O,107706.0,Launched,elastase inhibitor,CELA1|ELANE,pulmonary,acute lung injury,1990|1991
5724,BRD-K35945299,SJ-172550,CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|,1317464.0,Preclinical,MDM inhibitor,MDM4,,,4194
5727,BRD-K00004226,SK&F-10047-(+),C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C,3036222.0,Phase 1,sigma receptor agonist,SIGMAR1,,,10280
5728,BRD-K67304264,SKA-31,Nc1nc2c(ccc3ccccc23)s1,94880.0,Preclinical,potassium channel activator,KCNN4,,,3783
5729,BRD-K83607951,skepinone-L,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,45279963.0,Preclinical,p38 MAPK inhibitor,MAPK14,,,1432
5730,BRD-K01826815,SKF-38393,Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|,6603799.0,Preclinical,dopamine receptor agonist,CALY|DRD1|DRD5,,,50632|1816|1812
5731,BRD-A64227845,SKF-77434,Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|,6603997.0,Preclinical,dopamine receptor agonist,DRD1,,,1812
5732,BRD-A09828896,SKF-81297,Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1,11957706.0,Preclinical,dopamine receptor agonist,DRD1|DRD5,,,1816|1812
5733,BRD-A52588987,SKF-83566,CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|,6604885.0,Preclinical,dopamine receptor antagonist,DRD1|DRD5,,,1816|1812
5734,BRD-K96809896,SKF-86002,Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1,5228.0,Preclinical,p38 MAPK inhibitor,ALOX5|MAPK14,,,240|1432
5735,BRD-K01826728,SKF-89976A,OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|,6604015.0,Preclinical,GABA uptake inhibitor,SLC6A1,,,6529
5736,BRD-K49776472,SKF-91488,CN(C)CCCCSC(N)=N,5227.0,Preclinical,histamine N-methyltransferase inhibitor,HNMT,,,3176
5737,BRD-K01826819,SKF-96365,COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|,6604827.0,Preclinical,calcium channel blocker,CYP3A4|PKD2|TRPC1|TRPC3|TRPC4|TRPC5|TRPV2,,,51393|1576|25865|7220|7222|7223|7224
5738,BRD-K20755323,SKI-II,Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1,753704.0,Preclinical,sphingosine kinase inhibitor,SPHK1,,,8877
5740,BRD-K29895144,SKLB1002,COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,71461003.0,Preclinical,VEGFR inhibitor,KDR,,,3791
5741,BRD-K00004304,SLV-319-(+/-),"C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|",9826744.0,Phase 2,cannabinoid receptor antagonist,CNR1|DRD2|HTR1A,,,1268|1813|3350
5742,BRD-K34445261,SLV-320,O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|,,Phase 2,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
5744,BRD-K06191411,SM-164,CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1,17756618.0,Preclinical,XIAP inhibitor,BIRC2|BIRC3|XIAP,,,329|330|331
5745,BRD-K00004213,SM-21,"CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|",,Preclinical,sigma receptor antagonist,PGRMC1,,,10857
5746,BRD-K08478539,SMER-28,Brc1ccc2ncnc(NCC=C)c2c1,1560402.0,Preclinical,autophagy inducer,SNCA,,,6622
5747,BRD-K98396737,SMI-4a,FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1,1361334.0,Preclinical,Pim kinase inhibitor,PIM1,,,9361
5748,BRD-K00004310,SN-2,"Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|",,Preclinical,transient receptor potential channel agonist,MCOLN3,,,55283
5749,BRD-K89561498,SN-38,CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12,104842.0,Launched,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,7150
5751,BRD-A67006024,SNAP,"CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|",,Phase 2,nitric oxide donor,PTPN1,,,5770
5752,BRD-A21428877,SNAP-5089,"COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|",10326374.0,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CACNA1C|CACNA1D,,,775|776|146|147|150|151|152
5753,BRD-K49702221,SNAP-94847,CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1,16756754.0,Preclinical,,ADRA1A|DRD2,,,146|1813
5754,BRD-K29546239,SNC-80,CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1,123924.0,Preclinical,,OPRD1,,,4985
5755,BRD-K75016267,SNG-1153,CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F,71621167.0,Preclinical,selective estrogen receptor modulator (SERM),ESR1,,,2099
5756,BRD-K71512533,SNS-314,Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1,24995524.0,Phase 1,Aurora kinase inhibitor,AURKA|AURKB|AURKC,,,6795|9212|6790
5758,BRD-K73197500,SNX-5422,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|,,Phase 1/Phase 2,HSP inhibitor,HSP90AA1|HSP90AB1,,,3320|3326
5759,BRD-K85406984,sobetirome,CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O,9862248.0,Phase 1/Phase 2,thyroid hormone receptor agonist,THRA|THRB,,,7067|7068
5764,BRD-K05878375,sodium-butyrate,CCCC(O)=O,264.0,Phase 2,HDAC inhibitor,BCHE|FFAR2|FFAR3|HDAC1|HDAC2|HDAC3|HDAC8,,,8841|590|2865|2867|3065|3066|55869
5766,BRD-M58433298,sodium-dodecyl-sulfate,[Na].CCCCCCCCCCCCOS(O)(=O)=O,,Launched,,ALB,,,213
5769,BRD-K99308954,sodium-monofluorophosphate,OP(O)(F)=O,24267.0,Launched,,PYGM,dental,cavities,5837
5774,BRD-K00003543,sodium-stibogluconate,[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO,,Launched,tyrosine phosphatase inhibitor,PTPN6,infectious disease,leishmaniasis,5777
5776,BRD-A55664972,sodium-tetradecyl-sulfate,"CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|",51382662.0,Launched,,PROC,dermatology,varicose veins,5624
5777,BRD-K01039503,sofalcone,CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1,5282219.0,Launched,mucus protecting agent,CBR1,gastroenterology,peptic ulcer disease (PUD),873
5782,BRD-K69215269,solcitinib,CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12,44603362.0,Phase 1,JAK inhibitor,JAK1,,,3716
5783,BRD-K00003600,solifenacin-succinate,[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1,154059.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence|urinary frequency,1128|1129|1131|1132|1133
5787,BRD-K14681867,somatostatin,C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O,,Launched,somatostatin receptor agonist,OPRD1|OPRM1|SSTR1|SSTR2|SSTR3|SSTR4|SSTR5,hematology,hemorrhage,6752|6753|6754|6755|4985|4988|6751
5789,BRD-K19796430,sonidegib,C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1,24775005.0,Launched,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),54498
5791,BRD-K23984367,sorafenib,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,216239.0,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET,oncology,renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC),673|3815|5159|3791|2321|2322|2260|2324|6037|4921|5979
5794,BRD-A89164055,sorbinil,"Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|",337359.0,Phase 3,aldose reductase inhibitor,AKR1B1,,,231
5797,BRD-K05850076,sotagliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1,24831714.0,Phase 3,sodium/glucose cotransporter inhibitor,SLC5A1|SLC5A2,,,6523|6524
5798,BRD-A33168282,sotalol,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,67108155.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2|KCNH2,cardiology,atrial fibrillation (AF)|ventricular arrhythmias,153|154|3757
5799,BRD-K16761703,sotrastaurin,CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|,10296883.0,Phase 2,PKC inhibitor,PRKCA|PRKCB|PRKCD|PRKCE|PRKCH|PRKCQ,,,5578|5579|5580|5581|5583|5588
5800,BRD-K71900389,SP-100030,FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F,9910975.0,Preclinical,NFkB pathway inhibitor,JUN|NFKB1,,,3725|4790
5801,BRD-K28571773,SP-141,COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12,59620153.0,Preclinical,ubiquitin ligase inhibitor,MDM2,,,4193
5803,BRD-K68405354,spaglumic-acid,CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O,188803.0,Launched,glutamate receptor antagonist,GRM3,allergy,allergic conjunctivitis|allergic rhinitis,2913
5804,BRD-K07612980,sparfloxacin,C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1,6956367.0,Withdrawn,bacterial DNA gyrase inhibitor,TOP2A,,,7153
5805,BRD-A81539525,sparfosate,OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|,46936683.0,Phase 3,aspartate carbamoyltransferase inhibitor,CA2|CA4,,,760|762
5810,BRD-K84964099,spautin-1,Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1,51037431.0,Preclinical,deubiquitinase inhibitor,USP10|USP13,,,84669|8975
5812,BRD-K40438880,spermidine,NCCCCNCCCN,1102.0,Preclinical,glutamate receptor modulator,KCNJ4|TXNRD1,,,7296|3761
5813,BRD-K18375018,spermine,NCCCNCCCCNCCCN,1103.0,Preclinical,,CA14|CA4|CA6|CA9|CASR|GRIN1|GRIN2A|KCNJ4|ODC1|SMOX|SMS|TRPM4|TRPM5,,,768|54498|114787|10743|29850|54795|846|23632|3761|89874|2903|762|765
5814,BRD-K01825110,sphingosylphosphorylcholine,"CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|",5280613.0,Preclinical,gene expression stimulant,GPR12,,,2835
5815,BRD-K55468218,spiperone,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1,5265.0,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|ADRA1D|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7,neurology/psychiatry,schizophrenia,3352|3362|3363|146|147|1812|1813|1814|1815|1816|3350|106480180|3356|3358
5816,BRD-K28192623,spiradoline,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,55652.0,Phase 2,opioid receptor agonist,OPRK1,,,4986
5819,BRD-K90027355,spironolactone,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|,5833.0,Launched,mineralocorticoid receptor antagonist,AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG,endocrinology|cardiology|gastroenterology|rheumatology,hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia,773|774|775|776|778|779|781|782|783|784|785|786|9254|1585|6462|150350|8912|8913|4306|2908|367|55799|5241
5820,BRD-A72483914,spiroxatrine,"O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|",6603993.0,Preclinical,serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A|HTR2B,,,146|147|106480180|150|151|152|3350
5822,BRD-K27710560,splitomycin,O=C1CCc2c(O1)ccc1ccccc21,5269.0,Preclinical,SIRT inhibitor,SIRT1,,,23411
5823,BRD-K19203487,SPP301,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1,9912992.0,Phase 3,endothelin receptor antagonist,EDNRA,,,1909
5824,BRD-K63253858,SPP86,CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12,66549796.0,Preclinical,receptor tyrosine protein kinase inhibitor,RET,,,5979
5825,BRD-A08772153,SQ-109,CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|,,Phase 3,bacterial cell wall synthesis inhibitor,FDFT1,,,2222
5826,BRD-A56987319,SQ-22536,"Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|",22879197.0,Preclinical,adenylyl cyclase inhibitor,ADCY1,,,107
5829,BRD-K26501486,SR-1078,OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,17980288.0,Preclinical,retinoid receptor agonist,RORA|RORC,,,6097|6095
5831,BRD-K60931454,SR-140333,CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1,108167.0,Phase 2,neurokinin receptor antagonist,TACR1,,,6869
5832,BRD-K62814487,SR-1664,C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O,53239854.0,Preclinical,PPAR receptor ligand,PPARG,,,5468
5833,BRD-K11641193,SR-2211,OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F,51035449.0,Preclinical,retinoid receptor inverse agonist,RORC,,,6097
5834,BRD-K62562723,SR-2640,OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1,128355.0,Phase 2,leukotriene receptor antagonist,CYSLTR1,,,10800
5835,BRD-K35629949,SR-27897,OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl,122077.0,Phase 2,CCK receptor antagonist,CCKAR,,,886
5836,BRD-K60952143,SR-3306,Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1,57519510.0,Preclinical,JNK inhibitor,MAPK10|MAPK8|MAPK9,,,5601|5602|5599
5838,BRD-K50378376,SR-3576,COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC,70702008.0,Preclinical,JNK inhibitor,MAPK10,,,5602
5839,BRD-A86468475,SR-3677,CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|,93600633.0,Preclinical,rho associated kinase inhibitor,ROCK2,,,9475
5840,BRD-K09397065,SR-57227A,NC1CCN(CC1)c1cccc(Cl)n1,131747.0,Phase 2,serotonin receptor agonist,HTR3A,,,3359
5841,BRD-K35430135,SR-59230A,CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12,5311452.0,Preclinical,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,,153|154|155
5842,BRD-K19309090,SR-95639A,C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1,195165.0,Preclinical,acetylcholine receptor agonist,CHRM1,,,1128
5843,BRD-K50495309,SRC-kinase-inhibitor-I,COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC,1474853.0,Preclinical,SRC inhibitor,CSK|LCK|RIPK2,,,3932|1445|8767
5844,BRD-K62621335,SRPIN340,FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1,2797577.0,Preclinical,serine arginine protein kinase inhibitor,SRPK1|SRPK2,,,6732|6733
5845,BRD-K95926480,SRT1720,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,24180125.0,Preclinical,SIRT activator,SIRT1,,,23411
5846,BRD-K48452630,SRT2104,Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1,25108829.0,Phase 2,SIRT activator,SIRT1,,,23411
5849,BRD-K00004316,SSR180711,Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|,9797360.0,Phase 2,acetylcholine receptor agonist,CHRNA7,,,89832
5853,BRD-K68470841,ST-2825,NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12,24808138.0,Preclinical,myeloid differentiation primary response inhibitor,MYD88,,,4615
5855,BRD-K41783120,STA-5326,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,10173277.0,Phase 2,interleukin synthesis inhibitor,IL12A,,,3592
5856,BRD-K40853697,STAT3-inhibitor-VI,Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1,252682.0,Preclinical,STAT inhibitor,STAT3,,,6774
5860,BRD-K36739687,stemregenin-1,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,46199207.0,Preclinical,aryl hydrocarbon receptor antagonist,AHR,,,196
5863,BRD-K13049524,STF-083010,Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1,135398515.0,Preclinical,serine/threonine kinase inhibitor,ERN1,,,2081
5864,BRD-K39171998,STF-118804,Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1,20916937.0,Preclinical,NAMPT inhibitor,NAMPT,,,10135
5865,BRD-K22477529,STF-31,CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1,984333.0,Preclinical,NAMPT inhibitor,NAMPT|SLC2A1,,,6513|10135
5868,BRD-A72441487,stiripentol,"CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|",25271730.0,Launched,GABA uptake inhibitor,GABRA3,neurology/psychiatry,epilepsy,2556
5869,BRD-K33839500,stobadine,CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1,108089.0,Phase 2,adrenergic receptor antagonist,ADRA1A,,,146
5872,BRD-K83146339,strontium-ranelate,OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N,,Launched,bone formation stimulant|bone resorption inhibitor,CASR,orthopedics|rheumatology,osteoporosis|osteoarthritis,846
5873,BRD-K72572686,strychnine,O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|,441071.0,Preclinical,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA10|CHRNA9|GLRA1|GLRA2|GLRA3|GLRB,,,55584|8001|1128|1129|1131|1132|1133|2741|2742|2743|57053
5874,BRD-K00003547,SU014813,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,10138259.0,Phase 2,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,,,3791
5875,BRD-K02965346,SU11274,CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1,9549297.0,Preclinical,hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor,MET,,,8731
5876,BRD-K91106808,SU16f,Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O,5329150.0,Preclinical,PDGFR tyrosine kinase receptor inhibitor,PDGFRB,,,5159
5877,BRD-K32730239,SU3327,Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1,11837140.0,Preclinical,JNK inhibitor,MAPK8,,,5599
5878,BRD-K20287671,SU4312,CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1,6450842.0,Preclinical,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,KDR|PDGFRB,,,5159|3791
5879,BRD-K94883909,SU9516,COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1,5289419.0,Preclinical,CDK inhibitor,CDK1|CDK2|CDK4|CDK5,,,1017|1019|1020|983
5880,BRD-K23106423,substance-P,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O,36511.0,Phase 1,neurokinin receptor antagonist,TACR1|TACR2|TACR3,,,6865|6869|6870
5881,BRD-K45238818,succinic-acid,OC(=O)CCC(O)=O,21952380.0,Launched,,ALDH5A1|ASPH|BBOX1|HSD17B6|OXCT1|OXCT2|P3H1|P3H2|P3H3|P4HA1|P4HA2|PLOD1|PLOD3|SDHA|SDHB|SDHC|SDHD|SLC13A1|SLC13A2|SLC13A3|SLC25A10|SUCLA2|SUCLG1|SUCLG2|SUCNR1|TMLHE,,,8974|8985|5019|6561|10536|5033|55214|64175|55217|8630|444|1468|64064|642502|64849|56670|8801|9058|8803|8802|5351|8424|7915|6389|6390|6392
5882,BRD-K00003183,succinobucol,CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C,216325.0,Phase 2/Phase 3,antioxidant,VCAM1,,,7412
5883,BRD-K45497762,succinylcholine-chloride,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,5314.0,Launched,,CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10,neurology/psychiatry,muscle relaxant,89832|1129|1128|1131|1134|57053
5884,BRD-K01950558,succinylsulfathiazole,OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,5315.0,Phase 2,dihydrofolate reductase inhibitor,DHFR,,,1719
5887,BRD-K74724920,sucrose,OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,5988.0,Launched,,ACTA1|ATOX1|C22orf28|LYZ,,,4069|58|475|51493
5906,BRD-K87492696,sulfameter,COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1,5326.0,Launched,dihydrofolate reductase inhibitor,DHFR,infectious disease,urinary tract infections,1719
5914,BRD-K02594908,sulfanilamide,Nc1ccc(cc1)S(N)(=O)=O,5333.0,Launched,carbonic anhydrase inhibitor,CYP2C19|CYP2C9|CYP2D6|CYP2E1|CYP3A4,infectious disease,vulvovaginal candidiasis,1571|1576|1557|1559|1565
5917,BRD-K10671814,sulfaphenazole,Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1,5335.0,Launched,dihydropteroate synthetase inhibitor,DHPS,infectious disease,urinary tract infections,1725
5920,BRD-K10670311,sulfasalazine,OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1,,Launched,cyclooxygenase inhibitor,ACAT1|ALOX5|CHUK|IKBKB|PLA2G1B|PPARG|PTGS1|PTGS2|SLC46A1|SLC7A11|TBXAS1,gastroenterology,ulcerative colitis,6916|5319|682|5742|5743|240|113235|6646|1147|5468|3551
5923,BRD-K00004525,sulfinpyrazone,"O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5,r|",25273605.0,Launched,uricosuric blocker,ABCC1|FPR1|SLC22A12,rheumatology,gout,116085|4363|2357
5926,BRD-A58955223,sulforaphane,C[S@@](=O)CCCCN=C=S |r|,9577379.0,Phase 2,anticancer agent|aryl hydrocarbon receptor antagonist,NFE2L2,,,4780
5927,BRD-K01827279,sulindac,"CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|",16046677.0,Launched,cyclooxygenase inhibitor,AKR1B1,rheumatology,osteoarthritis|rheumatoid arthritis|ankylosing spondylitis,231
5930,BRD-K29570907,sulmetozine,COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1,65790.0,Launched,gastrin inhibitor,GAST,gastroenterology,peptic ulcer disease (PUD),2520
5936,BRD-K00003488,sultiame,NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O,5356.0,Phase 3,carbonic anhydrase inhibitor,CA2,,,760
5938,BRD-K30485548,sumanirole,CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23,9818479.0,Phase 3,dopamine receptor agonist,DRD2,,,1813
5939,BRD-K50938287,sumatriptan,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,5358.0,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7,neurology/psychiatry,migraine headache,3361|3362|3363|3350|3351|3352|3354|3355
5940,BRD-K71250460,SUN-11602,CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C,22245705.0,Preclinical,fibroblast growth factor mimetic,FGFR1,,,2260
5941,BRD-K36274133,SUN-B-8155,C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O,,Preclinical,calcitonin agonist,CALCR,,,799
5942,BRD-K42828737,sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,5329102.0,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET,oncology,gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET),5156|3815|5159|3791|2321|2322|2260|2324|5979|1436
5944,BRD-A34006693,suprofen,"C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|",688581.0,Withdrawn,cyclooxygenase inhibitor,PTGS1|PTGS2,,,5742|5743
5945,BRD-K70327167,suramin,Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O,5361.0,Launched,DNA synthesis inhibitor,F2|FSHR|P2RY1|P2RY11|P2RY13|P2RY2|PLA2G2A|RYR1|RYR2|SIRT5,infectious disease,African trypanosomiasis|onchocerciasis,2147|5028|53829|5029|5320|23408|6261|6262|692312|2492
5946,BRD-K98557884,suritozole,Cn1nc(-c2cccc(F)c2)n(C)c1=S,25431.0,Phase 2,GABA receptor inverse agonist,GABBR1,,,10537
5949,BRD-K15170068,swainsonine,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O,51683.0,Phase 2,alpha mannosidase inhibitor,MAN2A1,,,4124
5950,BRD-K45385835,SX-011,CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,9935015.0,Preclinical,MAP kinase inhibitor,MAPK14,,,1432
5952,BRD-K72106461,SYM-2081,C[C@H](C[C@H](N)C(O)=O)C(O)=O,95883.0,Preclinical,kainate receptor antagonist,GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SLC1A2,,,6506|2897|2899|2900|2901
5953,BRD-A77218119,SYM-2206,"CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|",92209239.0,Preclinical,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,,2890|2891|2892|2893
5955,BRD-K01825585,synephrine,CNC[C@@H](O)c1ccc(O)cc1 |&1:3|,667452.0,Launched,adrenergic receptor agonist,ADRA1A,otolaryngology,sinusitis,146
5956,BRD-K31843556,T-0070907,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1,2777391.0,Preclinical,PPAR receptor antagonist,PPARG,,,5468
5957,BRD-K63516691,T-0156,COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1,5368.0,Preclinical,phosphodiesterase inhibitor,PDE5A,,,8654
5959,BRD-K23383398,T-0901317,OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F,447912.0,Preclinical,LXR agonist,NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB,,,10499|8648|10062|7376|6257|8856
5961,BRD-K84925803,T-5224,OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O,23626877.0,Phase 2,AP inhibitor,JUN,,,3725
5962,BRD-K83492904,T-5601640,Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F,9438169.0,Preclinical,LIM kinase inhibitor,LIMK2,,,3985
5963,BRD-K09001147,T-62,Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1,855908.0,Phase 2,adenosine receptor modulator,ADORA2A,,,135
5965,BRD-K79856806,TA-01,Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F,91691129.0,Preclinical,casein kinase inhibitor|MAP kinase inhibitor,CSNK1D|CSNK1E|MAPK14,,,1432|1453|1454
5966,BRD-K53600683,tabimorelin,CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N,9810101.0,Phase 2,growth hormone secretagogue receptor agonist,GHSR,,,2693
5967,BRD-K73237276,tacalcitol,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,5283734.0,Launched,vitamin D receptor agonist,VDR,dermatology,psoriasis|chapped lips,1594
5968,BRD-K52313696,tacedinaline,CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N,2746.0,Phase 3,HDAC inhibitor,HDAC1,,,3065
5969,BRD-K81473089,tacrine,Nc1c2CCCCc2nc2ccccc12,1935.0,Launched,acetylcholinesterase inhibitor,ACHE|BCHE,neurology/psychiatry,Alzheimer's disease,43|590
5970,BRD-K69608737,tacrolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|,445643.0,Launched,calcineurin inhibitor,FKBP1A,transplant,organ rejection,2280
5971,BRD-K93645900,tadalafil,CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O,110635.0,Launched,phosphodiesterase inhibitor,PDE11A|PDE5A,urology,erectile dysfunction,50940|8654
5972,BRD-K23728141,tafamidis-meglumine,OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1,11001318.0,Launched,transthyretin amyloid inhibitor,TTR,neurology/psychiatry,familial amyloid polyneuropathy (FAP),7276
5974,BRD-K65059905,tafluprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1,9868491.0,Launched,prostaglandin inhibitor,PTGFR,ophthalmology,glaucoma|ocular hypertension,5737
5975,BRD-K18320600,tagatose,OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO,92092.0,Launched,phosphorylase inhibitor,PYGL,,,5836
5976,BRD-K57155378,TAK-063,COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1,46848915.0,Phase 2,phosphodiesterase inhibitor,PDE10A,,,10846
5977,BRD-K38793468,TAK-220,CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1,5275766.0,Phase 1,CC chemokine receptor antagonist,CCR5,,,1234
5979,BRD-K80343549,TAK-285,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,11620908.0,Phase 1,EGFR inhibitor,ERBB2,,,2064
5980,BRD-K67262033,TAK-593,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,24767976.0,Phase 1,VEGFR inhibitor,PDGFRA,,,5156
5981,BRD-K31866293,TAK-632,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,46209401.0,Preclinical,RAF inhibitor,BRAF,,,673
5983,BRD-K52751261,TAK-715,CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1,9952773.0,Phase 2,p38 MAPK inhibitor,MAPK14,,,1432
5984,BRD-K26667523,TAK-733,Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O,24963252.0,Phase 1,MEK inhibitor,MAP2K1,,,5604
5986,BRD-K58501140,TAK-875,Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1,24857286.0,Phase 3,insulin secretagogue,FFAR1,,,2864
5987,BRD-K01683783,TAK-901,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,16124208.0,Phase 1,Aurora kinase inhibitor,AURKB,,,9212
5988,BRD-K48059512,TAK-960,COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1,53357478.0,Phase 1,PLK inhibitor,PLK1,,,5347
5989,BRD-K37419961,talabostat,CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O,6918572.0,Phase 3,dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor,DPP4,,,1803
5990,BRD-K50498985,taladegib,CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F,49848070.0,Phase 2,smoothened receptor antagonist,DHH|IHH|SMO,,,54498|3549|50846
5991,BRD-K80359953,talampanel,C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|,164509.0,Phase 2,glutamate receptor antagonist,GRIA1|GRIA2|GRIA3|GRIA4,,,2890|2891|2892|2893
5993,BRD-A95755460,talarozole,"CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|",76958553.0,Phase 2,cytochrome P450 inhibitor,CYP26A1,,,1592
5994,BRD-K95142244,talazoparib,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,135565082.0,Launched,PARP inhibitor,PARP2,oncology,breast cancer,10038
5995,BRD-A94276798,talinolol,"CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|",156154.0,Launched,adrenergic receptor antagonist,ADRB1,cardiology,hypertension,153
5996,BRD-K75615183,talipexole,Nc1nc2CCN(CC=C)CCc2s1,5374.0,Launched,adrenergic receptor agonist|dopamine receptor agonist,ADRA2A|DRD2|HTR3A,infectious disease,genitial herpes,1813|150|3359
5997,BRD-K17555800,talmapimod,C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C,9871074.0,Phase 2,p38 MAPK inhibitor,IL1B|MAPK11|MAPK14|MT-CO2|TNF,,,5600|3553|107075310|7124|1432
5998,BRD-K47095176,talnetant,CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1,5311424.0,Phase 2,tachykinin antagonist,TACR2|TACR3,,,6865|6870
5999,BRD-A98378129,talniflumate,"FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|",25273599.0,Launched,cyclooxygenase inhibitor,CLCA1,neurology/psychiatry,pain relief,1179
6000,BRD-A02532772,talopram,CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|,76958671.0,Phase 2,adrenergic inhibitor,SLC6A2,,,6530
6002,BRD-K93869735,taltirelin,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,114750.0,Launched,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,7201
6005,BRD-K36627727,tamibarotene,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,108143.0,Launched,retinoid receptor agonist,RARA|RARB,hematologic malignancy,acute promyelocytic leukemia (APL),5914|5915
6007,BRD-K93754473,tamoxifen,CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,2733526.0,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ,oncology,breast cancer,2852|5578|5579|5580|5581|5582|5584|2099|2100|5588|5590|10682
6008,BRD-K74339692,tamsulosin,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O,129211.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology,benign prostatic hyperplasia (BPH),146|147
6009,BRD-K99604664,tanaproget,Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N,4369524.0,Phase 2,progesterone receptor agonist,PGR,,,5241
6010,BRD-K65904673,tandospirone,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1,91273.0,Launched,serotonin receptor agonist,HTR1A,neurology/psychiatry,generalized anxiety disorder (GAD)|dysthymic disorder,3350
6011,BRD-K89162000,tandutinib,COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1,3038522.0,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,CSF1R|FLT3|KIT|PDGFD|PDGFRB,,,5159|3815|2322|80310|1436
6012,BRD-K81473043,tanespimycin,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|",59996479.0,Phase 3,HSP inhibitor,HSP90AA1,,,3320
6014,BRD-K01584643,tannic-acid,Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1,16129778.0,Launched,PARG inhibitor,ANO1,gastroenterology,constipation,55107
6015,BRD-K34073885,tanshinone-I,Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,114917.0,Phase 2,AP inhibitor,IFNG,,,3458
6016,BRD-K00141480,tanshinone-IIA,Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21,164676.0,Phase 2/Phase 3,anti-inflammatory agent|interleukin inhibitor,IL1B|NR1I2|TNF,,,8856|3553|7124
6018,BRD-K88854110,taprenepag,OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1,18376177.0,Phase 2,prostaglandin receptor agonist,PTGER2,,,5732
6019,BRD-K00003568,tarafenacin,Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2,25147683.0,Phase 2,acetylcholine receptor antagonist,CHRM3,,,1131
6020,BRD-K35169477,taranabant,C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N,11226090.0,Phase 3,cannabinoid receptor inverse agonist,CNR1,,,1268
6021,BRD-K22227508,targinine,CNC(=N)NCCC[C@H](N)C(O)=O,46906075.0,Phase 3,nitric oxide synthase inhibitor,NOS3,,,342977
6022,BRD-K09353376,tariquidar,COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC,148201.0,Phase 3,P glycoprotein inhibitor,ABCB1,,,5243
6024,BRD-K09426783,TAS-103,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,135413533.0,Phase 1,topoisomerase inhibitor,TOP1,,,7150
6025,BRD-K44844162,taselisib,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,51001932.0,Phase 3,PI3K inhibitor,PIK3CA,,,5290
6026,BRD-K62971431,tasimelteon,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12,10220503.0,Launched,melatonin receptor agonist,MTNR1A|MTNR1B,neurology/psychiatry,Non-24-Hour Sleep-Wake Disorder,4544|4543
6028,BRD-K14653796,tasquinimod,COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12,54682876.0,Phase 3,angiogenesis inhibitor|S100A9 inhibitor,HDAC4,,,9759
6031,BRD-K81062487,taurocholate,C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,6675.0,Phase 1,G protein-coupled receptor agonist,CEL|FABP6|SLCO1C1,,,1056|2172|53919
6036,BRD-K94649603,taxifolin,O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1,439533.0,Phase 2,opioid receptor antagonist,ADIPOR2,,,79602
6037,BRD-K76841105,tazarotene,CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1,5381.0,Launched,retinoid receptor agonist,RARA|RARB|RARG|RXRB,dermatology,cosmetic|sunscreen lotion,6257|5914|5915|5916
6038,BRD-K11215326,tazemetostat,CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1,66558664.0,Launched,histone lysine methyltransferase inhibitor,EZH2,,,2146
6041,BRD-M77041484,TBOA-(DL),N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O,90479771.0,Preclinical,excitatory amino acid transporter inhibitor,SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7,,,6505|6506|6507|6511|6512
6042,BRD-A12147465,TC-A-2317,C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|,24783396.0,Preclinical,Aurora kinase inhibitor,AURKA,,,6790
6043,BRD-K29660062,TC-ASK-10,CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1,24944925.0,Preclinical,MAP kinase inhibitor,MAP3K5|MAP3K6,,,9064|4217
6044,BRD-K15256258,TC-E-5002,ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1,71735843.0,Preclinical,histone demethylase inhibitor,KDM2A|KDM4A|KDM4C|KDM5A|KDM6A|KDM7A|PHF8,,,5927|23081|7403|22992|9682|80853|23133
6045,BRD-A66521565,TC-E-5006,"C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|",97289132.0,Preclinical,gamma secretase modulator,APP,,,351
6046,BRD-K26041695,TC-F-2,CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O,25198728.0,Preclinical,FAAH inhibitor,FAAH,,,79152
6047,BRD-K16497916,TC-FPR-43,CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C,24776341.0,Preclinical,formyl peptide receptor agonist,FPR2,,,2358
6048,BRD-K27010807,TC-G-1000,Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|,10220232.0,Preclinical,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,,,152|150|151
6049,BRD-K76989898,TC-G-1004,COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C,25074316.0,Preclinical,adenosine receptor antagonist,ADORA2A,,,135
6050,BRD-K16939217,TC-G-1005,Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1,71450251.0,Preclinical,G protein-coupled receptor agonist,GPBAR1,,,151306
6051,BRD-K87199310,TC-G-1008,CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1,91826086.0,Preclinical,G protein-coupled receptor agonist,GPR39,,,2863
6052,BRD-K45044657,TC-H-106,Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1,16070100.0,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,,3065|3066|8841|55869
6053,BRD-K17621556,TC-I-15,CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1,90488948.0,Preclinical,integrin inhibitor,ITGA2|ITGB1,,,3688|3673
6054,BRD-A83792282,TC-I-2000,"Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|",57326391.0,Preclinical,transient receptor potential channel antagonist,TRPM8,,,79054
6055,BRD-K05262258,TC-I-2014,FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|,135883253.0,Preclinical,transient receptor potential channel antagonist,TRPM8,,,79054
6056,BRD-K32031961,TC-LPA5-4,COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O,66552906.0,Preclinical,lysophosphatidic acid receptor antagonist,LPAR5,,,57121
6057,BRD-K76792630,TC-Mps1-12,CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N,70682875.0,Preclinical,monopolar spindle 1 kinase inhibitor,TTK,,,7272
6058,BRD-K78161388,TC-N-1752,CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C,53361524.0,Preclinical,sodium channel blocker,SCN9A,,,6335
6059,BRD-K79608170,TC-NTR1-17,COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O,44157038.0,Preclinical,neurotensin agonist,NTSR1,,,4923
6060,BRD-K54297077,TC-O-9311,COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12,3376937.0,Preclinical,G protein-coupled receptor agonist,GPR139,,,124274
6061,BRD-K55013981,TC-OT-39,CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12,135413563.0,Preclinical,oxytocin receptor agonist|vasopressin receptor agonist,AVPR1A|OXT,,,552|5020
6062,BRD-K34362291,TC-S-7003,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1,11785878.0,Preclinical,SRC inhibitor,LCK,,,3932
6063,BRD-K89517477,TC-S-7004,COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1,57523919.0,Preclinical,DYRK inhibitor,DYRK1A|DYRK1B,,,1859|9149
6064,BRD-K89584803,TC-S-7005,C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1,24971422.0,Preclinical,PLK inhibitor,PLK2,,,10769
6065,BRD-K51776215,TC-S-7006,Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl,9549300.0,Preclinical,MAP kinase inhibitor,MAP3K8,,,1326
6066,BRD-K21894922,TC-S-7009,[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12,70697712.0,Preclinical,hypoxia inducible factor inhibitor,EPAS1,,,2034
6067,BRD-K87461578,TC-SP-14,OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1,51346934.0,Preclinical,sphingosine 1-phosphate receptor agonist,S1PR1,,,1901
6068,BRD-K01825674,TC1,"O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|",,Preclinical,beta-secretase inhibitor,BACE1,,,23621
6069,BRD-K24227647,TC2559,CCOc1cncc(\C=C\CCNC)c1,9823180.0,Preclinical,acetylcholine receptor agonist,CHRNA4,,,1137
6071,BRD-K09787262,TCN201,Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1,4787937.0,Preclinical,glutamate receptor antagonist,GRIN2A,,,2903
6072,BRD-K77915400,TCN238,Nc1nccc(\C=C\c2ccccc2)n1,46911068.0,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,,2914
6073,BRD-K00004294,TCS-2002,"Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|",44247646.0,Preclinical,glycogen synthase kinase inhibitor,GSK3B,,,2932
6074,BRD-K49461364,TCS-21311,CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|,50925411.0,Preclinical,JAK inhibitor,JAK3,,,3718
6076,BRD-K55216666,TCS-2314,Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1,11226207.0,Preclinical,integrin inhibitor,ITGA4|ITGB1,,,3688|3676
6077,BRD-K81935556,TCS-3035,OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1,2295463.0,Preclinical,G protein-coupled receptor agonist,GPR35,,,2859
6078,BRD-K81376179,TCS-359,COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O,1048845.0,Preclinical,FLT3 inhibitor,FLT3,,,2322
6079,BRD-A16560607,TCS-5861528,"CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|",1116244.0,Preclinical,transient receptor potential channel antagonist,TRPA1,,,8989
6080,BRD-K68358632,TCS-HDAC6-20b,CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2,23636017.0,Preclinical,HDAC inhibitor,HDAC6,,,10013
6081,BRD-K29424831,TCS-OX2-29,COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C,10408514.0,Preclinical,orexin receptor antagonist,HCRTR2,,,131450
6082,BRD-K08902330,TCS-PIM-1-1,Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1,1235170.0,Preclinical,Pim kinase inhibitor,PIM1,,,9361
6085,BRD-K28224173,tebipenem,"C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19,t:14|",9892071.0,Launched,bacterial cell wall synthesis inhibitor,CNR1,infectious disease|otolaryngology,pneumonia|otitis,1268
6086,BRD-K00003289,tecadenoson,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12,158795.0,Phase 2,adenosine receptor agonist,ADORA1,,,134
6087,BRD-K41662846,tecalcet,COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl,158797.0,Phase 2,calcium-sensing receptor agonist,CASR,,,846
6088,BRD-K48195801,tecastemizole,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,123618.0,Phase 3,histamine receptor antagonist,KCNH2,,,3757
6092,BRD-K88743730,tegaserod,CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12,135409453.0,Withdrawn,serotonin receptor partial agonist,HTR2A|HTR2B|HTR2C|HTR4,,,3360|3356|106480180|3358
6097,BRD-K51528698,teijin-compound-1,FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1,44453327.0,Preclinical,CC chemokine receptor antagonist,CCR2,,,729230
6098,BRD-K72912098,telaprevir,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,3010818.0,Launched,HCV inhibitor,CTSA|PGR,infectious disease,hepatitis C,5241|5476
6099,BRD-K84564571,telatinib,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,9808844.0,Phase 2,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,KDR,,,3791
6101,BRD-K91159026,telcagepant,Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F,11319053.0,Phase 3,calcitonin antagonist,CALCRL|RAMP1,,,10267|10203
6102,BRD-K06147391,telenzepine,CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1,5387.0,Phase 3,acetylcholine receptor antagonist,CHRM1,,,1128
6103,BRD-K82240271,telithromycin,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC,,Launched,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,CYP1A2|CYP2D6|CYP3A4|CYP3A5|CYP3A7,infectious disease,pneumonia,100861540|1544|1577|1576|1565
6105,BRD-K73999723,telmisartan,CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C,65999.0,Launched,angiotensin receptor antagonist,AGTR1|PPARG,cardiology,hypertension,185|5468
6106,BRD-K63178091,telotristat,Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,25025298.0,Launched,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,7166
6107,BRD-K94559059,telotristat-ethyl,CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1,25181577.0,Launched,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,7166
6111,BRD-K10784860,temocapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,443874.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology|nephrology,hypertension|congestive heart failure|diabetic nephropathy|coronary artery disease (CAD),1636
6113,BRD-K32107296,temozolomide,Cn1nnc2c(ncn2c1=O)C(N)=O,5394.0,Launched,DNA alkylating agent,MGMT,oncology,glioblastoma|astrocytoma,4255
6115,BRD-K08177763,temsirolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|",134812825.0,Launched,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),2475
6119,BRD-A42270467,tenatoprazole,COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|,11552393.0,Phase 2,ATPase inhibitor,IDO1,,,3620
6120,BRD-K48068743,teneligliptin,Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1,11949652.0,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
6121,BRD-K00004279,tenidap,"NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|",,Phase 3,cyclooxygenase inhibitor,KCNJ4|PTGS1,,,3761|5742
6123,BRD-K10362825,teniposide,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12,452548.0,Launched,topoisomerase inhibitor,TOP2A|TOP2B,hematologic malignancy,acute lymphoblastic leukemia (ALL),7153|7155
6126,BRD-K61868322,tenofovir-disoproxil,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C,5481350.0,Launched,nucleoside reverse transcriptase inhibitor,CYP1A2,infectious disease,human immunodeficiency virus (HIV-1)|hepatitis B,1544
6127,BRD-K05977823,tenovin-1,CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1,1013376.0,Preclinical,SIRT inhibitor|TP53 activator,SIRT1,,,23411
6128,BRD-K13949769,tenovin-6,CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1,24772043.0,Preclinical,SIRT inhibitor,SIRT1|SIRT2|SIRT3,,,23410|23411|22933
6129,BRD-A22844106,tenoxicam,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|,54677971.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology|orthopedics,rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis,5742|5743
6131,BRD-K89714990,tepoxalin,COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1,59757.0,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor,ALOX5,rheumatology|orthopedics,rheumatoid arthritis|hip dysplasia,240
6132,BRD-K01826017,TEPP-46,Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|,60156291.0,Preclinical,pyruvate kinase isozyme activator,PKM,,,5315
6134,BRD-K76788410,terameprocol,COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC,476861.0,Phase 1/Phase 2,lipoxygenase inhibitor,BIRC5|CDK1,,,332|983
6135,BRD-K01826569,terazosin,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|",1398859.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D,urology|cardiology,benign prostatic hyperplasia (BPH)|hypertension,146|147
6136,BRD-K68132782,terbinafine,CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12,1549008.0,Launched,fungal squalene epoxidase inhibitor,SQLE,infectious disease,tinea pedis|tinea cruris|tinea corporis,6713
6137,BRD-A50157456,terbutaline,CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|,11354816.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,bronchospasm|bronchitis|emphysema,154
6140,BRD-A06352418,terfenadine,"CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|",6604035.0,Withdrawn,histamine receptor antagonist,HRH1|KCNH1|KCNH2,,,3756|3269|3757
6141,BRD-A89207210,terguride,"CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8,&1:10,&2:11|",443951.0,Launched,dopamine receptor agonist|serotonin receptor antagonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C,neurology/psychiatry,Parkinson's Disease,3352|1815|146|106480180|1813|150|151|152|1814|3350|3356|3351|3358
6142,BRD-A42699921,teriflunomide,"CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|",,Launched,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,1723
6143,BRD-K73451719,terlipressin,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,133566182.0,Launched,vasopressin receptor agonist,AVPR1A,cardiology,hypotension,552
6147,BRD-K00024725,terreic-acid-(-),C[C@@H]1C(=O)[C@H]2O[C@H]2C(=O)C1=O |&1:1|,,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,BTK,,,695
6148,BRD-K43975632,terutroban,Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1,9938840.0,Phase 3,prostanoid receptor antagonist,TBXA2R,,,6915
6149,BRD-K15507868,tesaglitazar,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O,208901.0,Phase 3,insulin sensitizer|PPAR receptor agonist,PPARA|PPARG,,,5465|5468
6150,BRD-K00004564,tetomilast,CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O,3025803.0,Phase 2,phosphodiesterase inhibitor,PDE4D,,,5144
6151,BRD-K95739795,tetrabenazine,COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC,11634155.0,Launched,vesicular monoamine transporter inhibitor,SLC18A1|SLC18A2,infectious disease|neurology/psychiatry,cholera|Huntington's disease,6570|6571
6152,BRD-K45071273,tetracaine,CCCCNc1ccc(cc1)C(=O)OCCN(C)C,5411.0,Launched,membrane integrity inhibitor,SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,anesthetic,6336|11280|6323|6326|6328|6329|6331|6332|6334|6335
6155,BRD-K41298358,tetraethylenepentamine,NCCNCCNCCNCCN,8197.0,Phase 2/Phase 3,superoxide dismutase inhibitor,SOD1|SOD2,,,100129518|6647
6156,BRD-A36978621,tetrahydrofolic-acid,"Nc1nc(=O)c2N[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:19,&1:7|",135398650.0,Launched,,FOLR2,,,2350
6158,BRD-A86248581,tetrahydrouridine,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|",9543506.0,Phase 2,cytidine deaminase inhibitor,CDA,,,978
6161,BRD-A46393198,tetramisole,"C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|",26879.0,Launched,immunostimulant,ALPPL2|CHRNA3,infectious disease,gastrointestinal parasites,1136|251
6162,BRD-K08078237,tetrandrine,COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34,73078.0,Preclinical,calcium channel blocker,SLC6A3,,,6531
6163,BRD-A14757586,tetrazol-5-yl-glycine-(RS),"N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|",15024268.0,Preclinical,glutamate receptor agonist,GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D,,,114787|2903|2904|2905|2906
6164,BRD-A52660433,tetrindole,C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1,54792409.0,Phase 3,monoamine oxidase inhibitor,MAOA,,,4128
6167,BRD-K57708067,TFC-007,O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1,16040067.0,Preclinical,prostaglandin inhibitor,HPGDS,,,27306
6168,BRD-K97072811,TG-003,CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O,1893668.0,Preclinical,CLK inhibitor,CLK1|CLK4|DYRK1A|DYRK1B,,,1859|1195|57396|9149
6169,BRD-K14560436,TG-02,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|,16739650.0,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,CDK1|CDK2|CDK7|CDK9|FLT3|JAK2,,,1025|3717|2322|983|1017|1022
6170,BRD-K18424115,TG-100572,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,11712625.0,Preclinical,SRC inhibitor|VEGFR inhibitor,KDR|SRC,,,6714|3791
6172,BRD-K12735121,TG-100801,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl,11973736.0,Phase 2,SRC inhibitor|VEGFR inhibitor,CSK|FGFR1|FLT1|FLT4|KDR|SRC,,,1445|3791|2321|2324|2260|6714
6173,BRD-K39841531,TG-101209,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,16722832.0,Preclinical,JAK inhibitor,JAK2|JAK3,,,3717|3718
6174,BRD-K64785675,TG100-115,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,10427712.0,Phase 1/Phase 2,PI3K inhibitor,PIK3CA|PIK3CB|PIK3CD|PIK3CG,,,5290|5291|5294|22883
6176,BRD-A41692738,TGX-221,"C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|",51601993.0,Preclinical,PI3K inhibitor,PIK3CB|PIK3CD,,,5291|22883
6178,BRD-K01054709,TH-588,Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl,73389731.0,Preclinical,MTH1 inhibitor,NUDT1,,,4521
6180,BRD-A93255169,thalidomide,"O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|",92142.0,Launched,tumor necrosis factor production inhibitor,TNF,oncology,myeloma,7124
6182,BRD-K34888156,theobromine,Cn1cnc2n(C)c(=O)[nH]c(=O)c12,5429.0,Launched,phosphodiesterase inhibitor,ADORA1|ADORA2A|PDE4B,,,5142|134|135
6183,BRD-K38380126,thiamet-g,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|,24808478.0,Preclinical,GLCNAC phosphotransferase inhibitor,MGEA5,,,10724
6184,BRD-K95785345,thiamine,Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N,1130.0,Launched,vitamin B,SLC19A2|SLC19A3|TPK1,metabolism,thiamine deficiency,10560|27010|80704
6187,BRD-A23970436,thiamylal,"CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3,&2:5|",3033021.0,Launched,glutamate receptor antagonist,GABRA1,neurology/psychiatry,sedative,2554
6189,BRD-K69600043,thiethylperazine,CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,5440.0,Launched,dopamine receptor antagonist,DRD1|DRD2|DRD4,gastroenterology,nausea,1812|1813|1815
6190,BRD-K26619122,thiocolchicoside,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,9915886.0,Launched,GABA receptor antagonist,GABRA1|GABRB2|GABRG2|GLRA1|GLRB,neurology/psychiatry,muscle relaxant,2561|2566|2741|2743|2554
6191,BRD-A16347691,thioctic-acid,"OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|",445125.0,Launched,reducing agent,ACHE|PTGS2,nephrology,diabetic nephropathy,43|5743
6193,BRD-K49350383,thioguanine,Nc1nc2nc[nH]c2c(=S)[nH]1,2723601.0,Launched,purine antagonist,IMPDH1|IMPDH2,hematologic malignancy,acute myeloid leukemia (AML),727833|3615
6194,BRD-K61443650,thiomersal,CC[Hg]Sc1ccccc1C(O)=O,67361.0,Launched,other antibiotic,OXCT1,infectious disease,preservative,5019
6195,BRD-A72603112,thiopental,"CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|",3033017.0,Launched,GABA receptor antagonist,FAAH,neurology/psychiatry,anesthetic,79152
6196,BRD-A85424553,thioperamide,"S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r,c:18,20|",6604452.0,Preclinical,histamine receptor antagonist,HRH3|HRH4,,,59340|11255
6198,BRD-K08619574,thioproperazine,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,9429.0,Launched,dopamine receptor antagonist,ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A,neurology/psychiatry,schizophrenia,146|147|1812|1813|3350|3356
6199,BRD-A84481105,thioridazine,CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1,66062.0,Withdrawn,dopamine receptor antagonist,DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7,,,3362|3363|3269|1812|1813|1814|1815|1816|3350|3356|3358
6200,BRD-A56012032,thiorphan,"OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|",4369380.0,Phase 1,membrane metalloendopeptidase inhibitor,MME,,,4321
6201,BRD-K58049875,thiostrepton,"CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|",16154490.0,Launched,FOXM1 inhibitor|protein synthesis inhibitor,FOXM1,obstetrics/gynecology,mastitis,2305
6202,BRD-K09631521,thiotepa,S=P(N1CC1)(N1CC1)N1CC1,5453.0,Launched,cytochrome P450 inhibitor,CYP2B6|CYP3A4,oncology,breast cancer|ovarian cancer|bladder cancer,1576|1555
6203,BRD-K04175245,thiothixene,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1,941651.0,Launched,dopamine receptor antagonist,DRD1|DRD2|HRH1|HTR2A,neurology/psychiatry,schizophrenia,3269|3356|1812|1813
6204,BRD-K29254801,thiram,CN(C)C(=S)SSC(=S)N(C)C,5455.0,Launched,,JAK2,ophthalmology,contact dermatitis,3717
6210,BRD-K17458574,thymol,CC(C)c1ccc(C)cc1O,6989.0,Launched,GABA receptor positive allosteric modulator,TRPA1,infectious disease,ringworm|antiseptic,8989
6213,BRD-K66401437,THZ1,CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1,73602827.0,Preclinical,CDK inhibitor,CDK7,,,1022
6214,BRD-K02135007,THZ1-R,CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1,119081415.0,Preclinical,CDK inhibitor,CDK7,,,1022
6215,BRD-K95902121,THZ2,CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1,78357763.0,Preclinical,CDK inhibitor,CDK7,,,1022
6217,BRD-K60160658,tiagabine,Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C,60648.0,Launched,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,6529
6218,BRD-K01826304,tianeptine,"CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|",37888263.0,Launched,selective serotonin reuptake enhancer (SSRE),OPRD1|OPRK1|OPRM1,neurology/psychiatry|pulmonary|gastroenterology,depression|asthma|irritable bowel syndrome,4985|4986|4988
6219,BRD-K57432881,tiapride,CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O,5467.0,Launched,dopamine receptor antagonist,DRD2|DRD3,neurology/psychiatry,dyskinesia|abstinence from alcohol|psychosis,1813|1814
6220,BRD-A72988804,tiaprofenic-acid,"C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|",181380.0,Launched,cyclooxygenase inhibitor,PTGS2,rheumatology,rheumatoid arthritis,5743
6222,BRD-A82522119,tibolone,"C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|",124484332.0,Launched,androgen receptor agonist|estrogen receptor agonist|progesterone receptor agonist,ESR1,obstetrics/gynecology,endometriosis,2099
6223,BRD-K19939891,TIC10,"Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|",336423.0,Phase 2,AKT inhibitor|TRAIL modulator,AKT1|MAPK1,,,5594|207
6224,BRD-K25838957,ticagrelor,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,9871419.0,Launched,purinergic receptor antagonist,P2RY12,cardiology,acute coronary syndrome (ACS)|myocardial infarction,64805
6226,BRD-K00603606,ticlopidine,Clc1ccccc1CN1CCc2sccc2C1,5472.0,Launched,purinergic receptor antagonist,P2RY12,hematology|neurology/psychiatry,thrombosis|stroke,64805
6227,BRD-K81330143,tideglusib,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,11313622.0,Phase 2,glycogen synthase kinase inhibitor,GSK3B,,,2932
6228,BRD-A92800748,tie2-kinase-inhibitor,COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|,92852530.0,Preclinical,TIE tyrosine kinase inhibitor,KDR|MAPK14,,,1432|3791
6229,BRD-K34098590,tienilic-acid,OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,38409.0,Withdrawn,cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor,CYP2C9|SLC12A1,,,6557|1559
6230,BRD-K20568871,tifenazoxide,CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|,135410911.0,Phase 1,ATP-sensitive potassium channel agonist,ABCC8|KCNJ11,,,6833|3767
6234,BRD-K10845183,tiludronate,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,60937.0,Launched,bone resorption inhibitor|osteoclast inhibitor,ATP6V1A|MMP2|PTPN1,orthopedics,navicular syndrome,4313|5770|523
6235,BRD-A64406146,timofibrate,"CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|",51371472.0,Phase 2,cholesterol inhibitor|lipase clearing factor inhibitor,LPL,,,3936
6236,BRD-K08806317,timolol,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,33624.0,Launched,adrenergic receptor antagonist,ADRB1|ADRB2,ophthalmology,ocular hypertension|glaucoma,153|154
6244,BRD-K11107424,tiotidine,CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N,50287.0,Phase 2,histamine receptor antagonist,HRH2,,,1665
6245,BRD-K62782754,tiotropium,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1,,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema,1128|1129|1131
6246,BRD-K41876534,tioxolone,Oc1ccc2sc(=O)oc2c1,72139.0,Preclinical,carbonic anhydrase inhibitor,CA2,,,760
6248,BRD-K62965247,tipifarnib,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,159324.0,Phase 3,farnesyltransferase inhibitor,FNTA|FNTB,,,2339|100529261
6250,BRD-K30882994,tiplaxtinin,OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1,6450819.0,Phase 1,plasminogen activator inhibitor,SERPINE1,,,5054
6252,BRD-A73566563,tiprenolol,"CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|",76966339.0,Phase 2,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,,153|154|155
6254,BRD-K75250001,tiracizine,CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1,71264.0,Withdrawn,sodium channel blocker,SCN5A,,,6331
6257,BRD-K61236135,tiratricol,OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1,5803.0,Launched,thyroid hormone stimulant,THRA|THRB,endocrinology,Refetoff syndrome,7067|7068
6258,BRD-K37872686,tirofiban,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O,60947.0,Launched,platelet aggregation inhibitor|structural glycoprotein antagonist,ITGA2B|ITGB3,cardiology,myocardial infarction|refactory angina,3674|3690
6260,BRD-K33379087,tivantinib,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,11494412.0,Phase 3,tyrosine kinase inhibitor,MET,,,8731
6261,BRD-K53414658,tivozanib,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,9911830.0,Launched,VEGFR inhibitor,FLT1|FLT4|KDR|KIT|PDGFRA|PDGFRB,oncology,renal cell carcinoma (RCC),5156|3815|5159|3791|2321|2324
6262,BRD-K06335600,tizanidine,Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|,5487.0,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C|NISCH,neurology/psychiatry,spasms,152|11188|150|151
6265,BRD-K24527118,TMN-355,Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12,44249042.0,Preclinical,cyclophilin inhibitor,PPIA,,,5478
6268,BRD-K53597484,TNP-470,CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl,369976.0,Phase 2,methionine aminopeptidase inhibitor,METAP2,,,10988
6270,BRD-K01826767,tocainide,"C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|",3080825.0,Launched,sodium channel blocker,SCN5A,cardiology,cardiac arrythmia,6331
6271,BRD-K62040061,toceranib,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1,5329106.0,Launched,protein tyrosine kinase inhibitor,FLT1|FLT3|KDR|PDGFRA|PDGFRB,oncology,cutaneous mast cell tumors,5156|5159|3791|2321|2322
6274,BRD-K31283835,tofacitinib,C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N,9926791.0,Launched,JAK inhibitor,JAK1|JAK2|JAK3,rheumatology,rheumatoid arthritis,3716|3717|3718
6275,BRD-K94830213,tofisopam,"CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|",129009868.0,Launched,cytochrome P450 inhibitor|phosphodiesterase inhibitor,CYP3A4,neurology/psychiatry,anxiety|abstinence from alcohol,1576
6276,BRD-K96344439,tofogliflozin,CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1,46908929.0,Launched,sodium/glucose cotransporter inhibitor,GCK,endocrinology,diabetes mellitus,5871
6277,BRD-A60498477,tolamolol,"Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|",66743765.0,Phase 3,adrenergic receptor antagonist,ADRB1|ADRB2|ADRB3,,,153|154|155
6278,BRD-K32164935,tolazamide,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1,5503.0,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ10|KCNJ11,endocrinology,diabetes mellitus,6833|3766|3758|3767
6279,BRD-K46211610,tolazoline,C(C1=NCCN1)c1ccccc1 |t:1|,5504.0,Launched,adrenergic receptor antagonist,ADRA1A|ADRA2A|ADRA2B|ADRA2C|HRH1|HRH2,neurology/psychiatry,reverse sedative,1665|3269|146|150|151|152
6280,BRD-K85119730,tolbutamide,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,5505.0,Launched,ATP channel blocker,ABCC8|KCNJ1|KCNJ11|KCNJ8,endocrinology,diabetes mellitus,6833|3764|3758|3767
6281,BRD-K10852020,tolcapone,Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O,4659569.0,Withdrawn,catechol O methyltransferase inhibitor,COMT,,,1312
6283,BRD-K41772907,tolimidone,Cc1cccc(Oc2cnc(=O)[nH]c2)c1,39065.0,Phase 2,SRC activator,LYN|SRC,,,6714|4067
6284,BRD-K82562631,tolmetin,Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C,5509.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,rheumatology,rheumatoid arthritis|osteoarthritis,5742|5743
6286,BRD-K82687598,tolonidine,Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|,72138.0,Launched,adrenergic receptor antagonist,ADRA2A,,,150
6288,BRD-A67182178,toloxatone,"Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|",13753599.0,Launched,monoamine oxidase inhibitor,MAOA|MAOB,neurology/psychiatry,depression,4128|4129
6289,BRD-A27732521,tolperisone,C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|,688589.0,Launched,voltage-gated sodium channel blocker,CYP2C19|CYP2D6,neurology/psychiatry|infectious disease|rheumatology|cardiology,muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease,1565|1557
6290,BRD-K85693895,tolrestat,COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O,53359.0,Withdrawn,aldose reductase inhibitor,AKR1A1|AKR1B1|AKR1B10,,,57016|231|10327
6291,BRD-K54316499,tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C,443879.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5,urology,urinary incontinence|urinary frequency,1128|1129|1131|1132|1133
6293,BRD-A82035391,tolvaptan,"Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|",443894.0,Launched,vasopressin receptor antagonist,AVPR1A|AVPR2,endocrinology|cardiology|gastroenterology,hyponatremia|congestive heart failure|hepatic cirrhosis,552|554
6295,BRD-K74765201,tomelukast,CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O,3969.0,Phase 3,leukotriene receptor antagonist,CYSLTR1,,,10800
6299,BRD-K29653726,topiramate,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,5284627.0,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|migraine headache,2560|2561|2562|771|2563|2564|2565|2566|2567|2568|766|11280|6323|6326|6328|6329|6331|6332|6334|6335|6336|55879|2890|2891|2892|2893|2897|2899|2900|2901|762|759|760|2554|2555|2556|2557|2558|2559
6300,BRD-K77561571,topiroxostat,N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1,5288320.0,Launched,xanthine oxidase inhibitor,XDH,rheumatology|nephrology,gout|hyperuricemia,6652
6301,BRD-K55696337,topotecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O,60700.0,Launched,topoisomerase inhibitor,TOP1|TOP1MT,oncology,small cell lung cancer|cervical cancer,7150|116447
6302,BRD-K30480208,torasemide,CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1,51371498.0,Launched,electrolyte reabsorption inhibitor|thromboxane receptor antagonist,SLC12A1,cardiology,edema|congestive heart failure|hypertension,6557
6303,BRD-K55675242,torcetrapib,CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F,159325.0,Phase 3,cholesteryl ester transfer protein inhibitor,CETP,,,1071
6304,BRD-K91822704,torcitabine,Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,13711.0,Phase 2,DNA polymerase inhibitor,DCK|TK2,,,1633|7083
6305,BRD-K51350053,toremifene,CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1,3005573.0,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),ESR1,oncology,breast cancer,2099
6306,BRD-K40175214,torin-1,CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1,49836027.0,Preclinical,mTOR inhibitor,MTOR,,,2475
6307,BRD-K68174511,torin-2,Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1,51358113.0,Preclinical,mTOR inhibitor,MTOR,,,2475
6308,BRD-K92241597,tosedostat,CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1,15547703.0,Phase 2,peptidase inhibitor,ANPEP|LAP3|NPEPPS,,,9520|290|7852
6310,BRD-K26420709,toyocamycin,Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,11824.0,Phase 1,serine/threonine kinase inhibitor,ERN1,,,2081
6311,BRD-K93045741,tozadenant,COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12,11618368.0,Phase 3,adenosine receptor antagonist,ADORA2A,,,135
6312,BRD-K59369769,tozasertib,CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1,5494449.0,Phase 2,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,AURKA|AURKB|AURKC|LCK,,,6795|9212|6790|3932
6313,BRD-K87941707,TP-003,CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N,10001434.0,Preclinical,GABA receptor inverse agonist,GABRA1|GABRA2|GABRA3|GABRA5,,,2554|2555|2556|2558
6314,BRD-K84034737,TP-0903,CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl,56839178.0,Phase 1/Phase 2,AXL kinase inhibitor,AXL,,,558
6316,BRD-K51575138,TPCA-1,NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1,9903786.0,Preclinical,IKK inhibitor,IKBKB,,,3551
6320,BRD-K34154330,tracazolate,CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12,5522.0,Phase 2,GABA receptor modulator,GABRA1,,,2554
6322,BRD-K30071764,TRAM-34,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1,656734.0,Preclinical,potassium channel antagonist,KCNN4,,,3783
6323,BRD-K81341251,TRAM-39,Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1,9861261.0,Preclinical,calcium-activated potassium channel activator,KCNN4,,,3783
6324,BRD-K12343256,trametinib,CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O,11707110.0,Launched,MEK inhibitor,MAP2K1|MAP2K2,oncology,melanoma,5604|5605
6325,BRD-K82234479,tramiprosate,NCCCS(O)(=O)=O,6991996.0,Phase 3,beta amyloid protein neurotoxicity inhibitor,APP,,,351
6326,BRD-K28550399,trandolapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O,5484727.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension|myocardial infarction,1636
6327,BRD-K15014948,tranexamic-acid,NC[C@H]1CC[C@@H](CC1)C(O)=O |r|,,Launched,antifibrinolytic|plasminogen activator inhibitor,PLG,hematology,hemophilia,5340
6328,BRD-K17849083,tranilast,COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC,5282230.0,Launched,angiogenesis inhibitor,HPGDS|HRH1,pulmonary,asthma,27306|3269
6335,BRD-K00003699,tranylcypromine,"N[C@H]1C[C@@H]1c1ccccc1 |&1:1,3|",26070.0,Launched,monoamine oxidase inhibitor,KDM1A|MAOA|MAOB,neurology/psychiatry,depression,4128|4129|23028
6336,BRD-K69837166,trap-101,CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|,11494970.0,Preclinical,nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist,OPRL1,,,4987
6337,BRD-K95763993,trapidil,CCN(CC)c1cc(C)nc2ncnn12,5531.0,Launched,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),5156
6338,BRD-K23976833,travoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F,5282226.0,Launched,prostanoid receptor agonist,PTGFR,ophthalmology,ocular hypertension|glaucoma,5737
6339,BRD-K38158531,traxoprodil,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1,219101.0,Phase 2,glutamate receptor antagonist,GRIN2B,,,2904
6340,BRD-K70778732,trazodone,Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1,5533.0,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4,neurology/psychiatry,depression,6532|3269|146|106480180|150|3350|3356|3358
6342,BRD-K36407194,trelagliptin,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,15983988.0,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
6345,BRD-K37543758,trepibutone,CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O,5536.0,Launched,cholinergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,gastroenterology,irritable bowel syndrome,1128|1129|1131|1132
6346,BRD-K19706299,treprostinil,CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O,6918140.0,Launched,prostanoid receptor agonist,P2RY12|PPARD|PTGIR,pulmonary,pulmonary arterial hypertension (PAH),5739|5467|64805
6347,BRD-K84663978,trequinsin,COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC,,Phase 1,phosphodiesterase inhibitor,PDE5A,,,8654
6348,BRD-K08748705,tretazicar,NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O,89105.0,Phase 2,DNA replication inhibitor,NQO2,,,4835
6349,BRD-K71879491,tretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|,444795.0,Launched,retinoid receptor agonist|retinoid receptor ligand,ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG,hematologic malignancy,acute promyelocytic leukemia (APL),5915|5916|7182|5918|6096|6097|6257|6258|8854|216|5914|5467|9052|190
6351,BRD-K77554836,triamcinolone,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|",31307.0,Launched,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,2908
6352,BRD-K53790871,triamcinolone-acetonide,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|",6436.0,Launched,glucocorticoid receptor agonist|immunosuppressant,NR3C1|SERPINA6,dermatology,corticosteroid-responsive dermatoses,866|2908
6354,BRD-K92049597,triamterene,Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1,5546.0,Launched,sodium channel blocker,SCNN1A|SCNN1B|SCNN1D|SCNN1G,endocrinology|cardiology,hypokalemia|hypertension|edema,6337|6338|6339|6340
6355,BRD-K01669786,triapine,NC(=S)N\N=C\c1ncccc1N,9571836.0,Phase 2,ribonucleotide reductase inhibitor,RRM1|RRM2,,,6240|6241
6361,BRD-A28940325,trichlormethiazide,"NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|",12444480.0,Launched,chloride channel blocker,PTGS1|PTGS2|SLC12A1,cardiology,hypertension|edema,6557|5742|5743
6364,BRD-K68202742,trichostatin-a,C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C,444732.0,Phase 1,HDAC inhibitor,HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9,,,55869|9734|8841|10013|3065|3066|83933|10014|9759
6365,BRD-K80431395,triciribine,Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,65399.0,Phase 1/Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,,208|10000|207
6367,BRD-K81916719,triclabendazole,CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1,50248.0,Launched,microtubule inhibitor,DNMT1,infectious disease,tapeworm,1786
6369,BRD-K41731458,triclosan,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,5564.0,Launched,antibacterial agent,DNMT1,infectious disease,first-aid antiseptic,1786
6371,BRD-K37111771,trientine,NCCNCCNCCN,5565.0,Launched,chelating agent,CA14,metabolism,Wilson's disease,23632
6373,BRD-K89732114,trifluoperazine,CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,5566.0,Launched,dopamine receptor antagonist,ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1,neurology/psychiatry,schizophrenia,801|7137|6275|3269|50632|146|1813|1815|3356|3358
6374,BRD-K63675182,triflupromazine,CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F,5568.0,Launched,dopamine receptor antagonist,CHRM1|CHRM2|DRD1|DRD2|HTR2B,neurology/psychiatry|gastroenterology,psychosis|nausea|vomiting,1128|1129|1812|1813|106480180
6375,BRD-K03243820,trifluridine,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F,6256.0,Launched,DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor,TYMS,infectious disease,virus herpes simplex (HSV),7298
6376,BRD-K71696703,triflusal,CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F,9458.0,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,NFKB1|NOS2|PDE10A|PTGS1,neurology/psychiatry|cardiology,stroke|myocardial infarction|atrial fibrillation (AF),10846|339345|5742|4790
6378,BRD-K00003691,trihexyphenidyl,O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|,207845.0,Launched,acetylcholine receptor antagonist,CHRM1,neurology/psychiatry,parkinsonism,1128
6382,BRD-K00003635,trimebutine,CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|,13248159.0,Launched,opioid receptor agonist,OPRD1|OPRK1|OPRM1,gastroenterology,irritable bowel syndrome,4985|4986|4988
6383,BRD-K88366685,trimetazidine,COc1ccc(CN2CCNCC2)c(OC)c1OC,21109.0,Launched,3-ketoacyl CoA thiolase inhibitor,ACAA2,cardiology,angina pectoris,10449
6384,BRD-K16606819,trimethadione,CN1C(=O)OC(C)(C)C1=O,5576.0,Launched,oxazolidine antiepileptic,CACNA1G|CACNA1H|CACNA1I,neurology/psychiatry,seizures,8912|8913|150350
6385,BRD-K34415467,trimethobenzamide,COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,5577.0,Launched,histamine receptor antagonist,DRD2,gastroenterology,vomiting|nausea|gastroenteritis,1813
6386,BRD-K07208025,trimethoprim,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,5578.0,Launched,dihydrofolate reductase inhibitor,DHFR|TYMS,infectious disease|gastroenterology,urinary tract infections|ear infections|diarrhea,7298|1719
6387,BRD-A56241705,trimethoquinol,COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|,12224034.0,Launched,adrenergic receptor antagonist,ADRB2|ADRB3,pulmonary,asthma,154|155
6390,BRD-K13642819,trimetrexate,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,5583.0,Phase 3,dihydrofolate reductase inhibitor,DHFR,,,1719
6391,BRD-K01825162,trimipramine,C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|,6604024.0,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,SLC6A2|SLC6A3|SLC6A4,neurology/psychiatry,depression,6530|6531|6532
6393,BRD-K57033106,tripelennamine,CN(C)CCN(Cc1ccccc1)c1ccccn1,5587.0,Launched,histamine receptor antagonist,HRH1,pulmonary|allergy,asthma|allergic rhinitis|urticaria,3269
6394,BRD-K11742128,triprolidine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1,5282443.0,Launched,histamine receptor antagonist,HRH1,allergy,allergic rhinitis,3269
6395,BRD-K19427720,triptan,CC(C)C(C)(C)C,10044.0,Phase 1,serotonin receptor agonist,HTR1B|HTR1D,,,3352|3351
6396,BRD-K39484304,triptolide,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|,107985.0,Phase 3,RNA polymerase inhibitor,RELA,,,5970
6397,BRD-K62685538,triptorelin,CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,25074470.0,Launched,gonadotropin releasing factor hormone receptor agonist,GNRHR,oncology|endocrinology|obstetrics/gynecology,prostate cancer|breast cancer|precocious puberty|endometriosis|myoma|gender dysphoria,2798
6400,BRD-K83502127,trofinetide,NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O,3080768.0,Phase 2,cytokine production inhibitor,IFNG|IL6|TNF,,,3569|3458|7124
6402,BRD-A13084692,troglitazone,"Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|",9824580.0,Withdrawn,insulin sensitizer|PPAR receptor agonist,CYP2C8|PPARG|TRPM3,,,80036|5468|1558
6406,BRD-K47978074,trometamol,NC(CO)(CO)CO,6503.0,Launched,,AMD1|CANT1|DCN|NEIL1|VEGFA,,,1634|262|124583|79661|7422
6407,BRD-A84389633,"tropanyl-3,5-dimethylbenzoate","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|",,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,,9177|3359
6408,BRD-A34603619,tropesin,"COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24,r|",12606305.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,,,5742|5743
6409,BRD-A79672927,tropicamide,"CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|",688595.0,Launched,acetylcholine receptor antagonist,CHRM3|CHRM4,ophthalmology,mydriasis diagnostic|cycloplegia diagnostic,1131|1132
6411,BRD-K50866992,tropisetron,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12,,Launched,serotonin receptor antagonist,GLRA1|GLRA2|GLRB|HTR3A|HTR4,gastroenterology,nausea|vomiting,3360|2741|2742|2743|3359
6412,BRD-K00003641,trospium,"[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1,4,7|",,Launched,acetylcholine receptor antagonist,CHRM1,urology,urinary incontinence|urinary frequency,1128
6413,BRD-K00494077,trovafloxacin,N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F,,Withdrawn,bacterial DNA gyrase inhibitor,TOP2A,,,7153
6418,BRD-K35626314,TRV130,COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1,66553195.0,Phase 3,opioid receptor agonist,OPRM1,,,4988
6419,BRD-K76973696,tryptanthrin,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,73549.0,Preclinical,cyclooxygenase inhibitor,IDO1,,,3620
6420,BRD-K83776863,tryptophan,N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O,6923516.0,Launched,serotonin receptor partial agonist,CASR|IDO1|SLC36A1|WARS|WARS2,neurology/psychiatry|gastroenterology,anxiety|bloating|constipation|fatigue|sleeplessness,3620|846|10352|206358|7453
6422,BRD-K49685476,TTNPB,C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C,5289501.0,Phase 1,retinoid receptor agonist,RARA|RARB|RARG,,,5914|5915|5916
6423,BRD-K64852730,TTP-22,Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12,1536915.0,Preclinical,casein kinase inhibitor,CSNK2A1,,,1459
6426,BRD-K00627859,tubastatin-A,CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO,49850262.0,Preclinical,HDAC inhibitor,HDAC6,,,10013
6427,BRD-K99621550,tubocurarine,COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4,6000.0,Launched,acetylcholine receptor antagonist,ACHE|CHRNA2|HTR3A|HTR3B|KCNN1|KCNN2|KCNN3|ZACN,neurology/psychiatry,anesthetic,3780|3781|3782|43|1135|353174|9177|3359
6428,BRD-K26026438,tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|,51039094.0,Phase 3,EGFR inhibitor,ERBB2,,,2064
6431,BRD-K56086081,TUG-770,OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N,66553168.0,Preclinical,free fatty acid receptor agonist,FFAR1,,,2864
6432,BRD-K24282351,TUG-891,Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1,57522038.0,Preclinical,free fatty acid receptor agonist,FFAR4,,,338557
6433,BRD-K00003719,tulobuterol,CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|,688591.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,asthma,154
6435,BRD-K28360340,TW-37,CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O,11455910.0,Preclinical,BCL inhibitor,BCL2|BCL2L1|MCL1,,,4170|596|598
6436,BRD-K94176593,TWS-119,Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1,9549289.0,Preclinical,glycogen synthase kinase inhibitor,GSK3B|JUN|MYC,,,4609|2932|3725
6438,BRD-K66584608,TY-52156,CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1,16046248.0,Preclinical,sphingosine 1-phosphate receptor antagonist,S1PR3,,,1903
6442,BRD-K76064317,tyrphostin-AG-1296,COc1cc2ncc(nc2cc1OC)-c1ccccc1,2049.0,Preclinical,FLT3 inhibitor,FLT3,,,2322
6443,BRD-K68336408,tyrphostin-AG-1478,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,2051.0,Preclinical,EGFR inhibitor,EGFR|MAPK14,,,1432|1956
6444,BRD-K49657628,tyrphostin-AG-18,Oc1ccc(C=C(C#N)C#N)cc1O,2052.0,Preclinical,EGFR inhibitor|tyrosine kinase inhibitor,EGFR,,,1956
6445,BRD-K34533029,tyrphostin-AG-494,Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O,5328771.0,Preclinical,EGFR inhibitor,EGFR,,,1956
6446,BRD-K87919739,tyrphostin-AG-825,COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O,6091659.0,Preclinical,protein tyrosine kinase inhibitor,ERBB2,,,2064
6447,BRD-K17415526,tyrphostin-AG-835,C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1,5328769.0,Preclinical,protein tyrosine kinase inhibitor,EGFR,,,1956
6448,BRD-K59469039,tyrphostin-AG-879,CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C,135419190.0,Preclinical,tyrosine kinase inhibitor,ERBB2|KDR|NTRK1,,,2064|4914|3791
6449,BRD-K60184833,tyrphostin-AG-99,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,5328768.0,Preclinical,tyrosine kinase inhibitor,EGFR,,,1956
6451,BRD-K18787491,U-0126,Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N,54539763.0,Preclinical,MEK inhibitor,AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1,,,5600|5604|5605|5609|5578|6093|6446|207|6300|2932|6037|6198|1111|1432|5594|3932|5599
6452,BRD-K08953028,U-0521,CC(C)C(=O)c1ccc(O)c(O)c1,21632.0,Preclinical,catechol O methyltransferase inhibitor,COMT,,,1312
6453,BRD-K77867004,U-104,NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,310360.0,Phase 1/Phase 2,carbonic anhydrase inhibitor,CA1|CA12|CA2|CA9,,,760|768|771|759
6455,BRD-K53532120,U-50488-(-),CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,6604724.0,Preclinical,opioid receptor agonist,OPRK1,,,4986
6456,BRD-K20995441,U-54494A,CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1,183470.0,Preclinical,opioid receptor agonist,OPRK1,,,4986
6457,BRD-K77070363,U-75799E,C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,9919153.0,Phase 1,growth hormone releasing factor agonist,GHSR,,,2693
6458,BRD-K70281171,U-99194,CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,5626.0,Preclinical,dopamine receptor antagonist,DRD3,,,1814
6459,BRD-K38966689,UAMC-00039,N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1,11232124.0,Preclinical,dipeptidyl peptidase inhibitor,DPP4|DPP7,,,29952|1803
6460,BRD-A14574269,UB-165,"Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|",6604855.0,Preclinical,acetylcholine receptor agonist,CHRNA3|CHRNA4|CHRNB2,,,1136|1137|1141
6461,BRD-K59574735,ubenimex,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O,72172.0,Launched,leukotriene synthesis inhibitor,LTA4H|RNPEP,hematologic malignancy,acute myeloid leukemia (AML),4048|6051
6462,BRD-A45499626,UBP-296,"N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|",6420161.0,Preclinical,glutamate receptor antagonist,GRIK1,,,2897
6463,BRD-K79753741,UBP-302,N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O,6420161.0,Preclinical,glutamate receptor antagonist,GRIK1,,,2897
6464,BRD-K09597601,UBP-310,Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O,6420160.0,Preclinical,glutamate receptor antagonist,GRIK1|GRIK5,,,2897|2901
6465,BRD-K73610817,UC-112,Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12,3426979.0,Preclinical,XIAP inhibitor,XIAP,,,331
6468,BRD-K20480395,UF-010,CCCCNNC(=O)c1ccc(Br)cc1,4596836.0,Preclinical,HDAC inhibitor,HDAC1|HDAC2|HDAC3|HDAC8,,,3065|3066|8841|55869
6469,BRD-K84173274,ufenamate,CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,5632.0,Launched,cyclooxygenase inhibitor,PTGS1|PTGS2,dermatology,eczema|dermatitis,5742|5743
6470,BRD-K66715657,UH-232-(+),CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,6604756.0,Preclinical,dopamine receptor antagonist,DRD2|DRD3|DRD4|HTR1A,,,3350|1813|1814|1815
6471,BRD-K57011718,UK-356618,C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1,10370504.0,Preclinical,metalloproteinase inhibitor,MMP13|MMP14|MMP2|MMP3|MMP9,,,4322|4323|4313|4314|4318
6472,BRD-K06294530,UK-383367,NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO,9818682.0,Phase 1,procollagen C-endopeptidase inhibitor,BMP1,,,649
6473,BRD-K19558579,UK-5099,OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N,6438504.0,Preclinical,monocarboxylate transporter inhibitor,SLC16A1,,,6566
6476,BRD-K64381438,ulipristal,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|",130904.0,Launched,progesterone receptor antagonist,PGR,endocrinology,contraceptive,5241
6477,BRD-K46692793,umeclidinium,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,11519070.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM2|CHRM3,pulmonary,chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema,1128|1129|1131
6479,BRD-K77428767,UNC0224,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1,44251522.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,,79813|10919
6480,BRD-K74236984,UNC0321,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1,46901937.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,,10919
6481,BRD-K13060017,UNC0631,COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,53315868.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,,10919
6482,BRD-K86856088,UNC0638,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1,46224516.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,,79813|10919
6483,BRD-K60130390,UNC0642,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1,53315878.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,,79813|10919
6484,BRD-K87465484,UNC0646,COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,53315882.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT2,,,10919
6485,BRD-K02988401,UNC0737,COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C,52953431.0,Preclinical,histone lysine methyltransferase inhibitor,EHMT1|EHMT2,,,79813|10919
6486,BRD-K83189926,UNC1215,O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1,57339144.0,Preclinical,L3MBTL antagonist,L3MBTL3,,,84456
6487,BRD-K26989966,UNC1999,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C,72551585.0,Preclinical,histone lysine methyltransferase inhibitor,EZH2,,,2146
6488,BRD-K91283740,UNC2025,CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|,,Preclinical,FLT3 inhibitor|MER tyrosine kinase inhibitor,FLT3|MERTK,,,2322|10461
6489,BRD-K01773560,UNC2250,CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|,,Preclinical,MER tyrosine kinase inhibitor,MERTK,,,10461
6490,BRD-K60635008,UNC2327,O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1,71583615.0,Preclinical,protein arginine N-methyltransferase inhibitor,PRMT3,,,10196
6491,BRD-K46344388,UNC3230,NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1,46355372.0,Preclinical,phosphatidyl-inositol activator,PIP5K1C,,,23396
6492,BRD-K21906513,UNC669,Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1,46931242.0,Preclinical,L3MBTL antagonist,L3MBTL1,,,26013
6493,BRD-K22229656,UNC926,Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1,61041645.0,Preclinical,MBT inhibitor,L3MBTL1,,,26013
6497,BRD-K77950083,UPF-1069,O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1,25015515.0,Preclinical,PARP inhibitor,PARP2,,,10038
6499,BRD-K38332599,uprosertib,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,51042438.0,Phase 2,AKT inhibitor,AKT1|AKT2|AKT3,,,208|10000|207
6500,BRD-K80129304,uracil,O=c1cc[nH]c(=O)[nH]1,1174.0,Launched,,DPYD|UCKL1,,,54963|1806
6502,BRD-K73196317,urapidil,COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1,5639.0,Launched,adrenergic receptor antagonist,HTR1A,cardiology,hypertension,3350
6503,BRD-K92169341,URB597,NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1,1383884.0,Phase 1,FAAH inhibitor,FAAH|FAAH2|TRPA1,,,79152|158584|8989
6504,BRD-K88052444,urea,NC(N)=O,1176.0,Launched,hydroxy radical formation stimulant,ARG1|CA2|CTNNB1,dermatology,psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis,760|64129|1499
6506,BRD-K01295354,uric-acid,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,1175.0,Phase 3,,PYGL,,,5836
6507,BRD-K13050303,uridine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O,6029.0,Phase 2,dopamine receptor agonist,LSM6|TYMP,,,9997|11157
6508,BRD-K01825013,uridine-5'-triphosphate,"O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1,2,18,19,&1:5,&2:9|",6133.0,Launched,purinergic receptor activator,P2RY11|P2RY2|P2RY4|P2RY6|UCK2,,,5029|5030|5031|7371|692312
6510,BRD-K66908976,URMC-099,CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1,54764565.0,Preclinical,mixed lineage kinase inhibitor,CDKL2|DAPK3|FLT3|LRRK2|MAP3K10|MAP3K11|MAP3K2|MAP3K9|SRPK2,,,4293|4294|8999|4296|1613|6733|2322|10746|120892
6513,BRD-K15697815,ursodiol,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,31401.0,Launched,nuclear factor erythroid derived|like (NRF2) activator,AKR1C2|NR1H4,gastroenterology,gallstones,9971|1646
6514,BRD-K68185022,ursolic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|,64945.0,Phase 2/Phase 3,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,HSD11B1|PLA2G1B|PTPN1|PYGM,,,5770|3290|5837|5319
6515,BRD-A99182808,usniacin-(+),"CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21,&1:3,t:6|",,Preclinical,MAP kinase activator,PTPN1,,,5770
6516,BRD-A12417644,usniacin-(+),"CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|",,Preclinical,MAP kinase activator,PTPN1,,,5770
6523,BRD-K12994359,valdecoxib,Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1,119607.0,Withdrawn,cyclooxygenase inhibitor,CA12|PTGS2,,,771|5743
6524,BRD-A56613951,valethamate,"CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2,&2:4|",38989053.0,Launched,acetylcholine receptor antagonist,CHRM1|CHRM4|CHRM5,obstetrics/gynecology,labor induction,1128|1132|1133
6528,BRD-K41260949,valproic-acid,CCCC(CCC)C(O)=O,3121.0,Launched,benzodiazepine receptor agonist|HDAC inhibitor,ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,epilepsy|seizures|seizures,9734|11280|18|36|6323|6324|6326|6327|6328|6329|6330|6331|6332|6334|6335|6336|4967|7915|55800|3065|3066
6531,BRD-K72951360,valrubicin,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,454216.0,Launched,DNA inhibitor|topoisomerase inhibitor,TOP2A,oncology,bladder cancer,7153
6532,BRD-K45158365,valsartan,CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O,60846.0,Launched,angiotensin receptor antagonist,AGTR1,cardiology,hypertension|congestive heart failure|congestive heart failure,185
6533,BRD-K19412342,valspodar,C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C,5281884.0,Phase 3,P glycoprotein inhibitor,ABCB1,,,5243
6535,BRD-K77625799,vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,3081361.0,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA,oncology,medullary thyroid cancer (MTC),2048|2049|2050|2051|2064|2065|2066|2321|2324|5753|1956|285220|1969|6714|3791|5979|7422|7010|284656|2041|2042|2043|2044|2045|2046|2047
6536,BRD-K24258499,vanillin,COc1cc(C=O)ccc1O,1183.0,Preclinical,,ABAT|ALDH5A1,,,18|7915
6540,BRD-K32501161,vanoxerine,Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1,3455.0,Phase 3,dopamine reuptake inhibitor,SLC6A3,,,6531
6542,BRD-K13926615,vardenafil,CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1,135400189.0,Launched,phosphodiesterase inhibitor,PDE5A|PDE6G|PDE6H,urology,erectile dysfunction,5148|5149|8654
6543,BRD-K18855837,varenicline,"C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1,5|",5310966.0,Launched,acetylcholine receptor agonist,CHRNA3|CHRNA4|CHRNA6|CHRNA7,neurology/psychiatry,smoking cessation,1136|1137|89832|8973
6544,BRD-K09711437,varespladib,CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1,155815.0,Phase 3,secretory phospholipase inhibitor,PLA2G2A,,,5320
6545,BRD-K73028949,vasopressin,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O,133698096.0,Launched,vasopressin receptor agonist,AVPR1A|AVPR1B|AVPR2|OXTR,gastroenterology,abdominal distension,552|553|554|5021
6546,BRD-K70163715,vatalanib,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,151194.0,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,EGFR|FLT1|FLT4|KDR|PDGFRB,,,1956|5159|3791|2321|2324
6548,BRD-K36338614,VBY-825,CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1,70945511.0,Preclinical,cathepsin inhibitor,CTSB|CTSL|CTSS,,,1520|1514|1508
6550,BRD-K26756394,VE-821,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,51000408.0,Preclinical,ATR kinase inhibitor,ATR,,,545
6551,BRD-K04701033,VE-822,CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C,59472121.0,Phase 2,ATR kinase inhibitor,ATM|ATR|MTOR|PIK3CG,,,472|545|2475|5294
6553,BRD-K20168442,vecuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,39765.0,Launched,acetylcholine receptor antagonist,CHRNA2,neurology/psychiatry,muscle relaxant,1135
6554,BRD-K00004714,vedaprofen,"C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1,r|",25271747.0,Launched,anti-inflammatory agent,PTGS2,neurology/psychiatry|endocrinology,pain relief|fever,5743
6557,BRD-K12852738,veliflapon,OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1,123723.0,Phase 3,leukotriene synthesis inhibitor,ALOX5AP,,,241
6558,BRD-K87142802,veliparib,C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1,11960529.0,Phase 3,PARP inhibitor,PARP1|PARP2,,,10038|142
6559,BRD-K06357403,velneperit,CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|,,Phase 2,neuropeptide receptor antagonist,NPY5R,,,4889
6561,BRD-K56343971,vemurafenib,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F,42611257.0,Launched,RAF inhibitor,BRAF|RAF1,oncology,melanoma,673|6037
6562,BRD-K62391742,venetoclax,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|,49846579.0,Launched,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),596
6563,BRD-K01826548,venlafaxine,COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|,11846746.0,Launched,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninânorepinephrine reuptake inhibitor (SNRI),SLC6A2|SLC6A4,neurology/psychiatry,depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder,6530|6532
6564,BRD-K32330832,VER-155008,Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12,25195348.0,Preclinical,HSP inhibitor,HSPA1A,,,3303
6565,BRD-K38548312,VER-49009,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,4369536.0,Preclinical,HSP inhibitor,HSP90AA1,,,3320
6567,BRD-A09533288,verapamil,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|,2520.0,Launched,calcium channel blocker,CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CYP3A4|KCNA10|KCNA7|KCNH2|KCNJ11|NALCN|SCN5A|SLC29A4|SLC6A4,cardiology,hypertension,6532|773|774|775|776|778|779|782|783|784|785|3743|3744|259232|1576|3757|3767|6331|150350|8913|222962
6569,BRD-K47929404,vercirnon,CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1,10343454.0,Phase 3,CC chemokine receptor antagonist,CCR9,,,1238
6573,BRD-K36741660,verinurad,CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O,54767229.0,Phase 2,urate transporter inhibitor,SLC22A12,,,116085
6574,BRD-K19741547,vernakalant,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,9930049.0,Launched,potassium channel blocker,KCNA5,cardiology,atrial fibrillation (AF),3741
6577,BRD-K42673188,verubulin,COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12,11414799.0,Phase 2,tubulin polymerization inhibitor,TUBB,,,7280
6579,BRD-K14765469,vesamicol,O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1,659840.0,Preclinical,acetylcholinesterase inhibitor,SLC18A3,,,6572
6580,BRD-K13414800,vesnarinone,COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1,5663.0,Launched,phosphodiesterase inhibitor,KCNH2|PDE3A,cardiology,congestive heart failure,5139|3757
6581,BRD-A32269193,VGX-1027,"OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|",92981775.0,Phase 1,tumor necrosis factor receptor antagonist,TLR4,,,7099
6582,BRD-K84748119,vicriviroc,COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F,3009355.0,Phase 3,CC chemokine receptor antagonist,CCR5,,,1234
6583,BRD-K72093121,vidarabine,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,21704.0,Launched,antiviral,ADA,infectious disease,virus herpes simplex (HSV)|varicella-zoster virus (VZV),100
6584,BRD-K01825700,vigabatrin,N[C@@H](CCC(O)=O)C=C |&1:1|,40466946.0,Launched,GABA aminotransferase inhibitor,ABAT|SLC32A1,neurology/psychiatry,seizures|spasms,18|140679
6585,BRD-M36487418,vilanterol,OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl,44482554.0,Launched,adrenergic receptor agonist,ADRB2,pulmonary,chronic obstructive pulmonary disease (COPD),154
6586,BRD-K58010567,vilazodone,NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1,6918314.0,Launched,serotonin reuptake inhibitor,DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4,neurology/psychiatry,depression,3360|6532|3269|1813|1814|3350
6587,BRD-K00003565,vildagliptin,O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N,,Launched,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,1803
6588,BRD-A59198242,viloxazine,CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|,12226596.0,Launched,norepinephrine reuptake inhibitor,SLC6A2,neurology/psychiatry,depression,6530
6589,BRD-K06519765,vinblastine,CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|,13342.0,Launched,microtubule inhibitor|tubulin polymerization inhibitor,JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1,hematologic malignancy|infectious disease|oncology,Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma,51174|7846|51175|3725|7280|7283
6590,BRD-K40227168,vinburnine,CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41,71203.0,Launched,adrenergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,neurology/psychiatry,stroke,1128|1129|1131|1132
6591,BRD-K40902647,vincamine,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC,15376.0,Withdrawn,adrenergic receptor antagonist,CHRM1|CHRM2|CHRM3|CHRM4,,,1128|1129|1131|1132
6592,BRD-K12251893,vincristine,CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|,5388993.0,Launched,tubulin polymerization inhibitor,TUBA4A|TUBB,hematologic malignancy,acute lymphoblastic leukemia (ALL),7280|7277
6593,BRD-K59753975,vindesine,CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|,40839.0,Launched,tubulin polymerization inhibitor,TUBB|TUBB1,oncology,breast cancer|non-small cell lung cancer (NSCLC)|melanoma,7280|203068
6595,BRD-K04269837,vinorelbine,"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|",5311497.0,Launched,tubulin polymerization inhibitor,TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8,oncology,non-small cell lung cancer (NSCLC),7846|10376|84617|112714|347688|7277|7278|10381|7280|113457|10382|10383|347733|84790|203068
6596,BRD-K53318339,vinpocetine,CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|,443955.0,Launched,phosphodiesterase inhibitor|sodium channel blocker,PDE1A|PDE1C,neurology/psychiatry,stroke|senile dementia,5136|5137
6598,BRD-K56565215,vipadenant,Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N,21874557.0,Phase 1,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
6599,BRD-K44827188,vismodegib,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1,24776445.0,Launched,hedgehog pathway inhibitor|smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),54498
6602,BRD-K97091514,vitamin-E,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1,14985.0,Launched,LDL oxidation inhibitor|PKC inhibitor,ALOX5|DGKA|NR1I2|PPP2CA|PPP2CB|PRKCA|PRKCB|SEC14L2|SEC14L3|SEC14L4,,,266629|1606|284904|5578|5515|5516|5579|240|23541|8856
6606,BRD-K26122255,VLX600,CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,6806409.0,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,TP53|USP14,,,9097|7157
6607,BRD-K26122255,VLX600,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,6413301.0,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,TP53|USP14,,,9097|7157
6608,BRD-K89053832,VLX600,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,6413301.0,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,TP53|USP14,,,9097|7157
6610,BRD-K66850609,voglibose,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,444020.0,Launched,glucosidase inhibitor,MGAM,endocrinology,diabetes mellitus|hyperglycemia,8972
6611,BRD-K69776681,volasertib,CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O,,Phase 3,PLK inhibitor,PLK1,,,5347
6612,BRD-K23647661,volinanserin,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,5311271.0,Phase 3,serotonin receptor antagonist,HTR2A|HTR2B|HTR2C|KCNH2,,,3356|3757|106480180|3358
6613,BRD-K32768103,vonoprazan,CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1,15981397.0,Launched,potassium-competitive acid antagonist,ATP4A,gastroenterology,peptic ulcer disease (PUD),495
6614,BRD-K93442924,vorapaxar,CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1,10077130.0,Launched,thrombin inhibitor,F2R,cardiology,myocardial infarction|peripheral artery disease (PAD),2149
6616,BRD-K23677682,voreloxin,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,9952884.0,Phase 3,topoisomerase inhibitor,TOP2A,,,7153
6617,BRD-K06557128,voriconazole,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,71616.0,Launched,cytochrome P450 inhibitor,CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1,infectious disease,esophageal candidiasis|aspergillosis|skin infections,1576|1577|5742|1557|1559
6618,BRD-K81418486,vorinostat,ONC(=O)CCCCCCC(=O)Nc1ccccc1,5311.0,Launched,HDAC inhibitor,HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9,hematologic malignancy,cutaneous T-cell lymphoma (CTCL),55869|9734|8841|10013|79885|3065|3066|83933|10014
6619,BRD-K53963539,vortioxetine,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,9966051.0,Launched,serotonin receptor agonist|serotonin receptor antagonist,HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4,neurology/psychiatry,depression,3361|3362|3363|6532|3350|3351|3356|3358|3359
6622,BRD-K56291712,voxtalisib,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,16123056.0,Phase 2,mTOR inhibitor|PI3K inhibitor,MTOR|PIK3CA,,,5290|2475
6623,BRD-K21071223,VP-20629,OC(=O)CCc1c[nH]c2ccccc12,3744.0,Phase 1,beta amyloid antagonist,PLA2G2E|SLC36A1,,,30814|206358
6625,BRD-K72005722,VT-464,CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1,78357816.0,Phase 2,cytochrome P450 inhibitor,CYP17A1,,,1586
6626,BRD-K81694556,VTP-27999,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,16126898.0,Phase 1,renin inhibitor,REN,,,147040
6627,BRD-K48535733,VU0155069,C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1,25105713.0,Preclinical,phospholipase inhibitor,PLD1,,,5589
6628,BRD-K24187789,VU0238429,COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1,42633508.0,Preclinical,acetylcholine receptor allosteric modulator,CHRM5,,,1133
6629,BRD-K27074404,VU0240551,Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1,7211972.0,Preclinical,potassium/chloride cotransporter inhibitor,SLC12A5,,,57468
6630,BRD-K86109159,VU0357121,CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F,2296132.0,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,,2915
6631,BRD-K83649660,VU0360172,Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1,53318624.0,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,,2915
6632,BRD-K45462423,VU0361737,COc1cc(NC(=O)c2ccccn2)ccc1Cl,44191096.0,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,,2914
6633,BRD-K72687424,VU0364439,Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl,46934289.0,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,,2914
6634,BRD-K93317811,VU0364739,Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1,46937439.0,Preclinical,phospholipase inhibitor,PLD2,,,5338
6635,BRD-K66527818,VU0364770,Clc1cccc(NC(=O)c2ccccn2)c1,836002.0,Preclinical,glutamate receptor positive allosteric modulator,GRM4,,,2914
6636,BRD-K68674163,VU0422288,Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1,73058507.0,Preclinical,glutamate receptor positive allosteric modulator,GRM3,,,2913
6637,BRD-K12483104,VU10010,Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1,714286.0,Preclinical,acetylcholine receptor allosteric modulator,CHRM4,,,1132
6638,BRD-K87727457,VU152100,COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1,864492.0,Preclinical,acetylcholine receptor allosteric modulator,CHRM4,,,1132
6639,BRD-K48371964,VU1545,[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1,11625520.0,Preclinical,glutamate receptor positive allosteric modulator,GRM5,,,2915
6640,BRD-K54783522,VU29,[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1,11610682.0,Preclinical,glutamate receptor potentiator,GRM5,,,2915
6641,BRD-K72063794,VU591,[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1,44123657.0,Preclinical,potassium channel blocker,KCNJ1,,,3758
6642,BRD-K11046126,VUF10166,CN1CCN(CC1)c1nc2ccccc2nc1Cl,24278976.0,Preclinical,serotonin receptor antagonist,HTR3A|HTR3B,,,9177|3359
6643,BRD-K90082312,VUF10460,CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1,25129523.0,Preclinical,histamine receptor agonist,HRH4,,,59340
6644,BRD-A93717708,VUF11207,COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|,97018453.0,Preclinical,CC chemokine receptor agonist,ACKR3,,,57007
6645,BRD-K93725829,VX-11e,Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1,11634725.0,Preclinical,MAP kinase inhibitor,MAPK1,,,5594
6647,BRD-K07736136,VX-702,NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F,10341154.0,Phase 2,p38 MAPK inhibitor,IL1B|IL6|MAPK11|MAPK12|MAPK14|TNF,,,5600|3553|3569|7124|1432|6300
6648,BRD-K91900765,VX-745,Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1,3038525.0,Phase 2,p38 MAPK inhibitor,MAPK11|MAPK12|MAPK14,,,5600|6300|1432
6649,BRD-K78430341,VX-765,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,11398092.0,Phase 2,caspase inhibitor,CASP1,,,834
6650,BRD-A00559310,W-54011,COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|,59597209.0,Preclinical,anaphylatoxin chemotactic receptor antagonist,C5AR1,,,728
6652,BRD-K25991148,warfarin,CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|,54688261.0,Launched,vitamin K antagonist,VKORC1,hematology|cardiology,deep vein thrombosis (DVT)|pulmonary embolism (PE)|atrial fibrillation (AF)|myocardial infarction,79001
6653,BRD-K69812556,WAY-100635,COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1,5684.0,Phase 1,serotonin receptor antagonist,HTR1A,,,3350
6654,BRD-A62021152,WAY-161503,Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|,6604916.0,Preclinical,serotonin receptor agonist,HTR2C,,,3358
6655,BRD-K36198571,WAY-170523,Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO,9830392.0,Preclinical,metalloproteinase inhibitor,MMP13,,,4322
6656,BRD-K08223200,WAY-200070,Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1,135418373.0,Preclinical,estrogen receptor agonist,ERBB2|ERBB3|ERBB4|ESR2,,,2064|2065|2066|2100
6657,BRD-K08657056,WAY-207024,CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1,11496610.0,Preclinical,gonadotropin releasing factor hormone receptor antagonist,GNRHR|HRH2|TACR2,,,1665|6865|2798
6658,BRD-K63483542,WAY-208466,CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1,10337743.0,Preclinical,serotonin receptor agonist,DRD2|HTR2A|HTR2C|HTR6|HTR7,,,3362|3363|1813|3356|3358
6659,BRD-K96758128,WAY-213613,N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O,11531745.0,Preclinical,glutamate inhibitor,SLC1A2,,,6506
6661,BRD-K61871885,WAY-316606,FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1,16727102.0,Preclinical,secreted frizzled related protein inhibitor,SFRP1,,,6422
6662,BRD-K54640016,WAY-362450,CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|,10026128.0,Phase 1,FXR agonist,NR1H4,,,9971
6663,BRD-K85920262,WAY-600,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,25229526.0,Preclinical,mTOR inhibitor,MTOR,,,2475
6664,BRD-K55430733,WAY-629,C1CCc2c(C1)n1CCNCc3cccc2c13,6604933.0,Preclinical,serotonin receptor agonist,HTR2C,,,3358
6665,BRD-A01493904,WB-4101,COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|,13305910.0,Preclinical,adrenergic receptor antagonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A,,,146|147|150|151|152|3350
6666,BRD-K47726410,WDR5-0103,COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1,6457069.0,Preclinical,histone lysine methyltransferase inhibitor,WDR5,,,11091
6668,BRD-K50199947,WH-4-023,COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1,11844351.0,Preclinical,SRC inhibitor,LCK|SRC,,,6714|3932
6669,BRD-K07487750,WHI-P154,COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC,3795.0,Preclinical,JAK inhibitor,EGFR|JAK1|JAK2|JAK3,,,3716|1956|3717|3718
6670,BRD-K19316653,WIKI4,COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1,2984337.0,Preclinical,tankyrase inhibitor|WNT pathway inhibitor,TNKS2,,,80351
6671,BRD-K30930903,WIN-18446,ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl,15134.0,Preclinical,aldehyde dehydrogenase inhibitor,ALDH1A2,,,8854
6672,BRD-K22662557,WIN-64338,CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1,132928.0,Preclinical,bradykinin receptor antagonist,BDKRB2,,,623
6673,BRD-A18579359,wiskostatin,"CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|",981326.0,Preclinical,actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor,WASL,,,8976
6674,BRD-K78455053,wnt-c59,Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1,57519544.0,Preclinical,porcupine inhibitor,PORCN,,,64840
6675,BRD-K87343924,wortmannin,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|,312145.0,Preclinical,PI3K inhibitor,PI4KA|PI4KB|PIK3CA|PIK3CD|PIK3CG|PIK3R1|PLK1|PRKDC,,,22883|5347|5290|5294|5295|5297|5298|5591
6676,BRD-K05445342,WP1066,C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1,11210478.0,Phase 1,STAT inhibitor,STAT3,,,6774
6677,BRD-K43644456,WP1130,CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1,11222830.0,Preclinical,deubiquitinase inhibitor,JAK2|UCHL5|USP14|USP9X,,,51377|9097|3717|8239
6679,BRD-K45973863,WR99210,"CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|",121750.0,Preclinical,dihydrofolate reductase inhibitor,TYMS,infectious disease,malaria,7298
6680,BRD-K49389158,WWL-113,CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1,17759482.0,Preclinical,carboxylesterase inhibitor,CES3,,,23491
6681,BRD-K83176916,WWL-123,CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O,90209976.0,Preclinical,monoacylglycerol lipase inhibitor,ABHD6,,,57406
6683,BRD-K00003540,WYE-125132,"CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|",25227469.0,Preclinical,mTOR inhibitor,MTOR,,,2475
6684,BRD-K77008974,WYE-354,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,44219749.0,Preclinical,mTOR inhibitor,MTOR,,,2475
6685,BRD-K49900195,WYE-687,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1,25229450.0,Preclinical,mTOR inhibitor,MTOR,,,2475
6686,BRD-K73293050,WZ-3146,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,44607360.0,Preclinical,EGFR inhibitor,EGFR,,,1956
6687,BRD-K72420232,WZ-4002,COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1,44607530.0,Preclinical,EGFR inhibitor,EGFR|ERBB2,,,2064|1956
6688,BRD-K45909031,WZ4003,CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1,72200024.0,Preclinical,AMPK inhibitor,NUAK1|NUAK2,,,9891|81788
6689,BRD-K81728688,WZ8040,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,44607531.0,Preclinical,EGFR inhibitor,EGFR,,,1956
6690,BRD-K25359048,WZ811,C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1,11565518.0,Preclinical,CC chemokine receptor antagonist,CXCR4,,,7852
6691,BRD-K88358234,xaliproden,FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|,128919.0,Phase 3,serotonin receptor agonist,HTR1A,,,3350
6692,BRD-A59337442,xamoterol,OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1,6917710.0,Phase 3,adrenergic receptor agonist,ADRB1,,,153
6693,BRD-K72815923,xanomeline,CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|,60809.0,Phase 3,acetylcholine receptor agonist,CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6|HTR7,,,3362|3363|1128|1129|1131|1132|1133|106480180|3350|3351|3352|3354|3355|3356|3358
6695,BRD-K12762134,XAV-939,FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1,135418940.0,Preclinical,tankyrase inhibitor,TNKS|TNKS2,,,8658|80351
6696,BRD-K45875383,XBD173,CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1,6433109.0,Phase 2,benzodiazepine receptor ligand,TSPO,,,706
6697,BRD-K69211575,XD-14,CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1,52670832.0,Preclinical,bromodomain inhibitor,BRD2|BRD3|BRD4|BRDT,,,676|8019|23476|6046
6698,BRD-K42748308,XE-991,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12,656732.0,Preclinical,potassium channel blocker,KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5,,,3784|3785|3786|9132|56479
6702,BRD-K27393415,xipamide,Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O,26618.0,Launched,carbonic anhydrase inhibitor,SLC12A3,cardiology,edema|hypertension,6559
6703,BRD-K04266228,XL019,O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1,57990869.0,Phase 1,JAK inhibitor,JAK1|JAK2|JAK3,,,3716|3717|3718
6705,BRD-K95901403,XL147,Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1,1893730.0,Phase 2,PI3K inhibitor,PIK3CA|PIK3CD|PIK3CG,,,5290|22883|5294
6706,BRD-K14274271,XL228,CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1,59757974.0,Phase 1,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,IGF1R|SRC,,,3480|6714
6707,BRD-K03549949,XL388,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,59604787.0,Preclinical,mTOR inhibitor,MTOR,,,2475
6708,BRD-K03765900,XL647,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,,Phase 3,EGFR inhibitor|VEGFR inhibitor,EGFR|EPHB4|ERBB2|FLT4|KDR,,,2050|1956|3791|2064|2324
6710,BRD-K48449981,XMD17-109,CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1,71604307.0,Preclinical,MAP kinase inhibitor,MAPK7,,,5598
6711,BRD-K50387473,XMD8-92,CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1,46843772.0,Preclinical,MAP kinase inhibitor,DCLK2|MAPK7|PLK4|TNK1,,,10733|5598|166614|8711
6712,BRD-K21565985,xylazine,Cc1cccc(C)c1NC1=NCCCS1 |t:10|,5707.0,Launched,adrenergic receptor agonist,ADRA2A|ADRA2B|ADRA2C,neurology/psychiatry,anesthetic,152|150|151
6713,BRD-K08356259,xylometazoline,Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|,5709.0,Launched,adrenergic receptor agonist,ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C,otolaryngology|allergy,nasal congestion|allergic rhinitis,146|147|150|151|152
6715,BRD-K09317629,Y-11,OCC[N+]12CN3CN(CN(C3)C1)C2,427018.0,Preclinical,focal adhesion kinase inhibitor,PTK2,,,5747
6716,BRD-K94832621,Y-134,CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1,11784736.0,Preclinical,estrogen receptor antagonist,ESR1|ESR2,,,2099|2100
6717,BRD-K45117373,Y-26763,CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,121878.0,Phase 1,potassium channel activator,KCNJ8,,,3764
6718,BRD-K42679050,Y-27152,CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,6918184.0,Phase 1,potassium channel activator,KCNJ8,,,3764
6719,BRD-K44084986,Y-27632,C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1,,Preclinical,rho associated kinase inhibitor,PKIA|PKN2|PRKACA|PRKCE|ROCK1|ROCK2,,,5569|9475|5578|6093|5581|5586
6720,BRD-K48449073,Y-29794,CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1,195609.0,Preclinical,prolyl endopeptidase inhibitor,PREP,,,5550
6721,BRD-K96259238,Y-320,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,22227931.0,Preclinical,interleukin inhibitor,IL17A,,,3605
6722,BRD-K56751279,Y-39983,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,9810884.0,Phase 2,rho associated kinase inhibitor,ROCK1|ROCK2,,,9475|6093
6723,BRD-K81865756,Y16,Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1,989521.0,Preclinical,rho associated kinase inhibitor,RHOA,,,387
6724,BRD-K60476892,YC-1,OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12,5712.0,Preclinical,guanylyl cyclase activator,GUCY1A2|GUCY1A3|GUCY1B3|HIF1A,,,2977|3091|2982|2983
6725,BRD-K91403886,YIL-781,CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1,23631116.0,Preclinical,ghrelin receptor antagonist,GHSR,,,2693
6726,BRD-A62182663,YK-4-279,"COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|",93948843.0,Preclinical,apoptosis inhibitor,EWSR1|FLI1,,,2313|2130
6728,BRD-K09436144,YM-022,Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|,122130.0,Phase 2,CCK receptor antagonist,CCKBR,,,887
6729,BRD-K76703230,YM-155,COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O,10126189.0,Phase 2,survivin inhibitor,BIRC5,,,332
6732,BRD-K59650319,YM-298198,CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C,9819432.0,Preclinical,glutamate receptor antagonist,GRM1,,,2911
6733,BRD-K48059230,YM-298198-desmethyl,Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1,11716890.0,Preclinical,glutamate receptor antagonist,GRM1,,,2911
6734,BRD-K38398115,YM-511,Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1,177865.0,Phase 2,aromatase inhibitor,CYP19A1,,,1588
6735,BRD-K42563464,YM-58483,Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F,2455.0,Preclinical,calcium channel blocker,TRPC3|TRPC5|TRPM4,,,7224|54795|7222
6736,BRD-K91716465,YM-750,Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1,9911716.0,Phase 1,ACAT inhibitor,SOAT1,,,6646
6737,BRD-K06712146,YM-90709,COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC,1103147.0,Preclinical,IL5 inhibitor,CSF2RB|IL5RA,,,3568|1439
6738,BRD-K12932420,YM-976,CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1,6604918.0,Phase 1,phosphodiesterase inhibitor,PDE4A,,,5141
6740,BRD-K88570498,yoda-1,Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1,2746822.0,Preclinical,piezo channel activator,PIEZO1,,,9780
6741,BRD-K35586044,yohimbine,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,8969.0,Launched,adrenergic receptor antagonist,ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|KCNJ1|KCNJ10|KCNJ11|KCNJ12|KCNJ14|KCNJ15|KCNJ8,cardiology,cardiac arrythmia|bradycardia,1813|1814|150|3352|152|3354|151|3350|3355|3351|3356|3358|3361|3363|3758|106480180|3764|3766|3767|3768|3770|3772
6744,BRD-K53438416,YZ9,CCOC(=O)c1cc2ccc(O)cc2oc1=O,5289613.0,Preclinical,phosphofructokinase inhibitor,MIF|PFKFB3,,,5209|4282
6745,BRD-K16037980,Z160,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1,4988454.0,Phase 2,N-type calcium channel blocker,CACNA2D1,,,781
6746,BRD-K01826799,zacopride,"COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|",9819593.0,Phase 2,serotonin receptor antagonist,HTR3A|HTR3B|HTR4|HTR5A,,,3360|9177|3361|3359
6747,BRD-K71289571,zafirlukast,COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C,5717.0,Launched,leukotriene receptor antagonist,CYSLTR1|CYSLTR2,pulmonary,asthma,10800|57105
6749,BRD-A26032986,zaldaride,C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|,92460626.0,Phase 3,calmodulin antagonist,CALM1,,,801
6750,BRD-K12261274,zaltidine,Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1,56051.0,Phase 3,histamine receptor antagonist,HRH2,,,1665
6753,BRD-K80451230,zamifenacin,C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1,3086618.0,Phase 3,acetylcholine receptor antagonist,CHRM3,,,1131
6754,BRD-K23067689,zanamivir,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|,60855.0,Launched,neuraminidase inhibitor,NEU2,infectious disease,influenza A virus infection,4759
6757,BRD-K16542329,zaprinast,CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1,135399235.0,Phase 2,phosphodiesterase inhibitor,GPR35|PDE1A|PDE4D|PDE5A|PDE9A,,,5152|2859|8654|5136|5144
6758,BRD-K37561857,zardaverine,COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1,5723.0,Phase 2,phosphodiesterase inhibitor,PDE4D,,,5144
6759,BRD-K92446736,zatebradine,COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC,65637.0,Phase 3,HCN channel blocker,HCN1|HCN2|HCN3|HCN4,,,57657|610|348980|10021
6760,BRD-K22829793,ZCL-278,Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1,1791111.0,Preclinical,CDC inhibitor,CDC42,,,998
6762,BRD-K64157027,ZD-2079,O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1,158794.0,Phase 2,adrenergic receptor agonist,ADRB3,,,155
6763,BRD-K28971625,ZD-7114,COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1,121877.0,Phase 1,adrenergic receptor agonist,ADRB3,,,155
6764,BRD-K11373525,ZD-7155,CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1,4673492.0,Preclinical,angiotensin receptor antagonist,AGTR1,,,185
6765,BRD-K18678457,ZD-7288,CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1,123984.0,Phase 2,HCN channel blocker,HCN1|HCN2|HCN3|HCN4,,,57657|610|348980|10021
6767,BRD-K87714311,zebularine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O,100016.0,Preclinical,DNA methyltransferase inhibitor,CDA|DNMT1,,,978|1786
6768,BRD-K31553034,zibotentan,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1,9910224.0,Phase 3,endothelin receptor antagonist,EDNRA,,,1909
6769,BRD-K72903603,zidovudine,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,35370.0,Launched,nucleoside reverse transcriptase inhibitor,TERT,infectious disease,human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS),7015
6770,BRD-A56359832,zileuton,"C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|",10681296.0,Launched,leukotriene synthesis inhibitor|lipoxygenase inhibitor,ALOX5,pulmonary,asthma,240
6771,BRD-K42816473,zilpaterol,CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O,25218684.0,Launched,adrenergic receptor agonist,ADRB2,endocrinology,weight-gain aid,154
6772,BRD-K46914825,zimelidine,CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1,5365247.0,Withdrawn,selective serotonin reuptake inhibitor (SSRI),MAOA|MAOB|SLC6A4,,,4128|4129|6532
6775,BRD-K29582115,ziprasidone,Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12,60854.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A4,neurology/psychiatry,schizophrenia|bipolar disorder,6532|146|147|1812|1813|150|1815|3352|1816|151|152|1814|3350|3351|3354|3356|3358|3359|3362|3363|3269|1128|1129|1131|1132|1133
6777,BRD-K05151076,ZK-164015,CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1,9806489.0,Preclinical,estrogen receptor antagonist,ESR1|ESR2,,,2099|2100
6779,BRD-K91825936,ZK-811752,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O,512282.0,Phase 2,CC chemokine receptor antagonist,CCR1,,,1230
6780,BRD-K33882852,ZK-93423,CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC,121926.0,Phase 3,benzodiazepine receptor agonist,GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2,,,2561|2566|2554|2555|2556|2558
6781,BRD-K68392338,ZK-93426,CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C,115210.0,Phase 1,benzodiazepine receptor antagonist,GABRA1|GABRA2|GABRA3|GABRA5,,,2554|2555|2556|2558
6783,BRD-K64103579,ZLN024,Cc1ccc(OCCSc2ncccn2)c(Br)c1,1825716.0,Preclinical,AMPK activator,PRKAA1|PRKAB1|PRKAG1,,,5562|5571|5564
6785,BRD-K19605405,ZM-241385,Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1,176407.0,Preclinical,adenosine receptor antagonist,ADORA1|ADORA2A|ADORA2B|ADORA3,,,136|140|134|135
6786,BRD-K41337261,ZM-306416,COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC,5329006.0,Preclinical,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,EGFR|FLT1|FLT4|KDR,,,2321|1956|2324|3791
6787,BRD-K67831364,ZM-323881,Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O,16759369.0,Preclinical,VEGFR inhibitor,KDR,,,3791
6788,BRD-K73789395,ZM-336372,CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1,5730.0,Preclinical,RAF inhibitor,BRAF|LCK|MAPK14|RAF1,,,1432|673|3932|6037
6789,BRD-K40624912,ZM-39923,CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1,3797.0,Preclinical,JAK inhibitor,JAK1|JAK3,,,3716|3718
6790,BRD-K72703948,ZM-447439,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,9914412.0,Preclinical,Aurora kinase inhibitor,AURKA|AURKB,,,9212|6790
6791,BRD-K46654563,zofenopril-calcium,C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1,92400.0,Launched,angiotensin converting enzyme inhibitor,ACE,cardiology,hypertension,1636
6793,BRD-K84253429,zoledronic-acid,OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O,68740.0,Launched,bone resorption inhibitor,FDPS|GGPS1,endocrinology,Paget's disease,2224|9453
6796,BRD-K54314721,zolmitriptan,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,60857.0,Launched,serotonin receptor agonist,HTR1A|HTR1B|HTR1D|HTR1E|HTR1F,neurology/psychiatry,migraine headache,3350|3351|3352|3354|3355
6797,BRD-K81326768,zomepirac,Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1,5733.0,Withdrawn,prostaglandin synthesis inhibitor,PTGDR2,,,11251
6799,BRD-K43992824,zoniporide,NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12,6433110.0,Phase 3,sodium/hydrogen exchanger inhibitor,SLC9A1,,,6548
6800,BRD-K48300629,zonisamide,NS(=O)(=O)Cc1noc2ccccc12,5734.0,Launched,sodium channel blocker|T-type calcium channel blocker,CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A,neurology/psychiatry,seizures|epilepsy,768|771|11280|4128|4129|55800|6323|6324|6326|6327|6328|6329|6330|6331|6332|6334|6335|6336|377677|150350|23632|8913|8912|56287|56934|11238|759|760|761|762|763|765|766|767
6801,BRD-K47710001,zopolrestat,OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12,1613.0,Phase 2,,AKR1B1|AKR1B10,,,57016|231
6802,BRD-K70557564,zosuquidar,O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F,,Phase 3,P glycoprotein inhibitor,ABCB1|ABCB4,,,5243|5244
6803,BRD-K46843573,zotarolimus,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|",,Launched,mTOR inhibitor,FKBP1A,cardiology,coronary artery restenosis,2280
6804,BRD-K64557645,zotepine,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|,5736.0,Launched,dopamine receptor antagonist|serotonin receptor antagonist,ADRA2B|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR6|HTR7|SLC6A2|SLC6A4,neurology/psychiatry,schizophrenia,3352|3362|3363|6530|3269|6532|1813|1814|1815|151|3350|3354|3356|3351|3358
6807,BRD-K63068307,ZSTK-474,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,11647372.0,Phase 1/Phase 2,PI3K inhibitor,PIK3CB|PIK3CD|PIK3CG,,,5291|5294|22883
6808,BRD-K28761384,zuclopenthixol,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1,5311507.0,Launched,dopamine receptor antagonist,ADRA1A|ADRA2A|DRD1|DRD2|DRD5|HRH1|HTR2A,neurology/psychiatry,schizophrenia|bipolar disorder,3269|146|1812|1813|150|1816|3356
